Unnamed: 0,patient_filename,t,text,type,n,cmem_n_is_parsed,cmem_n_reasoning,cmem_n_rules_str,cmem_n_ans_str,cmem_n_memory_str,cmem_n_memory_len,cmem_n_memory_str_len,cmem_n_edit_distance,cmem_n_is_updated
873,TCGA-AR-A24N.AAF32BB7-716A-4C0E-AE7E-04F6A5BF5628,0,"Final Diagnosis. reast, left, simple mastectomy: Infiltrating ductal carcinoma, Nottingham grade II (of III), forming a 1.9 x 1.2 x 1.0 cm mass in. the superior breast (AJCC pTlc). A minor component of ductal carcinoma in situ, intermediate nuclear grade, is also present. Surgical resection margins are negative for tumor. The nearest (deep) margin is free by 0.2 cm. Lymph nodes, left axillary sentinel, excision: Multiple (3) left axillary sentinel lymph nodes are negative for tumor. Lymph. nodes No.1, and No.2A contain no blue dye, lymph node No.2B contains blue dye. Immunohistochemical cytokeratin stain. was. performed on the paraffin embedded sentinel lymph node tissue and confirms the H&E impression. Lymph node, left axillary, excision: A single left axillary lymph node is negative for tumor (AJCC pN0). Her-2/NEU analysis has been ordered on paraffin embedded tissue.",BRCA,0,True,"The report states that multiple (3) left axillary sentinel lymph nodes are negative for tumor and a single left axillary lymph node is also negative for tumor. This indicates that there is no evidence of cancer in the lymph nodes, which corresponds to an N0 stage in the AJCC staging system. ","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.",5.0,366.0,,
1475,TCGA-OL-A5RW.86B06754-B000-4F8B-9037-95E7A0BD4D20,0,"FINAL PATHOLOGIC DIAGNOSIS. A. Lymph node, right sentinel #1, excision: - One lymph node involved by metastatic carcinoma (1/1). B. Lymph node, right sentinel #2, excision: - One lymph node, negative for carcinoma (0/1). C. Lymph node, right sentinel #3, excision: - One lymph node, negative for carcinoma (0/1). D. Lymph node, right sentinel #4, excision: - One lymph node, negative for carcinoma (0/1). E. Breast, right, wire-localization lumpectomy: - Invasive ductal carcinoma, grade III/III, 2.0 cm in greatest dimension,. surgical margins negative (see pathologic parameters and comment below). - Previous biopsy site. Breast Pathologic Parameters. 1. Invasive carcinoma: A. Gross measurement: 2.0 cm. B. Composite histologic (modified SBR) grade: III/III. C. Associated intraductal carcinoma in situ (DCIS/LCIS): None. 2. Excisional biopsy margins: Free of tumor. - Invasive carcinoma 6.0 mm from closest margin (posterior). 4. Blood vessel and lymphatic invasion: Present in breast parenchyma. 5. Axillary lymph nodes: One of four sentinel lymph nodes involved by carcinoma. (1/4). - Size of largest metastatic deposit: 5.0 mm. - Extranodal extension: present (2.0 mm; largest focus). 6. Special studies (see. - ER: No expression. - PR: No expression. - Her2/neu antigen (FISH): Non-amplified (ratio: 1.91). 7. pTNM (AJCC, 7th edition, 2010): pT1c, N1(sn), MX. Clinical History: The patient is a. year-old female with breast cancer undergoing lumpectomy. Comment. Immunohistochemical stains show the tumor cells to be positive for CK7 and. negative for CK20 and TTF-1, consistent with the above diagnosis. D240 stain is. noncontributory. Specimens Received: A: Sentinel node #1. B: Sentinel node #2. C: Sentinel node #3. D: Sentinel node #4. E: Right breast partial; lumpectomy. Gross Description: The specimens are received in five containers each labeled with the patient's. name and medical record number. A. The first container is additionally identified as, 'sentinel node #1'. Received fresh and placed in formalin the specimen consists of a 4 X 3 X 1.2. lymph node. Specimen is serially sectioned and entirely submitted in cassettes. A1-A8. B. The second container is additionally identified as, 'sentinel node #2'. Received fresh and placed in formalin the specimen consists of a 1 X 1x 0.5 cm. lymph node. Specimen is entirely submitted in cassette B1. C. The third container is additionally identified as, 'sentinel node #3'. Received fresh and placed in formalin the specimen consists of a 1 X 1 X 1 cm. lymph node. Specimen is bisected and entirely submitted in cassette C1. D. The fourth container is additionally identified as, 'sentinel node #4'. Received fresh and placed in formalin the specimen consists of a 2 X 1 X 1 cm. lymph node. Specimen is serially sectioned and entirely submitted in cassette. D1. E. The fifth container is additionally identified as, 'right breast partial. mastectomy'. Received fresh on a radiographic grid is a 96.5 gm lumpectomy. specimen measuring 8.0 cm from medial to lateral, 8.5 cm from superior to. inferior and 3.0 cm from anterior to posterior. The specimen is oriented with a. short suture designating the superior pole and a long suture designating the. lateral pole. There is a wire entering at the superomedial aspect of the. specimen at grid C2. Accompanying the specimen is an x-ray demonstrating a. metallic clip located in grid position D3. The wire terminates in grid position. D4. There is a circled mass in grid positions C3-D3, D4. The margins are inked. as follows: anterior- black posterior - red superior - blue inferior - green. medial - yellow lateral - violet The specimen is serially sectioned from lateral. to medial into 8 slices. There is a 2.0 X 2.0 x 1.5 cm lesion located in slices. 5 to 7. It is located 1.6 cm from the black margin, 0.6 cm from the red margin,. 1.4 cm from the blue margin and 4.5 cm from the green margin. A metallic clip is. identified in slice #5. The wire enters the specimen in slice #6 and terminates. in slice #7. Tissue is banked from slices 4 and 6. Lumpectomy is entirely. submitted. E1-E5: slice 1, medial margin. E4-E10: slice 2. E11-E17: slice 3. E18-E28 : slice 4. E29-E41 : slice 5 (clip in E29-E31). E42-E52: slice 6 (mass in E42-E43). E53-E65: slice 7. E66-E83: slice 8. Tissue fixed for at least 6 hours in 10% NBF and no more than 72 hours.",BRCA,1,True,"The N stage is determined by the involvement of lymph nodes in the axilla. In this report, one out of four sentinel lymph nodes is involved (1/4). This corresponds to an N1 stage according to the AJCC 7th edition, 2010 staging system.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The N stage is determined by the number of involved lymph nodes and the size of the metastasis.
N1 stage corresponds to metastasis in 1-3 axillary lymph nodes, or in in-transit, satellite, or micrometastases (N1mi) and/or macrometastases (N1a or N1b) to the auxiliary lymph nodes.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.",5.0,366.0,72.0,False
1224,TCGA-E2-A15P.8C7442C0-540C-4023-BBFA-8482935259A7,0,"SPECIMENS: A. RIGHT BREAST NEEDLE LOCALIZATION. B. SENTINEL LYMPH NODE #1 RIGHT AXILLA. C. SENTINEL LYMPH NODE #2 RIGHT AXILLA. SPECIMEN(S): A. RIGHT BREAST NEEDLE LOCALIZATION. B. SENTINEL LYMPH NODE #1 RIGHT AXILLA. C. SENTINEL LYMPH NODE #2 RIGHT AXILLA. INTRAOPERATIVE CONSULTATION DIAGNOSIS: A- right breast: 1.5-cm mass at 0.5 cm from posterior margin. TPB/TPC- SLN #1, #2 right axilla: Negative for tumor. Diagnoses called by Dr. to Dr. at : (A) and. (B,C). GROSS DESCRIPTION: A. RIGHT BREAST NEEDLE LOC. Received fresh labeled with the patient's identification and ""right breast needle loc"" is a previously inked, oriented. (single stitch-anterior, double-lateral, triple-anterior) 31 g, 3.5 x 3.1 x 3.1 cm needle localized lumpectomy with. radiograph. Ink code: Anterior-yellow, posterior-black, medial-green, lateral-red, superior-blue, inferior-orange. Specimen is serially sectioned from superior to inferior into 8 slices revealing a 1.5x1.3 x 1.1 cm firm tan stellate. mass that is closest to the posterior margin at 0.5 cm. Tissue is procured. Representatively submitted: A1: superior margin, perpendicular sections. A2: slice 2, posterior medial. A3: slice 3, anterior medial. A4: slice 4, posterior lateral. A5: slice 5, anterior lateral (mass, clip). A6: slice 5, posterior lateral (mass). A7: slice 5, mid anterior. A8: slice 5, mid posterior. A9: slice 5, medial. A10: slice 6, anterior lateral (mass). A11: slice 6, posterior lateral. A12: slice 7, anterior lateral. A13: slice 7, posterior lateral. A14: slice 7, anterior medial. A15: slice 7, posterior medial. A16: inferior margin, perpendicular sections. B. SENTINEL LYMPH NODE #1 RIGHT AXILLA. Received fresh labeled with the patient's identification and ""sentinel lymph node #1"" is a 2 x 1 x 0.8 cm lymph node. Sectioned, touch preps are performed; lymph node is submitted entirely in cassette B1. C. SENTINEL LYMPH NODE #2 RIGHT AXILLA. Received fresh labeled with the patient's identification and ""sentinel lymph node #2"" is a 1 x 0.8 x 0.5 cm lymph. node. Sectioned, touch preps are performed; lymph node is submitted entirely in cassette C1. DIAGNOSIS: A. BREAST, RIGHT, WIDE LOCAL EXCISION: - INVASIVE DUCTAL CARCINOMA, SBR GRADE 2, MEASURING 1.1-CM. INTERMEDIATE NUCLEAR GRADE; DUCTAL CARCINOMA IN SITU, SOLID TYPE. - SURGICAL RESECTION MARGINS NEGATIVE FOR TUMOR. - FIBROADENOMA (0.2-CM). BIOPSY SITE CHANGES WITH FIBROSIS AND FOREIGN BODY GIANT CELL REACTION. - SEE SYNOPTIC REPORT. B. LYMPH NODE, SENTINEL #1, RIGHT AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). C. LYMPH NODE, SENTINEL #2, RIGHT AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Laterality: Right. Invasive Tumor. Absent. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 1. 1cm. Margins: Negative. Distance from closest margin: 0.5cm. deep. Tubular Score: 3. Nuclear Grade: 2. Mitotic Score: 1. Modified Scarff Bloom Richardson Grade: 2. Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node. Lymph node status: Negative 0/2. DCIS present. Margins uninvolved by DCIS. DCIS Quantity: Estimate 10%. DCIS Type: Solid. DCIS Location:Associated with invasive tumor. Nuclear grade: Intermediate. Necrosis: Absent. ER/PR/HER2 Results. ER: Pending. PR: Pending. HER2: Negative by IHC. Performed on Case: Pathological staging (pTN): pT 1c N 0. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. CLINICAL HISTORY: Right lateral breast 1.5-cm invasive breast cancer, posterior near fascia, fascia included with specimen. PRE-OPERATIVE DIAGNOSIS: None given. ADDENDUM: SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimen: Surgical Excision. Block Number: A6. ER: Positive Allred Score: 8 = Proportion Score 5 + Intensity Score 3. PR: Positive. Allred Score: 4 = Proportion Score 2 +. Intensity Score 2. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the proportion score. (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of cells staining, 4 = 31-60% of. cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak intensity of staining, 2 = intermediate. intensity of staining, 3 = strong intensity of staining), with a scoring range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score of less than. or equal to 2. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochem was performed using the mouse anti-human ER (ER 1D5, 1:100) and PR (PGR 136, 1:100). provided by Dakc. following the manufacturer S instructions. This assay was not modified. Interpretation of the ER/PR immunohistocnemical stain is guided by published results in the medical literature,. information provided by the reagent manufacturer and by internal review of staining performance. ONCOTYPE DX BREAST CANCER ASSAY. RESULTS: Recurrence Score: 22. CLINICAL EXPERIENCE: Patients with a recurrence score of: 22 in the clinical validation study had an average. rate of Distant Recurrence at 10 years of 14%. ER Score: 11.1 Positive. PR Score: 4.4 Negative. Her2 Score: 10. Negative. Interpretation: ER Negative < 6.5 Positive >= 6.5. PR Negative < 5.5 Positive >= 5.5. Her2 Negative <10.7 Positive >=11.5 Equivocal = 10.7 - 11.4. See separate (. ) report for further information. Microscopic/Diagnostic Dictation: Pathologist. Final Review: Pathologist. Final: Pathologist,. Addendum: Pathologist,. Addendum Final: Pathologist. Addendum: Pathologist,. Addendum Final: Pathologist,.",BRCA,0,True,"The report states that the sentinel lymph nodes 1 and 2 from the right axilla are negative for metastases (0/1). According to the rules provided, if there is no evidence of cancer in the lymph nodes, the N stage is N0. Therefore, the N stage for this patient is N0.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.",6.0,450.0,90.0,True
791,TCGA-AO-A0J5.5EFC16F4-7FC7-479E-93F7-AEDC2D350A22,3,"Clinical Diagnosis & History: year old female with stage IV breast carcinoma, debulking surgery. Specimens Submitted: 1: SP: Right breast and axillary contents level 1. DIAGNOSIS: 1. BREAST, RIGHT; MODIFIED RADICAL MASTECTOMY: - INVASIVE CARCINOMA, HISTOLOGIC GRADE II/III (MODERATE TUBULE. FORMATION) TO HISTOLOGIC GRADE III/III (SLIGHT OR NO TUBULE FORMATION). NUCLEAR GRADE III/III (MARKED VARIATION IN SIZE AND SHAPE), MEASURING AT. LEAST 10 CM IN LARGEST DIMENSION GROSSLY. INVASIVE CARCINOMA SHOWS. MICROPAPILLARY FEATURES. FOCAL EXTRACELLULAR MUCIN IS ALSO NOTED. - DUCTAL CARCINOMA IN SITU (DCIS) IS ALSO IDENTIFIED, SOLID CRIBRIFORM. MICROPAPILLARY AND FLAT TYPES, WITH HIGH NUCLEAR GRADE, AND EXTENSIVE. NECROSIS. - LOBULAR INVOLVEMENT BY DCIS IS PRESENT. - THE DCIS CONSTITUTES LESS THAN OR EQUAL TO 25% OF THE TOTAL TUMOR MASS,. AND IS PRESENT ADMIXED WITH AND AWAY FROM THE INVASIVE COMPONENT. - THE INVASIVE CARCINOMA IS LOCATED IN ALL FOUR QUADRANTS. - THE DCIS IS LOCATED IN ALL FOUR QUADRANTS. - THE NIPPLE IS INVOLVED BY INVASIVE CARCINOMA. - CALCIFICATIONS ARE PRESENT IN BOTH THE IN SITU AND INVASIVE CARCINOMA. - VASCULAR INVASION IS PRESENT. - THE SKIN IS INVOLVED BY INVASIVE CARCINOMA BY DIRECT EXTENSION INTO THE. DERMIS. - THE ATTACHED SKELETAL MUSCLE IS EXTENSIVELY INVOLVED BY INVASIVE CARCINOMA. BY DIRECT EXTENSION. - INVASIVE CARCINOMA IS CLOSE (LESS THAN 0.1 CM) FROM THE NEAREST DEEP. MARGIN. THE NON-NEOPLASTIC BREAST TISSUE IS UNREMARKABLE. FOCAL CHANGES OF PRIOR PROCEDURE ARE NOTED IN THE AXILLARY TAIL. - METASTATIC CARCINOMA IS PRESENT IN TWO OUT OF TWO LEVEL I LYMPH NODES. (2/2) ADDITIONAL SECTIONS OF THE AXILLARY TISSUE HAVE BEEN SUBMITTED AND. THE FINDINGS WILL BE REPORTED IN AN ADDENDUM. - NUMEROUS FOCI OF METASTATIC CARCINOMA ARE NOTED IN THE AXILLARY SOFT. TISSUE, WITH THE LARGEST MEASURING AT LEAST 1.4 CM. Immunohistochemical stains were performed on formalin-fixed tissue with. the following results for invasive carcinoma (block 1-8): ESTROGEN RECEPTOR. 90% nuclear staining with strong. intensity. PROGESTERONR RECERTOR. Negative (no nuclear staining). HER2. Equivocal (focal 2+). FISH will be performed. (5% of invasive tumor cells exhibit complete membranous staining;. Uniformity of staining: absent;. Homogeneous, dark circumferential pattern: absent). The carcinoma is positive for E-cadherin, supporting lobular. differentiation. Comment: Controls are satisfactory. Ventana' a PATHWAY anti-HER-2/neu is. an FDA-approved rabbit monoclonal primary antibody (clone 4B5) directed. against the internal domain of the c-erbB-2 oncoprotein (HER2) for. immunohistochemical detection of HER2 protein overexpression in breast. cancer tissue routinely processed for histologic evaluation The HER2 test. results are reported in accordance with the ASCO/CAP guideline. recommendations for HER2 testing in breast cancer (J Clin Oncol 2007;. 25(1):118-145). The ER and PR rabbit monoclonal antibodies are also FDA. approved. Some of the imnunohistochemistry and ISH tests were developed and their. performance characteristics were determined by the Department of Pathology. They have not been cleared or approved by the US Food and Drug. Administration. The FDA has determined that such clearance or approval is. not necessary. These tests are used for clinical purposes. They should not. be regarded as investigational or for research. This laboratory is certified. under the Clinical Laboratory Improvement Amendments of 1988 (CLIA , 88). as. qualified to perform high complexity clinical laboratory testing. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL) . AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Gross Description: M.D. M.D. 1) The specimen is received fresh labeled, ""right breast and axillary. contents level 1"",. It consists of a breast with attached. axillary contents. The breast measures 20 x 15 x 5 cm with overlying skin. ellipse measuring 18 x 7 x 0.2 cm. Situated centrally on the skin surface is. a. fixed, and retracted nipple measuring 1.5 x 1.0 x 1.0 cm. The surrounding. skin is markedly thickened (up to 0.6 cm) . A suture demarcates the axillary. contents which measures 7 x 5 x 2 cm. The posterior surface of the breast is. inked black and the anterior blue. Part of the posterior surface of the. breast is covered by dark red skeletal muscle, measuring 11 x 4 x 0.5 cm. The specimen is serially sectioned to reveal an irregular tumor bed (10 x. 8.3 x 5.1 cm) with poorly defined white, firm and tan areas. The tumor bed. occupies almost the entire breast volume, extending throughout all four. quadrants. The tumor bed is located 0.2 cm from the posterior margin, 0.3 cm. from the anterior margin, and 0.5 cm from the skeletal muscle. The remaining. breast tissue shows yellow fatty areas with foci of fibrosis. The axillary. tissue is dissected to reveal 13 possible lymph nodes, ranging in size from. 0.4 cm to 1.2 cm. Representative sections are submitted. All dissected lymph. nodes are entirely submitted. The specimen is photographed. Tissue is. submitted to TPS. Summary of sections: N - nipple, nipple base and tumor. s - thickened skin. PM - posterior margin. AM - anterior margin. DSM - deep skeletal muscle. T - tumor central region and closest margins, continuous cross sections,. taken from medial to lateral. UIQ - upper inner quadrant. LIQ - lower inner quadrant. UOQ - upper outer quadrant. LOQ - lower outer quadrant. L1 - axilla, level one lymph nodes. AX axillary tail, entirely submitted. Summary of Sections: Part 1: SP: Right breast and axillary contents level 1. Block. Sect. Site. PCs. 1. AM. 1. 11. ax. 11. 1. DSM. 1. 9. L1. 9. 2. LIQ. 2. 2. LOQ. 2. 3. N. 3. 1. PM. 1. 1. s. 1. 10. T. 10. 2. UIQ. 2. 2. UOQ. 2. Procedures/Addenda: Addendum. Date Complete: By: 1. Addendum Diagnosis. PART #1. RIGHT BREAST AND AXILLARY CONTENTS: THE REMAINING AXILLARY TISSUE IS ENTIRELY SUBMITTED. NO ADDITIONAL LYMPH. NODES ARE IDENTIFIED. ,MD.",BRCA,1,True,"The report states 'METASTATIC CARCINOMA IS PRESENT IN TWO OUT OF TWO LEVEL I LYMPH NODES. (2/2)', which indicates that the cancer has spread to level I lymph nodes but not to level II or III lymph nodes. According to the AJCC staging system for breast cancer, this would correspond to an N2 stage.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
If cancer is present in 1-3 axillary lymph nodes, or in nodes near the breast, the N stage is N1.
If cancer is present in 4-9 axillary lymph nodes, or in nodes around the internal mammary artery, the N stage is N2.
If cancer is present in 10 or more axillary lymph nodes, or in nodes in the infraclavicular region, the N stage is N3.",N2,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.",6.0,450.0,73.0,False
1167,TCGA-D8-A27I.FAB622C2-3E45-4E72-AA36-9530BB830993,0,"page 1 / 1. copy No. 4. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - right breasi with axillary tissues. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the right breast. Macroscopic description: Right breast'sized 19.3 x 14.2 x 5.8 cm removed along with axillary tissues sized 10 x 6 x 3 cm and a skin flap of 16.2 x 6.8 cm. Tumour sized 1.7 x 1.2 x 1.5 cm on the border of outer quadrants, located 6.3 cm from the upper boundary, 0.3 cm from the. base and 1.2 cm from the skin. Microscopic description: Carcinoma lobulare invasivum (classical type) multifocale - NHG2 (3 + 2 +1; 0 mitoses/10 HPF, visual area diameter 0.55 mm). Infiltratio carcinomatosa mamillae. Parenchymal atrophy showing in the glandular tissue. AXILLARY LYMPH NODES. Metastases carcinomatosae in lymphonodis (NO IV/X). Histopathological Diagnosis: Carcinoma lobulare invasivum multifocale mammae dextrae. Invasive multifocal lobular carcinoma of the right breast.3. Metastases carcinomatosae in lymphonodis axillae (NO IV/X). Cancer metastases in axillary lymph nodes. (NHG2, pTIc, pN2a).",BRCA,2,True,"The report indicates the presence of cancer metastases in axillary lymph nodes (pN2a), which means that the N stage is N2 according to the AJCC staging system for breast cancer. The number of positive lymph nodes is not specified in the report, but the N stage is determined by the presence of cancer in the lymph nodes, not the number of negative lymph nodes.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.",N2,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.",7.0,549.0,90.0,True
712,TCGA-AC-A3HN.F0308FC8-D8B4-487F-A072-05E66D01842A,1,"Path No.: Client: (Age: )F. Soc. Sec. #: Pre-Operative/Clinical History. Left breast cancer. Specimen(s) Received. A: LEFT AXILLA SENTINEL LYMPH NODE #1. B: LEFT AXILLA SENTINEL LYMPH NODE #2. C: LEFT AXILLA, ADDITIONAL AXILLARY TISSUE. D: BREAST, MASTECTOMY. Gross Description. Specimen A, received in formalin labeled left axilla sentinel node #1, consists of adipose tissue, 3.5 x 1.5 x 1.3 cm. Sections show a lymph node measuring 2.0 cm in greatest dimension, partially replaced by adipose tissue. The node is. sectioned and entirely submitted labeled (A1, A2). Specimen B, received in formalin labeled left axilla sentinel node #2, consists of adipose tissue, 2.0 x 1.5 x 0.8 cm. Sections show a single lymph node candidate measuring 1.0 cm in greatest dimension. The node is sectioned and. entirely submitted. (B1). Specimen C, received In formalin labeled left axilla additional axiliary tissue, consists of adipose tissue, 4.0 x 2.5 x 2.0 cm. in aggregate. Sections show a single lymph node candidate, 0.3 cm in greatest dimension. (C1). Microscopic Description. The microscopic findings are reflected in the diagnosis rendered. Diagnosis. A). LYMPH NODE, LEFT AXILLARY SENTINEL #1, EXCISION: ONE LYMPH NODE INVOLVED BY METASTATIC MAMMARY CARCINOMA (9 MM, NEGATIVE FOR. EXTRACAPSULAR EXTENSION). B). LYMPH NODE, LEFT AXILLARY SENTINEL #2, EXCISION: ONE LYMPH NODE INVOLVED BY MICROMETASTATIC MAMMARY CARCINOMA (1 MM, NEGATIVE. FOR EXTRACAPSULAR EXTENSION). C). LYMPH NODE; LEFT AXILLARY NONSENTINEL, EXCISION: ONE LYMPH NODE NEGATIVE FOR TUMOR. PHD HISTOLOGY REPORT. Ã©lectronically Reviewed and Signed Out By. Comment. All sentinel node blocks were examined with three 80 um interval H&E stained continu and two 80 um interval cytokeratin. AE1/AE3 immunostains. Positive and negative controls react satisfactorily. FDA required disclaimer: These tests were developed and their performance characteristics determined by. They have not been cleared. or approved by the U.S: Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used. for clinical purposes and should not be regarded as investigational or for research. This laboratory is certified under the Clinical Improvement. Amendments of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing. aquired information for predictive/prognostic markers: 1. Type of specimen fixation and detection system: Tissue is fixed in 10% formalin. Indirect biotin-free detection kit is used. 2. Clones used: ER (clone 6F11) Novocastra; PR (clone PGR 636). DakoCytomation; CD117 (polycional, DakoCytomation); HER2 (clone 485, Ventana, FDA approved); Ki-67 (clone K3, Cell Marque) p53 (cione DO7,. Novocastra), MSH6 (clone BC-44, Biocare), MSH2 (CellMarque clone G219-1129), MLH1 (Cell Marque clone G168-728), PMS2 (clone MRQ-28, Cell. Marque). 3. Criteria for positive results: ER and PR: >1% of tumor cells with nuclear staining; HER2; >30% of cells show complete membrane staining;. p53: >10% of tumor cells with nuclear staining; MMR Proteins: complete absence of tumor nuclear staining. CPT Code(s). A: 88307, 88342,. B: 88307, 88342,. C: 88305. D: 88307, 3260F. Procedures/Addenda. ADDENDUM. Addendum Comment. Gross Description. Specimen D is received in formalin labeled left breast, suture = axillary tail. Specimen type: Mastectomy without axillary tail and without pectoralis muscle. The specimen is oriented. by the surgeon as follows: suture = axillary tail. Specimen size/description: 755 gm. SI 17.5 cm, ML 16.5 cm, AP 6.0 cm. Laterality: Left. Tumor size: 3.0 x 2.5x 2.0 cm. Tumor site: Upper inner quadrant, 10-11 o'clock. Tumor description: Stellate, gritty, tan-white with a central 1.0 x 1.0 x 0.7 cm hemorrhagic ill-defined biopsy. site. Deep margin: 1.5 cm. Nipple/areolar complex: The areola measures 3.5 cm with a centrally retracted 0.6 x 0.6 cm nipple. There is a 5.5. x 4.0 cm area of blue dye superior the nipple/areolar area. PHD HISTOLOGY REPORT. Skin: The ellipse measures 22.0 x 10.5 cm. Lymph node sampling: Not applicable. Other: Sectioning of the surrounding breast tissue shows predominantly yellow lobular adipose. tissue admixed with dense, granular cystic breast tissue. Sections are submitted as follows: (D1,2) Nipple. (D3-7) Mass. (D8, 9) Upper inner quadrant. (D10, 11). Lower inner quadrant. (D12, 13). Lower outer quadrant. (D14, 15). Upper outer quadrant. (D16, 17). Deep margin. EO:vyb. ADDENDUM. Addendum Diagnosis. D) BREAST, LEFT, TOTAL MASTECTOMY: INVASIVE LOBULAR CARCINOMA, 3.0 CM, LOW COMBINED HISTOLOGIC GRADE WITH LOW. PROLIFERATIVE RATE. SURGICAL MARGINS NEGATIVE FOR TUMOR (SEE COMMENT). Addendum Comment. Summary of Pathologic Findings. Breast Carcinoma. Microscopic Examination. Specimen: Total breast. Procedure: Total mastectomy. Lymph node sampling: Sentinel node biopsies. Specimen Integrity: Single intact specimen. Specimen size: 17.5 cm greatest dimension. Laterality: Left. Tumor site: Upper inner quadrant, 9-10 o'clock position per previous diagnostic core biopsy. Size of invasive component: 3.0 cm greatest dimension. Tumor focality: Single focus. PHD HISTOLOGY REPORT. Macroscopic and microscopic extent of tumor: Skin: Uninvolved. Nipple: Paget disease absent. Skeletal muscle: Not present. Histologic type: Invasive lobular carcinoma. Combined histologic grade: Low combined histologic grade with low proliferative rate. Tubule formation: 3. Nuclear pleomorphism: 1. Mitotic count: 1 (field area 0.23 mm2). Total Nottingham score: 5. Lymph-vascular invasion: Absent. Ductal carcinoma in situ: Absent. Extensive intraductal component (EIC): Not applicable. Extent: Not applicable. Lobular carcinoma in situ: Absent. There are focal areas of atypical lobular hyperplasia. Deep margin: Not involved. Lymph nodes: Number of sentinel nodes examined: 2. Total number of nodes examined: 3. Number of nodes with macrometastasis: 1. Number of nodes with micrometastasis: 1. Number of nodes with isolated tumor cells: 0. Size of largest metastatic deposit: 9 mm. Extracapsular extension: Negative. Method of evaluation of sentinei lymph nodes: Three 80 um interval H&E stained sections and two 80 um interval cytokeratin AE1/AE3 immunohistochemical. stains on all sentinel lymph node blocks. TNM stage: pT2 N1a. Anciliary studies (estrogen receptor. progesterone receptor, HER2/neu and Ki-67): Performed on previous specimen,. see report for results. ADDENDUM. PHD HISTOLOGY REPORT. Addendum Comment. Total fixation time in formalin: 31.0 hours.",BRCA,1,True,"The report indicates that there are metastases in the sentinel lymph nodes, specifically in one node with a macrometastasis (9 mm) and one node with a micrometastasis (1 mm). This information satisfies the condition for N1 classification. The number of negative lymph nodes does not affect the N stage in the presence of positive lymph nodes, and other factors such as blue dye, immunohistochemical analysis, and Her-2/NEU analysis do not affect the N stage.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.",8.0,708.0,87.0,True
1463,TCGA-MS-A51U.58D54D1A-3A8D-40DD-A643-846CAF242494,1,"pN: Regional nodes (pN). pN1  total positive nodes). M: Distant metastases (M). M0 (clinically absent). SPECIMEN(S): A: Left sentinel lymph node #1. B: Left sentinel lymph node #2. C: Left breast with axillary lymph nodes. D: Right breast. FINAL DIAGNOSIS: Amended Microscopic Breast Carcinoma Checklist (see below). A. Lymph nodes, ""left sentinel lymph node #1,"" biopsy (including AFS1). - Metastatic carcinoma in one lymph node consistent with breast. primary (1/1). - Metastatic deposit measures 6mm in greatest dimension. - No extracapsular extension. B. Lymph nodes, ""left sentinel lymph node #2,"" biopsy (including BFS1). - Two lymph nodes with no evidence of malignancy (0/2). C. Breast left, modified radical mastectomy. - Invasive lobular carcinoma. - Multifocal with largest tumor 3.2 cm in greatest dimension in. upper outer quadrant; additional foci in retroareolar area and lower. outer quadrant up to 1.1cm in greatest dimension. - Histological grade = 2/3 (score: tubules 3 + nucleus 2 + mitoses 1 =. 6/9) by. criteria. - Mitotic index = <1/hpf (low). - Margins negative for invasive carcinoma (nearest = 1.2 cm; location: deep margin). - Lobular carcinoma in situ (LCIS). - LCIS comprises 5% of total carcinoma in specimen. - Nuclear grade 1/3 by SBR criteria (low). - Margins negative for LCIS. - Metastatic carcinoma present in one of fifteen lymph nodes (1/15). - Tumor deposit measures 4mm in greatest dimension, with no. extracapsular extension. - Nevus cell aggregate also identified. D. Breast, right, prophylactic simple mastectomy. - Fibrocystic changes. - Columnar cell hyperplasia. - Usual ductal hyperplasia. - No evidence of atypical hyperplasia, in situ carcinoma, or invasive. carcinoma. - Skin, nipple, and resection margins unremarkable. COMMENT: This report was amended to correct the number of positive nodes in the. microscopic section, in the ""Breast Carcinoma Checklist."" The Diagnosis. above is unchanged, and is correct, with a total of 2 positive nodes;. that count has been re-verified by review of the microscopic slides. The microscopic checklist section has now been corrected, to indicate. that a total of 2 nodes are positive. The ""N"" stage has thus been. corrected to pN1, as well. This case was discussed with. it a recent. conference, and he in fact pointed out this discrepancy. I informed him. at that time that I would make these corrections to the report. CLINICAL HISTORY: The patient is a. year-old woman with biopsy proven infiltrating. lobular cancer of the left breast (ER+ PR+ Her2/neu-). Operative. procedure: Sentinel lymph node biopsies, left modified radical. mastectomy and right simple mastectomy. GROSS: Received are four fresh containers each labeled with the patient's name. A. The first container is additionally labeled ""A - left. sentinel lymph node #1."" The specimen consists of a 2.1 X 2.06 cm. fragment of pale, yellow-tan, fibrofatty tissue. A single potential. lymph node is identified measuring 1.8 cm in greatest dimension. The. node is serially sectioned and entirely submitted for frozen section. analysis as AFS1. B. The next container is labeled ""B - left sentinel lymph node. #2."" The specimen consists of a 1.8 x 1.5 x 0.4 cm fragment of. yellow-tan, fibrofatty tissue. Two potential lymph nodes are identified. measuring 0.8 X 0.4 cm in greatest dimension. The smaller node is inked. black. The nodes are serially sectioned and entirely submitted for. frozen section analysis as BFS1. The remaining adipose tissue is. submitted for permanent sections in cassette B2. Summary of Sections: BFS1 - two potential sentinel lymph nodes, entirely submitted. B2 - remaining soft tissue. C. The next container is labeled ""C - left breast at 12 o'clock. with left axillary node dissection."" The specimen consists of a 613 gm. modified radical mastectomy with axillary tail. The breast measures 17. cm medial to lateral, 15.5 cm superior to inferior and 3.9 cm. superficial to deep. The attached axillary tail measures 8 X 7.5 x 2. cm. There is an attached ovoid portion of skin measuring 4 X 3.5 cm. with an everted, freely mobile nipple which measures 2.5 X 2.5 cm with. the areolar complex. The deep fascial plane is inked black, the. remaining superior half is inked blue with the remaining inferior half. inked green. The specimen is serially sectioned from medial to lateral. A gray-white, firm, irregularly-bordered mass is identified in the. upper outer quadrant measuring 3.2 X 2.2 X 1.3 cm in greatest dimension. This mass is consistent with a bilobed single mass. However, it could. represent two separate masses. The central area of the mass is. submitted which could represent normal parenchyma in between the two. masses. The mass is 1.8 cm to the deep margin and 2.5 cm to the nipple. A dumbbell-shaped biopsy clip is identified near the medial portion of. the mass. There are firm, indurated possibly calcified areas located. posteriorly to the nipple. The axillary tail is dissected to reveal 19. potential lymph nodes ranging in size from 0.3 to 2.6 cm in greatest. dimension. The nodes are entirely submitted. The specimen is sectioned. and laced in formalin. Summary of Sections: C1 - middle portion of mass. C2-C3 - medical portion of tumor. C4 - lateral portion of tumor with deep margin. C5 - lateral portion of tumor. C6 - representative upper inner quadrant. C7 - representative upper outer quadrant. C8 - representative lower outer quadrant. C9 - representative lower inner quadrant. C10 - representative retroareolar areas of induration. C11 - nipple. C12 - one potential lymph node, bisected, entirely submitted. C13 - one potential lymph node, bisected, entirely submitted. C14 - one potential lymph node, bisected, entirely submitted. C15 - six potential lymph nodes, submitted intact. C16 - six potential lymph nodes, submitted intact. C17 - four potential lymph nodes, submitted intact. D. The next container is additionally labeled ""D - right. breast."" The specimen consists of a 510 gm simple mastectomy measuring. 20 X 17x2.8 cm. Attached roughly ovoid portion of skin measures 3.9 X. 2.5 cm which is pale tan without lesions identified. The attached. nipple is everted and freely mobile and measures 2.7 x 2.0 cm with the. areolar complex. The deep fascial plane is inked black. The remaining. specimen is inked blue. The specimen is unoriented. It is serially. sectioned to reveal yellow-tan, lobulated parenchyma with interspersed,. dense and gray-white fibrosis and fibrocystic change. A small 0.6 cm. area of hemorrhage is identified located at the periphery. Masses or. lesions suspicious for malignant process are not grossly identified. The specimen is arbitrarily divided into quadrants and representative. sections are submitted. The specimen is sectioned and placed in. formalin . Summary of Sections: D1 nipple. D2-D3 - representative of quadrant 1. D4-D5 - representative of quadrant 2. D6-D7 - representative of quadrant 3. D8-D9 - representative of quadrant 4. INTRAOPERATIVE CONSULTATION: FROZEN SECTION DIAGNOSIS: AFS1: Left sentinel lymph node #1 - ""Metastatic breast carcinoma in. one lymph node."". FROZEN SECTION DIAGNOSIS: BFS1: Left sentinel lymph node #2 - ""Two lymph nodes with no evidence. of malignancy."". MICROSCOPIC: Microscopic examination is performed. Permanent sections confirm the. frozen section diagnoses. Breast carcinoma checklist: Operative procedure: mastectomy. Specimen size: 17 x 15.5 X 3.9 cm. Specimen integrity: Intact. Tumor location: Upper outer quadrant, lower outer quadrant, and. sub-areolar. Tumor focality: Multifocal. Tumor size: 3.2 x 2.2x1.3 cm, with other nodules as large as 1.1 cm. Tumor extent: tumor limited to breast, without invasion of skin or. muscle. Tumor type: Infiltrating lobular carcinoma. Histologic grade: 2/3 (score: tubules 3 + nucleus 2 + mitoses 1 = 6/9). by ESBR criteria. Mitotic index: <1/hpf (low). Lymphovascular invasion: Present. Perineural invasion: Absent. Margins of invasive carcinoma: Negative (nearest = 12 mm; location;. deep). In situ carcinoma: Present; Lobular carcinoma in situ (LCIS). Extent of in situ carcinoma: Non-extensive, comprises 5% of total. carcinoma. Grade of in situ carcinoma: 1/3 by SBR criteria (low). Margins of in situ carcinoma: Negative. Paget's disease: Absent. Number of Lymph nodes examined: 18. Number of Lymph nodes positive: 2 (1/3 sentinel nodes, and 1/15. nodes from mastectomy). Size of largest metastatic focus: 6 mm. Extracapsular extension: Absent. Receptor studies (performed on prior biopsy). ER +. PR:+. her2/neu:-. AJCC Cancer Staging: pT: Primary tumor (pT). pT2.",BRCA,1,True,"The report states that there are 2 positive lymph nodes out of 18 examined (1/3 sentinel nodes, and 1/15 nodes from mastectomy). This information indicates that the N stage is N1, as per the rule: 'The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.'","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in clinically apparent ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in clinically apparent ipsilateral internal mammary nodes in the presence of 1 or more positive axillary lymph nodes, or in more than 2 ipsilateral supraclavicular lymph nodes.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.",8.0,708.0,75.0,False
1171,TCGA-D8-A27N.69007BC0-E1DF-4E68-BA6A-352F6A12F233,1,"page 1 / 1. copy No. 5. Examination: Histopathological examination. Examination Nc. Age: -. Gender: F. Material: Multiple organ resection - right breast. Unit in charge: (. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the right breast - status post biopsy, contents of the right axillary cavity. Macroscopic description: Right breast.ised 20 x 17.5 x 6 cm removed without axillary tissues and with a skin flap of 15.5 x 5 cm. Weight 1200. g. Tumour sized 3.0 x 3.2 x 2.5 cm found in the upper outer quadrant, located 4 cm from the upper boundary,. 0.8 cm from the base and 1.3 cm from the skin. Microscopic description: Carcinoma ductale invasivum - NHG2 (3 + 2 + 2/16 mitoses/10 HPF - visual area: 0.55mm). Foci of carcinoma ductale in situ DCIS found within and outside the tumour (solid and cribrate type with medium and. high nuclear atypia, comedo necrosis and calcinations, 40% of the tumour). Glandular texture showing parenchymal atrophy. AXILLARY LYMPH NODES: Lymphonodulitis reactiva (No II). Histopathological Diagnosis: Carcinoma ductale invasivum et ductale in situ. Invasive ductal carcinoma and carcinoma in situ of the right breast. I. Metastases carcinomatosae in lymphonodis axillae (No IV/XIX) (NHG2, pT2, pN2a). dr. Compliance validated by: dr.",BRCA,2,True,"The report mentions 'Metastases carcinomatosae in lymphonodis axillae (No IV/XIX)' which indicates the presence of cancer metastases in axillary lymph nodes. According to the rules provided, the presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3. More specifically, N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes. Therefore, the N stage for this report is N2.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.",N2,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.",10.0,1068.0,80.0,True
1033,TCGA-BH-A0HL.79DAEAE5-A177-40E0-9BFC-54DC9F544764,1,"FINAL DIAGNOSIS: PART 1: RIGHT AXILLARY SENTINEL LYMPH NODE #1, EXCISION -. LYMPH NODE WITH METASTATIC DUCTAL CARCINOMA, PAPILLARY TYPE, EXHIBITING EXTRACAPSULAR. SPREAD MEASURING 0.3 CM (See comment). PART 2: BREAST, RIGHT; MODIFIED RADICAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA. PAPILLARY TYPE, ARISING IN A BACKGROUND OF INTRACYSTIC. PAPILLARY CARCINOMA. B. NOTTINGHAM GRADE 2 (NUCLEAR 2, TUBULES 3, MITOSIS 1; TOTAL NOTTINGHAM SCORE 6/9). C. TUMOR SIZE IS 3 X2.5X2.4CM. D. DUCTAL CARCINOMA IN SITU, PAPILLARY AND MICROPAPILLARY, NUCLEAR GRADE 2, PRESENT. ADJACENT AND AWAY FROM THE TUMOR, AND ACCOUNTING FOR 5% OF TUMOR MASS. E. NO ANGIOLYMPHATIC IDENTIFIED. F. ALL MARGINS ARE FREE OF THE INVASIVE AND IN SITU CARCINOMA. CLOSEST MARGIN IS THE. ANTERIOR MARGIN (SKIN), WHICH IS 1.2 CM FROM THE TUMOR. G. ORGANIZING HEMATOMA WITH GRANULATION TISSUE, HEMOSIDERIN-LADEN MACROPHAGES, FAT. NECROSIS AND FOREIGN BODY GIANT CELL REACTION (BIOPSY SITE). H. NIPPLE AND SKIN WITH DUCT ECTASIA AND HEMOSIDERIN-LADEN MACROPHAGES WITHIN THE LUMINA. OF SOME OF THE LACTIFEROUS DUCTS. I. J. ONE OF SIXTEEN AXILLARY SENTINEL LYMPH NODES WITH METASTATIC DUCTAL CARCINOMA (1/16). FIBROCYSTIC CHANGES. CASE SYNOPSIS: SYNOPTIC - PRIMARY IVVASIVE CARCINOMA OF BREAST. LATERALITY: Right. PROCEDURE: Modified radical mastectomy. Lower outer quadrant. Lower inner quadrant. SIZE OF TUMOR: Maximum dimension invasive component: 3 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR AGGREGATE SIZE: Sum of the sizes of multiple invasive tumors: 3 cm. TUMOR TYPE (invasive component): Papillary carcinoma. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 3. Mitotic activity score: 1. Total Nottingham score: 6. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: Yes, benign zones. TUMOR TYPE, IN SITU: Papillary. DCIS admixed and outside of invasive carcinoma component. Percent of tumor occupied by in situ component: 5 %. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: SURG MARGINS INVOLVED BY IN SITU COMPONENT: PAGET'S DISEASE OF NIPPLE: LYMPH NODES POSITIVE: 2. LYMPH NODES EXAMINED: 17. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: ONLY KERATIN POSITIVE CELLS ARE PRESENT: SIZE OF NODAL METASTASES: Diameter of largest lymph node metastasis: 3 mm. LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: METASTASES TO IPSILATERAL INTERNAL MAMMARY LYMPH NODE (IF APPLICABLE): SKIN INVOLVED (ULCERATION): NON-NEOPLASTIC BREAST TISSUE: FCD. T STAGE, PATHOLOGIC: pT2. N STAGE, PATHOLOGIC: pN1. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: unknown. PROGESTERONE RECEPTORS: unknown. HER2/NEU: unknown.",BRCA,1,True,"The report indicates that one out of sixteen axillary sentinel lymph nodes has metastatic ductal carcinoma, which falls under the N1 classification in the AJCC staging system for breast cancer. The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes, and the presence of metastases in 1-3 axillary lymph nodes determines the N stage as N1.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.",11.0,1177.0,95.0,True
562,TCGA-A2-A4RY.2D6815B5-7704-4D67-93D1-78EDD924F131,2,"Specimen. ) Status: Sp type: SURGICAL P. M.D. PREOPERATIVE DIAGNOSIS. BREAST CANCER, BENIGN MAMMARY DYSPLASIA. OPERATION PERFORMED. DOCTOR (S) : PROCEDURE: MASTECTOMY MODIFIED RADICAL/TOTAL MASTECTOMY. TISSUE REMOVED. A. RIGHT AXILLARY LYMPH NODE LEVEL 2. B. RIGHT AXILLARY LYMPH NODE LEVEL 3. C. LEFT MASTECTOMY STITCH AT. D. RIGHT MODIFIED RADICAL MASTECTOMY STITCH AT. GROSS DESCRIPTION. RECEIVED IN 4 PARTS. PART A RECEIVED LABELED. RIGHT AXILLARY LEVEL 2 LYMPH. NODES IS A NODULAR PORTION OF YELLOW FATTY TISSUE MEASURING 3.7 X 2.2 X. 0.7 CM IN GREATEST DIMENSION. FOUR FIRM OVOID STRUCTURES ARE IDENTIFIED. MEASURING FROM 0.4 TO 1 CM IN GREATEST DIMENSION. THE LARGER NODES ARE. EACH SECTIONED AND GROSSLY POSITIVE. ONE-HALF OF EACH OF THESE IS. SUBMITTED ALONG WITH THE UNSECTIONED SMALLER NODE LABELED A. THE. REMAINING NODAL TISSUE IS SUBMITTED PER CLINICAL BREAST CARE PROJECT. RESEARCH PROTOCOL LABELED P1-P3. PART B RECEIVED LABELED. RIGHT AXILLARY LEVEL 3 LYMPH. NODE IS A FIRM 0.8 CM IN GREATEST DIMENSION NODULE AND AN IRREGULAR. PORTION OF NODULAR YELLOW FATTY TISSUE MEASURING 6 X 1.5 X 0.7 CM. FIVE. FIRM OVOID STRUCTURES ARE IDENTIFIED IN THIS PORTION OF FATTY TISSUE. THREE OF THE NODULES ARE SUBMITTED UNSECTIONED LABELED B1. ONE-HALF. FROM 2 SEPARATE GROSSLY POSITIVE NODES ARE SUBMITTED IN B2 WITH THE. REMAINING TISSUE FROM THESE 2 NODES SUBMITTED AS P4. THE LARGEST NODE. MEASURING 1.4 CM IN GREATEST DIMENSION IS GROSSLY FOCALLY POSITIVE. THIS. IS SUBMITTED BISECTED AS B3. PART C RECEIVED LABELED. LEFT MASTECTOMY STITCH AT 12. O'CLOCK IS A 1310 GRAM SIMPLE MASTECTOMY MEASURING 23 CM FROM MEDIAL TO. LATERAL, 23.5 CM FROM SUPERIOR TO INFERIOR, AND UP TO 5.5 CM FROM. Specimen. Sp type: GICAL P. M.D. GROSS DESCRIPTION. ANTERIOR TO DEEP. THE NIPPLE IS UNREMARKABLE WITHIN A 14 x 5 CM SKIN. ELLIPSE. A SUTURE DENOTES 12 O'CLOCK. THE ANTERIOR ASPECT IS MARKED. WITH BLUE INK, THE DEEP MARGIN WITH BLACK. SECTIONING REVEALS THE. CENTRAL 50% OF THE SPECIMEN TO CONSIST OF DENSE TAN FIBROUS TISSUE. THIS. IS SURROUNDED BY A PERIMETER OF YELLOW FATTY TISSUE. NO MASSES ARE. IDENTIFIED. REPRESENTATIVE SECTIONS ARE SUBMITTED AS. FOLLOWS: C1--NIPPLE, C2--CENTRAL DEEP MARGIN, C3 AND 4--UPPER OUTER QUADRANT, C5. AND 6--UPPER INNER QUADRANT, C7 AND 8--LOWER INNER QUADRANT, C9 AND. 10--LOWER OUTER QUADRANT. ADDITIONALLY WITHIN THE CONTAINER AND. INCLUDED THE WEIGHT ARE ADDITIONAL MULTIPLE IRREGULAR FRAGMENTS OF. YELLOW-RED FATTY TISSUE IN AGGREGATE MEASURING 10 X 10 x 2.3 CM. SECTIONING REVEALS BLAND YELLOW FATTY TISSUE AND REPRESENTATIVE SECTIONS. ARE SUBMITTED LABELED C11 THROUGH 13. NOTE: MIRROR IMAGE SECTIONS OF THE NIPPLE ARE SUBMITTED AS P15 AND. MIRROR IMAGE SECTIONS TO C3, C5, C7, AND C9 ARE SUBMITTED FROZEN IN OCT. PER CLINICAL BREAST CARE PROJECT RESEARCH PROTOCOL. PART D RECEIVED LABELED. RIGHT MODIFIED RADICAL. MASTECTOMY STITCH AT 12 O'CLOCK IS A 1460 GRAM RIGHT MODIFIED RADICAL. MASTECTOMY. THE MASTECTOMY PORTION MEASURES 24.5 CM FROM MEDIAL TO. LATERAL, 26 CM FROM SUPERIOR TO INFERIOR, AND UP TO 6.5 CM FROM ANTERIOR. TO POSTERIOR. THE AXILLARY PORTION MEASURES 10 x 9 x 2.5 CM. THE. ANTERIOR MARGIN IS MARKED BLUE. THE DEEP IS MARKED BLACK. THE NIPPLE. IS UNREMARKABLE AND SITS IN THE MORE SUPERIOR PORTION OF THE SKIN. ELLIPSE. THE SKIN ELLIPSE MEASURES 14 x 5.5 CM. THE 12 O'CLOCK SUTURE. IS JUST TO THE MEDIAL SIDE OF THE AREOLA. THE AXILLARY TAIL IS REMOVED. AND RED INK IS PLACED IN THIS AREA TO INDICATE THAT IT IS NOT TRUE. MARGIN. UPON A QUICK PALPATION OF THE AXILLARY TAIL THREE ARE 3. PROMINENT STRUCTURES. THE 1ST IS A 0.8 CM IN GREATEST DIMENSION LYMPH. NODE WHICH IS GROSSLY NEGATIVE AND IS SUBMITTED BISECTED AS D1. THE 2ND. IS A 2.5 CM GROSSLY NEGATIVE NODAL STRUCTURE SUBMITTED BISECTED AS D2. THE 3RD STRUCTURE IS A 3.8 CM IN GREATEST DIMENSION GROSSLY POSITIVE. LYMPH NODE OF WHICH ONE FULL CROSS SECTION IS SUBMITTED IN D3 AND 4. A. COIL CLIP IS IDENTIFIED AND THE AREA OF THE CLIP IS SUBMITTED IN D5. THIS IS THE SAME NODE AS D3 AND 4. PORTIONS OF THIS LARGEST NODE ARE. ALSO SUBMITTED IN P5 AND 6. SECTIONING REVEALS THE CENTRAL PORTION OF. THE BREAST TO CONSIST OF DENSE TAN FIBROUS TISSUE AND THIS EXTENDS TO AN. ILL-DEFINED GRAY-TAN MASS AT 9 O'CLOCK WHICH MEASURES 5.5 CM FROM MEDIAL. TO LATERAL, 8 CM FROM SUPERIOR TO INFERIOR BY PALPATION, AND 4.5 CM FROM. ANTERIOR TO POSTERIOR. GROSSLY IT IS 1 CM FROM BOTH THE ANTERIOR AND. DEEP MARGIN. SECTIONS ARE SUBMITTED AS FOLLOWS: D6--NIPPLE, D7 THROUGH. D9--SECTIONS OF DEEP MARGIN BENEATH LESION, D10 THROUGH D14--A CONTINUOUS. SECTION OF THE LESION FROM SUPERIOR TO INFERIOR WHERE THE RED ENDS ARE. Specimen. eq#: SP type: SURGICAL P. .D. GROSS DESCRIPTION. THE AREA WHERE THE ONE STRIP WAS SEPARATED FROM THE ADJACENT SECTION,. 015--SECTION OF THE FAR LATERAL PORTION OF THE GROSS LESION, D16--SECTION. FROM THE FAR MEDIAL PORTION OF THE GROSS LESION, D17--TISSUE DEEP TO THE. 5 CROSS SECTIONS, 018--TISSUE ANTERIOR TO TE 5 CROSS SECTIONS,. D19--RANDOM SECTION OF LESION FROM THE MIDPORTION, D20--RANDOM TUMOR. INFERIOR-EDG D21--UPPER INNER QUADRANT 2. CM.EROM GROSS TUMOR,. D22--UPPER OUTER QUADRANT 3 CM FROM GROSS TUMOR, D23--LOWER OUTER. QUADRANT 3 CM FROM GROSS TUMOR, D24--LOWER INNER QUADRANT 5 CM FROM GROSS. TUMOR. FURTHER EXAMINATION OF THE AXILLARY TAIL: EIGHTEEN (18) ADDITIONAL. NODAL STRUCTURES ARE IDENTIFIED. THESE ARE SUBMITTED AS FOLLOWS: D25-6. NODES NOT SECTIONED, D26--ONE-HALF OF 2 GROSSLY POSITIVE LYMPH NODES. PLUS 1 GROSSLY FAT REPLACED LYMPH NODE, BISECTED, D27--4 NODES, EACH. BISECTED, D28--2 NODES, EACH BISECTED, D29--3 NODES, EACH BISECTED. SECTIONS PER CLINICAL BREAST CARE RESEARCH PROTOCOL ARE SUBMITTED FROM. THE LYMPH NODE WITH THE CLIP LABELED P5 AND P6; TWO OF THE GROSSLY. POSITIVE LYMPH NODES IN CASSETTE D26 AS P16; AND SECTIONS OF THE TUMOR. AS P7 THROUGH P14 WITH MIRROR IMAGE SECTIONS FROZEN IN OCT OF P7, P8,. p9, AND 013 AS WELL AS TISSUE FROZEN IN OCT AS MIRROR IMAGE TO THE. NIPPLE (D6) AND OF THE RANDOM QUADRANT SECTIONS (D21 THROUGH D24). COMMENT: THIS SPECIMEN EXCEEDS THE MAXIMUM CAP/ASCO. GUIDELINE OF 48 HOURS FORMALIN FIXATION. PATH PROCEDURES. PROCEDURES: 88305/2, 88307, 88309, A BLK, B BLK/3, C BLK/13, D BLK/29. FINAL DIAGNOSIS. PART A RIGHT AXILLARY LEVEL 2 LYMPH NODE SAMPLING: METASTATIC. CARCINOMA CONSISTENT WITH LOBULAR CARCINOMA OF PRIMARY BREAST ORIGIN. INVOLVING 4 OF 4 LYMPH NODES WITH THE TUMOR REPLACING 80-90% OF THE. CELLS IN EACH NODE AND THE LARGEST FOCUS OF TUMOR SPANNING A DISTANCE OF. APPROXIMATELY 9 MM. PART B RIGHT AXILLARY LEVEL 3 LYMPH NODE SAMPLING: METASTATIC 6/16 LN (level 3). Specimen: eceived: ) Status: aq#. Sp type: SURGICAL P. M.D. FINAL D1AGNOSIS. CARCINOMA IDENTIFIED IN 6 OF 6 LYMPH NODES. PART C LEFT MASTECTOMY: SKIN AND FATTY BREAST TISSUE WITH FOCAL. FIBROCYSTIC CHANGES PRESENT. NO EVIDENCE OF MALIGNANCY OR ATYPIA. PART-D RIGHT MODIFIED RADICAL MASTECTOMY: MULTICENTRIC IN SITU AND. INFILTRATING LOBULAR CARCINOMA OF THE PLEOMORPHIC TYPE, NUCLEAR GRADE. 2-3 OF 3 WITH A LOW MITOTIC INDEX WITH DOCUMENTED MICROSCOPIC EVIDENCE. OF TUMOR SPANNING A DISTANCE OF AT LEAST 78 MM IN A SUPERIOR TO INFERIOR. DIRECTION. THE TUMOR WAS 8 MM FROM THE CLOSEST DEEP MARGIN. METASTATIC. CARCINOMA IDENTIFIED IN 8 OF 20 AXILLARY LYMPH NODES WITH THE LARGEST. FOCUS OF TUMOR SPANNING A DISTANCE OF 20 MM AND FOCAL MICROSCOPIC. PERINODAL SOFT TISSUE INVASION PRESENT. M.D.",BRCA,3,True,"The report states that metastatic carcinoma was identified in 6 out of 6 lymph nodes from right axillary level 2 and level 3. This indicates that the N stage is at least N1, as it involves axillary lymph nodes. Since there are 6 positive lymph nodes, the N stage is N2, as N2 is determined by the presence of metastases in 4-9 axillary lymph nodes.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.",N2,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.",12.0,1346.0,93.0,True
671,TCGA-A8-A09D.C4A1A482-6AE5-4807-BA05-C73AC0898546,1,"Diagnosis: Poorly differentiated invasive ductal carcinoma (tumor diameter: 2.2 cm) with focal. intraductal components. Concluding tumor classification: NOS, G III, pT2N1aLOVORO. (compare E. no. xxxx).",BRCA,1,True,"The report indicates a diagnosis of invasive ductal carcinoma with a tumor diameter of 2.2 cm and a pathologic T stage of T2 (pT2). The N stage is specified as N1a, which means there is metastasis in 1-3 axillary lymph nodes (N1). The N1a subclassification does not affect the primary N stage determination.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.",12.0,1346.0,100.0,True
801,TCGA-AO-A0JF.D58E5D64-B5B9-4487-8E46-225AE3617C14,0,"Clinical Diagnosis & History: 1.2. cm invasive duct carcinoma left breast upper outer quadrant (on core. biopsy) for left wide excision SLNB, possible left ALND. Specimens Submitted: 1: SP: Sentinel node #1 level one left axilla (fs). 2: SP: Sentinel node #2 level one left axilla (fs). 3: SP: Excision of tumor left breast two o'clock. 4: SP: Superior margin left breast. 5: SP: Medial margin left breast. 6: SP: Inferior margin left breast. 7: SP: Lateral margin left breast. 8: SP: Non-sentinel node left axilla. 9: SP: Posterior margin left breast. 10: SP: Levels one and two left axillary contents. DIAGNOSIS: 1. LYMPH NODE, SENTINEL #1, LEVEL I, LEFT AXILLA; EXCISION: - METASTATIC ADENOCARCINOMA IN ONE LYMPH NODE (1/1). THE METASTATIC FOCUS MEASURES 5 MM IN GREATEST DIMENSION. - NEGATIVE FOR EXTRACAPSULAR EXTENSION. 2. LYMPH NODE, SENTINEL #2 LEVEL I LEFT AXILLA; EXCISION: METASTATIC ADENOCARCINOMA IN ONE LYMPH NODE (1/1). THE METASTATIC FOCUS MEASURES 6 MM IN GREATEST DIMENSION. - EXTRACAPSULAR EXTENSION (>2MM) IS PRESENT. 3. BREAST, LEFT, 2 O'CLOCK; EXCISION: - INVASIVE DUCTAL CARCINOMA, NOS TYPE, HISTOLOGIC GRADE II/III. (MODERATE TUBULE FORMATION), NUCLEAR GRADE I/III (SLIGHT OR NO VARIATION IN. SIZE AND SHAPE), MEASURING 2.0 CM IN LARGEST DIMENSION MICROSCOPICALLY. - DUCTAL CARCINOMA IN SITU (DCIS) IS ALSO IDENTIFIED, SOLID TYPE WITH LOW TO. INTERMEDIATE NUCLEAR GRADE. - THE DCIS CONSTITUTES LESS THAN OR EQUAL TO 25% OF THE TOTAL TUMOR MASS,. AND IS PRESENT ADMIXED WITH THE INVASIVE COMPONENT. - CALCIFICATIONS ARE PRESENT IN THE INVASIVE CARCINOMA ONLY. FOCAL VASCULAR INVASION IS PRESENT. FOR SURGICAL MARGINS SEE PARTS 4-7, AND 9. THE NON-NEOPLASTIC BREAST TISSUE THE NON-NEOPLASTIC BREAST TISSUE. SHOWS BIOPSY SITE CHANGES. RESULTS OF 108, PR, HER2-NEU) ARE AS FOLLOWS: ESTROGEN RECEPTOR. 95% nuclear staining with inhensity. PROGESTERONE RECEPTOR. 70% nucl. ith moderate intensity. HER2. Negative (1+). (<5% of invasive tumor cells exhibit weak complete membranous staining;. Uniformity of staining: absent;. Homogeneous, dark circumferential pattern: absent). Comment: Controls are satisfactory. PATHWAY anti-HER-2/neu is an. FDA-approved rabbit monoclonal primary antibody (clone 485) directed against. the internal domain of the c-erbB-2 oncoprotein (HER2) for. immunohistochemical detection of HER2 protein overexpression in breast. cancer tissue routinely processed for histologic evaluation. The HER2 test. results are reported in accordance with the ASCO/CAP guideline. recommendations for HER2 testing in breast cancer (J Clin Oncol 2007;. 25 (1) :118-145) The ER and PR rabbit monoclonal antibodies are also FDA. approved. 4. BREAST, LEFT, SUPERIOR MARGIN; EXCISION: - BENIGN BREAST TISSUE WITH PROLIFERATIVE FIBROCYSTIC CHANGES. 5. BREAST, LEFT, MEDIAL MARGIN; EXCISION: BENIGN BREAST TISSUE WITH FOCAL USUAL DUCTAL HYPERPLASIA. 6. BREAST, LEFT, INFERIOR MARGIN; EXCISION: - BENIGN BREAST TISSUE WITH FOCAL USUAL DUCTAL HYPERPLASIA. 7. BREAST, LEFT, LATERAL MARGIN; EXCISION: - BENIGN BREAST TISSUE WITH FOCAL USUAL DUCTAL HYPERPLASIA. LYMPH NODE, NON-SENTINEL, LEFT AXILLA; EXCISION: - ONE BENIGN LYMPH NODK (0/1). 9. BREAST, LEFT, POSTERIOR MARGIN; EXCISION: BENIGN BREAST TISSUE PREDOMINANTLY COMPOSED OF FIBROADIPOSK. ELEMENTS. SKELETAL MUSCLE TISSUE ALSO PRESENT. 10. LYMPH NODES, LEFT AXILLARY CONTENTS, LEVELS ONE AND TWO, EXCISION: ELEVEN BENIGN LYMPH NODES (0/11). Some of the mmunohistochemistry and. :ests were developed and their. performance characteristics were determined by. They have not been cleared or approved by the US FOO ana urug. Administration. The FDA has determined that such clearance or approval is. not necessary. These tests are used for clinical purposes. They should not. be regarded as investigational or for research. This laboratory is certified. under the Clinical Laboratory Improvement Amendments of 1988 (CLIA , 88) as. qualified to perform high complexity clinical laboratory testing. I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES - (AND/OR OTHER MATERIAL) . AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Gross Description: 1. 1) The specimen is received fresh for frozen labeled, ""Sentinel node #1,. level 1, left axilla"", and consists of one fatty lymph node measuring 2.5 x. 1.5 x 1.5 cm, which is trisected and representatively submitted. A portion. of tissue sent to TPS. The remaining lymph node is submitted to permanent. Summary of sections: fac -- lymph node frozen section control. RS- remaining lymph node. 2) The specimen is received fresh for frozen labeled, ""Sentinel node #2,. level 1, left axilla"", and consists of one fatty lymph node measuring 2.4 x. 1.5 x 1.2 cm, which is trisected and representatively submitted. A portion. of tissue sent to TPS. The remaining lymph node is submitted to permanent. Summary of sections: fsc -- lymph node frozen section control. RS- remaining lymph node. 3) The specimen is received unoriented and fresh, labeled ""excision of. tumor, left breast two o' clock"" and consists of a piece of fibrofatty. breast tissue measuring 5.2 x 5.0 x 2.3 cm. The specimen is entirely inked. black. Serial sectioning reveals a spiculated, white mass measuring 1.2 x. 1.2 x 1.1 cm. Sectioning through the remaining breast tissue reveals yellow. adipose tissue. A clip is identified. The tumor is entirely submitted and. the remaining tissue is representatively submitted and a small portion is. given to TPS. Summary of sections: MT - tumor and closest tissue edge. T - tumor (clip was in block 2). SS - serial sections remaining tissue. 4) The specimen is received fresh, labeled ""superior margin left breast"" and. consists of a piece of fibrofatty breast tissue measuring 5.0 x 3.0 cm, and. 1.3 cm thick. A stitch marks the new margin of excision, which is inked. black. The tissue is serially sectioned and entirely submitted. Summary of sections: u - sequential sections. 5) The specimen is received fresh, labeled ""medial margin left breast"" and. consists of a piece of fibrofatty breast tissue measuring 3.2 x 2.5 cm, and. 1.2 cm thick. A stitch marks the new margin of excision, which is inked. black. The tissue is serially sectioned and entirely submitted. Summary of sections: u - sequential sections. 6) The specimen is received fresh, labeled inferior margin left breast"" and. consists of a piece of fibrofatty breast tissue measuring 4.0 x 3.0 cm, and. 1.3 cm thick. A stitch marks the new margin of excision, which is inked. black. The tiasue is serially sectioned and entirely submitted. Summary of sections: u - sequential sections. 7) The specimen is received fresh, labeled ""lateral margin left breast"" and. consists of a piece of fibrofatty breast tissue measuring 4.4 x 2.8 cm, and. 1.2 cm thick. A stitch marks the new margin of excision, which is inked. black. The tiasue is serially sectioned and entirely submitted. Summary of sections: u - sequential sections. 8) The specimen is received in formalin, labeled ""Non-sentinel node left. axilla"" and consists of a single pink tan fatty lymph node measuring 0.9 cm. The lymph node is bisected and entirely submitted. Summary of sections: BLN-bisected lymph node. 9). The specimen is received fresh, labeled ""posterior margin, left breast"". and consists of a piece of fibrofatty breast tissue measuring 4.2 x 3.0 cm,. and 0.5 cm thick. The specimen is unoriented, entirely inked black. sectioned and submitted in its entirety. Summary of sections: SS - sequential sections. 10) The specimen is received fresh labeled ""levels one and two left axillary. contents"" It consists of a fragment of yellow adipose tissue measuring 12.5. x 10.5 x 2.8 cm. The levels are not designated. Numerous lymph nodes are. identified ranging in size from 0.4 cm up to 2.0 cm, and all are submitted. Summary: RLN-representative lymph node (multiple). ARLN-additional representative lymph nodes. LN-lymph nodes. Summary of Sections: Part 1: SP: Sentinel node #1 level one left axilla (fs). Block. Sect. Site. PCs. 1. fsc. 1. 1. rs. 1. Part 2: SP: Sentinel node #2 level one left axilla (fs). Block. Sect. Site. PCs. 1. fsc. 1. 1. rs. 1. Part 3: SP: Excision of tumor left breast two o'clock. Block. Sect. Site. PCs. 1. MT. 1. 1. SS. 1. 2. T. 2. Part 4: SP: Superior margin left breast. Block. Sect. Site. PCs. 6. u. 6. Part 5: SP: Medial margin left breast. Block. Sect. Site. PCs. 6. u. 6. Part 6: SP: Inferior margin left breast. Block. Sect. Site. PCs. 6. u. 6. Part 7: SP: Lateral margin left breast. Block. Sect. Site. PCs. 6. u. 6. Part 8: SP: Non-sentinel node left axilla. Block. Sect. Site. PCs. 1. bln. 1. Part 9: SP: Posterior margin left breast. Block. Sect. Site. PCs. 6. ss. 6. Part 10: SP: Levels one and two left axillary contents. Block. Sect. Site. PCs. 5. arln. 5. 5. LN. 12. 4. RLN. 4. Intraoperative Consultation: Note: The diagnoses given in this section pertain only to the tissue sample. examined at the time of the intraoperative consultation. 1). FROZEN SECTION DIAGNOSIS: SP: Sentinel node #1 level one left. axilla (fs) : Metastatic ductal carcinoma (1/1). PERMANENT DIAGNOSIS: SAME. 2). FROZEN SECTION DIAGNOSIS: SP: Sentinel node #2 level one. left axilla (fs) Metastatic ductal carcinoma with extranodal extension. (1/1). PERMANENT DIAGNOSIS: SAME. Note: The diagnoses given in this section pertain only to the tissue sample. examined at the time of the intraoperative consultation. 1). FROZEN SECTION DIAGNOSIS: SP: Sentinel node #1 level one left. axilla (fs) : Metastatic ductal carcinoma (1/1). PERMANENT DIAGNOSIS: SAME. 2). FROZEN SECTION DIAGNOSIS: SP: Sentinel node #2 level one. left axilla (fs) : Metastatic ductal carcinoma with extranodal extension. (1/1). PERMANENT DIAGNOSIS: SAME.",BRCA,1,True,"The report indicates the presence of metastatic adenocarcinoma in one sentinel lymph node for level one of the left axilla (1/1) for both nodes 1 and 2, with the largest metastatic focus measuring 6 mm in greatest dimension in node 2, and extracapsular extension present in node 2. This satisfies the criteria for N1 classification, which is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.",13.0,1448.0,96.0,True
1147,TCGA-D8-A1XL.762963FB-3D8C-4616-8C8C-0CD3E45FD243,1,"page 1 / 2. conv No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: 1. lesion excision - from the left breast outer upper quadrant. Unit in charge: Central C. Expected time of examination: 5 working days. Clinical diagnosis: and left axillary nodes in one block. Results of immunohistochemicarexaminanon: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in over 75% of neoplastic cell. nuclei. HER2 protein stained with HercepTestâ¢M by DAKO. Score = 2+, FISH verification recommended. Macroscopic description: Partial resection of breast - outer upper quadrant. Breast segment sized 8.4 x 7.4 x 2.6 cm with a 2.8 x 6.8 cm skin flap and axillary tissue sized 8 x 9 x 2, no RTG. Tumour cross section sized 3.0 x 1.8 x 2.9 cm. Margin: to the base 0.1 cm, to the front skin surface 0.2 cm, to the sternum 3.5 cm, to the axilla 2.2 cm, to the shoulder 1.3 cm,. lower 0.8 cm. Microscopic description: Carcinoma ductale invasivum NHG3 (3 + 2 + 3/19 mitoses/10 HPF - visual area of 0.55 mm). Largest dimension of the lesion 3.0 cm. Minimum margin at the base side < 0.05 cm. The other margins as in macroscopic description. Lymph nodes: Metastases carcinomatosae in lymphonodis (No II / XIII). Infiltratio carcinomatosa capsulae lymphonodorum et telae adiposae perinodalis. Histopathological diagnosis: Carcinoma ductale invasivum NHG3, pT2, pN1a. Invasive ductal carcinoma of the left breast. Compliance validated t. Examination: Intraoperative examination. page 2 / 2. Fyamination No.: Results of immunohistochemical. examination: RESULT OF HER2/neu GENE AMPLIFICATION with the FISH method by Path Vysion HER2 DNA Probe Kit. HER-2 GENE AMPLIFICATION NOT FOUND.",BRCA,1,True,"The report indicates the presence of metastases in 1-3 axillary lymph nodes (pN1a), which corresponds to the N1 stage according to the rules provided.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.",13.0,1448.0,100.0,True
746,TCGA-AN-A04C.045B2852-E1FF-4376-8F39-60FC940224D0,1,Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Left Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: Radical mastectomy Grade: 2. T Stage: 2 N Stage: 1 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,BRCA,1,True,"The N stage is determined by the presence of cancer metastases in lymph nodes. According to the report, the N stage is 1, which indicates the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.",13.0,1448.0,100.0,True
930,TCGA-B6-A0RP.889D6E80-A656-49FA-9DFA-1674EB3877F6,1,"Surgica. CLINICAL HISTORY: Biopsy of right and left breast in. On the right side we only did a. limited dissection of nodes. GROSS EXAMINATION: A. ""Left breast and axilla"", fresh. Received is a left modified radial. mÃ¡stectomy specimen consisting of skin, breast tissue and attached axillary. tail. The skin ellipse measures 21 x 10.5 cm. The nipple and areola are. located centrally on this. The nipple is retracted. There is a partially. healed incision site running circumferentially around the lateral areola from. approximately the 1:00 to the 4:00 position which measures 4 cm in length. No. additional skin lesions are noted. The underlying breast tissue measures 23 x. 13 x 7 cm. Margins are inked blue, and the specimen is serially sectioned. There is a large, grossly apparent tumor in the upper outer quadrant which is. extremely firm, gray-tan, infiltrates into surrounding breast tissue, and. measures 2.6 x 2.5 x 1.5 cm. This tumor grossly extends to within 1.3 cm of. the deep surgical margin. This lesion will be designated as ""lesion #1. Further sectioning demonstrates a healing biopsy site subjacent to the areola,. located at the junction between upper and lower outer quadrants. In this. region, the biopsy cavity measures up to 2.3 x 0.3 x 0.2 cm. At the nipple,. in the region of retraction, there is firm, white tumor; there is also diffuse. firmness about the biopsy cavity suspicious for residual tumor in an area. measuring 2.8 cm in greatest dimension. This measures 4.0 cm from the deep. margin of resection and is distinctly separate from the previously described. lesion. The second area of abnormality shall be designated as ""lesion #2.'. Further sectioning in the left lower outer quadrant reveals a third nodule;. this is firm, gray, infiltrates into surrounding fibrous parenchyma, and. measures 1.0 cm in greatest dimension. It measures 3.5 cm from the deep. surgical margin, and is distinctly separate from the other two nodules. This. shall be designated as ""lesion #3."". Sections through the remainder of the breast shows firm fibrous breast. parenchyma but no additional discrete masses. Sections are submitted as. follows: A1- nipple and areola and incision site with grossly apparent tumor (lesion. #2). A2-A4- sections of biopsy site with surrounding induration (lesion #2). A5- tangential sections of margin deep to lesion #2. A6-A8- sections through lesion #1 (closest approach of tumor to superior. margin in A8.). A9- tumor #1 approaching superior margin, and tangential sections of deep. margin. A10- fibrous parenchyma between tumor number one and two, grossly free of. tumor. A11- random sections, upper inner quadrant. A12- random sections, upper outer quadrant. A13-14- small tumor in lower outer quadrant (lesion #3) . A15- additional sections, lower outer quadrant. ESE. A16- lower inner quadrant. The attached axillary tail measures 12 x 6 x 3 cm. Within this, multiple. lymph nodes are identified; at least two nodes appear grossly involved with. tumor. 1 of 4. A17- single 3 cm lymph node, grossly positive (a portion of this lymph node is. submitted to Tissue Bank) . A18- multiple lower level axillary lymph node candidates. A19- single lower level axillary lymph node, bisected. A20- single large mid axillary lymph node, bisected. A21- multiple mid axillary lymph nodes. A22- distal axillary lymph nodes. Note: A portion of tumor number one, skin, and grossly positive lymph node. tissue have all been submitted to the Tissue Bank. Per the surgeon, ER/PR. analyses have already been performed, and therefore no additional tissue is. banked for receptor analysis. B. ""Right breast and axillary contents"", fresh. Received is a right mastectomy. specimen with a 15 x 8.5 cm ellipse of tan skin. The nipple and areola are. located relatively centrally and somewhat inferiorly; there is no nipple. retraction. There is a healing peri-areolar incision site running from. approximately the 10:00 to 1:00 position in the upper outer and portion of. upper inner quadrant which measures 4.5 cm in length. There is an elevated. brown skin nodule measuring 1.3 x 1.3 x 0.2 cm located at the lateral tip of. the skin ellipse, which is grossly consistent with a seborrheic keratosis. other skin lesions are identified. The underlying breast tissue measures 20 x 11 x 3 cm. Sectioning through the. breast parenchyma after margins are inked reveals dense fibrous parenchyma. In. the upper breast, at the junction of upper inner and upper outer quadrant,. there is a healing biopsy cavity which measures 3.5 x 3 x 2 cm; this is. surrounded by fat necrosis and firm tissue and has a hemorrhagic rim with no. definite gross residual tumor. The biopsy changes extend to within 2.5 cm of. the deep margin. No masses or other abnormalities are identified. Block Summary: B1- sections of seborrheic keratosis. B2- nipple and areola, and skin with healing biopsy scar. B3- B5- sections of wall of biopsy cavity. B6- margins to deep to biopsy site (tangential). B7- random sections, upper outer quadrant. B8- random sections, upper inner quadrant. B9- random sections, lower inner quadrant. B10-random sections, lower outer quadrant. There is no definite axillary tail attached to the specimen. There is a strip. of fibrofatty tissue measuring 6 x 2 x 1 cm, in which no lymph nodes are. grossly identified. Sections of fibrofatty axillary tissue are submitted in. Blocks B11 and B12. MICROSCOPIC EXAMINATION: Sectoions of lesion #1 of the left breast show infiltrating duct carcinoma. Tumor cells are arranged as tubules and in nests, and infiltrate into. surrounding fibrous stroma and fat with accompanying desmoplastic response. There is a moderate degree of nuclear pleomorphism. Focally, comedo and. cribriform intraductal carcinoma is present in association with this mass. (A7), although this intraductal component is minor. Sections of lesion #2 of the left breast show tumor which predominantly has. the appearance of infiltrating lobular carcinoma, with tumor infiltrating in. linear ""indian file"" rows. Nuclei are relatively small and bland. There is. extensive infiltration of areolar smooth muscle and fibrous parenchyma, as. well as extensive perineural invasion. In several small foci, small tubles of. neoplastic cells are present. There are several foci of associated. intraductal carcinoma with cancerization of lobules/ lobular carcinoma in. situ. Sections of lesion #3 of the left breast show a lesion with a papillary. appearance; in most areas, this appears to be an intraductal process, although. 2 of 4. in one area an associated component of invasive duct carcinoma is seen. Papillomas are present in adjacent breast tissue. DIAGNOSIS: A. ""LEFT BREAST AND AXILLA"": LEFT BREAST WITH THREE SEPARATE FOCI OF BREAST CARCINOMA. CARCINOMA NUMBER ONE (A1-A3) : INFILTRATING DUCT CARCINOMA (UPPER OUTER. QUADRANT), 2.6 x 2.5 x 1.5 CM, N.S.A.B.P. NUCLEAR GRADE MODERATELY. DIFFERENTIATED, HISTOLOGIC GRADE 2/3. INTRADUCTAL CARCINOMA COMEDO AND CRIBRIFORM TYPES, COMPRISES LESS. THAN 5% OF THE TUMOR. VASCULAR INVASION IS PRESENT. DEEP MARGIN FREE OF CARCINOMA. CARCINOMA NUMBER TWO (A6-8) : TUBULOLOBUAR CARCINOMA WITH PREDOMINANTLY. LOBULAR FEATURES (SUBAREOLAR REGION AT JUNCTION BETWEEN UPPER AND LOWER. OUTER QUADRANTS), IN REGION OF HEALING BIOPSY SITE, 2.8 CM IN GREATEST. DIMENSION. INTRADUCTAL CARCINOMA/ LOBULAR CARCINOMA IN. SITU IS PRESENT, COMPRISING LESS THAN 1% OF THE TUMOR. TUMOR EXTENDS INTO THE LARGE DUCTS AND SOFT TISSUE OF THE NIPPLE. DEFINITIVE VASCULAR INVASION IS NOT PRESENT. DEEP MARGIN FREE OF CARCINOMA. CARCINOMA NUMBER THREE (A13-A14) : INFILTRATING DUCT CARCINOMA ARISING. IN A REGION OF PAPILLARY INTRADUCTAL CARCINOMA (LOWER OUTER QUADRANT) ,. 1.0 CM IN GREATEST DIMENSION, N.S.A.B.P. NUCLEAR GRADE MODERATELY. DIFFERENTIATED, HISTOLOGIC GRADE 2/3. DEEP MARGIN FREE OF TUMOR. NO DEFINITE VASCULAR INVASION IDENTIFIED. REMAINDER OF BREAST WITH MULTIFOCAL INTRADUCTAL CARCINOMA (SOLID AND. CRIBRIFORM TYPES) WITH CANCERIZATION OF LOBULES, LOBULAR CARCINOMA IN. SITUE, FLORID EPITHELIAL HYPERPLASIA OF USUAL TYPE, INTRADUCTAL. PAPILLOMA (A13). APOCRINE METAPLASIA, ADENOSIS, DUCT ECTASIA, AND. MICROCYSTS. TWO OF FIFTEEN LEFT AXILLARY LYMPH NODES INVOLVED WITH METASTATIC. CARCINOMA (2/15) (TUBULOLOBULAR PATTERN). SKIN WITH HEALING WOUND AND NO EVIDENCE OF MALIGNANCY. B. ""RIGHT BREAST AND AXILLARY CONTENTS"": BREAST WITH HEALING BIOPSY SITE WITH FAT NECROSIS, FOREIGN BODY REACTION,. AND GRANULATION TISSUE. MULTIFOCAL INTRADUCTAL CARCINOMA, SOLID TYPE, WITH CANCERIZATION OF. LOBULES, INCLUDING REGIONS AROUND BIOPSY CAVITY (B5) AND IN LOWER OUTER. QUADRANT (B10) . FOCAL INFILTRATING DUCT CARCINOMA (B2), N.S.A.B.P. NUCLEAR GRADE WELL. DIFFERENTIATED, HISTOLOGIC GRADE 1/3. DEEP MARGIN FREE OF CARCINOMA. SKIN WITH HEALING WOUND, SEBORRHEIC KERATOSIS, EPIDERMAL INCLUSION CYST,. AND NO EVIDENCE OF MALIGNANCY. REMAINDER OF BREAST WITH FLORID EPITHELIAL HYPERPLASIA OF USUAL TYPE,. ADENOSIS, AND APOCRINE METAPLASIA. NO LYMPH NODES IDENTIFIED IN LIMITED AXILLARY DISSECTION. 3 of 4.",BRCA,1,True,"The report states that two out of fifteen left axillary lymph nodes are involved with metastatic carcinoma. This corresponds to the N2 classification, which is determined by the presence of metastases in 4-9 axillary lymph nodes.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N2,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,97.0,True
677,TCGA-A8-A09N.F5A97F05-4B5C-4B10-BF10-5DDE7D412BCF,1,"4. Invasive ductal breast carcinoma (max. diameter 2.2 cm, now also in some sections. malignancy grade III) with angioinvasion in the immediate tumor periphery, also with. concomitant high-grade DCIS (procomponent > 10). Distant fibrolipomatous parenchyma of. the breast (with cystic duct ectasia) with risk lesions of unsettled to atypical ductal. hyperplasia, but tumor-free. Minimal width of caudal and dorsal safety margin 0.7-0.8 cm. Histologically unremarkable skin spindle. Tumor classification: G3 (L1, V0), pT2, pN3a, MX, R0.",BRCA,3,True,"The report indicates that the tumor is a pT2 (maximum diameter of 2.2 cm) and pN3a, which means that there are metastases in 10 or more axillary lymph nodes or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases. This information is sufficient to determine the N stage as N3.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N3,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
665,TCGA-A8-A096.91BFC77A-E56F-49F0-A294-A5EE9F266FB6,1,"Diagnosis: 1. Moderately differentiated invasive ductal carcinoma (tumor diameter 4.0 cm). In conjunction with the preliminary finding, this gives rise to the following tumor. classification: NOS, G II, pT2NOi+(sn)LOVORO.",BRCA,0,True,"The report indicates that there is no evidence of cancer in the lymph nodes, as shown by 'pT2NOi+(sn)'. The 'NO' denotes that there are no cancer metastases in the lymph nodes. According to the rules provided, the absence of cancer in the lymph nodes is the primary determinant of the N stage, and the number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,49.0,False
1197,TCGA-E2-A14R.0B6DCA80-3108-4D25-B095-3EC704598B23,1,"SPECIMENS: A. SENTINEL NODE #1 LEFT AXILLA. B. SENTINEL NODE #2 LEFT AXILLA. C. SENTINEL NODE #3 LEFT AXILLA. D. WIDE LOCAL EXCISION LEFT BREAST NEEDLE LOCALIZATION. E. INFERIOR MARGIN LEFT BREAST. F. LATERAL MARGIN LEFT BREAST. G. MEDIAL MARGIN LEFT BREAST. H. POSTERIOR MARGIN LEFT BREAST. I. SENTINEL NODE #4 LEFT AXILLA. J. SENTINEL NODE #5 LEFT AXILLA. K. SENTINEL NODE #6 LEFT AXILLA. SPECIMEN(S): A. SENTINEL NODE #1 LEFT AXILLA. B. SENTINEL NODE #2 LEFT AXILLA. C. SENTINEL NODE #3 LEFT AXILLA. D. WIDE LOCAL EXCISION LEFT BREAST NEEDLE LOCALIZATION. E. INFERIOR MARGIN LEFT BREAST. F. LATERAL MARGIN LEFT BREAST. G. MEDIAL MARGIN LEFT BREAST. H. POSTERIOR MARGIN LEFT BREAST. I. SENTINEL NODE #4 LEFT AXILLA. J. SENTINEL NODE #5 LEFT AXILLA. K. SENTINEL NODE #6 LEFT AXILLA. INTRAOPERATIVE CONSULTATION DIAGNOSIS: TPA-TPC: One lymph node each part, negative for carcinoma. D: Gross assessment 2.0 cm mass >0.5 cm all margins and 1.0 cm satellite nodule at inferior margin. TPI: One lymph node, negative for carcinoma. TPJ/FSJ: 2 lymph nodes, negative for carcinoma. TPK: One lymph node, negative for carcinoma. By Dr. called to Dr. at 1. (A),. (B),. C), : (D) and. (I, JJK). GROSS DESCRIPTION: A. SENTINEL NODE #1, LEFT AXILLA. Received fresh and labeled with the patient name designated ""A - sentinel node #1, left axilla"", is a fragment of. beige-tan possible lymphoid tissue measuring 2.0 x 2.0 1.2 cm. The specimen is serially sectioned, touch prep. performed. The entire specimen is submitted in cassette A1 and A2. B. SENTINEL NODE #2, LEFT AXILLA. Received fresh and labeled with the patient name designated ""B - sentinel node #2, left axilla"", is a fragment of. beige-tan possible lymphoid tissue measuring 1.0x 1.0 x 1.3 cm. The specimen is serially sectioned, touch. prep. performed. The entire specimen is submitted in cassette B1 and B2. C. SENTINEL NODE #3, LEFT AXILLA. Received fresh and labeled with the patient name designated ""C - sentinel node #3"", is a fragment of beige-tan. possible lymphoid tissue measuring 0.7 x 0.5 x 0.3 cm. The specimen is serially sectioned, touch prep performed. The entire specimen is submitted in cassette C1. D. LEFT BREAST WIDE NEEDLE LOCALIZATION. Received in fresh state the specimen labeled with patients name and identification number and labeled as wide local. excision left breast needle localization. The specimen consists of 293 grams resected breast tissue measuring 12.5. cm from medial to lateral, 7.5 cm from anterior to posterior and 6.0 cm from superior to inferior. The margins of. specimen are oriented with sutures, single indicating anterior, double-lateral and triple-superior. There is a. localization needle coursing from the superior to the inferior aspect of the specimen and the accompanying. radiogram that shows density located in the mid portion of the specimen. The margins of specimen are color coded. as follows: Inferior-orange, superior-red, lateral-yellow, anterior-blue, medial-green and posterior-black. At mid. portion of the specimen is a firm palpable mass which on cut section shows solid firm mass with nodular and. lobulated pushing borders with a tan white cut surface with total dimensions of 4.0 x 3.0 x 0.9 cm. A metallic clip is. identified within the main portion of the tumor and the surrounding breast tissue consists mostly of fatty parenchyma. The tumor grossly 0.9 cm from the nearest inferior margin. Multiple sections are submitted and labeled as follows: D1-D8: One en bloc section of tumor with margins. D9: Cross section of tumor. D10-D18: En bloc section of tumor with margins, (block 15 section taken site of apparent previous biopsy site. wherein a clip was identified). D19: Sections of gross fat necrosis. D20: Sections from posterior and medial margins. D21: Sections from inferior and medial margins. D22-D23: Sections from the posterior margin. D24-D25: Sections from lateral margin. n26-D27: Additional medial margin. E. LEFT BREAST INFERIOR MARGIN. Stitch marks new margin. Received fresh is an oriented 17.0-gram fragment of fibrofatty tissue 6.0 x 5.0 x 2.0 cm. The new true margin is inked blue, the specimen is serially sectioned and submitted in toto in cassette E1-E11. F. LEFT BREAST LATERAL MARGIN. Stitch at new lateral margin. Received fresh is an oriented tan-pink fragment of fibrofatty tissue 5.0 x 2.0 x 1.5 cm. The new true margin is inked blue. Also separate within the container is an unoriented tan-pink fragment of fibrofatty. tissue 5.5 x 4.0 x 2.0 cm. The specimen is inked blue. The entire specimen is submitted as follows: F1-F5: Oriented tissue fragment. F6-F12: Unoriented tissue fragment. G. LEFT BREAST MEDIAL MARGIN. Irregular fragment of fibrofatty tissue measuring 3.5 x 2.0 x 1.0 cm. Submitted in toto in cassettes labeled G1-G2. H. LEFT BREAST POSTERIOR MARGIN. Received fresh is an unoriented 3.0-gram tan-pink fragment of fibrofatty tissue 4.0 x 2.0 x 1.5 cm. The specimen is. inked blue, serially sectioned and submitted in toto in cassette H1 and H2. I. SENTINEL NODE #4, LEFT AXILLA. Received fresh is a tan-pink lymph node 0.8 x 0.7 x 0.7 cm. The specimen is serially sectioned, touch preps are. taken. The specimen is submitted entirely in cassette I1. J. SENTINEL NODE #5, LEFT AXILLA. Received fresh are 2 tan-pink lymph nodes 1.5 x 1.0 x 1.0 cm and 0.8 x 0.5 x 0.5 cm. A portion of the larger lymph. node is submitted for frozen section in FSJ1. Touch preps are taken. The remainder of the lymph node is submitted. as follows: J2-J3: One lymph node. J4: One lymph node. K. SENTINEL NODE #6, LEFT AXILLA. Received fresh is a tan-pink lymph node 0.7 x 0.6 x 0.5 cm. The specimen is bisected. Touch preps are taken and. the specimen is submitted entirely in cassette K1. DIAGNOSIS: A. SENTINEL LYMPH NODE #1, LEFT AXILLA. - ONE LYMPH NODE, NEGATIVE FOR TUMOR (0/1). B. SENTINEL LYMPH NODE #2, LEFT AXILLA. - ONE LYMPH NODE, NEGATIVE FOR TUMOR (0/1). C. SENTINEL LYMPH NODE #3, LEFT AXILLA. - ONE LYMPH NODE, NEGATIVE FOR TUMOR (0/1). D. LEFT BREAST, NEEDLE LOCALIZATION WIDE LOCAL EXCISION: - INVASIVE DUCTAL CARCINOMA WITH AREAS OF NECROSIS, SBR GRADE III OF. LEFT BREAST. - SIZE OF TUMOR: 4.0 x 3.0 x 0.9 CM. - PREDOMINANTLY FATTY BREAST TISSUE WITH FOCAL AREAS OF COLUMNAR. CELL CHANGE. - POST BIOPSY SITE CHANGES. - MARGINS OF RESECTION-NEGATIVE FOR TUMOR. E. LEFT BREAST, INFERIOR MARGIN: - PREDOMINANTLY FATTY BREAST TISSUE-NEGATIVE FOR TUMOR. F. LEFT BREAST, LATERAL MARGIN: - FATTY BREAST TISSUE-NEGATIVE FOR TUMOR. G. LEFT BREAST, MEDIAL MARGIN: - FATTY TISSUE AND 1 MM FOCUS OF LYMPH NODE-NEGATIVE FOR TUMOR (0/1). H. LEFT BREAST, POSTERIOR MARGIN: - FATTY BREAST TISSUE INCLUDING SKELETAL MUSCLE TISSUE-NEGATIVE FOR TUMOR. I. SENTINEL LYMPH NODE #4, LEFT AXILLA: - ONE LYMPH NODE, NEGATIVE FOR TUMOR (0/1). J. SENTINEL LYMPH NODE, #5 LEFT AXILLA: - TWO LYMPH NODES, NEGATIVE FOR TUMOR (0/2). K. SENTINEL LYMPH NODE #6, LEFT AXILLA: - ONE LYMPH NODE, NEGATIVE FOR TUMOR (0/1). Note: specimen # D- grossly, of what appears clinically as two tumor is only one large tumor with lobulated and. nodulat extensions. the main bulk of the specimen consist mostly of fatty breast tissue,. SYNOPTIC REPORT - BREAST. Specimens Involved. Specimens: D: WIDE LOCAL EXCISION LEFT BREAST NEEDLE LOCALIZATION. Specimen Type: Excision. Needle Localization: Laterality: Left. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 4cm. Additional dimensions: 3cm x 0.9cm. Tumor Site: Central. Margins: Negative. Distance from closest margin: 1.5cm. superior. Tubular Score: 3. Nuclear Grade: 3. Mitotic Score: 3. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Present. Vascular/Lymphatic Invasion: Indeterminate. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node only. Lymph node status: Negative 0/8. Non-neoplastic areas: Post biopsy site changes. DCIS not present. Pathological staging (pTN): pT 2 N 0. SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimens Involved. Specimens: D: WIDE LOCAL EXCISION LEFT BREAST NEEDLE LOCALIZATION. Specimen: Surgical Excision. Block Number: D9. ER: Negative Allred Score: 0 = Proportion Score 0 + Intensity Score 0. PR: Negative Allred Score: 0 = Proportion Score 0 + Intensity Score 0. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the proportion score. (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of cells staining, 4 = 31-60% of. cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak intensity of staining, 2 = intermediate. intensity of staining, 3 = strong intensity of staining), with a scoring range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score of less than. or equal to 2. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochemistry was performed using the mouse anti-human ER (ER 1D5, 1:100) and PR (PGR 136, 1:100). provided by Dako. a) following the manufacturer S instructions. This assay was not modified. Interpretation of the ER/PR immunonistochemical stain is guided by published results in the medical literature,. information provided by the reagent manufacturer and by internal review of staining performance. CLINICAL HISTORY: -year-old Caucasian female with palpable left breast mass. Ultrasound showed 2 masses at 12 o'clock position,. largest one 2.0 cm. Core biopsy showed DCIS, here for wide local excision and sentinel node biopsy. PRE-OPERATIVE DIAGNOSIS: None given. ADDENDUM: SYNOPTIC REPORT - BREAST HER-2 RESULTS. Specimen: Surgical Excision. Block Number: D9. Interpretation: NEGATIVE. Intensity: 1+. % Tumor Staining: 8%. Fish Ordered: No. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Her2 analysis. was performed using the FDA approved Dako HercepTest (TM) test kit (Dako, Carpenteria, CA) using rabbit anti-. human HER2. This assay was not modified. External kit-slides provided by the manufacturer (cell lines with high,. low and negative HER2 protein expression) and in-house known HER2 amplified control tissue were evaluated along. with the test tissue. Adequate, well preserved, clear-cut invasive carcinoma was identified for HER2 evaluation. Interpretation of the HER2 immunohistochemical stain is guided by published results in the medical literature,. information provided by the reagent manufacturer and by internal review of staining performance. This assay has been validated according to the 2007 joint recommendations and guidelines from ASCO and CAP. and from the NCCN HER2 testing in Breast Cancer Task Force. The Pathology Department takes full responsibility. for this test's performance. Microscopic/Diagnostic Dictation: Pathologist. Microscopic/Diagnostic Dictation: Pathologist,. Final Review: Pathologist. Final: Pathologist,. Addendum: Pathologist,. Addendum Final: Pathologist.",BRCA,0,True,"The report states that all sentinel lymph nodes (A, B, C, I, J, K) were negative for tumor (0/1, 0/1, 0/1, 0/1, 0/2, 0/1 respectively). Therefore, there is no evidence of cancer in the lymph nodes, which means the N stage is N0.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1436,TCGA-LL-A7SZ.3FA5FACA-8A6B-4F42-A557-3B69866859E7,1,"RUN DATE: RUN TIME. RUN USER: LOC: AGE/SX: ROOM: REG DR: BED: SPEC # : RECD: COLL: TIME IN FORMALIN: hrs. COLD ISCHEMA TIME: mins. CLINICAL INFORMATION: Pre-Op Diagnosis: Remarks: Specimen (s) : Left breast, stitch left axillary apex. MICROSCOPIC DIAGNOSIS. LEFT BREAST, SKIN-SPARING RADICAL MASTECTOMY: INVASIVE DUCTAL CARCINOMA, HIGH GRADE. NOTTINGHAM HISTOLOGIC SCORE. - GLANDULAR/TUBULAR DIFFERENTIATION SCORE 3. - NUCLEAR PLEOMORPHISM SCORE 3. - MITOTIC RATE SCORE 2. - OVERALL GRADE 3 (8 OF 9). MARGINS UNINVOLVED BY INVASIVE CARCINOMA. CARCINOMA IS 5.5 MM FROM THE CLOSEST MARGIN (POSTERIOR MARGIN). MINUTE FOCUS OF HIGH-GRADE DCIS PRESENT WITHIN AREA OF CARCINOMA (1 MM IN SIZE). LYMPH-VASCULAR INVASION IDENTIFIED. METASTATIC CARCINOMA INVOLVING TWO (2) OF ELEVEN (11) LYMPH NODES (2/11). LARGEST TUMOR DEPOSIT IS 14.5 MM. EXTRACAPSULAR EXTENSION IDENTIFIED. SEE SYNOPTIC REPORT. COMMENT(S). SURGICAL PATHOLOGY CANCER CASE SUMMARY - APPROVED BY. PROCEDURE: Total mastectomy, skin sparing. LYMPH NODE SAMPLING: Axillary dissection. SPECIMEN LATERALITY. Left. TUMOR SITE: Upper outer quadrant. HISTOLOGIC TYPE OF INVASIVE. CARCINOMA: Invasive ductal carcinoma. TUMOR SIZE: Greatest dimension of largest focus of invasion. 25 mm. Additional dimensions: 22 x 20 mm. HISTOLOGIC GRADE (NOTTINGHAM. HISTOLOGIC SCORE) : Glandular/tubular differentiation : score 3. Nuclear pleomorphism: score 3. RUN DATE: RUN TIME. RUN USER: SPEC #: COMMENT (S). Mitotic rate: score 2. Overall grade: grade 3. TUMOR FOCALITY: Single focus of invasive carcinoma. DUCTAL CARCINOMA IN SITU: DCIS is present. Estimated size of DCIS 1 mm. Architectural pattern: comedo. Nuclear grade: grade III. Necrosis: present, central. LOBULAR CARCINOMA IN SITU: Not identified. MARGINS. Invasive carcinoma : Margins uninvolved by invasive carcinoma. Distance from closest margin: 5.5 mm. posterior. DCIS: Margins uninvolved by DCIS. LYMPH NODES: Number of sentinel lymph nodes examined : 0. Total number of lymph nodes examined: 11. Number of lymph nodes with macrometastases: 2. Number of lymph nodes with ITC: 0. Size of largest metastatic deposit: 14.5 mm. Extranodal extension : present. Method of evaluation of sentinel lymph nodes. H&E. multiple levels. LYMPH-VASCULAR INVASION: Present. DERMAL LYMPH-VASCULAR INVASION: Not identified. PATHOLOGIC STAGING: Primary tumor pT2. Regional lymph nodes: pN1a. Distant metastasis: not applicable. ANCILLARY STUDIES: (RESULTS FROM CASE -. Estrogen Receptor positive (99% of tumor cells. with nuclear positivity). Progesterone Receptor: positive (99% of tumor. cells with nuclear positivity. Her2/neu: Immunoperoxidase studies negative (1+). GROSS DESCRIPTION: Received fresh is a skin-sparing left radical mastectomy weighing 756 grams and measuring. 27 cm from medial to the axillary tail. 18 cm from superior to inferior. and 2.5 cm. anterior to posterior. There is a linear portion of skin including nipple measuring 9 x. 2.1 cm. A mass is palpated in the lower portion of the upper outer quadrant . The deep. margin underlying this tumor is inked black. and the anterior margin is inked blue. A cut. is made from the posterior side. and a portion of tumor is given to the Tumor Bank. The. tumor measures 2.5 x 2.2 x 2.0 cm. It is firm with focal areas of hemorrhage. There is an. adjacent vell-circumscribed tan-white soft. freely mobile area measuring up to 4.5 cm in. greatest dimension. The carcinoma measures 0.8 cm from the posterior black-inked margin. and 0.9 cm from the anterior blue-inked margin. The other margins are greater than 3 cm. RUN DATE. RUN TIME: RUN USER: SPEC #. GROSS DESCRIPTION: (Continued). from the tumor including the nipple. The remainder of the breast is serially sectioned to. reveal no additional masses, cysts or other gross abnormalities There is a fat to fibrous. ratio. of up to 50:50. The most fibrotic areas are closest to the lateral quadrants,. particularly the upper outer quadrant . The detached axillary tail itself measures 13.2 x. 5.5 x 2.6 cm. Serial section reveals multiple lymph nodes, the largest of which measures. 2.2 x 1.5 x 1 cm. Sections are as follows: tumor as it most closely approximates the anterior margin. 2. tumor as it most closely approximates the posterior margin. 3. additional representative section of tumor. 4. representative section of fibrotic area adjacent to tumor. 5. representative section of nipple. 6-7. additional representative sections of very fibrotic areas in the. lateral quadrant. 8. representative sections of the medial quadrants. 9-10. multiple lymph nodes. 11-12. one lymph node each, bisected. PHOTO IXICUMENTATION. (signature on file).",BRCA,1,True,"The report indicates that there are 11 lymph nodes examined, out of which 2 have metastatic carcinoma (2/11). This satisfies the criteria for N1 classification, which is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
974,TCGA-BH-A0BA.142F03FE-5B60-416D-8DCD-EC34DB5495DB,2,"FINAL DIAGNOSIS: PART 1: LEFT AXILLA, SENTINEL LYMPH NODE #1, BIOPSY -. ONE LEFT AXILLARY SENTINEL LYMPH NODE #1 WITH METASTATIC BREAST CARCINOMA (1/1). PART 2: BREAST, LEET, MODIFIED RADICAL MASTECTOMY -. A. MULTIFOCAL INFILTRATING MIXED DUCTAL AND LOBULAR CARCINOMA (see comment). B. TUMOR MEASURES 6.0 X 5.5 X 2.5 CM. C. THE TUMOR IS LOCATED IN THE UPPER OUTER, LOWER OUTER, UPPER INNER AND LOWER INNER. QUADRANTS AND IN THE CENTRAL AREA (MULTICENTRIC TUMOR ). D. ANGIOLYMPHATIC INVASION IDENTIFIED. E. LOBULAR CARCINOMA IN SITU ACCOUNTING FOR 10% OF THE TUMOR, ADMIXED WITH THE TUMOR. F. ALL MARGINS ARE NEGATIVE FOR INVASIVE MIXED DUCTAL - LOBULAR CARCINOMA AND LOBULAR. CARCINOMA IN SITU. G. NIPPLE WITH FOCAL INVASIVE CARCINOMA IN THE DEEP STROMAL TISSUE. H. NIPPLE AND SKIN OF THE BREAST WITH DUCT ECTASIA AND CHRONIC INFLAMMATION. I. ESTROGEN RECEPTOR POSITIVE, PROGESTERONE RECEPTOR POSITIVE, HER-2/NEU NEGATIVE FOR. (SCORE +1) AS PER CORE BIOPSY. J. BIOPSY SITE CHANGES. K. FIBROCYSTIC CHANGES WITH DUCTAL EPITHELIAL HYPERPLASIA. L. COLUMNAR CELL CHANGES. M. MICROSCOPIC PERIPHERAL DUCTAL PAPILLOMA. N. AXILLARY TAIL WITH TWENTY OUT OF TWENTY LYMPH NODES WITH METASTATIC CARCINOMA (0.5 TO. 2.2 CM IN MAXIMUM DIAMETER) (20/20) TOW HAVE EXTRA CAPSULAR SPREAD-. PART 3: LEFT PECTORALIS MINOR MUSCLE, EXCISION -. STRIATED SKELETAL MUSCLE FREE OF TUMOR CONFIRM BY IMMUNOSTAIN FOR. PART 4: LEFT AXILLA, LEVEL 3, LYMPH NODE, EXCISION -. SIX LYMPH NODES LEVEL 3 ALL POSITIVE FOR METASTATIC CARCINOMA (6/6) (see comment). CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Modified radical mastectomy. Central subareolar. Upper outer quadrant. Upper inner quadrant. Lower outer quadrant. Lower inner quadrant. Not specified. SIZE OF TUMOR: Maximum dimension invasive component: 6.0 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR AGGREGATE SIZE: Sum of the sizes of multiple invasive tumors: 6.3 cm. TUMOR TYPE (invasive component): Other Type(s): MIXED D &L. HISTOLOGIC TYPE: Classical, Pleomorphic. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 3. Mitotic activity score: 1. Total Nottingham score: 6. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: TUMOR TYPE, IN SITU: Yes, benign zones. SURGICAL MARGINS INVOLVED BY INVASIVE LCIS, Percent COMPONENT: of tumor occupied by in situ component: 10 %. SURG MARGINS INVOLVED BY IN SITU COMPONENT: PAGET'S DISEASE OF NIPPLE: LYMPH NODES POSITIVE: 27. LYMPH NODES EXAMINED: 27. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain, Keratin stain. SENTINEL NODE METASTASIS: ONLY KERATIN POSITIVE CELLS ARE PRESENT: SIZE OF NODAL METASTASES: LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: Diameter of largest lymph node metastasis: 20 mm. METASTASES TO IPSILATERAL INTERNAL MAMMARY LYMPH NODE (IF APPLICABLE): SKIN INVOLVED (ULCERATION): NON-NEOPLASTIC BREAST TISSUE: ALH, Papilloma, FCD. T STAGE, PATHOLOGIC: pT3. N STAGE, PATHOLOGIC:",BRCA,3,True,"The report indicates that there are 27 positive lymph nodes out of 27 examined (27/27). According to the rules provided, N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases. In this case, the patient has metastases in 10 or more axillary lymph nodes, which meets the criteria for N3 classification.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N3,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
560,TCGA-A2-A4RW.C1D4D6BB-AF86-4208-A729-C61365941217,1,"34. Unit#: : Specimen: Spec Type: SURGICAL P. PREOPERATIVE DIAGNOSIS. RIGHT BREAST CANCER INVASIVE. OPERATION PERFORMED. DOCTOR. PROCEDURE: MASTECTOMY MODIFIED RADICAL. TISSUE REMOVED. A. RT BREAST MASTECTOMY. B. RT AXILLARY NODE DISSECTION. GROSS DESCRIPTION. RECEIVED IN 2 PARTS. A RECEIVED LABELED. RIGHT BREAST STITCH 12 O'CLOCK IS A. 650 GRAM SIMPLE MASTECTOMY SPECIMEN MEASURING 23.5 X 21.5 x 3.7 CM. THE. NIPPLE IS UNREMARKABLE WITHIN A SKIN ELLIPSE MEASURING 23.5 x 12.5 CM. A SUTURE DENOTES 12 O'CLOCK. THE SUPERFICIAL ASPECT IS MARKED WITH BLUE. INK, THE DEEP WITH BLACK. SECTIONING REVEALS A CENTRAL PORTION OF THE. BREAST TO BE A MIXTURE OF TAN FIBROUS TISSUE AND YELLOW FAT. THE. PERIMETER CONSISTS OF BLAND YELLOW FATTY TISSUE. IN THE 10 O'CLOCK AREA. OF THE BREAST IS A FIRM MASS MEASURING 4 CM FROM MEDIAL TO LATERAL BY. 3.5 CM FROM SUPERIOR TO INFERIOR AND 2.1 CM FROM ANTERIOR TO POSTERIOR. THERE IS A SMALL RIM OF FATTY TISSUE DEEP TO THE LESION. GROSSLY THERE. IS AT LEAST 0.5 CM OF TISSUE. THIS DOES NOT INVOLVE THE SKIN GROSSLY. SECTIONS ARE SUBMITTED AS FOLLOWS: A1--NIPPLE, A2 AND 3--LESION IN DEEP. MARGIN, A4--FAR LATERAL ASPECT OF LESION WITH SKIN, A5--GROSS MEDIAL. ASPECT OF LESION 4 CM FROM A4, AND A10 IS THE TISSUE SUPERFICIAL TO A8. SUPERFICIAL TO DEEP MEASUREMENT. SECTIONS OF THE LESION ARE ALSO. SUBMITTED PER PROTOCOL. A BOWTIE-SHAPED CLIP IS IDENTIFIED WITHIN THE. LESION, A11--TUMOR, A12--UPPER INNER QUADRANT, A13--UPPER OUTER QUADRANT. LATERAL TO LESION, A14--LOWER OUTER QUADRANT, A15--LOWER INNER QUADRANT. B RECEIVED LABELED. RIGHT AXILLARY NODE DISSECTION ARE 2. IRREGULAR PORTIONS OF YELLOW-RED FATTY TISSUE TOGETHER MEASURING 9 X 7 x. 2.5 CM. THIS TISSUE IS EXAMINED FOR LYMPH NODES. THE LARGEST NODE. WHICH IS 2.5 CM IN DIAMETER DEMONSTRATES A ROD-SHAPED METAL CLIP. IT. HAS ILL-DEFINED BORDERS. ONE-HALF IS SUBMITTED IN B1. THE REMAINDER IS. Specimen: q#. Spec Type: GROSS DESCRIPTION. TAKEN PER PROTOCOL. ADDITIONAL NODES ARE ALSO IDENTIFIED AND SUBMITTED. AS. FOLLOWS. THERE IS A 2ND 2.5 CM LYMPH NODE WHICH IS GROSSLY. UNREMARKABLE. ONE-HALF IS SUBMITTED AS B2. THE REMAINDER IS TAKEN PER. PROTOCOL. A 1.7 CM LYMPH NODE IS BISECTED, ONE-HALF SUBMITTED IN B3,. THE REMAINDER SUBMITTED PER PROTOCOL. ADDITIONAL NODES ARE THEN. SUBMITTED AS FOLLOWS: B4--2 NODES EACH BISECTED, B5--3 NODES EACH. BISECTED, B6--3 NODES EACH BISECTED, B7--1 NODE TOTAL, B8--5 NODES,. B9~-4 NODES, B10-4 NODES. FORMALIN FIXATION TIME IS 6 HOURS AND 10 MINUTES. PATH PROCEDURES. PROCEDURES: 88309, A BLK/15, B BLK/10. FINAL DIAGNOSIS. PART A RIGHT BREAST, SIMPLE MASTECTOMY: 1. INTRALOBULAR AND INFILTRATING LOBULAR CARCINOMA OF THE PLEOMORPHIC. TYPE. THE INVASIVE COMPONENT SHOWS NUCLEAR GRADE 2/3, LOW MITOTIC. INDEX AND TUBULE FORMATION 3 FOR A TOTAL NOTTINGHAM SCORE OF. LCIS. WITH RARE FOCI OF LUMINAL NECROSIS COMPRISES APPROXIMATELY 30% OF THE. TUMOR. 2. THE TUMOR HAS A MAXIMUM GROSS DIMENSION OF 4 CM ALTHOUGH RARE IN. SITU AND INVASIVE FOCI ARE IDENTIFIED IN A RANDOM SECTION FROM THE. LOWER OUTER QUADRANT. 3. INVASIVE TUMOR IS FOCALLY IDENTIFIED 4 MM FROM THE NEAREST INKED. SUPERFICIAL MARGIN (A2) AND 4 MM FROM THE SKIN SURFACE (A4) . 4. THE BIOPSY SITE. ) AND A BOWTIE-SHAPED CLIP ARE IDENTIFIED. 5. ALTHOUGH LYMPHOVASCULAR INVASION IS NOT IDENTIFIED, PERINEURAL. INVASION IS PRESENT. PART B RIGHT AXILLA,. IS IDENTIFIED IN ALL. OF LYMPH THE NODE 27 LYMPH DISSECTION: NODES EXAMINED. METASTATIC FOCAL BREAST EXTRANODAL CARCINOMA 27/27/20. EXTENSION INTO THE PERINODAL FAT IS PRESENT. A BIOPSY SITE INCLUDING A. Specimen: Spec Type: 1, D.O. FINAL DIAGNOSIS. ROD-SHAPED METAL CLIP IS ALSO PRESENT. :, M.D.",BRCA,3,True,"The report states that there were 27 lymph nodes examined in the right axillary node dissection, and metastatic focal breast carcinoma was found in all 27 nodes (27/27/20). This indicates that the N stage is N2, as this classification is determined by the presence of metastases in 4-9 axillary lymph nodes.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N2,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
956,TCGA-B6-A408.F5A14797-6676-4331-9424-D8B820008924,1,"AP Surgical Pathology: Additional Info 4. CLINICAL HISTORY: Left breast cancer. Per E browser, invasive ductal carcinoma with lobular. features in the left axillary tail. GROSS EXAMINATION: A. ""Left breast with axillary contents"", received unfixed and placed in. formalin is a 842 gram, 24 x 18.5 x 7 cm mastectomy specimen with a 20 x 10 cm. attached skin ellipse and a 1.1 cm nipple. The specimen is received with. incisions in the lateral aspect of the breast and in the axillary tail. The. specimen is oriented with a long suture at the lateral edge. Per requisition. there is also a short stitch to indicate superior, but no short stitch is. present on the specimen. There is a 2.1 x 2 x 1.2 cm firm, tan mass at lateral 3:00. The mass is 0.3 cm. from the closest deep margin, 2 cm from the superior margin, 5.8 cm from the. inferior margin, 3.5 cm from the lateral margin and 20 cm from the medial. margin. The mass is 0.2 cm from the overlying skin, which is slightly. puckered. The remainder of the breast consists of grossly unremarkable. fibroadipose tissue. Multiple lymph nodes are identified in the axillary tail,. 1.7 cm in greatest dimension. BLOCK SUMMARY: A1-8-. entire mass with the closest approach to skin in A1 and closest. approach to deep margin in A2. superior margin nearest to tumor, tangential. A10-13-. intact lymph node candidates. A14-16-. one lymph node, bisected in each. A17-. representative upper inner quadrant. A18-. representative lower inner quadrant. A19-. representative upper outer quadrant. A20-. representative lower outer quadrant. A21-. nipple. MICROSCOPIC EXAMINATION: Microscopic examination is performed. PATHOLOGIC STAGE: PROCEDURE: MODIFIED RADICAL MASTECTOMY. PATHOLOGIC STAGE (AJCC. Edition) : pT2 pN3a pMX site: breast, Nos C50.9. NOTE: Information on pathology stage and the operative procedure is. transmitted to this Institution's Cancer Registry as required for. accreditation by the Commission on Cancer. Pathology stage is based solely. upon the current tissue specimen being evaluated, and does not incorporate. information on any specimens submitted separately to our Cytology section,. past pathology information, imaging studies, or clinical or operative. findings. Pathology stage is only a component to be considered in determining. the clinical stage, and should not be confused with nor substituted for it. The exact operative procedure is available in the surgeon's operative report. DIAGNOSIS: A. ""LEFT BREAST WITH AXILLARY CONTENTS"" (MODIFIED RADICAL MASTECTOMY). RESIDUAL INVASIVE ADENOCARCINOMA OF THE BREAST. HISTOLOGIC TYPE: DUCTAL WITH LOBULAR FEATURES. NOTTINGHAM COMBINED HISTOLOGIC GRADE: 2 OF 3. TUBULE FORMATION SCORE: 2. NUCLEAR PLEOMORPHISM SCORE: 3. MITOTIC RATE SCORE: 2. GROSS TUMOR SIZE: 2.1 x 2 x 1.2 CM. SIZE OF INVASIVE COMPONENT: 2.1 CM. LOCATION OF THE TUMOR: 3:00, LATERAL NEAR THE AXILLARY TAIL. LYMPHATIC/VASCULAR INVASION: PRESENT. MULTIFOCAL TUMOR: ABSENT. IN-SITU CARCINOMA: PRESENT. TYPE OF IN-SITU CARCINOMA: CRIBRIFORM. NUCLEAR GRADE OF IN-SITU CARCINOMA: 2 OF 3. NECROSIS: PRESENT. DCIS EXTENDING OUTSIDE INVASIVE TUMOR MASS: ABSENT. SIZE OF IN-SITU CARCINOMA: NOT APPLICABLE. NIPPLE STATUS: FREE OF TUMOR. SKIN STATUS: FREE OF TUMOR. MUSCLE STATUS: NOT SAMPLED. STATUS OF NON-NEOPLASTIC BREAST TISSUE: FIBROCYSTIC CHANGES. HEMATOMA. SURGICAL MARGIN STATUS: NEGATIVE. AXILLARY LYMPH NODE STATUS TEN OF TWENTY-THREE LYMPH NODES POSITIVE. FOR METASTATIC CARCINOMA (10/23). SIZE OF LARGEST LYMPH NODE METASTASIS: 1.1 CM. EXTRANODAL EXTENSION: PRESENT. ESTROGEN/PROGESTERONE RECEPTOR, CELL CYCLE, EGFR AND HER2/NEU ANALYSIS: NOT PERFORMED. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es) . ADDENDUM 1: Please see. for results of supplementary. tests. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es) .",BRCA,3,True,"The report states that ten out of twenty-three lymph nodes are positive for metastatic carcinoma (10/23). This falls under the N3 classification, which is determined by the presence of metastases in 10 or more axillary lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion. Extranodal extension is present, but it does not change the N stage according to the rules.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N3,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
923,TCGA-B6-A0IQ.0ED7357E-662C-4D65-82ED-29739919068F,2,"Patierit. CLINICAL HISTORY: Infiltrating ductal cancer by incisional biopsy. GROSS EXAMINATION: A. ""Left breast"". Received fresh is a 600 gram, 17 x 14 x 4 cm breast with a. 7. x 5 x 2.5 cm axillary tail. There is a 15 x 10 cm skin ellipse with a 4 cm. in diameter areolar and a 1 cm in diameter nipple. 5 cm superior and lateral. to the nipple is a 2.5 cm well-healed scar. On cut section, a 5.5 x 4 x 3.5. cm firm tan-white mass lies deep to the skin incision. Within the mass is a. 1. x 1 x 1 cm hemorrhagic capsule. The mass appears well-circumscribed but. approaches to within 2 mm of the deep margin. No other lesions are noted. BLOCK SUMMARY: A1-A2- nipple. A3- scar and previous biopsy capsule. A4-A5- representative sections of tumor. A6-A7- deep margin. A8- upper inner quadrant. A9- lower inner quadrant. A10- lower outer quadrant. All- upper outer quadrant. A12- six lymph node candidates, proximal third. A13- five lymph node candidates, middle third. A14- five lymph node candidates, distal third. A15- four lymph node candidates, distal third. A16- four lymph node candidates, distal third. B. ""Rotter's node"". Received fresh is a 1.2 x 0.7 x 0.5 cm firm node which is. bisected and submitted in toto in Block B1. MICROSCOPIC EXAMINATION: The carcinoma is growing as rounded masses composed of nests and trabeculae. of carcinoma. There is extensive necrosis. 10 mitoses per 10 high power fields. are present. The pattern of growth makes it difficult to be certain what is. invasive and what is in-situ with cancerization of the lobules. DIAGNOSIS: A. ""LEFT BREAST"" (MASTECTOMY). BREAST WITH RESIDUAL INFILTRATING DUCTAL CARCINOMA, NSABP HISTOLOGIC GRADE. 3, NUCLEAR GRADE MODERATELY-DIFFERENTIATED. SIZE IS 5.5 x 4 x 3.5 CM. INCLUDING PRIOR BIOPSY CAVITY. LESS THAN 5% IDENTIFIABLE AS INTRADUCTAL CARCINOMA, SOLID AND COMEDO TYPES. THE CARCINOMA IS WITHIN 1 MM OF THE DEEP MARGIN. NO LYMPHATIC INVASION IS SEEN. BENIGN CHANGES OF THE BREAST INCLUDING APOCRINE METAPLASIA AND DUCT. ECTASIA. NIPPLE WITH NO PATHOLOGIC DIAGNOSIS. 26 LYMPH NODES WITH NO EVIDENCE OF MALIGNANCY. B. ""ROTTER'S NODE"" (EXCISION) : eBrowser Result for: 1 of 2. ONE LYMPH NODE, POSITIVE FOR CARCINOMA. eBrowser Result for;. 2 of 2.",BRCA,1,True,The report indicates that 26 lymph nodes were examined and one was found to be positive for carcinoma. This satisfies the criteria for N1 classification: 'N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.',"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
760,TCGA-AN-A0FN.6B53F577-5EB6-4AF5-9773-3654D3432BE4,0,Diagnosis: Breast Cancer Histological description: Infiltrative lobular carcinoma. Anatomic Site: Right breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: surgery Grade: 2. T Stage: 1 N Stage: 0 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,BRCA,0,True,"The N stage in this report is N0, as there is no evidence of cancer in the lymph nodes (N Stage: 0). This is in line with the rule 'If there is no evidence of cancer in the lymph nodes, the N stage is N0'.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1472,TCGA-OL-A5DA.5049C91E-F4BB-4AA7-BE64-837168189379,1,"):5849C91E-F4BB-4AA7-BE64-837168189379. FINAL PATHOLOGIC DIAGNOSIS. Sentinel node biopsy and partial mastectomy,. A. Right axillary sentinel node: - Single lymph node, no tumor (0/1). B. Right breast partial mastectomy: - Invasive lobular carcinoma, SBR grade II, with focal necrosis. - Focal atypical ductal hyperplasia and atypical columnar cell change. - Uninvolved breast parenchyma with apocrine metaplasia. Breast Pathologic Parameters. 1. Invasive carcinoma: A. Combined gross and microscopic measurement: 3.2cm. B. Composite histologic (modified SBR) grade II. - Architecture: 3. - Nuclear grade: 2. - Mitotic count: 1. C. Associated ductal carcinoma in situ (DCIS): Absent. 2. Excisional biopsy margins: Free of tumor. - Invasive carcinoma 1mm from superior (closest) margin (slide B14). - Additional margins greater than 2mm away. 3. Blood vessel and lymphatic invasion: Absent. 4. Axillary lymph nodes: Negative for tumor. 5. Special studies (see. - Expression of ER in 68% of invasive tumor nuclei. - Expression of PR in 66% of invasive tumor nuclei. - Her2/neu antigen (FISH): Non-amplified (ratio: 1). 6. pTNM: pT2, NO(sn), MX. Clinical History: This patient is a -year-old female with a right breast mass. The patient. self-palpated a breast mass in the right upper outer quadrant in. was sent for diagnostic mammography and ultrasound which revealed a. worrisome mass approximately 2.5 cm in size. An ultrasound-guided core biopsy. and clip placement was done. This was read as 3invasive mammary carcinoma with. lobular features4 by. The patient underwent a breast MRI on the. which demonstrated an irregularly shaped, posteriorly. positioned mass at 11 o'clock in the right breast measuring 4.5 X 2.5 cm. The. left breast and bilateral axillae were normal. The patient undergoes right. sentinel lymph node biopsy and right breast partial mastectomy with needle. localization. Comment. The tumor cells are negative for E-cadherin consistent with a lobular phenotype. AE1/AE3 stain is negative on the sentinel node. Specimens Received: A: Right axillary sentinel lymph node. B: Right Breast Partial Mastectomy. Gross Description: The specimen is received in two containers each labeled with the patient's name. and medical record number. A. Part A is additionally designated 31 right axillary sentinel node #14. Received fresh for frozen diagnosis is a 0.9 x 0.7 x 0.6 cm lymph node which is. bisected and entirely frozen and read as 3no evidence of metastatic tumor4 per. The remnant of frozen tissue is entirely submitted in cassette A1FS. B. Part B is additionally designated 32. right breast partial mastectomy4. Received fresh on an AccuGrid with accompanying radiograph is a 185.5 gm partial. mastectomy specimen. The specimen bears two needle localization wires and a. double long stitch as well as double short stitch for orientation. The overall. measurements are as follows: superior to inferior 9.8 cm, medial to lateral 9.5. cm, anterior to posterior 3.7 cm. The requisition designates the double long. stitch as lateral margin and short stitch as superior margin. The accompanying. radiograph demonstrates an irregularly shaped stellate mass within the partial. mastectomy specimen overlying quadrant C2, C3, D3 and D2. There is a needle. localization wire which enters at A3 and terminates at E1. There is a second. needle localization wire which enters A5 and terminates at E4. The mass is in. between these two wires. Thereis a single clip in quadrant D2. The specimen is inked as follows: anterior=black, posterior=red, lateral=violet,. medial=yellow, superior=blue and inferior=green. The specimen is serially. sectioned from lateral to medial into nine slices to demonstrate an irregularly. shaped, firm, white-tan mass present in slices #4 through #8. Needle. localization wires terminate in slices #3 and #8. The clip is not identified. The dimensions of the mass are 2.8 x 2.4 x 1.5 cm. The mass is present 0.2 cm. from the anterior margin, 2.7 cm from the inferior margin, 1.6 cm from the. superior margin, and greater than 2 cm from both lateral and medial margins. The remainder of the specimen demonstrates grossly unremarkable breast. parenchyma consisting of lobular, soft, yellow-tan tissue with intervening white. fibrous septa. Representative sections are submitted as follows: 31,B2: lateral margin, serially sectioned, entirely submitted. B3,B4: medial margin, serially sectioned, entirely submitted. B5: closest approach of mass to anterior margin, slice #5. B6: closest approach to superior margin, slice #6. B7: closest approach of mass to inferior margin, slice #6. B8: mass, representative section slice #6. B9: additional representative section of mass, slice #7. B10: representative section of tissue at termination of localization wire,. slice #3. B11,B12: tissue at needle localization wire termination, slice #8. B13,B14: representative sections of nodular tan-white breast parenchyma,. slice #9. B15,B16: representative sections of nodular tan-white breast parenchyma,. slice #10. B17: representative section of unremarkable breast parenchyma, slice #8. B18: representative section of unremarkable breast parenchyma, slice #12. Intraoperative Consult Diagnosis: A1FS. Right axillary sentinel lymph node: No evidence of metastatic tumor.",BRCA,0,True,"The report states that there is no evidence of cancer in the sentinel lymph node (0/1) and no axillary lymph nodes were involved. This meets the criteria for N0 staging, which is the absence of cancer in the lymph nodes.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,49.0,False
1239,TCGA-E2-A1IH.12DAEBF2-CDBF-4D90-9C74-2A2AEF1E8433,0,"SPECIMENS: A. SENTINEL NODE #1 LEFT AXILLA. B. SENTINEL NODE #2 LEFT AXILLA. C. LEFT BREAST MASS WITH NEEDLE LOCALIZATION cacF : Sik. breast, NOS C509 2/8/11. D. ADDITIONAL MARGIN LEFT BREAST. SPECIMEN(S): A. SENTINEL NODE #1 LEFT AXILLA. B. SENTINEL NODE #2 LEFT AXILLA. C. LEFT BREAST MASS WITH NEEDLE LOCALIZATION. D. ADDITIONAL MARGIN LEFT BREAST. GROSS DESCRIPTION: A. SENTINEL NODE #1 LEFT AXILLA. Received fresh is a tan pink lymph node 1.5 x 1.0 x 0.7cm. The specimen is serially sectioned and one. touch prep is taken. Toto A1. B. SLN #2 LEFT AXILLA. Received fresh is a tan pink lymph node 1.0 x 0.7 x 0.5cm. The specimen is serially sectioned and one. touch prep is taken. Toto B1. C. LEFT BREAST NEEDLE LOCALIZATION. Single stitch: Anterior. Double stitch: Lateral. Triple stitch: Superior. Received fresh is a 79g oriented WLE breast specimen 2.5cm from anterior to posterior, 7.5cm from. superior to inferior and 8.5cm from medial to lateral, with needle localization wire and attached. radiograph. The specimen is inked as follows: Anterior-Blue, Posterior-Black, Superior-Red, Inferior-. Orange, Medial-Green, Lateral-Yellow. The specimen is serially sectioned from lateral to medial in to 8. slices: slice 1 being most medial, slice 8 being most lateral. The cut surfaces reveal a gray white firm. well circumscribed mass 1.5 x 1.0 x 0.8cm, 0.6cm from the closest deep margin, 0.7cm from the. anterior margin and 0.8cm from the medial margin. The mass is located in slice 2 and 3. The remaining. cut surfaces reveal yellow lobulated adipose tissue interdispersed with gray white fibrous tissue. A. portion of the specimen is submitted for tissue procurement. Representative sections are submitted as. follows: C1-C5: medial margin perpendicular sections from superior to inferior slice 1. C6: superior margin slice 2. C7: mass with anterior and deep margin slice 2. C8: inferior margin slice 2. C9: superior margin slice 3. C10: mass with anterior margin slice 3. C11: mass with deep margin slice 3. C12: inferior margin slice 3. C13: next to mass with anterior margin slice 4. C14: next to mass with deep margin slice 4. C15: slice 5. C16: lateral margin perpendicular sections slice 8. As per attached diagram. D. ADDITIONAL MEDIAL MARGIN LEFT BREAST: Stitch at new margin. Received fresh is a 4g oriented tan pink fragment of fibrofatty tissue 5.0 x 2.0 x 1.0cm. The new true. margin is inked Black and the specimen is serially sectioned to reveal grossly unremarkable breast. parenchyma. Toto D1-D4. DIAGNOSIS: A. LYMPH NODE, SENTINE# 1, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). B. LYMPH NODE, SENTINE# 2, LEFT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). C. BREAST, LEFT, WIDE LOCAL EXCISION: - INVASIVE, LOBULAR CARCINOMA, SBR GRADE 2, MEASURING 1.5 CM. - SURGICAL MARGINS ARE NEGATIVE FOR TUMOR. - SEE SYNOPTIC REPORT AND SEE NOTE. D. BREAST, LEFT, ADDITIONAL MEDIAL MARGIN, EXCISION: - BREAST TISSUE, NO TUMOR SEEN. NOTE: The tumor is negative for E-cadherin, compatible with lobular phenotype. SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Yes - For mass. Laterality: Left. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive lobular carcinoma 8520/3. Tumor size: 1.5cm. Tumor Site: Upper inner quadrant. Margins: Negative. Tubular Score: 3. Nuclear Grade: 2. Mitotic Score: 1. Modified Scarff Bloom Richardson Grade: 2. Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node only. Lymph node status: Negative 0/2. DCIS not present. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Pending by FISH. Pathological staging (pTN): pT 1c N 0. SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimen: Surgical Excision. Block Number: ER: Positive. Allred Score: 8 = Proportion Score 5. +. Intensity Score 3. PR: Positive. Allred Score: 8 = Proportion Score 5 + Intensity Score 3. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the. proportion score (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of. cells staining, 4 = 31-60% of cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak. intensity of staining, 2 = intermediate intensity of staining, 3 = strong intensity of staining), with a scoring. range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score. of less than or equal to 2. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochemistry was performed using the mouse anti-human ER (ER 1D5, 1:100) and PR (PGR. 136, 1:100) provided by. following the manufacturer s instructions. This. assay was not modified. Interpretation of the ER/PR immunohistochemical stain is guided by published. results in the medical literature, information provided by the reagent manufacturer and by internal. review of staining performance. SYNOPTIC REPORT - BREAST HER-2 RESULTS. Specimen: Surgical Excision. Block Number: Interpretation: EQUIVOCAL. Intensity: 2+. % Tumor Staining: 20%. Fish Ordered: METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Her2 analysis was performed using the FDA approved Dako HercepTest (TM) test kit. using rabbit anti-human HER2. This assay was not modified. External kit-slides. provided by the manufacturer (cell lines with high, low and negative HER2 protein expression) and in-. house known HER2 amplified control tissue were evaluated along with the test tissue. Adequate, well. preserved, clear-cut invasive carcinoma was identified for HER2 evaluation. Interpretation of the HER2. immunohistochemical stain is guided by published results in the medical literature, information provided. by the reagent manufacturer and by internal review of staining performance. This assay has been validated according to the 2007 joint recommendations and guidelines from. ASCO and CAP and from the NCCN HER2 testing in Breast Cancer Task Force. takes full responsibility for this test's performance. CLINICAL HISTORY: woman with Left Breast Ca: Invasive Ductal 11 o'clock. 1.7cm on mammogram. PRE-OPERATIVE DIAGNOSIS: Left Breast Ca. INTRAOPERATIVE CONSULTATION: TPA/TPB: Negative for tumor. Diagnosis called to Dr at. by Dr. C. GROSS INSPECTION: 1.5cm mass 0.6cm from the closest deep margin, 0.7cm from anterior. margin. Diagnosis called to Dr. at. by Dr. D. GROSS INSPECTION: New medial margin. Negative for tumor. Diagnosis called to Dr. at. 1 by. Dr. ADDENDUM: FISH for HER-2 amplification for this case was attempted multiple times using multiple blocks from this. case. In each instance the tissue would not remain on the slide for analysis. As a result of this one block. will be sent to another laboratory for further testing. This case was sent to the for second opinion for HER-2 FISH. The results reported below are the. verbatim results of this referral. HER2 Amp. Breast Cancer. FISH. Specimen. Tissue-Paraffin. Specimen ID. Source. Left breast. Reason For Referral. r/o HER2 gene amplification. Fixative. Formalin. Method: FISH using probes for HER2 (17q12) and a chromosome 17 centromere (D17Z1) control probe. (PathVysion,. Two technologists score signals in 60 total nuclei from invasive or. metastatic tumor and concurrent controls. nuc ish (D17Z1x2, Her2x3-5). The HER2 to D17Z1 ratio is 2.28. Interpretation: The invasive tumor nuclei have an amplified HER2D17Z1 ratio (per ASCO/CAP. The HER2D17Z1 ratio is 2.28. In our opinion, this result may not. guidelines). reflect centromere true HER2 and amplification. 3-5 copies of Most the HER2 nuclei gene. have 2 This copies result of the indicates chromosome the. 17 tumor has. additional copies of the HER2 gene (i.e., duplication), but does not have sufficient. copies to suggest high level HER2 amplification. It is not known if HER2. duplication is associated with HER2 over-expression in breast adenocarcinoma. ASCO/CAP reporting guidelines (Wolff et al, Arch Path Lab Med 131:18-43, 2007). A HER2D17Z1 ratio less than 1.8 indicates absence of HER2 gene amplification. A HER2D17Z1 ratio from 1.8-2.2 is equivocal for HER2 gene amplification. A HER2D17Z1 ratio greater than 2.2 indicates HER2 gene amplification. DISCLAIMER: This test was developed and its performance characteristics determined. by Laboratory Medicine and Pathology, It is intended as. an adjunct to existing prognostic clinical and pathologic information for breast cancer. patients. This test is not intended to diagnose or screen for breast cancer. Per ASCO/. CAP guidelines, HER2FISH test results are valid for non-decalcified paraffin embedded. specimens fixed in 10% neutral buffered formalin between 6 and 48 hours. Results from. specimens fixed outside these parameters should be interpreted accordingly. Consultant. Report Data. Microscopic/Diagnostic Dictation: M.D., Pathologist,. Microscopia/Diagnostic Dictation: M.D., Pathologist. Final Review: M.D., Pathologist,. Final:, M.D., Pathologist,. Addendum: M.D., Pathologist,. Addendum Final: M.D., Pathologist, I. Addendum: M.D., Pathologist. Addendum Review: M.D., Patnologi: Addendum Final: M.D., Pathologist,.",BRCA,0,True,"The report states that there is no evidence of cancer in the lymph nodes (0/2). This is the primary determinant of the N stage, and the number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes. Therefore, the N stage is N0.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
734,TCGA-AC-A7VB.53881871-C36B-4622-BFC6-4DA3635D7B26,0,"Provider Group : Date of Service: Date Received: FINAL SURGICAL PATHOLOGY REPORT. Diagnosis: A. - F. RIGHT BREAST AND AXILLARY LYMPH NODES, MASTECTOMY, SENTINEL. LYMPH NODE BIOPSIES, AND AXILLARY LYMPH NODE DISSECTION: - Multifocal invasive ductal carcinoma, Nottingham grades 2-3. See comment. - Largest tumor nodule: 1.5 cm in diameter (6 o'clock aspect). - Two smaller nodules: 0.6 and 0.8 cm (7-8 o'clock aspect). - Ductal carcinoma in situ (DCIS), high nuclear grade, solid type. - DCIS comprises less than 10% of biopsy tissue volume, and is associated. with all three invasive tumor nodules. - Mastectomy margins are free of tumor. - Carcinoma is 3 cm from the inferior margin and is at least 6 cm from. all other margins. Metastatic carcinoma in three of fifteen lymph nodes (3/15). - Largest metastatic focus: 0.9 cm in diameter. - Extranodal extension present. - Positive lymph nodes are sentinel lymph nodes #2, #3, and #4. PATHOLOGIC TUMOR STAGING SYNOPSIS: Type and grade (invasive): Invasive ductal carcinoma, Nottingham grade 2-3. Type and grade (in situ): DCIS, high-nuclear grade. Primary tumor: pT1c(m). Regional lymph nodes: pN1c. Distant metastasis: Not applicable. Stage: IIA. Lymphovascular invasion: Indeterminate. Margin status: Negative. COMMENT: The three foci of invasive carcinoma have similar histologic features,. although the tumor grade is somewhat variable in the largest tumor nodule, where. there is a variable rate of mitosis, and nuclear pleomorphism ranging from. intermediate to high-grade. The smaller tumor nodules contain high-grade malignant. Printed: This report continues. Acct No. -. Pathology - Page 1/6. Page 1 Doc# 1. FINAL SURGICAL PATHOLOGY REPORT. epithelial cells arranged in solid sheets with frequent mitoses, compatible with. Nottingham grade 3. There is enough morphologic similarity between three nodules. to suggest that they have a common origin. Intradepartmental consultation: concurs with this impression. Invasive Breast Cancer Tumor Staging Information. AJCC Cancer Staging Handbook, 7th Ed. and CAP Protocol (revised June 2012). Previous pathology specimens: his report continues (FINAL). Printed: MR No. -. lage 2 Doc# 1. Pathology - Page 2/6. SPECIMEN IDENTIFICATION. Procedure/specimen type: Modified radical mastectomy. Laterality: Right. Lymph node sampling: Sentinel lymph node biopsies followed by lymph. node dissection. INVASIVE CARCINOMA TUMOR CHARACTERISTICS. Histologic type: Invasive ductal carcinoma (multifocal). Tumor sites: 6:00-8:00. Tumor size: Largest tumor nodule 1.5 cm. Tumor focality: Multifocal. Histologic grade (Nottingham Score): 2-3 of 3. Tubule formation: 3 of 3. Nuclear pleomorphism: 2-3 of 3. Mitotic rate: 2-3 of 3 (variable mitotic rate). Lymphovascular invasion: Indeterminate. Macroscopic and microscopic extent of tumor: No skin or chest wall invasion identified. DUCTAL CARCINOMA IN SITU (DCIS): Present in association with three invasive tumor. nodules. MARGINS. Invasive carcinoma: Negative. Ductal carcinoma in situ: Negative. LYMPH NODES. Total lymph nodes examined. 15. Number of lymph nodes involved. 3. Size of largest metastatic deposit: 0.9 cm. Extranodal extension: Present. PATHOLOGIC STAGING: Primary Tumor (pT): pTic(m). Regional lymph nodes (pN): pN1a. Distant metastasis (pM): Not applicable. AJCC Stage: IIA. ANCILLARY STUDIES: on 2. previous biopsies (additional HER2 studies. pending, to be reported in an addendum). Estrogen receptor: 85-96% positive cells, strong intensity. Progesterone receptor: 0% positive cells. HER2: Additional studies pending, to be reported in an. addendum. Printed: This report continues. Acct No. Pathology - Page 3/6. Page 3 Doc# 1. FINAL SURGICAL PATHOLOGY REPORT. Ki-67: Variable, previously reported 7-69%. Source of Specimen: A. Sentinel lymph node;#1--. right axillary. B. Sentinel lymph node;#2--. right axillary. C. Sentinel lymph node;#3-. right axillary. D. Sentinel lymph node;#4. right axillary. E. Breast surgical;right. F. Axillary nodes right. Clinical History/Operative Dx: Right breast cancer. Intraoperative Diagnosis: A. Sentinel node #1. - diagnosis: Negative for carcinoma. B. Sentinel node #2. - diagnosis: Rare atypical cells, suspicious for carcinoma. (Defer to. permanents). D. Sentinel node #4. and. - diagnosis: Positive for carcinoma. The intraoperative interpretation(s) was/were performed and rendered at. Gross Description: A. Part A is designated as sentinel node #1. right axilla, touch prep. Initially received in the fresh. state four frozen section/touch prep evaluation is a 1.0 x 0.8 x 0.6 cm piece of red-tan soft tissue. Examination reveals a 0.7 x 0.6 x 0.5 cm lymph node. The cut surfaces are fatty and rubbery, pink and. tan. Two touch imprint slides are prepared for microscopic evaluation. The lymph node is entirely. Printed: This report continues. Acct No. Pathology - Page 4/6. age 4 Doc# 1. FINAL SURGICAL PATHOLOGY REPORT. submitted for routine histology in A1 with a sentinel node protocol performed. B. Part B is sentinel node #2. Initially received in the fresh state for touch prep/frozen section. evaluation is a 1.5 X 1.2 x 1. 0 cm yellow-tan portion of tissue. Examination reveals a 0.8 x 0.6 x 0.6 cm. lymph node. Sectioning demonstrates a rubbery, pink and tan cut surfaces. Two touch imprint slides are. submitted for microscopic evaluation. The Ivmph node is entirely submitted for routine histology in B1. with a sentinel node protocol performed. C. Part C designated as sentinel node #3. right axillary. Received in formalin is a 1.5 x 1.5 x 0.7. cm fragment of fat. Examination reveals two possible apparent lymph nodes, 0.8 x 0.6 x 0.4 cm each. The. lymph node is serially sectioned and entirely submitted for microscopic evaluation in C1 with a sentinel. lymph node protocol performed. D. Part D is designated as sentinel node #4. right axillary. Initially received in the fresh state for. frozen section/touch imprint evaluation is a 1.5 X 1.2x 1.0 cm yellow-green portion of fatty soft tissue. Examination reveals a 1.0 x 0.8 x 0.8 cm dense, pink-gray lymph node. Two touch imprint slides and a. representative section is submitted for frozen section evaluation. The residual frozen tissue is submitted in. D1 for permanent sections and the touch imprint aspect of the lymph node is submitted in D2 for. permanent sections with a sentinel lymph node protocol performed. E. Received fresh labeled ""right breast."" Sutures present for orientation purposes. A portion of tumor is. submitted for. Laterality: Right. Specimen: Mastectomy. Size of mastectomy: (M-L x S-I x A-P): 23.5 x 19x 5 cm. Axillary tail: Not present. Skin: 24 x 18 cm, pigmented skin. Nipple/areola: Yes, center of skin. Specimen weight: 971 grams. Ink code: Blue - superior-anterior, orange - inferior-anterior, black - deep. Stabs: Total # 11, M-I= 1, L-S= 11. Nipple in slab #6. Time of resection: Time placed into formalin: Time out of formalin: Lesion 1: Biopsy site present. Size: 1.5 x 1.4 x 0.8 cm, stellate, gray-white, firm mass. Location: 6:00. Involves slabs # 3-4. Distance to nearest margin(s): 3 cm from inferior margin, 6 cm from deep margin. Lesion #2: Biopsy site present. Size: 0.8 x 0.5 x 0.5 cm. Location: 7:00. Involves slabs #2-3. Distance to nearest margin(s): 6 cm from inferior. Printed: This report continues (FINAL). MR No. -. Acct No. -. Pathology - Page 5/6. - Page 5 Doc# 1. FINAL SURGICAL PATHOLOGY REPORT. Lesion #3: No biopsy site present. Size: 0.6 x 0.6 x 0.5 cm. Location: 7:00. Involves slabs #4. Distance to nearest margin(s): 5 cm from inferior. Non-lesional breast: Fibrofatty breast tissue. Cassette summary: E1) smallest 7:00 tumor, previously biopsied (portion of the small tumor submitted for. E2-E4) largest 6:00 lesion,. E5) central breast tissue,. E6-E7) lateral breast tissue,. E8) nipple/subareolar breast tissue,. E9) representative breast tissue,. E10-E11) fibrous tissue medial to largest tumor,. E12) representative medial breast tissue,. E13) mass #3, 7:00,. E14-E15) central posterior breast tissue. F. Part F is which axillary nodes, right. Received in formalin is an 83 gram partially tattered portion of. yellow-tan fatty soft tissue, 13.0 x 9.0 x 2.6 cm. Examination reveals eleven lymph nodes ranging from 0.2. cm to 1.9 X 1.4 x 1.2 cm in greatest dimension. The lymph nodes are entirely submitted for microscopic. evaluation. Cassette summary: F1) four lymph nodes,. Ne. F2) four lymph nodes,. F3) one lymph node, bisected,. F4) one lymph node, bisected,. F5-F6) largest lymph node, serially sectioned. Microscopic Description: A. - C. Immunohistochemical stain: CK OSCAR, showing focal metastatic carcinoma in specimens B and. C. D. Immunohistochemical stain: CK OSCAR, highlighting metastatic carcinoma. HER2 - results pending, to. be reported in an addendum. E. Immunohistochemical stain: HER2, to be reported in an addendum. F. Microscopic sections have been examined. The microscopic findings are reflected in the diagnosis. rendered. Printed: END OF REPORT (FINAL). MR No. -. Acct No. 'atient Name -. Pathology - Page 6/6. uge 6 Doc# 1.",BRCA,1,True,The report indicates that there are 3 positive lymph nodes out of 15 examined. This corresponds to the N1 stage in the AJCC staging system for breast cancer.,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1501,TCGA-S3-AA0Z.6EC48BF8-C9AE-4B53-9DF4-850A5BAC6A6E,1,"Temporary Copy. Diagnosis. A. SENTINEL LYMPH NODE, BIOPSY: - METASTATIC CARCINOMA IN TWO OF FOUR LYMPH NODES (2/4). B. LEFT BREAST, TOTAL MASTECTOMY: - INVASIVE DUCTAL CARCINOMA, PRESENT AS TWO SEPARATE FOCI AT 12 AND 3. O'CLOCK, 3.5 AND 2.5 CM IN GREATEST DIEMENSION RESPECTIVELY. - MARGINS OF RESECTION ARE FREE OF CARCINOMA. - SEE SYNOPTIC REPORT. C. LYMPH NODES,. LEVEL 1 AND 2, LYMPHADENECTOMY: Carenoma, in ichating 850013 duct Nos. - NO TUMOR SEEN IN EIGHT LYMPH NODES (0/8). - SEE SPECIAL STAINS SECTION. (Electronic signature). Verified: Synoptic Report. SPECIMEN: Total breast (including nipple and skin). PROCEDURE: Total mastectomy (including nipple and skin). LYMPH NODE SAMPLING: Axillary dissection (partial or complete dissection). SPECIMEN INTEGRITY: Single intact specimen (margins can be evaluated). SPECIMEN SIZE: Greatest dimension: 18 cm. Additional dimensions: 16 x 3 cm. SPECIMEN LATERALITY: Left. TUMOR SITE: INVASIVE CARCINOMA: Position: 12 o clock (, second mass at 3 o'clock). TUMOR SIZE: SIZE OF LARGEST INVASIVE CARCINOMA: Greatest dimension of largest focus of invasion over 0,1 cm: 3.5 cm. TUMOR FOCALITY;. Multiple foci of invasive carcinoma. Number of foci; 2. Sizes of individual foci: 3.5 and 2.5. MACROSCOPIC AND MICROSCOPIC EXTENT OF TUMOR: Skin: Invasive carcinoma does not invade into the dermis or epidermis. Nipple: DCIS does not involve the nipple epidermis. DUCTAL CARCINOMA IN SITU (DCIS): DCIS is present. Extensive intraductal component (EIC) negative. SIZE (EXTENT) OF DCIS: Estimated size (extent) of DCIS (greatest dimension using gross and microscopic evaluation) is at least. Temporary Copy. 0.35 cm. ARCHITECTURAL PATTERNS: Cribriform. NUCLEAR GRADE: Grade II (intermediate). NECROSIS: Not identified. LOBULAR CARCINOMA IN SITU (LCIS): Not identified. HISTOLOGIC TYPE OF INVASIVE CARCINOMA: Invasive ductal carcinoma (no special type or not otherwise specified). GLANDULAR (ACINAR)/TUBULAR DIFFERENTIATION: Score 3: <10% of tumor area forming glandular/tubular structures. NUCLEAR PLEOMORPHISM: Score 2: Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in. both size and shape. MITOTIC COUNT: Score 3. OVERALL GRADE: Grade 3: scores of 8 or 9. MARGINS: Margins uninvolved by invasive carcinoma. Distance from closest margin: 5 mm (anterior). Margins uninvolved by DCIS (if present). LYMPH-VASCULAR INVASION: Present. DERMAL LYMPH-VASCULAR INVASION: Not identified. LYMPH NODES: Number of sentinel lymph nodes examined: 4. Total number of lymph nodes examined (sentinel and nonsentinel): 12. Number of lymph nodes with macrometastases (>0.2 cm): 2. Number of lymph nodes with micrometastases (>0.2 mm to 0.2 cm and/or >200 cells): 0. Number of lymph nodes with isolated tumor cells (less than or equal to 0.2 mm and less than or equal to. 200 cells): 0. Size of largest metastatic deposit: 1.1 cm. METHOD OF EVALUATION OF SENTINAL LYMPH NODES: Hematoxylin and cosin (H&E), one level. PRIMARY TUMOR (INVASIVE CARCINOMA (pT): pT2: Tumor >20 mm but less than or equal to 50 mm in greatest dimension. REGIONAL LYMPH NODES (pN): pN1a: Metastases in 1 to 3 axillary lymph nodes, at least 1 metastasis greater than 2.0 mm. DISTANT METASTASIS (M): Not applicable. ADDITIONAL PATHOLOGIC FINDINGS: intraductal papillomas, proliferative fibrocystic changes. MICROCALCIFICATIONS: Present in non-neoplastic tissue. Temporary Copy. Specimen Source. A. Lymph Nodes, Sentinel. B. Breast Biopsy, Left, Review of Margins. C. Level 1 and 2 Axillary nodes. Clinical Information. Patient with multicentric left breast cancer, for mastectomy (12:00 and 3:00), marks lateral breast and lymph. node biopsy. PRE-OP DIAGNOSIS: Left breast cancer. POST-OP DIAGNOSIS: Same. TYPE OF PROCEDURE: Lymph node biopsy, left mastectomy node dissection with immediate reconstruction. with tissue expanders. Gross Description. The specimen is received in two parts. A. The specimen is labeled ""SENTINEL NODE"" and is received unfixed for frozen section diagnosis. It consists. of a fibrofatty pink-yellow tissue measuring 3.5 x 2.5 x 1.3 cm. On sectioning there are four lymph nodes. ranging from 0.4-1.5 cm in maximum dimensions. The lymph nodes are entirely submitted in cassettes FS A1. one large lymph node bisected and one small lymph node, FS A2 one lymph node bisected, FS A3 one lymph. node bisected. Time specimen was removed from the patient: Time specimen was placed in formalin: Ischemic time: 2 hours 9 minutes. Specimen left OR. at. Front desk. B. The specimen is labeled ""LEFT TOTAL MASTECTOMY"" it is received unfixed (the specimen is in formalin. for more than 6 hours and less than 48 hours). It consists of a 490 g left mastectomy with a suture designated. lateral breast measuring 18 x 16 x 3 cm. The round skin ellipse measures 5.5 x 4.0 cm in maximum dimensions. The nipple is flat and an unremarkable measures 1.4 x 1,4 cm in maximum dimensions. The areolar is dark. brown and unremarkable. The fascia is smooth and glistening. The anterior margin is inked red and the deep. posterior margin of resection is inked black. On sectioning, there is an ill-defined cavitated mass surrounded by. firm fibrous pink-yellow tissue measuring 3.5 x 2.5 x 2.5 cm. The mass is at 12:00, approximately 5 cm from the. nipple, 0.5 cm from the anterior margin and 3.5 cm from the posterior margin. On further sectioning there is a. second lobulated firm pink yellow mass measuring 2.5 x 2.0 x 1.2 cm., this mass is at 3:00, approximately 7 cm. from the first mass at 12:00, 5 cm from the nipple, 0.6 cm from the anterior margin and 2.3 cm from the deep. posterior margin mass. The surrounding breast parenchyma is nodular and shows an area of hemorrhage. previously inked blue. Representative sections are submitted. Section Key: B1 - nipple and skin. B2 - anterior margin and deep posterior margin corresponding to 12:00 mass. B3 - B4 random sections of mass corresponding to 12:00. B5 - anterior margin and deep posterior margin corresponding to 3:00 mass. B6 - B7 random sections of mass corresponding to 3:00. Temporary Copy. D: B8 - random sections of nodular fibrous tissue surrounding the 12:00 mass. B9 - random sections of nodule fibrous tissue surrounding the 3:00 mass. B10 - upper inner quadrant. B11 - lower inner quadrant. B12 - upper outer quadrant. B13 - lower outer quadrant. Time specimen was removed from the patient: Time specimen was placed in formalin: Ischemic time: 40 minutes. C. The specimen is labeled ""LEVEL I AND II AXILLARY NODES"" and is received unfixed. It consists of a. nodular fatty yellow-pink tissue measuring 8 x 7.2 x 1.6 cm. On sectioning, there are eight fatty lymph nodes. ranging from 0.5-2.5 cm in maximum dimensions. The lymph nodes are entirely submitted. Section Key: C1 - C2 largest lymph node bisected. C3 - one lymph node bisected. C4 - one lymph node bisected. C5 - one lymph node bisected. C6 - two lymph nodes. C7 - two lymph nodes. Time specimen was removed from the patient: Time specimen was placed in formalin: Ischemic time: 3 hours 30 minutes. Special Stains / Slides. immunohistochemical studies were performed on formalin fixed, paraffin-embedded tissue (Block C6) with. adequate positive and negative control sections. Cytokeratins AE1/AE3 fail to reveal metastatic carcinoma. IMMUNOHISTOCHEMICAL EVALUATION OF ESTROGEN RECEPTORS, PROGESTERONE. RECEPTORS, AND HER-2NEU IN INVASIVE MAMMARY CARCINOMA, FOCUS AT 12 O'CLOCK. (BLOCK B4): ESTROGEN RECEPTORS: 60%, POSITIVE, STAINING INTENSITY: WEAK TO MODERATE. PROGESTERONE RECEPTORS: 0 %, NEGATIVE. HER-2NEU: SCORE 1+, NEGATIVE. Temporary Copy. D. IMMUNOHISTOCHEMICAL EVALUATION OF ESTROGEN RECEPTORS, PROGESTERONE. RECEPTORS, AND HER-2NEU IN INVASIVE MAMMARY CARCINOMA, FOCUS AT 3. O'CLOCK(BLOCK B7): ESTROGEN RECEPTORS: 90%, POSITIVE, STAINING INTENSITY: MODERATE. PROGESTERONE RECEPTORS: 2 %, POSITIVE, STAINING INTENSITY: WEAK. HER-2NEU: SCORE 2+, EQUIVOCAL. Immunohistochemical studies were performed on formalin fixed paraffin embedded tissue (Blocks B4 and B7). using the following monoclonal antibodies: Estrogen receptor (Clone SP1), Progesterone receptor (Clone 1E2). and Her-2neu (. Clone 4B5); control sections for HER-2Neu are provided within a kit (score 0 MCF-7,. score 1+ T-47D, score 2+ MDA-MB-453, score 3+ BT-474). Detection system used: polymer. Primary. antibodies, reagents and control sections for HER-2neu are all provided by. All controls show appropriate reactivity. Reactivity of Estrogen and Progesterone receptors is determined based on the percentage of positively. stained nuclei of tumor cells. Reference values (CAP accreditation program checklist 2010 and guidelines on. webpage): Positive: nuclear-staining in 1% or greater than 1% of invasive carcinoma cells. Negative : nuclear staining in less than 1% of invasive carcinoma cells. Staining intensity: is reported as weak, moderate or strong. HER-2neu reactivity is reported applying the CAP scoring guidelines (CAP accreditation program checklist. 2010 and guidelines on webpage): Score 0 = Negative: No immunoreactivity, or faint weak immunoreactivity in <10% of tumor cells but only a. portion of the membrane is positive.. Score 1 = Negative: Faint weak immunoreactivity in 10% or >10% of tumor cells but only a portion of the. membrane is positive. Score 2+ = Equivocal: Weak to moderate complete membrane immunoreactivity in >10% of tumor cells or. circumferential intense membrane staining in <30% of cells. Score 3+ = Positive: More than 30% of the tumor cells must show circumferential intense and uniform. membrane staining. A homogeneous (chicken wire) pattern should be present. Equivocal results for HER-2neu (Score 2+) will be subsequently followed by a reflex dual-color ISH testing. The performance characteristics of these antibodies were determined by the. They have not been cleared or approved by the U.S. Food. and Drug Administration The FDA has determined that such clearance or approval is not necessary. These tests are used. for. clinical. purposes. They should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory. Improvement Amendments of 1988 (CLIA-88) as qualified to perform high-complexity clinical laboratory testing. 6 FS, 23 H&E, 7 IHC. Tissue Code. Addendum Repart. Temporary Copy. Addendum Report. ASSAY PERFORMED: HER2 GENE AMPLIFICATION BY DUAL IN SITU HYBRIDIZATION. USING THE INFORM HER2 Dual ISH DNA PROBE COCKTAIL. Number of nuclei scored: 20. Total HER2 signals: 42. Total CHR 17 signals;. 33. HER2/CHR 17 ratio: 1.3. INTERPRETATION: -/NEGATIVE FOR HER2 GENE AMPLIFICATION. NOTE: THE ASSAY WAS PERFORMED AS A REFLEX TEST AFTER THE HER2/NEU. IMMUNOSTAIN WAS 2+. SPECIMEN TYPE: The. HER2 Dual ISH DNA is performed on a formalin-fixed paraffin-embedded. tissue slide from block B7. DESCRIPTION OF THE ASSAY: The. HER2 Dual ISH DNA Probe assay. enables the HER2 gene and Chrl7 centromere to be co-hybridized and visualized via light microscopy. on the same slide. Specifically for this assay, HER2 is detected by a dinitrophenyl (DNP) labeled probe. visualized utilizing. SISH DNP (silver in situ hybridization) detection kit. The Chr17 centromere is. targeted with a digoxigenin (DIG) labeled probe and detected using. Red ISH DIG detection kit. Dual. ISH staining results in visualization by light microscopy and which HER2 appears as discrete black signals. (SISH) and Chrl7 as red signals in nuclei of normal cells serving as internal positive control for staining) as. well as in carcinoma cells. SLIDE SCORING: Once an adequate target area is identified the reader records the scores for HER2 and. Chr17 copy numbers that are present in 20 representative nuclei. If the resulting HER2 / Chr17 ratio falls within. 1.8-2.2 (EQUIVOCAL) the reader is recommended to score an additional 20 nuclei and the resulting ratio is. calculated from the total 40 nuclei. HER2 gene status is reported as non-amplified (HER2/ Chr 17 < 2.0) or. amplified (HER2/Chrl7>2.0). The performance characteristics of this assay were determined by the. This assay has been approved by the U.S. Food and Drug. Administration This laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) as qualified to. perform high-complexity clinical laboratory testing. cpt: 88368 x2. (Electronic signature). Verified:",BRCA,1,True,"The report states that there are metastases in 2 out of 4 sentinel lymph nodes, and no other information is provided that would indicate a higher N stage. Therefore, the N stage is N1.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
584,TCGA-A7-A26H.1159E2EF-6407-4D90-8ED6-7AB04CF4FB32,0,"DEPARTMENT OF PATHOLOGY AND LABORATORY MEDICINE. Date Coll: SPECIMEN. A. Left axillary sentinel node. B. Left breast (arrow points up). C. Right axillary sentinel node. D. Right axillary sentinel node #2 active in blue. E. Right breast (arrow points up). F. Left axillary contents. CLINICAL NOTES. PRE-OP DIAGNOSIS: Bilateral breast. FROZEN SECTION DIAGNOSIS. A) Sentinel lymph node, left axilla, biopsy: One lymph node,. positive for carcinoma. C. Sentinel lymph node, opsy: One lymph node,. negative for carcinoma. D. Sentinel lymph node, right axilia #2, biopsy: One lymph node,. negative for carcinoma. GROSS DESCRIPTION. A. The specimen is received unfixed labeled ""left axillary sentinel. noand consists of a yellow and red piece of soft tissue measuring. 2.5 x 2 x 0.8 cm. On cut section there is a contained lymph node. measuring 1.2 cm. in greatest dimension. The node is bis -and. submitted all for frozen section diagnosis as requested. B. The specimen is received unfixed labeled ""left breast. arrow points up"" and consists of a breast resection. specimen measuring 19.5 x 18.5 x 3.0 cm. There is an overlying. white ellipse of skin measuring 16 x 9.3 cm. There is a central. areola measuring 3 x 4 cm. and a central nipple measuring 1.2 x 1. x. 0.4 cm. There is an arrow incised in the skin and there is an area. of induration at the superior edge of the areola that might be. a. biopsy scar. It measures 1.5 x 0.7 cm. The deep surface of the. specimen is inked. The breast is sectioned at 1 cm. intervals in. the deep surface towards the skin. Some blue-domed cysts are. present. There is a relatively central red area compatible with a. biopsy site defect and there is some firmness around this area. The. firm area measures 1.5 x 1.5 x approximately 1.5 cm. This area. is. central and inferior and there is another area that is central below. the indurated part of the skin that looks like carcinoma grossly and. measures 1.2 x 1.5 x approximately 1.5 cm. A portion of the larger. area is taken for research purposes. Sections after fixation. Block summary: 1,2 nipple and skin with tumor; 3 deep margin; 4-6. biopsy site; 7-10 quadrants (UO, UI, LO, LI). C. Received unfixed labeled ""right axillary sentinel node"". and consist of two pieces of yellow and red soft tissue. measuring 2 x 1.8 x 0.7 cm. and 2.5 x 2.5 x 0.7 cm. There is a. contained lymph node measuring 1 cm. in greatest dimension and the. entire node is submitted for frozen section diagnosis as requested. D. Received unfixed labeled ""right axillary sentinel node. #2 active in blue"" and consist of a yellow, red and blue. piece of soft tissue measuring 5.5 x 3 x 0.6 cm. There is. a. partially blue contained lymph node measuring 2.3 cm. in greatest. dimension. The specimen is submitted all for frozen section. diagnosis as requested. E. [The original gross dictation on specimen E. is lost.] The. specimen was received unfixed labeled right breast and consisted of. a 27 x 19 x 4.5 cm breast resection specimen with overlying ellipse. of skin measuring 16.5 x 9 cm. There was a central areola and. nipple. An area of arrow was incised to the skin. Some blue dye. and. injected. The deep surface the specimen was inked and the breast. resection at 1 cm intervals from the deep surface towards the skin. There was a central biopsy site and additional relatively central. firm area compatible with carcinoma. Block summary: 1, nipple; 3 skin; 4 - deep margin; 5-7 biopsy. site; 8,9 area resembling tumor; 10-13 quadrants (UO.UI.LO.LI). F. The specimen was received unfixed, labeled ""left. axillary contents"" and consists of a yellow and pink of. soft tissue measuring 12 x 8 x 2 cm. RS-2. MICROSCOPIC DESCRIPTION. A. Metastatic carcinoma is present in one lymph node. The tumor is. 0.7 cm in diameter. No extranodal tumor is seen. B. Invasive carcinoma. Tumor type: Infiltrating ductal carcinoma. Tumor grade: 1 (Elston SBR grade; A/N/M = 2/2/1). Mitotic index: 3 mitoses/10 HPFs (1 HPF = 0.196 sq mm). Tumor size: 1.5 cm. Vessel invasion: Absent. Calcification: Absent. pTNM stage: T1 pN1a. Prognostic markers: Requested. Nipple: Carcinoma is present in skin adjacent to the nipple. Deep margin: Negative for malignancy. Nontumorous breast: Sections from the biopsy site away from. the tumor show scar, cyst formation, columnar metaplasia,. benign calcification, usual ductal hyperplasia and focal atypical. ductal hyperplasia. C. A Single lymph node is negative for malignancy. D. A single lymph node is negative for malignancy. E. Invasive carcinoma. Tumor type: Infiltrating ductal carcinoma. Tumor grade: 2 (Elston SBR grade; A/N/M = 3/2/1). Mitotic index: 3 mitoses/10 HPFs (1 HPF = 0.196 sq mm). Tumor size: 1.2 cm on the glass slide. Vessel invasion: Absent. Calcification: Absent. pTNM stage: T1. Prognostic markers: See previous biopsy. The tumor is specimen E from the right breast has a central fibrotic. focus. Sections near the biopsy site away from the gross carcinoma. described above show columnar metaplasia, usual ductal hyperplasia,. cyst formation apocrine metaplasia. An atypical area is p63. positive. F. There is no evidence of malignancy in any of 4 lymph nodes. 4x6,25x3,20,14x3. DIAGNOSIS. A. Sentinel lymph node, left axilla, biopsy: Metastatic carcinoma in. a single lymph node. B. Breast, left, resection: Infiltrating ductal carcinoma, Elston. SBR grade 1. C. Sentinel lymph node, right axilla, biopsy: A single lymph node is. negative for malignancy. D. Sentinel lymph node #2, right axilla, biopsy: A single lymph node. is negative for malignancy. E. Breast, right, resection: Infiltrating ductal carcinoma, Elston. SBR grade 2 F. Lymph nodes, left axilla, blopsy: There is no. evidence of malignancy in any of 4 lymph nodes. ictronic Signature).",BRCA,1,True,"The report indicates that there is metastatic carcinoma present in one lymph node in the left axilla, which is the sentinel node (A). This satisfies the criteria for N1 classification, which is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1324,TCGA-E9-A3X8.00058FFD-35E6-4891-8B01-DAB3AE9EBF78,1,"Laterality:Left-UOC. Path Report: BREAST TISSUE CHECKLIST. Specimen type: Radical mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 3.5 X 3.5 x 3.5 cm. Grossly evident lesion: Yes. Histologic type: Lobular carcinoma. Histologic grade: Not specified. Tumor extent: Not specified. Lymph nodes: 4/8 positive for metastasis (Axillary 4/8). Extracapsular invasion of the lymph nodes: Not specified. Margins: Not specified. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: ER,PR-8 points, HER2NEU-O.",BRCA,1,True,"The report indicates that there are 4 out of 8 axillary lymph nodes positive for metastases. According to the rules provided, N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes. Therefore, the N stage for this patient is N2.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N2,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1287,TCGA-E9-A1R3.BE186852-8596-4CDB-B5C4-AA5838C15B5F,1,"OC ID. Gross Description: Mammary gland with the tumour of 2.5 x 2.2 cm in size; fatty tissue lymph nodes are dense, hyperemic. Microscopic Description: Infiltrating duct carcinoma, G2. Ten dissected lymph nodes demonstrate metastases. Diagnosis Details: Tumor Features: Unknown, Tumor Extent: T2 tumor size more than 2cm not more than 5 cm, Venous Invasion: Absent,. Margins: Absent, Treatment Effect: Comments: Postoperative staging reads: T2N3aM0. BREAST TISSUE CHECKLIST. Specimen type: Radical mastectomy. Specimen size: Not specified. Tumor site: Upper inner quadrant. Tumor size: 2.2 x 0: x 2.5 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal carcinoma. Histologic grade: Moderately differentiated. Tumor extent: Not specified. Lymph nodes: 10/10 positive for metastasis (Axillary 10/10). Extracapsular invasion of the lymph nodes: Not specified. Margins: Uninvolved. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None. Laterality: Right, upper outer quadrant.",BRCA,3,True,"The report indicates that 10/10 lymph nodes are positive for metastases. According to the rules provided, N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes. Therefore, the N stage for this patient is N3.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N3,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1152,TCGA-D8-A1XS.6C97C157-05A0-45CE-91E9-3DC8946EFEDE,1,"page 1 / 1. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: M. Material: Multiple organ resection - left breast With axillary tissues. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the left breast. Upper outer quad. Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in over 75% of. neoplastic cell nuclei. HER2 protein stained with HercepTestâ¢M by DAKO. Positive reaction in invasive cancerous cells ( Score = 3+. Compliance validateu. Macroscopic description: Left breast sized 17.5 x 14 x 3 cm removed along with axillary tissues sized 8 x 12 x 3 cm and a skin flap of 13 x 5 cm. Tumour sized. 3.5 x 2.5 x 2.0 cm found on the boundary of outer quadrants, located 4.7 cm from the lower boundary, 0.15 cm from the base and. 0.8 cm from the skin. Lymph nodes from 0.2 to 2.8 cm. Microscopic description: Carcinoma ductale invasivum (partim Carcinoma micropapillare) - NHG2 (3+2+2/11 mitoses/10 HPF - visual area: 0.55mm). Foci of carcinoma ductale in situ (DCIS) present within the tumour (micropapillary and cribrate type with medium nuclear atypia. Mamilla sine laesionibus). Glandular tissue showing gynaecomasthia. Axillary lymph nodes: Metastases et micrometastases carcinomatosae in lymphonodis (No XXV/XXVIII). Infiltratio capsulac lymphonodorum et telae. perinodalis. Histopathological diagnosis: Carcinoma ductale invasivum partim carcinoma micropapillare invasivum. Invasive ductal and partially micropapillar carcinoma. of the left breas). Metastases et micrometastases carcinomatosae in lymphonodis axillae (No XXV/XXVIII). Cancer metastases. and micrometastases in axillary lymph nodes (NHG2; pT2; pN3a). Compliance validated h.",BRCA,3,True,"The report indicates the presence of cancer metastases in axillary lymph nodes, specifically 25 out of 28 nodes are involved (Metastases et micrometastases carcinomatosae in lymphonodis axillae (No XXV/XXVIII)). This corresponds to the N3 classification, which is determined by the presence of metastases in 10 or more axillary lymph nodes.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N3,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1154,TCGA-D8-A1XU.845F8FCF-CF3C-4CEF-B673-A57DE626939C,0,"page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Total organ resection - left breast. Material collected on: I. Expected time of examination: up to 8 working days. Clinical diagnosis: Bifocal cancer of the left breast. Simple mastectomy. Results of immunohistochemical examination: Focus marked as R1: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in 10-75% of neoplastic cell nuclei. HER2 protein stained using rabbit antibody Ventana PATHWAY HER-2/neu (4B5). Negative reaction in invasive cancerous cells. (Score = 1+). Focus marked as R2: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in 10-75% of neoplastic cell nuclei. HER2 protein stained using rabbit antibody Ventana PATHWAY HER-2/neu (4B5). Negative reaction in invasive cancerous cells. (Score = 1+). Compliance valid. Macroscopic description: Carcinoma ductale bifocale - NHG2 (3 + 2+1:0 mitoses/ 10 HPF, visual area diameter: 0,55 mm). Carcinoma ductale in situ (DCIS) within the tumours (solid and cribrate type with high nuclear atypia, and point and comedo. necrosis, 10% of the tumour areas). Invasio carcinomatosa vasorum. In situ lesion of the type cancerisatio lobulorum. Mamilla sine laesionibus. Glandular tissue showing parenchymal atrophy. Examination: Histopathological examination. page 2 / 2. Gender: F. Histopathological diagnosis: Carcinoma ducale bifocale invasivum et in situ mammae sinistrae. Invasive bifocal ductal carcinoma and carcinoma in situ of the. left breast (NHG2, pTic, pNO (SN)). Invasio carcinomatosa vasorum. Vascular invasion. Compliance valida.",BRCA,0,True,"The report states that there is no evidence of cancer in the lymph nodes (pNO). This is the primary determinant of the N stage, and the number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes. Therefore, the N stage is N0.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
947,TCGA-B6-A1KC.E1FDF8EB-9D75-4629-9C78-6019DAF8190E,1,", Surgical Pathology: Additional Info. CLINICAL HISTORY: Per Browser: Right breast mass at 9:00 position, invasive ductal carcinoma. GROSS EXAMINATION: A. ""Sentinel node #1, hot and blue"". Received fresh and placed in formalin is. a 2 x 1 x 1 cm brown-yellow fragment of fibroadipose tissue. The specimen is. sectioned and submitted entirely in block A1. B. ""Sentinel node #2, hot not blue"". Received fresh and placed in formalin is. a 3.5 x 1.5 x 1.2 cm fragment of brown-yellow fibroadipose tissue. The. specimen is sectioned and submitted entirely in blocks B1 and B2. C. ""Right breast mass"". Received fresh and placed in formalin is a 10.5 (M-L). by 7.7 (A-P) by 4.0 (S-I) cm excisional breast biopsy. The anterior is inked. blue, the posterior is inked black, the superior is inked red, and the. inferior is inked yellow. There is a 4.6 x 1.5 cm ellipse of skin. There is. a 2.0 x 1.8 x 1.0 cm well circumscribed firm white nodule in the anterior. middle portion of the biopsy. The mass approaches within 2.0 mm of the. anterior margin and within 0.5 cm of the ellipse of skin. Representative. sections are taken medially to laterally from blocks C1-C25. BLOCK SUMMARY: C1-. most medial section. C2-. second most medial section. C3-10- representative sections moving laterally towards mass. C11-21- representative sections with mass. C22-25- representative section moving laterally. D. ""Final anterior, inferior margin"". Received fresh and placed in formalin. is a 3 x 2 x 1 cm fragment of brown-yellow fibroadipose tissue. A stitch is. placed on the margin by the surgeon. Blue ink is placed next to the suture,. the suture is removed, and the specimen is bisected. The inked blue side is. placed in blocks D1 and D2. The rest of the specimen is placed in block D3. Dr. Dr. slides to Dr. MICROSCOPIC EXAMINATION: Microscopic examination is performed. DIAGNOSIS: A. ""SENTINEL NODE #1, HOT AND BLUE"", (EXCISIONAL BIOPSY) : METASTATIC CARCINOMA IN ONE LYMPH NODE (1/1). SIZE OF METASTASIS: 0.8 CM. NEGATIVE FOR EXTRACAPSULAR EXTENSION. B. ""SENTINEL NODE #2, HOT NOT BLUE"", (EXCISIONAL BIOPSY). ONE LYMPH NODE (0/1), NEGATIVE FOR MALIGNANCY. IMMUNOHISTOCHEMICAL STAINS FOR CYTOKERATIN ARE NEGATIVE. C. ""RIGHT BREAST MASS"", (EXCISIONAL BIOPSY) : INVASIVE ADENOCARCINOMA OF THE BREAST. HISTOLOGIC TYPE: DUCTAL. https://. NOTTINGHAM COMBINED HISTOLOGIC GRADE: 3 OF 3. TUBULE FORMATION SCORE: 3. NUCLEAR PLEOMORPHISM SCORE: 3. MITOTIC RATE SCORE: 2. GROSS TUMOR SIZE: 2.0 x 1.8 X 1.0 CM. SIZE OF INVASIVE COMPONENT: 2.0 x 1.8 x 1.0 CM. LYMPHATIC/VASCULAR INVASION: PRESENT. MULTIFOCAL TUMOR: ABSENT. IN-SITU CARCINOMA: PRESENT. TYPE OF IN-SITU CARCINOMA: CRIBRIFORM AND COMEDO. NUCLEAR GRADE OF IN-SITU CARCINOMA: 3 OF 3. NECROSIS: PRESENT. DCIS EXTENDING OUTSIDE INVASIVE TUMOR MASS: ABSENT. SIZE OF IN-SITU CARCINOMA: SOLITARY MICROSCOPIC FOCUS (<0.2 CM). STATUS OF NON-NEOPLASTIC BREAST TISSUE: MINUTE FIBROADENOMA, APOCRINE. METAPLASIA. SKIN FREE OF TUMOR. SIZE OF BIOPSY: 10.5 x 7.7 x 4.0 CM. MICROCALCIFICATIONS: PRESENT IN ASSOCIATION WITH IN-SITU CARCINOMA. SURGICAL MARGIN STATUS: ANTERIOR MARGIN CLOSE (TUMOR GROSSLY APPROACHES TO. WITHIN 0.2 CM OF THE MARGIN) . SEE FINAL ANTERIOR. MARGIN, SPECIMEN ""D"" BELOW. ESTROGEN/PROGESTERONE RECEPTOR, CELL CYCLE, AND HER2/NEU ANALYSIS: PERFORMED PREVIOUSLY, SEE. D. ""FINAL ANTERIOR, INFERIOR MARGIN"", (EXCISION) : ADIPOSE AND BREAST PARENCHYMA, NEGATIVE FOR MALIGNANCY. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es). , M.D. Page #. CI ADDENDUM 1: Please see. for results of supplementary. tests. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es) . M.D., Ph.D. Pager. https://.",BRCA,1,True,"Based on the pathology report, sentinel node #1 was found to have metastatic carcinoma (1/1) with a metastasis size of 0.8 cm and no extracapsular extension. This indicates that the N stage is N1, as the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved determines the N1 classification.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1134,TCGA-D8-A1JU.B5074D1A-C617-414F-B349-6096F59E122D,0,"page 1 / 1. Examination: Histopathological examination. PESEL: Gender: F. Material: Multiple organ resection - left breast. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the left breast - lesion in the upper outer quadrant. Results of immunohistochemical examination: Estrogen receptors found in 75% of neoplastic cell nuclei. Progesterone receptors found in 75% of neoplastic. cell. nuclei. HER2 protein stained with HercepTestâ¢ by DAKO. Negative reaction in invasive cancerous cells. (Score = 1+ ). Macroscopic description: Left breast sized 20 x 13 x 2 cm removed without axillary tissues. Skin flap. 20 x 9.5 cm in size. Tumour sized 1.7 x 1.8 x 1.5 cm found on the boundary of outer quadrants, placed 2 cm. from the lower edge, 0.2 cm from the base and 1.0 cm from the skin. Cysts of 0.1 - 0.5 cm in the crass-. section. Microscopic description: Carcinoma ductale invasivum NHG1 (2+2+1 /1 mitosis /10 HPF, vision area diameter 0.57 mm). Additionally, focuses of carcinoma ductale in situ: cribrate type with medium nuclear atopia, no. necrosis, found in the glandular tissue (30% of the tumour cross-section). Glandular tissue showing lesions of the type: mastopathia fibrosa et cystica, adenosis sclerosans,. fiat epithellal atypia ( FEA). fibrocystic changes, sclerosing adenosis. Histopathological diagnosis: (including test No. G-15785/10): Carcinoma ductale invasivum et in situ mammae sinistrae. ( NHG 1, pT1c, pNo/sn/). Invasive and in situ ductal carcinoma of the left breast.",BRCA,0,True,"The report states 'pNo/sn/' under the 'Histopathological diagnosis' section, which indicates that there is no evidence of cancer in the lymph nodes (pNo). This is consistent with the rule that the absence of cancer in the lymph nodes is the primary determinant of the N stage, and the number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
745,TCGA-AN-A04A.6FB7A794-C3E7-4501-A844-CF65B9C3D32C,1,Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Left Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: Radical mastectomy Grade: 2. T Stage: 2 N Stage: 2 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,BRCA,2,True,"The report indicates that the patient is female with a diagnosis of breast cancer, specifically infiltrative ductal carcinoma located in the left breast. The T stage is 2, and the N stage is 2, while the M stage is 0. Based on the rules provided, the N stage is determined by the presence of metastases in 4-9 axillary lymph nodes or in infradiaphragmatic (lower) nodes. Therefore, the N stage for this patient is N2.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N2,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1061,TCGA-BH-A18T.B8FF655E-47AB-4BB0-B119-1402A335126A,1,"PATIENT HISTORY: The patient is a -year-oid female with no clinical history or LMP given. PRE-OP DIAGNOSIS: Right breast CA. POST-OP DIAGNOSIS: Same. PROCEDURE: Right segmental mastÃ©ctomy, sentinel node. ADDENDA: Addendum. ESTROGEN/PROGESTERONE AND HER-2/NEU REPORT. Using appropriate positive and negative controis, the test for the presence of these hormone receptor proteins is. performed by the immunoperoxidase method. and reported according to the. consensus statement on adjuvant. therapy for breast cancer, of,. A positive ER or PR tumor shows any nuclear immunostaining, and is. semiquantitated as indicated below. Semiquantitative Statement. ER negative. Percent cells staining as: (0 100%). PR negative. Percent cells staining as: (0 100%). HER-2/NEU DAKO HERCEPTEST: A WEAK TO MODERATE COMPLETE MEMBRANE STAINING IS OBSERVED IN MORE. THAN 10% OF THE TUMOR CELLS. HER-2/NEU IS INTERPRETED AS WEAKLY POSITIVE (SCORE 2+). NOTE: Her-2/Neu FISH was ordered and will be subsequently reported. The Her-2/neu and estrogeniprogesterone receptor assays were performed with FDA approved. methods. FINAL DIAGNOSIS: PART 1: BREAST, RIGHT, SEGMENTAL MASTECTOMY -. A. INFILTRATING DUCTAL CARCINOMA, 3.1 CM, POORLY DIFFERENTIATED, NOTTINGHAM SCORE - 9/9. (TUBULES = 3, NUCLEAR GRADE = 3, MITOSES = 3). B. LYMPHOVASCULAR INVASION IS IDENTIFIED. C. SEPARATE FOCI OF DUCTAL CARCINOMA IN SITU, SOLID TYPE, HIGH NUCLEAR GRADE. D. THE DUCTAL CARCINOMA IN SITU EXTENDS CLOSE (<0.1CM) TO THE POSTERIOR SURGICAL MARGIN. OF RECECTION. E. ALL SURGICAL MARGINS OF RESECTION ARE FREE OF TUMOR. F. NON-NEOPLASTIC BREAST WITH FIBROCYTIC CHANGES. PART 2: SENTINEL LYMPH NODE #1, RIGHT AXILLA, BIOPSY -. ONE (1) LYMPH NODE, NEGATIVE FOR TUMOR (0/1), (see comment). PART 3: SENTINEL LYMPH NODE #2, RIGHT AXILLA, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR TUMOR, (0/1), (see comment). PART 4: NON-SENTINEL LYMPH NODE, RIGHT AXILLA, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR TUMOR, (0/1). COMMENT: Cytokeratin (AE1/3) stains have been performed and confirm the negative status of the sentinal lymph nodes.",BRCA,0,True,"The report indicates that sentinel lymph nodes #1, #2, and a non-sentinel lymph node from the right axilla are all negative for tumor (0/1). The cytokeratin (AE1/3) stains confirm the negative status of the sentinel lymph nodes. According to the rules, the absence of cancer in the lymph nodes is the primary determinant of the N stage, and the number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes. Therefore, the N stage is N0.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,49.0,False
1210,TCGA-E2-A155.C3E398CE-1918-4107-948C-6579B1DA1F77,1,"SPECIMENS: A. LEFT BREAST AND AXILLARY CONTENTS LEVEL 1 AND 2. B. ADDITIONAL LEFT AXILLARY CONTENTS. SPECIMEN(S): A. LEFT BREAST AND AXILLARY CONTENTS LEVEL 1 AND 2. B. ADDITIONAL LEFT AXILLARY CONTENTS. GROSS DESCRIPTION: A. LEFT BREAST AND AXILLARY CONTENTS LEVEL 1 AND 2. Received fresh labeled with the patient's identification and ""left breast and axillary contents levels one and two. (suture in axillary tail)"" is an oriented 1794 g, 31 x 22 x 4.5 cm mastectomy with 27 x 16 skin ellipse and 1.1-cm flat. nipple. Skin has 4 brown macules ranging from 0.2 to 0.4 cm. In code: Anterior/superior-blue, anterior/inferior-. orange, posterior-black Specimen is serially sectioned into 11 slices from medial to lateral with nipple in slice7. #1- is a 2.5 x 2.5 x 1.7 cm firm tan stellate mass which is located at the 12 o'clock position, 4.2 cm from the deep. revealing 4 lesions. margin and 2 cm from the anterior margin (slices 6-7). #2- is a 1.3 x 1.1 x 1 cm firm tan stellate mass which is. located 0.3 cm medial to lesion #1, 5 cm from the deep margin and 1.3 cm from the anterior margin at roughly the 9. o'clock position (slice 5). #3- is a 2.5 x 2.2 x 1.5 cm firm tan stellate mass located 0.4 cm medial to lesion #2, 4 cm. from the deep margin and 1.5 cm from the anterior margin at roughly the 9 o'clock position (slice 4). #4- is a 1 x 1. x. 0.6 cm firm granular mass located 2.5 cm posterior lesion #3, 1.3 cm from the deep margin and 4.5 cm from the. anterior margin (slice 4). Adjacent to the deep margin, in slice 7, is a 0.9 x 0.6 x 0.4 cm firm tan lymph node. Within. the axillary tail are multiple lymph nodes ranging from 0.3 to 3.5 cm. The largest lymph node is nodular and a portion. is procured. Representatively submitted. A1: slice 4, lesion #3. A2: slice 4, tissue connecting lesions #3 and #4. A3: slice 4, lesion #4. A4: slice 4, deep margin lesion 4. A5: slice 5, tissue between lesions 3/4 and #2. A6: slice 5, lesion #2. A7 slice 6, tissue between lesions 2 and 1. A8: slice 6, superior to lesion 1. A9: slice 6, superior part of lesion 1. A10: slice 6, inferior part of lesion 1. A11: slice 6, inferior to lesion 1. A12: slice 6, anterior to lesion 1. A13: slice 7, lateral to lesion 1. A14: slice 3, upper inner quadrant. A15: slice 8, upper outer quadrant. A16: slice 9, lower outer quadrant. A17: slice 3, lower inner quadrant. A18-A19: nipple, perpendicular sections. A20: skin with macules. A21: intramammary lymph node. A22: 5 lymph nodes. A23: 4 lymph nodes. A24-A26: 1 lymph node each. A27-A28: 1 lymph node. A29-A30: 1 lymph node. A31-A36: 1 lymph node. B. ADDITIONAL LEFT AXILLARY CONTENTS. Received fresh labeled with the patient's identification and ""additional left axillary contents"" is a piece of fatty tissue. measuring 6.3 x 4.7 x 0.6 cm. One lymph node is identified. Submitted entirely. B1: 1 lymph node. B2-B4: remainder of soft tissue. DIAGNOSIS: A. BREAST, LEFT, MASTECTOMY WITH AXILLARY NODE DISSECTION: - MULTIPLE FOCI OF INVASIVE DUCTAL CARCINOMA, SBR GRADE 3 WITH MICROPAPILLARY FEATURES,. LARGEST FOCUS MEASURING 2.5-CM. - HIGH NUCLEAR GRADE, DUCTAL CARCINOMA IN SITU, SOLID AND CRIBRIFORM TYPES WITH LOBULAR. EXTENSION, CENTRAL NECROSIS AND MICROCALCIFICATIONS. - SURGICAL RESECTION MARGINS NEGATIVE FOR TUMOR. - METASTATIC CARCINOMA TO ONE OF TWELVE AXILLARY LYMPH NODES (1/12), MEASURING 3.5-CM. WITH FOCAL EXTRANODAL EXTENSION. - METASTATIC CARCINOMA TO ONE OF TWO INTRAMAMMARY LYMPH NODES (1/2), MEASURING 0.8-CM. WITH FOCAL EXTRANODAL EXTENSION. - SEE SYNOPTIC REPORT AND SEE NOTE. B. LYMPH NODES, ADDITIONAL LEFT AXILLARY CONTENTS, DISSECTION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). NOTE: Four tumor nodules are grossly identified. Microscopically 3 of them are invasive ductal carcinoma that. have. the same morphology and one is DCIS. The tissues in between these nodules show scattered foci of DCIS. Therefore, these foci may be interconnected through DCIS. Largest confluent invasive tumor measures 2.5-cm. Two intramammary lymph nodes are identified, one is positive for metastatic carcinoma. SYNOPTIC REPORT - BREAST. Specimen Type: Mastectomy. Needle Localization: Laterality: Left. Invasive Tumor: Present. Multifocality: Yes. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 2.5cm. Tumor Site: Upper inner quadrant. Lower inner quadrant. Margins: Negative. Tubular Score: 3. Nuclear Grade: 2. Mitotic Score: 3. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Absent. Vascular/Lymphatic Invasion: Indeterminate. Lobular neoplasia: None. Lymph nodes: Axillary dissection. Lymph node status: Positive 2 / 15 Extranodal extension. DCIS present. DCIS Quantity: Estimate 10%. DCIS Type: Solid. Cribriform. DCIS Location: Associated with invasive tumor. Nuclear grade: High. Necrosis: Present. ER/PR/HER2 Results. ER: Positive. PR: Negative. HER2: Negative by IHC. Performed on Case: Pathological staging (pTN): pT 2 N 1c. CLINICAL HISTORY: None given. PRE-OPERATIVE DIAGNOSIS: Left breast cancer. Microscopic/Diagnostic Dictation: Pathologist. Final Review: Pathologist,. Final: Pathologist, (.",BRCA,1,True,"The report indicates that there is metastatic carcinoma present in one out of twelve axillary lymph nodes and one out of two intramammary lymph nodes, which falls under the N1 classification in the AJCC staging system. The number of negative lymph nodes does not affect the N stage in the presence of positive lymph nodes, and the size of the metastases or the presence of microscopic perinodal soft tissue invasion does not affect the N stage.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
941,TCGA-B6-A0WY.C0E92852-4146-468C-9713-2DE9C3316B9F,2,"surgical Pathology;. CLINICAL HISTORY: Breast lesion. GROSS EXAMINATION: A. ""Left breast excision, long lateral, short superior"", in formalin. The. specimen consists of a 9.5 x 8.8 x 2.3 cm sample of firm, white, fibroadipose. tissue with an attached skin ellipse measuring 4.8 x 0.7 cm. The skin. includes a 3.5 cm scar. The specimen is inked as follows: superior margin. blue; inferior margin black; deep surgical margin green. The specimen is. sectioned serially from medial to lateral revealing a firm, white, scirrhous. lesion diffusely involving the entire specimen and extending to all margins. There are focal areas of punctate hemorrhage and cyst formation. BLOCK SUMMARY: A1 representative sample of tissue from extreme medial portion of sample. A2-A6 representative slices of tissue through mid medial portion of sample. showing approach to all surgical margins, divided into five portions. A7-A11 representative slice of tissue taken from mid-lateral portion of. sample, showing approach to all surgical margins, divided into five portions. A12 representative sample of tissue taken from extreme lateral portion of. sample. B. ""Axillary dissection"", fresh. The specimen consists of a 7.5 x 7.0 x 2.0. cm sample of fibroadipose tissue. Several sutures are attached, however, the. specimen is unoriented. Twenty-one lymph node candidates were identified. within the samples. The largest measures 2.0 x 1.3 x 0.8 cm and is firm in. consistency. BLOCK SUMMARY: B1 five lymph node candidates. B2 eight lymph node candidates. B3 six lymph node candidates. B4 one (bisected) lymph node candidate. B5 one (bisected) lymph node candidate. Dr. REVISED DIAGNOSIS. A. ""LEFT BREAST EXCISION, LONG LATERAL, SHORT SUPERIOR"" (EXCISIONAL BIOPSY) : INFILTRATING ADENOCARCINOMA, HISTOLOGIC TYPE INFILTRATING DUCTAL. N.S.A.B.P. HISTOLOGIC GRADE, 2 TO 3, NUCLEAR GRADE, 2. GROSS TUMOR SIZE, 1.6 CM. SIZE OF INVASION COMPONENT, 1.5 CM. IN SITU CARCINOMA, PRESENT. OCCUPYING 10% OF TUMOR. EXTENSIVE INTRADUCTAL COMPONENT, NOT PRESENT. TYPE OF IN SITU CARCINOMA, SOLID. SURROUNDING NON-NEOPLASTIC BREAST TISSUE SHOWS DUCT ECTASIA INTRADUCTAL. PAPILLOMATOSIS, AND APOCRINE METAPLASIA. LYMPHATIC/VASCULAR INVASION, PRESENT AND EXTENSIVE. SURGICAL MARGIN STATUS, CLOSE MULTIFOCALLY WITH CARCINOMA MOST CLOSELY. APPROACHING SUPERIOR MARGIN. ALL MARGINS TECHNICALLY FREE OF MALIGNANCY. ESTROGEN/PROGESTERONE AND CELL CYCLE ANALYSIS PENDING, YES ON FRESH. TISSUE. B. ""AXILLARY LYMPH NODES"" (AXILLARY DISSECTION) : (umor sire. HITAA Primaty. (circie): 1 of 2. initinis. THREE OF TWENTY-ONE LYMPH NODE ARE POSITIVE FOR METASTATIC CARCINOMA. ONE LYMPH NODE SHOWS EXTRACAPSULAR EXTENSION. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es). M.D. Pager#. ADDENDUM 1: Material was sent to. for assay of the. Progesterone receptors. The Estrogen receptor was judged as positive within an. estimated fmol valve of 20. The Progesterone receptor activity was judged as. negative with an estimated fmol valve of 4. Please refer to report. for more complete details. M.D. Pager#. 2 of 2.",BRCA,1,True,"The report indicates that out of 21 examined lymph nodes, 3 were positive for metastatic carcinoma. This information corresponds to the N1 classification, which is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved. The number of negative lymph nodes does not affect the N stage in the presence of positive lymph nodes, and extracapsular extension in a lymph node does not change the N stage.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1303,TCGA-E9-A228.B0E8F3C1-E996-4E70-9630-AC95AF6E4EDC,1,"aterality: Right, lower inner quadrant. Path Report BREAST TISSUE CHECKLIST. Specimen type: Mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 2.5x2x2cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal carcinoma. Histologic grade: Moderately differentiated. Tumor extent: Not specified. Lymph nodes: 2/12 positive for metastasis (Subclavicular 2/12). Extracapsular invasion of the lymph nodes: Not specified. Margins: Not specified. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None.",BRCA,1,True,"The report indicates that there are 2 out of 12 lymph nodes positive for metastases, which falls into the N2 classification of the AJCC staging system for breast cancer, as it is determined by the presence of metastases in 4-9 axillary lymph nodes.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N2,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
900,TCGA-AR-A2LR.C310F4EC-D8B1-45C4-8D55-705A9EE35902,0,"Final Diagnosis. A. Breast, right with axillary sentinel lymph nodes, simple mastectomy: Metaplastic carcinoma,. matrix-producing type, Nottingham grade III (of III) is identified forming a 2.7 x 2.3 x 1.7 cm. mass in the superior/central region adjacent to a 2.8 x 2.2 x 1.5 cm fibrotic/scarred prior. lumpectomy site in the upper inner quadrant. Ductal carcinoma in situ, high nuclear grade with. necrosis is focally present. Angiolymphatic invasion is absent. The non-neoplastic breast. parenchyma shows proliferative fibrocystic changes. Biopsy site changes present. The tumor. does not involve the nipple, overlying skin, or underlying chest wall. All surgical resection. margins, including the deep margin, are negative for tumor (minimum tumor free margin, 3.2 cm,. anterior/superior margin). Multiple (5) attached right axillary sentinel lymph nodes, all without. blue dye, are negative for metastatic carcinoma. Immunohistochemical cytokeratin stain was. performed on the paraffin embedded sentinel lymph node tissue and confirms the H&E. impression. B. Lymph node, left axillary sentinel No. 1, biopsy: A single left axillary sentinel lymph node is. negative for metastatic carcinoma. Blue dye is identified. C. Lymph node, left axillary sentinel No. 2, biopsy: A single left axillary sentinel lymph node is. negative for metastatic carcinoma. Blue dye is identified. D. Breast, right lateral skin flap, excision: Portion of skin and subcutaneous tissue without. diagnostic abnormality. E. Breast, left, simple mastectomy: Benign breast parenchyma and nipple. Multiple (3) left. axillary sentinel lymph nodes (with blue dye) and a single left axillary lymph node (without blue. dye) are negative for metastatic carcinoma. F. Breast, left inferior skin flap, excision: Portion of skin and breast parenchyma. Without. diagnostic abnormality. G. Breast, left superior skin flap, excision: Portion of skin and breast parenchyma. Without. diagnostic abnormality. H. Breast, left lateral skin flap, excision: Portion of skin and breast parenchyma. Without. diagnostic abnormality.",BRCA,0,True,"The report states that there is no evidence of cancer in any of the 10 examined lymph nodes (5 from the right axillary sentinel lymph nodes, 3 left axillary sentinel lymph nodes with blue dye, 1 left axillary lymph node without blue dye, and 1 breast, right lateral skin flap excision). This is consistent with an N0 stage, which indicates no metastasis to the lymph nodes.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,49.0,False
503,TCGA-A2-A0ET.E9D3FFF1-5FB2-4F17-9C1D-D9775E3CC5AC,1,"Specimen #: Race: WHITE. Physician (s) : SPECIMEN: A: RIGHT BREAST LUMPECTOMY. B: RIGHT AXILLARY NODE DISSECTION. FINAL DIAGNOSIS: A. BREAST, RIGHT, LUMPECTOMY: TUMOR TYPE: INVASIVE DUCTAL CARCINOMA. NOTTINGHAM GRADE: MODERATELY DIFFERENTIATED (G2). NOTTINGHAM SCORE: 6/9. (Tubules= 2, Nuclei=2, Mitoses= 2; mitotic count 10 per 10 HPF at. 20x power-0.5 field diameter). TUMOR SIZE (GREATEST DIMENSION) : 1.9 CM (measured microscopically) . TUMOR NECROSIS: ABSENT. MICROCALCIFICATIONS: ABSENT. VENOUS / LYMPHATIC INVASION: ABSENT. MARGINS : - INVASIVE CARCINOMA PRESENT 1.2 CM FROM ANTERIOR MARGIN. DUCTAL CARCINOMA IN SITU PRESENT 0.5 CM FROM INFERIOR MARGIN. INTRADUCTAL COMPONENT: DUCTAL CARCINOMA IN SITU, CRIBIFORM TYPE, LOW. NUCLEAR GRADE. LYMPH NODES: FIVE OF SIXTEEN POSTIVE FOR TUMOR. (see specimen B). SKIN INVOLVEMENT: ABSENT. MULTICENTRICITY: ABSENT. ESTROGEN RECEPTORS: POSITIVE. (see. PROGESTERONE RECEPTORS NEGATIVE. (see. HER 2 NEU by IHC: NEGATIVE. (see. PATHOLOGIC STAGE: pT1c N2a Mx. ADDITIONAL PATHOLOGIC CHANGES: BENIGN FIBROCYSTIC CHANGES. B. SOFT TISSUE, RIGHT AXILLA, LYMPH NODE DISSECTION: - FIVE OF SIXTEEN LYMPH NODES POSITIVE FOR METASTATIC CARCINOMA. Specimen #: CLINICAL DIAGNOSIS AND HISTORY: -year-old female with 2.0 cm right breast mass found on routine. mammagram. Patient was also found to have two lymph nodes seen. largest 1.5 cm, BIRIDS-5 Ultrasound guided biopsy of breast mass showed. Grade I Invasive Ductal Carcinoma with DCIS and FNA of axillary lymph node. showing metastatic carcinoma from primary breast on. PRE-OPERATIVE DIAGNOSIS: Right breast cancer. GROSS DESCRIPTION: A. Received fresh, labeled with the patient's name,. designated ""RIGHT BREAST LUMPECTOMY"" is an irregular, oblong portion of. soft tissue oriented with a short stitch superior and a long stitch. medial. The specimen measures 14.0 cm in medial to lateral, 7.0 cm. superior to inferior, and 2.5 cm anterior to posterior. The lightly. pigmented superficial skin ellipse measures 8.5 x 2.2 cm and is otherwise. unremarkable. The specimen is inked as follows superior = blue, inferior. = green, medial = red, lateral = yellow, anterior = orange, and posterior. = black. Serial sections reveal a firm, pink-white, gray mass measuring. 3.3. x 2.2 x 1.5 cm. The mass is well circumscribed, and approaches the. margins as follows: 0.2 cm from the deep margin, 0.5 cm from the anterior. margin, 1.5 cm from the inferior margin, and 1.8 cm from the superior. margin. The remainder of the specimen is predominantly composed of. lobulated, yellow-tan, adipose tissue. The fibrous tissue comprises. 5%. of. the cut surface, and is tan-white, markedly dense, and otherwise. unremarkable. Representative sections are submitted as follows: Cassette Summary : A1: Mass. A2: Adjacent normal. A3: Skin. A4-A5: Additional sections adjacent to mass. A6-A9: Additional sections of mass. A10-12 Additional sections adjacent to A1 and A9. Matched sections of A1-A2 are submitted in. or CBCP protocol. The specimen was placed in formalin at. pm for a total time in. formalin for approximately 28 hours. B. Received fresh, labeled with the patient's name,. designated ""RIGHT AXILLARY NODE DISSECTION"" is an 11.0 x 8.0 x 2.5 cm. irregular, unoriented portion of soft tissue. Serial sectioning reveals. Y. Specimen # : GROSS DESCRIPTION (continued). 16 lymph nodes ranging in size from 0.7 x 0.7 x 0.5 cm to 4.0 x 2.0 x 1. . 0. cm. On sectioning, four of the lymph nodes show a firm, pink-tan, cut. surface consistent with metastatic involvement. The remaining lymph nodes. are pink-yellow and otherwise unremarkable. Representative sections are. submitted as follows: Cassette Summary : B1-B4: Largest lymph node. B5: Lymph node #1. B6: Lymph node #2. B7: Lymph node #3. B8: Lymph node #4. B9: One lymph node. B10: One lymph node. B11: One lymph node bisected. B12: One lymph node bisected. B13: One lymph node bisected. B14: Two lymph nodes, each bisected. B15: Four lymph nodes. Matched sections of B1, B5-B10 - are submitted in. or CBCP protocol.",BRCA,2,True,"The report states that five out of sixteen lymph nodes are positive for metastatic carcinoma (specimen B). This corresponds to the N2 classification, which is determined by the presence of metastases in 4-9 axillary lymph nodes.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N2,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
637,TCGA-A8-A081.DE25BF82-5F7A-489B-BFC1-9386C44E7D62,1,"Diagnosis: 1. Ablated (right) breast sample with a moderately differentiated invasive ductal. carcinoma (tumor diameter: 3.0 cm; minimum distance to dorsal margin 0.3 cm, other. margins are 1 cm and remain free). In conclusion, this is a moderately differentiated invasive ductal carcinoma. Concluding tumor classification: NOS, G II, pT2N0(sn)LOVORO.",BRCA,0,True,"The report indicates that the tumor was found in the right breast and had a diameter of 3.0 cm, with a minimum distance to the dorsal margin of 0.3 cm and other margins being 1 cm, leaving them free of cancer. The report also mentions that there is no evidence of cancer in the lymph nodes, with the notation (sn) indicating that sentinel lymph nodes were examined. Based on the rules provided, the absence of cancer in the lymph nodes is the primary determinant of the N stage, and the number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes. Therefore, the N stage for this patient is N0.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1399,TCGA-HN-A2OB.32AE5A1A-703B-43C3-948A-719A90DDACC5,1,Sample Preparation. Fresh Frozen. Site of Primary (Event). right breast. Site of Tissue. Breast. Year of Sample Collection. Age at Sample Collection (yrs). 45. Sample Comments. Days to Procedure Date. 0. Days to Diagnosis. 14. Type of Procedure. Surgical resection. Site of Primary (Histology). Right breast. Bilateral Disease. Tumour Size (cm). 2.7000000000000002. Histology. Other. Grade/Differentiation. Grade X - Unknown. Pathological T. T2. Pathological N. N1a. Number of Nodes Sampled. 5. Number of Nodes Positive. 2. Clinical M. M0. Histology Comments. Histologic type: Invasive lobular (e cadherin negative). Modified Scarff. Bloom Richardson Grade: 1/3 (2). Total score 4/9. SBR (Scarff-Bloom-Richardson) score. 4. ER Status. Positive NOS. PR Status. Positive NOS. HER2 Status. Negative. Lymph Node Metastases. None Documented.,BRCA,1,True,"The N stage is determined by the presence of cancer metastases in lymph nodes. According to the report, the patient has cancer metastases in 2 out of 5 sampled axillary lymph nodes (N1a). The number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion, is the key factor in determining the N stage in the presence of metastases.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1502,TCGA-S3-AA10.6A981CB0-F551-48B1-AB91-5D5585A7F282,1,"Temporary Copy. Diagnosis. A. RIGHT BREAST, MASTECTOMY: - HIGH-GRADE INVASIVE DUCTAL CARCINOMA; SEE SYNOPTIC REPORT. - NEGATIVE MARGINS. - SKIN AND NIPPLE WITHOUT SIGNIFICANT PATHOLOGIC ABNORMALITY. - FOUR LYMPH NODES, NEGATIVE FOR TUMOR (0/4); SEE SPECIAL STAINS. (Electronic signature). Verified: Synoptic Report. TUMOR SIZE: SIZE OF LARGEST INVASIVE CARCINOMA: Greatest dimension of largest focus of invasion over 0.1 cm: 2.5 cm. Additional dimensions: 2.5 x 1.5 cm. TUMOR FOCALITY: Single focus of invasive carcinoma. MACROSCOPIC AND MICROSCOPIC EXTENT OF TUMOR: Skin: Invasive carcinoma does not invade into the dermis or epidermis. Nipple: DCIS does not involve the nipple epidermis. Skeletal Muscle: Skeietal muscle is present and is free of carcinoma. DUCTAL CARCINOMA IN SITU (DCIS): No DCIS is present. LOBULAR CARCINOMA IN SITU (LCIS): Not identified. HISTOLOGIC TYPE OF INVASIVE CARCINOMA: Invasive ductal carcinoma (no special type or not otherwise specified). GLANDULAR (ACINAR)/TUBULAR DIFFERENTIATION: Score 3: <10% of tumor area forming glandular/tubular structures. NUCLEAR PLEOMORPHISM: Score 3: Vesicular nuclei, often with prominent nucleoli, exhibiting marked variation in size and shape,. occasionally with very large and bizarre forms. MITOTIC COUNT: Score 3. Number of mitoses per 10 high-power fields: 88. Diameter of microscope field: 0.55 mm. OVERALL GRADE: Grade 3: scores of 8 or 9. MARGINS: Margins uninvolved by invasive carcinoma. Distance from anterior margin: 4.0 mm. Distance from posterior margin: 2.0 mm. TREATMENT EFFECT: RESPONSE TO PRESURGICAL THERAPY: IN THE BREAST: No known presurgical therapy. TREATMENT EFFECT: RESPONSE TO PRESURGICAL THERAPY: IN THE LYMPH NODES: No known presurgical therapy. LYMPH-VASCULAR INVASION: Not identified. Temporary Copy. DERMAL LYMPH-VASCULAR INVASION: Not identified. LYMPH NODES: Total number of lymph nodes examined (sentinel and nonsentinel): 4. Number of lymph nodes with macrometastases (>0.2 cm): 0. Number of lymph nodes with micrometastases (>0.2 mm to 0.2 cm and/or >200 cells): 0. METHOD OF EV /ALUATION OF SENTINAL LYMPH NODES: Hematoxylin and eosin (H&E), one level. Immunohistochemistry. PRIMARY TUMOR (INVASIVE CARCINOMA (pT): pT2: Tumor >20 mm but less than or equal to 50 mm in greatest dimension. REGIONAL LYMPH NODES (pN): pN0: No regional lymph node metastasis identified histologically. DISTANT METASTASIS (M): Not applicable. ADDITIONAL PATHOLOGIC FINDINGS: Benign breast with calcifications. ESTROGEN RECEPTOR: Performed on this specimen. No immunoreactive tumor cells present. PROGESTERONE RECEPTOR: Performed on this specimen. No immunoreactive tumor cells present. HER2/NEU IMMUNOPEROXIDASE STUDIES: Performed on this specimen. Negative (Score 0). MICROCALCIFICATIONS: Present in non-neoplastic tissue. Specimen Source. A. RT Breast and Axillary Contents. Clinical Information. None. PRE-OP DIAGNOSIS: Right breast CA. POST-OP DIAGNOSIS: Same. TYPE OF PROCEDURE: Right modified mastectomy. Gross Description. The specimen is labeled ""RIGHT BREAST AND AXILLARY CONTENTS"" and is received unfixed (the. specimen is in formalin for more than 6 hours and less than 48 hours). It consists of a 420 g right mastectomy. with axillary contents weighing 420 g measuring 18 x 10 x 3.0 cm. The axillary content measures 6.0 x 5.5 x 3.0. cm. The nipple is unremarkable measures 1.3 x 1.3 cm in maximum dimensions. Solar is unremarkable. The left. fascia is smooth and glistening. The anterior margin is inked red and the deep posterior margin is inked black. On sectioning, there is a well-circumscribed lobulated focally hemorrhagic pink-tan mass measuring 2.5 x 2.5 x. 1.5 cm. The mass is close to the deep posterior margin in the outer quadrant close to the axillary contents. The. mass is 0.7 cm from the anterior margin and approximately 12 cm from the nipple. On further sectioning the. breast parenchyma is nodular, there are no other lesions grossly identified. There are four fatty lymph nodes. Temporary Copy. ranging from 0.5-2.0 cm in maximum dimensions. Representative sections are submitted. Section Key: Al - A2 tumor markers with deep margin. A3 tumor. A4 - nipple and skin. A5 - anterior margin close to mass. A6 - upper inner quadrant. A7 - lower inner quadrant. A8 - random sections from central breast. A9 - upper outer quadrant. A10 - lower outer quadrant. All - one lymph node bisected. A12 - one lymph node bisected. A13 - two lymph nodes. Time specimen was removed from the patient (procedure time): Time specimen was placed in formalin: Ischemic time: 1 hour 20 minutes. Special Stains / Slides. IMMUNOHISTOCHEMICAL EVALUATION OF ESTROGEN RECEPTORS, PROGESTERONE. RECEPTORS, AND HER-2NEU IN INVASIVE MAMMARY CARCINOMA . ESTROGEN RECEPTORS: 0 %, NEGATIVE. PROGESTERONE RECEPTORS: 0 %, NEGATIVE. STAINING INTENSITY: HER-2NEU: SCORE 0, NEGATIVE. Immunohistochemical studies were performed on formalin fixed paraffin embedded tissue (Block A2) using the. following monoclonal antibodies; Estrogen receptor (Clone SP1), Progesterone receptor (Clone 1E2) and. Her-2neu (. Clone 4B5); control sections for HER-2Neu are provided within a kit (score 0 MCF-7, score. 1+ T-47D, score 2+ MDA-MB-453, score 3+ BT-474). Detection system used: polymer. Primary antibodies,. reagents and control sections for HER-2neu are all provided by. All controls show appropriate reactivity. Reactivity of Estrogen and Progesterone receptors is determined based on the percentage of positively. stained nuclei of tumor cells. Reference values (CAP accreditation program checklist 2010 and guidelines on. webpage): Positive: nuclear staining in 1% or greater than 1% of invasive carcinoma cells. Negative : nuclear staining in less than 1% of invasive carcinoma cells. Staining intensity: is reported as weak, moderate or strong. Temporary Copy. HER-2neu reactivity is reported applying the CAP scoring guidelines (CAP accreditation program checklist. 2010 and guidelines on webpage): Score 0 = Negative: No immunoreactivity, or faint weak immunoreactivity in <10% of tumor cells but only a. portion of the membrane is positive.. Score 1 = Negative: Faint weak immunoreactivity in 10% or >10% of tumor cells but only a portion of the. membrane is positive. Score 2+ = Equivocal: Weak to moderate complete membrane immunoreactivity in >10% of tumor cells or. circumferential intense membrane staining in <30% of cells. Score 3+ = Positive: More than 30% of the tumor cells must show circumferential intense and uniform. membrane staining. A homogeneous (chicken wire) pattern should be present. Equivocal results for HER-2neu (Score 2+) will be subsequently followed by a reflex dual-color ISH testing. Additional immunohistochemical studies fpr AE1/AE3 were performed on formalin fixed, paraffin-embedded. tissue (Blocks A11-13) with adequate positive and negative control sections. All stains were negative. The performance characteristics of these antibodies were determined by the. They have not been cleared or approved by the U.S. Food. and Drug Administration. The FDA has determined that such clearance or approval is not necessary. These tests are used for clinical. purposes. They should not be regarded as investigational or for research. This laboratory is certified under the Clinical Laboratory. Improvement Amendments of 1988 (CLIA-88) as qualified to perform high-complexity clinical laboratory testing. Tissue Code.",BRCA,0,True,"The report states that 'Total number of lymph nodes examined (sentinel and nonsentinel): 4. Number of lymph nodes with macrometastases (>0.2 cm): 0. Number of lymph nodes with micrometastases (>0.2 mm to 0.2 cm and/or >200 cells): 0.' This indicates that there is no evidence of cancer in the lymph nodes, which means the N stage is N0, in accordance with the rule 'If there is no evidence of cancer in the lymph nodes, the N stage is N0'.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1056,TCGA-BH-A18N.60E8A9CF-3E2D-4E36-947D-448BA27C6561,1,"PATIENT HISTORY: DATE of LMP. DATE or LAST DELIVERY: PRE-OP DIAGNOSIS: CA L BREAST. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE: LEFT MODIFIED RADICAL MASTECTOMY. CLINICAL HISTORY: MATERIAL SUBMITTED: LEFT (MOD) RADICAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. Lt breast & axillary content. FINAL DIAGNOSIS: FINAL DIAGNOSIS: BREAST AND AXILLA, LEFT, MODIFIED RADICAL MASTECTOMY: - INFILTRATING DUCTAL CARCINOMA (""A2-A7""), 4.5 BY 4.5 BY 3.5 CM, NOTTINGHAM 6/9 (TUBULES 3, NUCLEI 2,. MITOSIS 1), WITH LYMPHOVASCULAR PERMEATION, INVOLVING THE DEEP DERMIS. DUCTAL CARCINOMA IN-SITU, SOLID TYPE, NUCLEAR GRADE 2, LESS THAN 1t. - MARGINS OF RESECTION ARE FREE OF TUMOR. - NIRPLE FREE OF TUMOR. TWO. OF. TWENTY-SIX (2/26) LEFT AXILLARY LYMPH NODES INVOLVED WITH TUMOR, LARGEST LYMPH NODE 2.3 CM IS. REPLACED BY TUMOR. NOTE: ER/PR immunoperoxidase assay and Her-2/NEU testing was performed on block ""A6"". Cross. refer. ESTROGEN/PROGESTERONE AND HER-2/NEU REPORT. Using appropriate positive and negative controls, the test for the presence of these hormone receptor. proteins is performed by the immunoperoxidase method, and reported according to the. consensus statement. on adjuvant therapy for breast cancer, of. A positive ER or PR tumo. anows any nuclear. immunostaining, and is semiquantitated as indicated below. Result Semiquantitative Statement. ER positive Percent cells staining as: (0- 0% 1+ 10%; 2+ 10%; 3+ 80%). PR positive Percent cells staining as: (0- or; 1+ or; 2+ 10%; 3+ 90%). HER-2/NEU - DAKO HERCEPTEST: A FAINT/BARELY PERCEPTIBLE MEMBRANE STAINING IS DETECTED IN MORE THAN 10% OF. THE TUMOR CELLS. THE CELLS ARE ONLY STAINED IN PART OF THEIR MEMBRANE. HER-2/NEU IS INTERPRITED AS NEGATIVE. (SCORE 1+). NOTE: The Her-2/NEU and estrogen assays were performed with FDA approved. methods The progesterone. receptor immunoperoxidase test used in this case has been developed and the performance characteristics. determined by the Department of Pathology at. They have not been. cleared or approved by the U.S. Food and Drug Actministration.",BRCA,1,True,"The report indicates that 2 out of 26 left axillary lymph nodes were involved with tumor. This corresponds to the N1 classification, which is determined by the presence of metastases in 1-3 axillary lymph nodes. The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases, and the N stage is not affected by the size of the metastases or the presence of microscopic perinodal soft tissue invasion.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
698,TCGA-AC-A2BK.3E54B0CE-8863-4728-BC95-A47C1869F52A,1,"MRN : OV. MD. Laboratory Patient Report. Print Date/Time: Histopathological Examination. 4. - Received: ; Complete. Pre-op Diagnosis : Left Breast Car. MD. Specimens. Breast, left. Frozen Diagnosis. : GROSS EXAMINATION: The specimen is received in a container labeled with the. name of the patient and labeled as breast, left. The. specimen consists of a mastectomy designated left which. measures en bloc 31 x 20 x 5.5 cm and weighs 1515 g. Anteriorly located is an ellipse of brown skin which. measures 22 x 17 cm. Centrally located is a 4.5 cm diameter. areolar complex with slightly retracted nipple which is. sampled in block 1. The deep margin is inked and the. specimen is serially sectioned and shows a gray-tan firm. mass in the upper outer quadrant. This mass measures 2.8. x. 2.5 x 2.3 cm and grossly extends to within 1 cm of the inked. deep margin. A section of skin overlying the mass is. submitted in block 2. A section of the Inked deep margin is. submitted in block 3. Sections of the mass are submitted in. block 4-7. The remaining breast is composed of yellow. lobulated adipose tissue admixed with islands of gray-white. rubbery tissue. The breast is divided into four quadrants;. upper inner, lower inner, upper outer and lower outer and. sampled in blocks 8-11. The attached axillary tissue is. dissected for lymph nodes with the lower part sampled in. blocks 12-14 in the upper part sampled in blocks 15-16. DIAGNOSIS BASED ON GROSS AND MICROSCOPIC EXAMINATION: SPECIMEN TYPE: Modified radical mastectomy. LYMPH NODE SAMPLING: Axillary dissection. LATERALITY Left. TUMOR SITE: Upper outer quadrant. SIZE OF INVASIVE COMPONENT: Greatest dimension. 2.8 cm. ADDITIONAL DIMENSIONS: 2.5 x 2.3 cm. HISTOLOGIC TYPE: Invasive ductal carcinuna. THIS CONFIDENTIAL AND PRIVILEGED DOCUMENT/INFORMATION IS PROTECTED BY. FEDERAL AND STATE LAW. UNAUTHORIZED DISCLOSURE, DISSEMINATION. OR DUPLICATION IS PROHIBITED. Path # : 4. Visit # : HISTOLOGIC GRADE: Nottingham histologic score 3/3. DUCT IN SITU COMPONENT: Not identified. MICROCALCIFICATIONS Not identified. EXTENT OF INVASION. PRIMARY TUMOR (PT) : pT2: Tumor more than 2.0 cm but not more. than 5.0 cm in greatest dimension. REGIONAL LYMPH NODES (PN) : pN2a: Metastases in 4 to 9. axillary lymph nodes. NUMBER EXAMINED: 23. NUMBER INVOLVED: 6. DISTANT METASTASIS (PM) : PMX. MARGINS : Uninvolved by invasive carcinoma. DISTANCE TO NEAREST MARGIN: 1.0 cm to deep margin. VENOUS/LYMPHATIC (LARGE/SMALL VESSEL) INVASION (V/L) : Present. Summary of pathologic staging: pT2N2aMXG3 . Intradepartmental consultation obtained. COMMENT: Immunohistochemical stains for estrogen and. progesterone receptors and HER2 are pending and will be. supplementally reported when complete. M.D. ., MD. THIS CONFIDENTIAL AND PRIVILEGED DOCUMENT/INFORMATION IS PROTECTED BY. FEDERAL AND STATE LAW. UNAUTHORIZED DISCLOSURE, DISSEMINATION. OR DUPLICATION IS PROHIBITED. Path # : of 2. Visit # :",BRCA,2,True,The report indicates that there are 6 positive lymph nodes out of 23 examined (pN2a). This corresponds to the N2 stage in the AJCC staging system.,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N2,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
762,TCGA-AN-A0FT.338D5387-0CFB-4D91-944F-1F054C21C769,1,Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Right breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: surgery Grade: 2. T Stage: 2 N Stage: 1 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,BRCA,1,True,"The N stage is 1, as indicated in the pathology report. This is because there is evidence of cancer metastases in 1-3 axillary lymph nodes, which falls under the N1 classification according to the rules.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
648,TCGA-A8-A08H.33188769-D86E-41AD-A74D-31A7C2DD08B7,1,"Diagnosis: 1. Tumor-free structurally intact lymph nodes. 2. Invasive ductal breast carcinoma (maximum diameter 2.5 cm, malignancy grade II) at the. site of the macroscopically described nodular formation. In the immediate tumor periphery. high-grade DCIS (procomponent of tumor < 10%) with inclusion also of coarse calcification. Remaining glandular tissue, rich in fatty tissue, in involution and free of atypia. Histologically. unremarkable skin spindle. Tumor classification: G2 (L0, V0), pTlc, pN0 (sn), MX, R0 (minimum width of dorsocranial. safety margin 1 cm!).",BRCA,0,True,"The report indicates that there is no evidence of cancer in the lymph nodes, as stated in the diagnosis ('Tumor-free structurally intact lymph nodes') and in the pN0 (sn) classification. Therefore, the N stage is N0.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,49.0,False
711,TCGA-AC-A3EH.3094774B-B764-4D60-BFF3-48FEF39F4BEA,2,"Sex: Female. DIAGNOSIS. DIAGNOSIS: Breast, right, axillary contents; modified radical mastectomy and axillary node dissection: Tumor Characteristics: 1. Histologic type: Pleomorphic lobular carcinoma, confirmed by negative e-cadherin stain. 2. Size: 10.0 x 10.0 x 7.2 cm. 3. Tumor focality: Unifocal. 4. Elston modification of Bloom-Richardson grade: a. Architectural score: 3/3. b. Nuclear score: 2/3. C. Mitotic score: 1/3. d. Total score: 6/9 = Grade: II. 5. In situ component: Not identified. 6. Lymphovascular space invasion: Present. 7. Skin involvement Not identified. 8. Microcalcifications: Present and associated with invasive carcinoma. Surgical Margin Status: 1. Deep surgical margin free of tumor by 2.5 cm as measured grossly. Lymph Node Status: 1. Total number of lymph nodes received: 12. 2. Total number of lymph nodes containing metastatic carcinoma: 3. Size of largest metastasis: 2.5 cm. 4. Extracapsular extension of tumor: Present. Other: 1. pTNM stage: pT3 N2. CLINICAL INFORMATION: CLINICAL HISTORY: Preoperative Diagnosie: Right MET. Postoperative Diagnosis: Symptams/Radiologic Findings: SPECIMENS: Right breast and axillary contents. at. SPECIMEN DATA. GROSS DESCRIPTION: The specimen is received. right breast and axillary contents the specimen consists of a portion of fibroadipose breast tissue and overlying. skin that measures 18.0 by 8.0 cm and weighs 1,529 gm. The skin surface measures 23.0 x 13.8 cm is light tan wrinkled there is a scar within the outer. quadrant measuring 3.0 cm that is 9.2 cm in the nipple there is slight ecchymosis noted within the upper outer quadrant. No other lesions are identified. The. nipple. is. eccentrically. placed appears grossly unremarkable. Sectioning reveais a firm gray-tan lobular mass that measures 10.0 x 10.0 x 7.2 cm. that is centrally located it is within 2.5 cm of the deep margin of resection the surrounding breast tissue reveais yellow-tan fatty fibroadipose tissue with. areas. of. gray fibrous tissue. Attached to the specimen is a portion of axillary contents measuring 10.0 x 6.0 x 3.0 cm there are twelve possible lymph. nodes that measure from 0.3 to 2.7 cm. Received with the specimen is a separate piece of skin and underlying subcutaneous tisaue 14.0 x 4.0 x 1.5. cm. sectioning cut surface is yellow-tan fatty fibroadipose tissue lesions not identified grossly. Received with specimen are three cassettes labeled. with. a. yellow. one. additionally. labeled -16 green one additionally labeled - 17 and the blue one additionally labeled - 18. Representative. sections are submitted in cassettes labeled. las follows: Nipple - block 1; Deep margin overlying mass - block 2; Sections from the mass -. blocks 3-8; Random sections from the upper inner quadrant - block 9; Lower inner quadrant - block 10; Lower outer quadrant - block 11; Upper outer. quadrant - block 12; Six probable nodes - block 13; Two probable nodes each bisected - block 14; One probable node bisected block 15; One probable. node. trisected - block 16-18; One probable node bisected - block 19; One probable lymph node sectioned - blocks 20-23; Sections from separately.",BRCA,3,True,"The report indicates that there were 12 lymph nodes received, out of which 3 contained metastatic carcinoma. This corresponds to the N2 classification, which is determined by the presence of metastases in 4-9 axillary lymph nodes. The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases, and the N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N2,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1354,TCGA-EW-A1PA.A68B2364-89DA-4DC7-9AA7-A08BBCC85025,1,"F. Pathologic Interpretation: A. Left breast lumpectomy with needle localization (short stith- superior, long lateral): - Invasive ductal carcinoma, Nottingham grade 2 (3+2+2), 2.5 cm in greatest linear dimension. Associated ductal carcinoma in situ, intermediate grade (DIN2), cribriform type with necrosis. - The margins are free from tumor. - Distance from the nearest margin is 1.8 cm (superior). - Lymphovascular space invasion is identified. - No malignancy seen in skin. - Microcalcifications. - Previous biopsy site. B. Skin left breast: - No malignancy seen in skin. C. Additional tissue superior to the two small nodules blue Indicates true margin: - Invasive ductal carcinoma, 0.4 cm in greatest linear dimension. - The distance from the true margin is 1.0 cm. D. Left axillary contents;. - Metastatic carcinoma in one out of thirteen lymph nodes with extranodal extension (1/13). - Size of metastatic tumor is 2.0 cm. E. Right breast tissue: - No malignancy seen in skin. - Fibroadenoma. Tumor Summary (Invasive Carcinoma of the Breast): Specimen Type: Partial breast. Procedure: Excision with wire-guided localization. Lymph Node Sampling: Axillary dissection (partial or complete dissection). Specimen Integrity: Single intact specimen (margins can be evaluated). Specimen Size: Greatest dimension: 16cm. Additional dimensions: 12 x 3 cm. Specimen Laterality: Left. Tumor Size: Size of Largest Invasive Carcinoma: Greatest dimension of largest focus of invasion: 2.5 cm. Additional dimensions: 2x1 cm. Tumor Focality: Multiple foci of invasive carcinoma. Number of focl: 2. Sizes of individual foci: 2.5 cm and 0,4 cm. Macroscopic and Microscopic Extent of Tumor: Skln: Invasive carcinoma does not invade into the dermis or epidermis. Nipple: DCIS does not involve the nipple epidermis. Skeletal Muscle: No skeletal muscle present. Ductal Carcinoma in Situ: DCIS is present. Histologic Type of Invasive Carcinoma: Invasive ductal carcinoma (no special type or not otherwise specified). Histologic Grade: Glandular (Acinar)/Tubular Differentiation: Score 3. Nuclear Pleomorphism: Score 2. Mitotic Count: Score 2. Overall Grade: Grade 2. Margins: Uninvolved by invasive carcinoma. Distance from closest margin: 1.0 cm (superior). Lymph-Vascular Invasion: Present. Dermal Lymph-Vascular Invasion: Not identified. Lymph Nodes: SURGICAL PATHOL Report. Number of sentinel lymph nodes examined: 0. Total number of lymph nodes examined (sentinel and nonsentinel): 12. Number of lymph nodes with macrometastases: 1. Number of lymph nodes with isolated tumor cells: 2.0 cm. Extranodal Extension: Present. Method of Evaluation of Sentinel Lymph Nodes: Hematoxylin and eosin (H&E), one level. Pathologic Staging (pTNM). Primary Tumor: pT2. Regional Lymph Nodes: pN1a. Distant Metastasis: Not applicable. Anciliary Studies: Estrogen Receptor: Performed on another specimen. Specify specimen: Results: Immunoreactive tumor cells present. Progesterone Receptor: Performed on another specimen. Specify specimen: Results: Immunoreactive tumor cells present. Her2: Performed on another specimen. Specify specimen: Results: Negative (Score 0). Microcalcifications: Present in invasive carcinoma. NOTE: Some immunohistochemical antibodies are analyte specific reagents (ASRs) validated by our laboratory (Her 2, Parvo, H. pylori, HBcore). These ASRs are clinically useful indicators that. do. require FDA approval. These clones are used: ID5=ER, PgR 636=PR, A485=HER2, H-11=EGFR, CCH2/DDG9=CMV, F39.4 1=AR end HPV by ISH. All immunohistochemical stains are used. with formalin or molecular fixed, paraffin embedded tissue. Detection is by LSAB. The results are read by a pathologist as positive or negative. '. MD. As the attending pathologist, / attest that I: (i) Examined the relevant. preparation(s) for the specimen(s); and (1) Rendered the diagnosis(es). Clinical History: Female with left breast cancer. Pre Operative Diagnosis: Left breast cancer. Specimen(s) Received: A: Left breast lumpectomy with needle localization (short stith- superior, long lateral ) fresh. B: Skin left breeast (perm). C: Additional tissue superior to the two small nodules blue indicates true margin (perm). D: Left axillary contents (perm). E: Right breast tissue (perm). Gross Description: A. Received fresh and labeled ""left breast lumpectomy with needle localization (short stith- superior, long lateral fresh"". specimen is inked for evaluation of margins as follows: posterior, black; anterior, yellow; superior, blue; Inferior, green;. lateral, orange; medial, red. The specimen weighs 299.0 grams and measures 16.0 cm from medial to lateral, 12.0 cm. Inferior to superior and 3.0 cm anterior to posterior. It is oval in shape, yellow in color, soft in consistency. The specimen. has an ellipse of skin measuring 3.0 x 1.0 cm. Serial sectioning of the specimen reveals an oval mass with infiltrating. borders and measures approximately 2.5 x 2.0 X 1.0 cm. The mass occupies 10% of the entire specimen. It is white in. color and firm in consistency. The distance of the mass from the margin is as follows: posterior 2.0 cm, inferior 2,0 cm,. anterior 3.0 cm, superior 3.0 cm, medial 10.0 cm, lateral 9.0 cm. The remaining of the breast parenchyma appears. unremarkable with fat to stroma ratio 90:10. The mass has a clip. A section of mass was submitted to tissue bank. Sections submitted as follows: SURGICAL PATHOL Report. 1-8. Sections of the mass in toto. 9&10. Representative section from the superior margin). 11&12. Representative section from inferior margin. 13&14. Representative section from lateral margin. 15&16. Representative section from medial margin. 17&18. Representative section from posterior margin. 19820. Representative section from anterior margin. 21. Representative section from the remaining breast parenchyma. 22. Representative section of the skin. B. Received in formalin and labeled ""skin left breast"" is a skin tag measuring 5.0 x 1.0 cm. Representative section submitted. in one cassette. C. Received in formalin and labeled ""additional tissue superior to the two small nodules blue indicates true margin (perm)"" is. oval in shape. The surgeon inked the true margin in blue. Resident inked true margin in black. It measures 3.0 x 1.0 x 1.0. cm. it is submitted in toto in eight cassettes. D. Received in formalin and labeled ""left axillary contents (perm)"" is axillary contents measuring 10.0 x 8.0 x 3.5 cm. It is. yellow in color and soft in consistency. There are 13 lymph nodes. The largest lymph node measures 2.0 x 2.0 cm. The. lymph nodes are submitted as follows: 1-8. One lymph node per cassette. 9. Two lymph nodes. 10. Three lymph nodes. E. Received in formalin and labeled ""right breast tissue (perm)"" is a soft, yellow breast tissue measuring 14.0 x 5.0 x 3.0 cm. Serial sectioning does not reveal any gross lesions. The breast parenchyma appears to be normal with fat to stroma ratio. 90:10. It has a skin tag measuring 3.0 x 1.0 cm. Sections are submitted as follows: 1. Section from skin. 2-4. Representative section of stroma. MD. ICD-9(s): 174.8 196.3 217.",BRCA,1,True,"The report indicates that there is metastatic carcinoma in one out of thirteen lymph nodes with extranodal extension (1/13). This satisfies the criteria for N1 classification, which is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1116,TCGA-D8-A1J9.D80E9389-AAD8-4EEB-9DE0-5DE57B5E5F6B,0,"page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - left breast with axillary tissues. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the left breast. Results of immunohistochemical examination: Estrogen receptors found in 10-75% of neoplastic cell nuclei. No progesterone receptors found in neoplastic cell nuclei. HER2 protein stained with HercepTestâ¢M by DAKO. Positive reaction in invasive cancerous cells ( Score = 3+ ). Macroscopic description: Left breast sized 18 x 12.5 x 2.5 cm removed along with axillary tissues sized 9 x 5 x 1 cm and a 14 x 4 cm skin flap. Weight. 350 g. Tumour sized 1.8 x 1.5 x 1.9 cm on the boundary of outer quadrants, 2.0 cm from the lower boundary, 0.3 cm from. the base and 0.7 cm from the skin. Microscopic description: Carcinoma ductale invasivum - NHG2 (2 + 3 +1:4 mitoses/10 HPF, visual area diameter 0.55 mm). Mamilla sine laesionibus. Lesions of the type mastopathia fibrosa et cystic, calcificationes. Invasive lesions situated 7 cm from the base. Axillary lymph nodes: Lymphonodultis chronica et sinus histiocytosis (No. VI). page 2 / 2. Histopathological diagnosis: Carcinoma ductale invasivum mammae sinistrae. Invasive ductal carcinoma of the left breast. (NHG2, pT1c, pNO ). CALL YOUR DOCTOR WITH THIS REPORT!.",BRCA,0,True,"The report indicates that there is no evidence of cancer in the lymph nodes (pNO), which is stated in the 'N stage' section of the histopathological diagnosis. This is consistent with the rules that the absence of cancer in the lymph nodes is the primary determinant of the N stage and that the number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",pNO,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,49.0,False
878,TCGA-AR-A24S.C0A8A457-8790-4745-BD5D-AFBE55254A1C,0,"Final Diagnosis. Breast, right, wide local excision: Infiltrating ductal carcinoma, Nottingham grade II (of III) [tubules 3/3, nuclei 2/3, mitoses. 1/3,. Nottingham score 6/9], forming a 1.3 x 1.1 x 1.0 cm mass. Ductal carcinoma in situ is absent. An intramammary lymph node. present is negative for metastatic carcinoma. Angiolymphatic invasion is absent. The non-neoplastic breast parenchyma shows. nonproliferative fibrocystic changes. Biopsy site changes present. All surgical resection margins are negative for tumor. (minimum tumor free margin, 0.5 cm, deep margin). (AJCCpT1c). Lymph nodes, right axillary sentinel, excision: Multiple (2) sentinel lymph nodes are negative for metastatic carcinoma [AJCC. pN0(i-)(sn)]. Blue dye is identified in sentinel lymph node No. 1 only. Immunohistochemical cytokeratin stain was performed on. the paraffin embedded sentinel lymph node tissue and confirms the H&E impression. Lymph node, right intramammary, excision: A single intramammary lymph node is negative for metastatic carcinoma. Lymph node, right axillary, excision: A single right axillary lymph node is negative for metastatic carcinoma. HER2/neu ordered.",BRCA,0,True,"The report states that there is no evidence of cancer in the lymph nodes, including the right axillary sentinel lymph nodes (2 nodes), intramammary lymph node, and a single right axillary lymph node. This is the primary determinant of the N stage. Additionally, there is no mention of metastases in axillary lymph nodes or infradiaphragmatic (lower) nodes. The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes. The presence of blue dye in a lymph node and immunohistochemical analysis of lymph nodes do not affect the N stage. Her-2/NEU analysis does not affect the N stage.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1306,TCGA-E9-A22B.FC896EB8-1CEC-46A0-82E1-E3FBFAAB69F1,0,"site : breast, NOS C50.9 the 4/2/11. Laterality:Right, upper outer quadrant. Path Report: BREAST TISSUE CHECKLIST. Specimen type: Radical mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 1.8 x 1.6x1.6cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal and lobular carcinoma. Histologic grade: Tumor extent: Not specified. Lymph nodes: 0/4 positive for metastasis (Regional 0/4). Extracapsular invasion of the lymph nodes: Not specified. Margins: Not specified. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None.",BRCA,0,True,"The report indicates that there are 0/4 positive lymph nodes (Regional 0/4) which means there is no evidence of cancer in the lymph nodes. Based on the rules provided, the N stage is determined by the absence or presence of cancer in the lymph nodes, and the number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes. Therefore, the N stage for this report is N0.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
990,TCGA-BH-A0BZ.1B56E5A6-35B8-4C60-8BC5-68716C946799,2,"FINAL DIAGNOSIS: BREASI, LEFT MODIFIED RADICAL MASTECTOMY AND AXILLARY DISSECTION -. A. INFILTRATING DUCTAL CARCINOMA. ) (see comment). B. NOTTINGHAM SCORE: 8/9 (TUBULES - 3, NUCLEI - 3, MITOSES - 2). C. LYMPHOVASCULAR PERMEATION IS PRESENT. D. DUCTAL CARCINOMA IN SITU, SOLID AND CRIBRIFORM TYPES, NUCLEAR GRADE 3, WITH COMEDO. NECROSIS, ASSOCIATED MICROCALCIFICATION AND RETROGRADE CANCERIZATION OF LOBULES,. REPRESENTING LESS THAN 1% OF TUMOR VOLUME. DUCTAL CARCINOMA IN SITU IS PRESENT ADMIXED. WITH THE INVASIVE TUMOR. E. MARGINS OF RESECTION AND SKELETAL MUSCLE ARE FREE OF TUMOR. F. NIPPLE, FREE OF TUMOR. G. SKIN WITH ACROCHORDON (FIBROEPITHELIAL POLYP), NO TUMOR SEEN. H. CHANGES CONSISTENT WITH PREVIOUS BIOPSY SITE, SEE PRIOR. I. FIBROCYSTIC CHANGES WITH DUCTAL EPITHELIAL HYPERPLASIA AND COLUMNAR CELL CHANGES. J. IMMUNOHISTOCHEMICAL STAININGS FOR ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR WERE. PREVIOUSLY PERFORMED ON. AND WERE REPORTED AS FOLLOWS: ESTROGEN RECEPTOR -. POSITIVE, PROGESTERONE RECEPTOR - POSITIVE, AND HER-2/neu - NEGATIVE (SCORE: 1+). K. METASTATIC ADENOCARCINOMA INVOLVING ONE OUT OF TWENTY-THREE (1/23) LEFT AXILLARY LYMPH. NODES, UP TO 1.1 CM (SS, TT, and UU), SEE PRIOR LEFT AXILLARY FINE NEEDLE ASPIRATION CYTOLOGY. (see comment). CASE STNOPSIS. SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Modified radical mastectomy. Not specified. SIZE OF TUMOR: Maximum dimension invasive component: 8.3 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 3. Tubule formation: 3. Mitotic activity score: 2. Total Nottingham score: 8. Nottingham grade (1, 2, 3): 3. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: Yes, malignant zones. TUMOR TYPE, IN SITU: Cribriform. Solid. DCIS admixed with invasive carcinoma. Percent of tumor occupied by in situ component: 1 %. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: SURG MARGINS INVOLVED BY IN SITU COMPONENT: PAGET'S DISEASE OF NIPPLE: LYMPH NODES POSITIVE: 1. LYMPH NODES EXAMINED: 23. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. NON-NEOPLASTIC BREAST TISSUE FCD Diameter of largest lymph node metastasis: 11 mm. SIZE OF NODAL METASTASES: T STAGE, PATHOLOGIC: N STAGE, PATHOLOGIC: M STAGE, PATHOLOGIC: ESTROGEN RECEPTORS: PROGESTERONE RECEPTORS. HER2/NEU:",BRCA,1,True,"The report indicates that there is metastatic adenocarcinoma present in one out of twenty-three (1/23) left axillary lymph nodes, which falls under the N1 classification in the AJCC staging system for breast cancer. This classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
610,TCGA-A8-A06O.EB9B8904-F6CC-451F-8628-50CC71F1F7C3,0,"Diagnosis: Poorly differentiated invasive ductal carcinoma with focal intraductal spread. (maximum microscopic tumor diameter: 1.5 cm; distance from nearest resection. margin less than 0.1 cm) with multiple ulcerations of the skin. Diagnosis: 1. Ablated breast sample with a further focus of poorly differentiated invasive ductal. carcinoma (tumor diameter: 1.5 cm; distance from dorsal margin 0.8 cm and from. nearest lateral resection margin 1 cm, other margins remain free). Concluding tumor classification: NOS, G III, pT1c(m)pNO(0/13)LOVORO.",BRCA,0,True,"The report indicates that there is no evidence of cancer in the lymph nodes, as shown by the 'pNO(0/13)' notation. This means that out of 13 lymph nodes examined, none contained cancer metastases. According to the rules provided, the absence of cancer in the lymph nodes is the primary determinant of the N stage, and the number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes. Therefore, the N stage for this patient is N0.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,49.0,False
643,TCGA-A8-A08A.6D2212CE-C80F-4545-A895-3F1B6E4C6DB6,0,"Diagnosis: Left breast segment (upper medial) with a 1.7 cm well differentiated (G1) invasive ductal. breast carcinoma. Carcinoma-free resection margins, carcinoma-free skin. Considering the tumor-free medial follow-up resection material (sample : 3), the carcinoma. was certainly excised in toto. Tumor stage: pTlc, GI, pLO, pV0, pNO (0/1, SLN), pRO.",BRCA,0,True,"The report states that the lymph node status is pNO (0/1, SLN), which means no cancer was found in the sentinel lymph node (SLN). According to the rules provided, if there is no evidence of cancer in the lymph nodes, the N stage is N0. The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes. The presence of blue dye in a lymph node, immunohistochemical analysis, Her-2/NEU analysis, and the type of carcinoma or presence of intraductal carcinoma do not affect the N stage. Therefore, the N stage for this patient is N0.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,42.0,False
1140,TCGA-D8-A1XB.B7367E27-2A40-4E8F-8975-D5665E6506D9,1,"page 1 / 1. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - right breast with axillary tissues. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer in the upper outer quadrant sucking skin. Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in over 75% of neoplastic cell. nuclei. HER2 protein stained with HercepTestâ¢M by DAKO. Negative reaction in invasive carcinoma cells ( Score = 1+). Compliance validated b. Macroscopic description: Right breast sized 18 x 12.5 x 3 cm removed along with axillary tissues sized 10 x 6 x 2 cm, a skin flap of 16.5 x 5.3 cm, and a piece. of the muscle sized 1 x 1 x 0.4 cm. Tumour sized 2.1 x 1 x 1.5 cm found in upper outer quadrant, located 1.5 cm from the upper boundary, 0.2 cm from the base and. 0 cm from the skin. Microscopic description: Carcinoma ductale invasivum - NHG1 (2+2+1/10 mitoses/10 HPF - visual area 0.55mm). Foci of carcinoma ductale in situ (DCIS). found within the tumour (cribrate type, with medium nuclear atypia, without necrosis, with calcifications covering 5% of the. tumour). Calcificationes in tumore. Mamilla sine laesionibus. Glandular tissue showing lesions of the type mastopathia fibrosa, microcalcificationes, fibroadenoma. AXILLARY LYMPH NODES: Metastases in lymphonodo (NO 1/X). Infiltratio capsulae lymphonodo et telae perinodalis. Histopathological diagnosis: Carcinoma ductale invasivum et ductale in situ mammae dextrae. Metastases lymphonodo axillae (No I/X). (NHG1,. pT2, pNla). Invasive ductal carcinoma and ductal carcinoma in situ of the right breast. Cancer metastases in axillary. lymph nodes (No I/X). (NHG1, pT2, pNla).",BRCA,1,True,"The report indicates the presence of cancer metastases in 1/X axillary lymph nodes (N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes). The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases, and the N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1335,TCGA-EW-A1IZ.F5EF4698-364C-4A5B-A8EC-1CF231BEEF31,1,"F. Pathologic Interpretation: A. Right breast short stich superior long lateral right single mastectomy: - Benign mammary parenchyma, no malignancy seen. B. Left breast and level I and II of axilla to tumor short superior, left lateral: - Invasive ductal carcinoma, Nottingham grade 3 (3+3+2), 2.8 cm in greatest linear dimension, focally presert at the. anterior specimen margin. - Ductal carcinoma in situ, high grade (DIN 3) solid type. - Organizing previous biopsy cavity. - Lymphovascular space invasion is present. - Metastatic carcinoma in four out of nine lymph nodes (4/9). - Receptors to follow. C. Additional fat above left breast tumor: - No malignancy seen in adipose tissue. D. Left level III axilla: - No malignancy seen in four lymph nodes (0/4). Tumor Summary (Invasive Carcinoma of the Breast): Specimen Type: Total breast (including nipple and skin). Procedure: Total mastectomy (including nipple and skin). Lymph Node Sampling: Axillary dissection (partial or complete dissection). Specimen Integrity: Single intact specimen (margins can be evaluated). Specimen Laterality: Left. Tumor Site: Lower outer quadrant; Lower inner quadrant. Tumor Size: Size of Largest Invasive Carcinoma: Greatest dimension of largest focus of invasion: 2.8 cm. Tumor Focality: Single focus of invasive carcinoma. Macroscopic and Microscopic Extent of Tumor: Skin: Invasive carcinoma does not invade into the dermis or epidermis. Nipple: DCIS does not involve the nipple epidermis. Skeletal Muscle: No skeletal muscle present. Ductal Carcinoma in Situ: DCIS is present. Architectural Patterns: Solid. Nuclear Grade: Grade III (high). Lobular Carcinoma in Situ: Not identified. Histologic Type of Invasive Carcinoma: Invasive ductal carcinoma (no special type or not otherwise specified). Histologic Grade: Glandular (Acinar)/Tubular Differentiation: Score 3. Nuclear Pleomorphism: Score 3. Mitotic Count: Score 2. Overall Grade: Grade 3. Margins: Uninvolved by invasive carcinoma. Distance from posterior margin: 2 cm. Uninvolved by DCIS (if present). Lymph-Vascular Invasion: Present. Dermal Lymph-Vascular Invasion: Not identified. Lymph Nodes: Number of sentinel lymph nodes examined: 0. Total number of lymph nodes examined (sentinel and nonsentinel): 13. Number of lymph nodes with macrometastases: 4. Size of largest metastatic deposit: 2.0 cm. Extranodal Extension: Not identified. SURGICAL PATHOL Report. Method of Evaluation of Sentinel Lymph Nodes: Hematoxylin and eosin (H&E), one level. Pathologic Staging (pTNM). TNM Descriptore: m (multiple foci of invasive carcinoma). Primary TumorÂ¿pT2. Regional Lymph Nodes: pN2. Distant Metastasis: Not applicable. Anciliary Studies: Estrogen Receptor: Pending. Progesterone Receptor: Pending. Her2: Pending. NOTE: Some immunohistochemical antibodies are analyte spectific reagents (ASRs) validated by our laboratory (Her 2, Pervo, H. pylori, HBcore). These ASRs are clinically indicators that do. not require FDA approval. These clones are used: ID5=ER, POR 636=PR, A485HER2, H-11=EGFR, CCH2/DDG9=CMV, F39.4 1=AR and HPV by ISH. All immunohistochemidelt stains are used. with formalin or molecular fixed, paraffin embedded fissue. Detection is by LSAB. The results are read by a pathologist as positive or negative. As the attending pathologist, / attest that 1: (i) Exemined the relevent. preperation(s) for the specimen(s); and (i) Rendered the diagnosis(es). Procedures/Addenda. Addendum. Date Complete: Addendum Diagnosis. The tumor cells are positive for ER and PR and negative for HER2 by immunohistochemistry. Immunohistochemistry for p63 was. used in the evaluation of the specimen. Clinical History: female with left breast cancer. Pre Operative Diagnosis: Left breast cancer. Specimen(s) Received: A: Right breast short stich superior long lateral right single mastectomy (fresh). B: Left breast and level 1 and Il of axilla to tumor short superior, left lateral (fresh). C: Additional fat above left breast tumor (perm). D: Left level III axilla (perm). Gross Description: A. Received fresh and labeled ""right breast short stich superior long lateral right single mastectomy (fresh)"" is a breast. specimen measuring 18.0 x 15.0 x 5.0 cm. It has a white-tan ellipse of skin measuring 4.0 x 1.0 cm. The nipplÃ© measures. 1.0 x 1.0 cm. The skin is unremarkable and nipple is unremarkable. Deep margin is smooth, facial plane without any. SURGICAL PATHOL Report. skeletal muscle. Deep margin is inked in black. Serial sectioning of the mastectomy specimen does not reveal any gross. lesion. Specimen submitted as follows: 1&2. Sections from upper outer quadrant. 3&4. Representative section from lower outer quadrant. 5&6. Representative section from upper inner quadrant. 7&8. Representative section from lower inner quadrant. 9&10. Representative section from central quadrant. 11. Representative section from nipple. B. Received fresh and labeled ""left breast and level 1 and II of axilla to tumor short superior, left lateral (fresh)"" is a. mastectomy specimen measuring 19.0 x 17.0 x 3.0 cm. It has a white-tan ellipse of skin measuring 2.5 x 2.0 cm. The. axillary tail measures 13.0 x 9.0 cm. The skin and nipple are unremarkable. Deep margin is smooth, facial plane without. any skeletal muscle. Deep margin is inked black, superior margin is inked blue, medial margin is inked red and inferior. margin is inked green. Serial sectioning of the mastectomy specimen reveals a 2.8 x 2.0 x 1.5 cm firm gray mass located. in the lower outer quadrant, less than 0.1 cm from the inked anterior specimen margin. There is also a 1 x 1 1 cm. mass. in the lower inner quadrant. The mass is well defined. It has a clip in it. in the upper inner quadrant, there is an area of. necrosis measuring 2.0 x 2.0 x 1.0 cm. it is brown in color and soft in consistency. Remainder of the breast parenchyma is. predominantly white and firm with small cyst measuring up to 0.3 cm in greatest dimension. The axillary tail is yellow and. soft. There are 13 possible lymph nodes. The largest measures 3.0 cm in greatest dimension. Sections submitte as. follows: 1-8. Mass in the lower inner quadrant. 9&10. Area of necrosis. 11&12 Representative section from upper outer quadrant. 13&14 Representative section from lower outer quadrant. 15&16 Representative section from upper inner quadrant. 17&18 Representative section from lower inner quadrant. 19820. Representative section from the central quadrant. 21. Representative section from the nipple. 22-24. Contains representative section from the largest lymph node. 25-37. One fymph node per cassette. 38-41. Additional section of mass in lower outer quadrant. C. Received in formalin and labeled ""additional fat above left breast tumor"" is a soft fragment measuring 2.5 x 1.0x 1.0 cm. Submitted in toto in three cassettes. D. Received in formalin and labeled ""left level III axilla"" is a pale yellow, soft tissue fragment measuring 4.0 x 3.0 x 2.0 cm. Four possible lymph nodes are bisected and submitted in toto in four cassettes. ICD-9(s);. 174.5 174.3 196.3.",BRCA,2,True,"The report indicates that there are 13 lymph nodes examined in total, and metastatic carcinoma is found in 4 out of 9 lymph nodes from level I and II of the axilla. There is no mention of metastases in infradiaphragmatic (lower) nodes or ipsilateral internal mammary nodes. Therefore, based on the rules provided, the N stage is N2.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N2,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1009,TCGA-BH-A0DZ.16DE55CE-076E-43D3-84BD-332A79B95EFD,1,"P.22/33. BIAGNOSIS: AREAST. LEFT. BOTAL MASTECTOMY -. COBULAR NEOPLASIA (ATYPICAL LOBULAR HYPERPLASIA) (sec comment). B. FIBROADENOMÃ, DUCTAL EPITHELIAL HYPERPLASIA, FIBROCYSTIC CHANGE. C. SKIN AND NIPPLE, NO TUMOR SEEN. PART 2: BREAST, RIGHT, TOTAL MASTECTOMY -. A. INFILTRATING DUCTAL CARCINOMA, NOS TYPE, MODERATELY DIFFERENTIATED. 8. THE TUMOR IS MULTIFOCAL, MULTICENTRIC, LOCATED AT THE JUNCTION OF UPPER OUTER QUADRANT. (UOQ) AND UPPER INNER QUADRANT (UIO) AS WELL AS IN THE UPPER OUTER QUADRANT (UOO). c. THE TUMOR NODULES MEASURE 2.5 CM (GROSS MEASUREMENT) AND 0.5 CM (MICROSCOPIC. MEASUREMENT) RESPECTIVELY. D. NOTTINGHAM SCORE 6/9 (TUBULES 2. NUCLEAR GRADE 2, MITOSIS 2),OVERALL GRADE 2/3. E. NO DEFINITIVE LYMPHOVASCULAR INVASION IS IDENTIFIED. F. DUCTAL CARCINOMA IN 8ITU, SOLID TYPE WITH COMEDO NECROSIS, NUCLEAR GRADE 3 WITH. LOBULAR EXTENSION, COMPRISING 25% OF THE TOTAL TUMOR VOLUME AND IS PRESENT IN. ASSOCIATION AND AWAY FROM THE INVASIVE CARCINOMA. G. MARGIN3: DEEP AND ANTERIOR MARGISN OF RESECTION ARE FREE OF INVASIVE AS WELL AS IN SITU. CARCINOMA, CLOSEST ANTERIOR MARGIN IS 7MM AWAY. K. ATYPICAL DUCTAL HYPERPLASIA. PREVIOUS BIOPSY SITE CHANGES (I/1 AND #2), ( 3EC COMMENT-2). I. FIBROADENOMA, PSEUDOANGIOMATOUS STROMAL HYPERFLASIA (PASH), COLUMNAR CELL CHANGE. J. SKIN AND NIPPLE, NO TUMOR SEEN. K. ER-POSITIVE, PR-POSITIVE. MER 2/NEU -STRONGLY POSITIVE (IHC 3+ AS WELL AS FISH-AMPLIFICATION),. CROSS REFER. PART 3: #1 SENTINEL LYMPH NODE, RIGHT AXILLA, BIOPSY-. ONE LYMPH NODE WITH METASTATIC CARCINOMA, THE METASTATIC FOCUS MEASURES 6MM (ON GLASS. SLIDE) FOCAL EXTRACAPSULAR EXTENSION IS IDENTIFIED (1/1). PART 4: #2 SENTINEL LYMPH NODE, RIGHT AXILLA, BIOPSY. ONE BENIGN LYMPH NODE, NO TUMOR SEEN (0/1). PART 5: #3 SENTINEL LYMPH NODE, RIGHT AXILLA, BIOPSY -. ONE BENIGN LYMPM NOPE, NO TUMOR SEEN (0/1). PART 6: #4 SENTINEL LYMPH NODE, RIGHT AXILLA, BIOPSY -. ONE BENIGN LYMPH NODE, NO TUMOR SEEN (0/1). PART 7: NON-SENTINEL LYMPH NODE, RIGHT AXILLA, BIOPSY-. ONE BENIGN LYMPH NODE, NO TUMOR SEEN (0/1). LATERALITY: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. PROCEDURE: Right. Simple mastactoiny. Upper outer quacrant. SIZE OF TUMOR: Upper inner quadrant. MULTICENTRICTYMOUTIFOCAUTY OF Maximum INVASIVE dimension FOCI: Invasivo component: , 5 on. TUMOR AGGREGATE SIZE: TUMOR TYPE (invasivo component): Sum of the sizes of multiple invasive tumors: 3.0 cm. NOTTINGHAM SCORE: Ductal adenocamino, NOS. Nuclear grade: 2. Tubule formation 2. Milorie activily 2. total Nottingham score: G. ANO|OLYMPHATIC INVASION: No Nottingham grade (1. 2, 3): 2. DERMAL LYMPHATIC INVASION: CALCIFICATION: TUMOR TYPE, IN SITU: Yes, malignant zonea. Solid. Comedo. SURGICAL MARGINS INVOLVED By INVASIVE of COMPONENT: tumor occupied by In situ component: 25 %. Percent DCIS admixed und outsino of Invasivo carcinoma component. SURG MARGINS INVOLVED BY IN SITU No COMPONENT: PAGET'S DISEASE OF NIPPLE: LYMPH NODES POSITIVE: LYMPH NODES EXAMINED: 1. METHOD(S) OF LYMPH NODE EXAMINATION: 4. Discrepancy. SENTINEL NODE METASTASIS: H/E stain. ONLY KERATIN POSITIVE CELLS ARE Yes PRESENT: initials Mittory. CUALI,. SIZE OF NODAL METASTASES: LYMPH NODE META8TASIS(-ES) WITH Diameter EXTRACAPSULAR of targest lymph EXTENSION: node motestasis: 8 mm. METASTASES TO IPSILATERAL INTERNAL No Yes MAMMARY LYMPH NODE (IF APPLICABLE): T STAGE, PATHOLOCIC. SKIN INVOLVED (ULCERATION): N STAGE, PATHOLOGIC-. p12. M STAGE, PATHOLOGIC: pN1. ESTROGEN RECEPTORS. pMX. poritive. PROGESTERONE RECEPTORS: HER2/NEU: positive. 3+.",BRCA,1,True,"The report indicates that there is metastatic carcinoma present in one sentinel lymph node in the right axilla, with a maximum focus measuring 6mm and focal extracapsular extension. This satisfies the criteria for N1 classification, which is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1112,TCGA-D8-A145.1D26CB97-536A-4D10-A593-73C3A846BB13,0,"page 1 / 2. Examination: Histopathological examination. PESEL: Gender: F. Material: Multiple organ resection - right breast. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the right breast. Macroscopic description: Right breast, sized 18.3 x 18.8 x 4.2 cm, removed without axillary tissues and with a skin flap of 14.6 x 7.1 cm. Weight 580 g. Tumour sized 1.6 x 1.2 x 1.8 cm on the boundary of outer quadrants, placed 5.2 cm from the outer edge, 1.2. cm from the base and 0.8 cm from the skin. Status after core needle biopsy (test No. Microscopic description: Carcinoma ductale - NHG2 (3 + 2+1:2 mitoses/ 10 HPF, visual area diameter 0.55 mm),. papilloma intraductale mamillae. Glandular tissue showing parenchyma atrophy. Examination result: Including test No. anc. Carcinoma ductale invasivum mammae dextrae. Metastases carcinomatosae in lymphonodo axillae (No I/VII). (NHG2, pT1c, pN1a) INVASIVE DOAL CARCIANNAA OF THE RIGHT BREAST. Comr. bv: Examination performed or.. Results of immunohistochemical examination: Estrogen receptors found in 75% of neoplastic cell nuclei. Progesterone receptors found in 10% of. neoplastic cell nuclei. HER2 protein stained with HercepTestâ¢M by DAKO. Score = 2+, verification by the FISH method recommended.",BRCA,1,True,"The report mentions 'Metastases carcinomatosae in lymphonodo axillae (No I/VII)', which indicates the presence of cancer metastases in 1-3 axillary lymph nodes. This corresponds to the N1 classification.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
805,TCGA-AO-A0JL.C2976F78-89AF-4461-8D22-BFEBC0504722,1,"clinical Diagnosis & History: %/O female with left breast mass. Mammo showed 2 lesions in UOQ left. breast. Core biopaies IDC and DCIS. Proceeding to MRM. Specimens Submitted: 1: SP: Left breast with level 1 and low level 2 axillary contents. 2: SP: Additional level 2 left axillary contents. 3: SP: Left level 2 and level 3 axillary contents. DIAGNOSIS: 1). BREAST WITH LEVEL I AND LOW LEVEL II AXILLARY CONTENTS, LEFT;. MODIFIED RADICAL MASTECTOMY AND AXILLARY LYMPH NODE DISSECTION: - TWO SEPARATE TUMOR NODULES: ONE IS LOCATED IN THE UPPER OUTER. QUADRANT AND SHOWS AN INVASIVE DUCTAL CARCINOMA, POORLY DIFFERENTIATED. (HISTOLOGIC GRADE III/III, NUCLEAR GRADE III/III), MEASURING 3.9 CM IN. LARGEST DIMENSION GROSSLY. THE SECOND IS LOCATED IN THE UPPER AND LOWER OUTER QUADRANTS AT 3:00 AND IS. COMPOSED OF PREDOMINANTLY DUCTAL CARCINOMA IN SITU (DCIS) WITH SEVERAL FOCI. OF INVASIVE DUCTAL CARCINOMA, POORLY DIFFERENTIATED AND SIMILAR TO ABOVE,. RANGING IN SIZE FROM LESS THAN 0.1 CM TO ABOUT 0.4 CM. - THE DUCTAL CARCINOMA IN SITU (DCIS) IS OF THE SOLID AND CRIBRIFORM TYPES. WITH HIGH NUCLEAR GRADE, EXTENSIVE NECROSIS AND FOCALLY INVOLVES A LARGE. LACTIFEROUS DUCT OF THE NIPPLE. - CALCIFICATIONS ARE PRESENT IN THE IN SITU AND INVASIVE CARCINOMA, AND IN. BENIGN BREAST PARENCHYMA. - VASCULAR INVASION IS PRESENT. - NO INVOLVEMENT OF THE SURGICAL MARGINS BY EITHER INVASIVE OR IN SITU. CARCINOMA IS IDENTIFIED. - NO SKIN INVOLVEMENT BY CARCINOMA IS IDENTIFIED. - THE REMAINING BREAST TISSUE SHOWS PREVIOUS BIOPSY SITE AND MILD. FIBROCYSTIC CHANGES. - THE LYMPH NODE STATUS IS AS FOLLOWS (EXPRESSED AS THE NUMBER OF POSITIVE. LYMPH NODES IN RELATION TO THE TOTAL NUMBER OF LYMPH NODES EXAMINED) : THERE IS EXTRANODAL TUMOR EXTENSION (>2 MM). - RESULTS OF IMMUNOHISTOCHEMICAL STAINS ARE AS FOLLOWS: ER: 0% NUCLEAR STAINING. PR: 0% NUCLEAR STAINING. HER-2/NEU (HERCEPTEST) : NEGATIVE (STAINING INTENSITY OF 1+). 2). AXILLARY CONTENTS, LEFT ADDITIONAL LEVEL II; DISSECTION: TWELVE BENIGN LYMPH NODES (0/12). 3). AXILLARY CONTENTS, LEFT LEVELS II AND III; DISSECTION: - THREE BENIGN LYMPH NODES (0/3). I ATTEST THAT THE ABOVE DIAGNOSIS IS BASED UPON MY PERSONAL EXAMINATION OF. THE SLIDES (AND/OR OTHER MATERIAL), AND THAT I HAVE REVIEWED AND APPROVED. THIS REPORT. Special Studies: Special Stain. Comment. ER-C. PR-C. HER2-0. NEG CONT. IMM RECUT. NEG-HER2. Gross Description: 1). The specimen is received fresh labeled, ""Left breast with level 1 and. low level 2 axillary contents, stitch marks axillary contents and consists. of a breast with attached axillary tail. The breast measures 37.0 x 26.0. x. 6.7 cm with overlying skin ellipse measuring 36.5 x 18.0 cm. Situated on. the skin surface is an everted nipple measuring 1.4 x 1.2 x 0.1 cm and. areola measuring 4.8 x 4.5 cm. The skin shows no visible scars. A suture. demarcates the axillary tail which measures 11.0 x 4.0 x 3.5 cm. The. posterior surface of the breast is inked black and the specimen is serially. sectioned to reveal a white tan firm ill-defined mass in the upper outer. quadrant measuring 3.9 x 3.7 x 3.3 cm, located 1.5 from the deep margin. There is a biopsy site identified in the lower outer quadrant, corresponding. to the three o'clock position, measuring 2.0 x 2.0 x 1.5 cm. The remaining. breast tissue shows predominantly yellow lobulated adipose tissue admixed. with white-tan fibrous soft tissue with no other gross identifiable lesions. The axillary tissue is dissected to reveal several grossly positive lymph. nodes, measuring up to 4.5 cm. Representative sections of the mastectomy. specimen and all identified axillary lymph nodes are submitted (the large. grossly positive lymph nodes are representatively submitted). Tissue. is. taken for TPS. Summary of sections: N - nipple. NB - nipple base. s skin. D - deep margin. T tumor. BX - separate biopsy site. UIQ - upper inner quadrant. LIQ - lower inner quadrant. UOQ - upper outer quadrant. LOQ - lower outer quadrant. LN - individual lymph nodes. 2). The specimen is received in formalin, labeled ""Additional level 2. left axillary contents"" and consists of an axillary dissection measuring 7 x. 4.5 x 0.8 cm. The specimen consists of soft yellow-tan lobulated tissue. with several pink-tan lymph nodes identified on cut section ranging from 0.2. cm to 1.8 cm in greatest dimension. The specimen is submitted for lymph. node digest dissection. Summary of sections: LN - lymph nodes. 3). The specimen is received in formalin, labeled ""Left level 2 and level. 3 axillary contents"" and consists of an unoriented axillary dissection. measuring 7.5 x 4.7 x 1.8 cm. The specimen consists of yellow tan lobulated. tissue, which on sectioning reveals several pink-tan lymph nodes ranging. from 0.2 cm to 2.3 cm in greatest dimension. The specimen is submitted for. lymph node dissection. Summary of sections: LN - lymph nodes. Summary of Sections: Part 1: SP: Left breast with level 1 and low level 2 axillary contents. Block. Sect. Site. PCs. 3. BX. 3. 1. D. 1. 2. LIQ. 2. 4. LN. 4. 2. LOQ. 2. 1. N. 1. 1. NB. 1. 1. s. 1. 3. T. 3. 2. UIQ. 2. 2. 2. Part 2: SP: Additional level 2 left axillary contents. Block. Sect. Site. PCs. 4. LN. 4. 2art 3: . SP: Left level 2 and level 3 axillary contents. Block. Sect. Site. PCs. 2. LN. 2.",BRCA,2,True,"The report indicates that there is extranodal tumor extension (>2 mm) in one or more lymph nodes, but it does not specify the exact number of positive lymph nodes. However, the report does mention that a total of 17 lymph nodes were examined (12 from additional level II and 5 from levels II and III), all of which were benign. Therefore, the N stage would be N1, which is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved. This is in line with the rules that the absence of cancer in the lymph nodes is the primary determinant of the N stage, and the presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
700,TCGA-AC-A2FB.F6CFE506-16BA-475A-A81F-1AC4B2EFE24A,1,"Histopathological Examination. 1 Complete: Pre-Op Diagnosis : Absenge of Rreast, Personal History Of Breast Cancer -. MD. Specimens. : Breast, left simple mastectomy for expo study. Suture. marking margins: long-lateral, short-superior. Lymph Node, Sentinel left axillary. Frozen Diagnosis. : GROSS EXAMINATION: A. The specimen is received in a container labeled with the. name of the patient and identified as breast, left simple. mastectomy. The specimen consists of a mastectomy measuring. en bloc 11.5 x 9.! x 4 cm and weighing 158 grams. There is. an anterior ellipse of skin measuring 6 x 3 cm with a. central 3 cm areolar complex with retracted nipple. Sections. of nipple/areola are sampled in block 1. The skin is. sampled in block 2. The superficial superior margin is. inked orange and the superficial inferior margin is inked. blue. The deep margin is inked green and the specimen. sectioned, showing an oval grey-tan firm mass measuring 2.8. cm in the upper inner quadrant of the breast. Grossly, this. mass is 0.4 cm from the inked deep margin of resection,. which is submitted in block 3. Sections of the mass are. submitted in blocks 4-7. The remaining breast is composed. of yellow lobulated adipose tissue admixed with islands of. gray-white rubbery tissue. The breast is divided into four. quadrants, upper inner, lower inner, upper outer and lower. outer and sampled in blocks 8-11 respectively Minimal. axillary tissue is present and no lymph nodes are. identified. Formalin fixation time is 11 hours. B. The specimen is received in a container labeled with the. name of the patient and identified as lymph axillary. sentinel node. Specimen Size: 1.8 x 1.5 x 1 cm. No. of Nodes 1. Size of Nodes : 1.8 cm. The specimen is sectioned and entirely submitted. THIS CONFIDENTIAL AND PRIVILEGED DOCUMENT/INFORMATION IS PROTECTED BY. FEDERAL AND STATE LAW. UNAUTHORIZED DISCLOSURE, DISSEMINATION. OR DUPLICATION IS PROHIBITED. Path # : . of 3. Visit # : DIAGNOSIS BASED ON GROSS AND MICROSCOPIC EXAMINATION: : A. Breast, left, simple mastectomy: Invasive lobular adenocarcinoma,apleomorphic variant,. Nottingham grade 2, 2.8 cm (see cancer case summary. checklist below). B. Lymph node, left axillary sentinel, excision: - One lvmph node, no tumor present (0/1). MACROSCOPIC. SPECIMEN TYPE: Mastectomy. LYMPH NODE SAMPLING: Sentinel lymph node only. LATERALITY Left. TUMOR SITE: Upper inner quadrant. MICROSCOPIC. SIZE OF INVASIVE COMPONENT: Greatest dimension: 2.8 cm (based on gross tumor size) . HISTOLOGIC TYPE: Invasive lobular adenocarcinoma,. pleomorphic variant. HISTOLOGIC GRADE: NOTTINGHAM HISTOLOGIC SCORE. Tubule formation: Minimal less than 10% (score=3). Nuclear pleomorphism: Moderate increase in size, ect. (score=2). Mitotic count for a 40 x objective with a field area of. 0.152 MMTT: 0-5 mitoses per 10 HPF (score=1). Total Nottingham Score: Grade 2 (6-7 points). EXTENT OF INVASION. PRIMARY TUMOR (PT) : pT2: Tumor more than 2.0 but not more. than 5.0 cm in greatest dimension. REGIONAL LYMPH NODES (PN) : pNO: No regional lymph node. metastasis histologically (i.e. none greater than 0.2 mm). no additional examination for isolated tumor cells. Number examined: 1. Number involved 0. DISTANT METASTASIS (PM) : pMX: Cannot be assessed. MARGINS: Uninvolved by invasive carcinoma. Distance of carcinoma from closest margin: 4 mm (deep. margin) . VENOUS/LYMPHATIC (LARGE/SMALL VESSEL) INVASION (V/L) : Absent. MICROCALCIFICATIONS: Present in non-neoplastic tissue. ADDITIONAL PATHOLOGIC FINDINGS : Proliferative fibrocystic changes with ductal hyperplasia,. columnar cell change, sclerosing adenosis (confirmed by. presence of p63 positive myoepithelial cells surrounding. epithelial structures, with appropriate controls), apocrine. metaplasia, and associated microcalcifications. THIS CONFIDENTIAL AND PRIVILEGED DOCUMENT/INFORMATION IS PROTECTED BY. FEDERAL AND STATE LAW. UNAUTHORIZED DISCLOSURE, DISSEMINATION. OR DUPLICATION IS PROHIBITED. Path # : of 3. Visit # : Prior bropsy site. COMMENT: Estrogen and progesterone receptors and Her2neu studies were. performed on the prior biopsy. with results of. estrogen receptor 2+, progesterone receptor 3+, and HER2/neu. 3+. E cadherin, also performed on the prior biopsy, was. negative, confirming a lobular phenotype. Intradepartmental consultation obtained. Results communicated to. THIS CONFIDENTIAL AND PRIVILEGED DOCUMENT/INFORMATION IS PROTECTED BY. FEDERAL AND STATE LAW. UNAUTHORIZED DISCLOSURE, DISSEMINATION. OR DUPLICATION IS PROHIBITED. Path # : I. Visit # :",BRCA,0,True,"The report indicates that one sentinel lymph node was excised and no tumor was found in it (0/1). According to the rules provided, the absence of cancer in the lymph nodes is the primary determinant of the N stage, and the number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes. Therefore, the N stage is N0.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,49.0,False
1514,TCGA-XX-A89A.5D85E578-64B4-4238-922E-802B8ED87800,2,"Research Gross Description. Research Dx. Left breast (1945 g), mastectomy: Invasive lobular carcinoma. 7 regional lymph nodes, negative for malignancy (0/7). Tumor site: Upper outer quadrant ( 2-3:00). Tumor size: Between 7 and 9 cm. Histopathologic type: Invasive lobular carcinoma. Histopathologic grade (Nottingham): 2. Mitotic count: Low proliferative rate. Pathologic tumor stage: pT3. Margin status: Distance of carcinoma from margins: Superior: 0.8 cm. Inferior: At least 1 cm. Medial: Greater than 2 cm. Lateral: Greater than 2 cm. Anterior: 1 cm. Posterior: Greater than 1 cm. Associated in situ carcinoma: Type: Lobular carcinoma in situ (rare focus). Extensive (>25% of total tumor): No. Separate (extra-tumoral) foci away from main lesion: Not identified. Peritumoral angiolymphatic invasion: Not identified. Dermal angiolymphatic invasion: Not identified. Estrogen receptor: Positive (70 % of tumor cell nuclei staining moderately to strongly). Progesterone receptor: Positive (70 % of tumor cell nuclei staining moderately to strongly). HER-2/neu (ERBB2): Negative (score 0). Duration of fixation in 10% NBF: 12 hours 24 minutes. Appropriate internal and external controls: Yes. Standard assay conditions met? Yes. Pathologic lymph node stage: pNO (including sentinel): No regional lymph node metastasis. Number of nodes positive for metastasis/total number nodes sampled: 0/11. Maximum diameter of largest lymph node metastasis: Not applicable. Extranodal extension by tumor: Not applicable. Distant metastasis: M-not applicable. Additional pathologic findings: Fibrocystic change and usual ductal hyperplasia; seborrheic. keratosis. TNM descriptors (if applicable): AJCC Staging (7th Edition): pT3 pNO M-not applicable. Research QC. T1 Tumor: 50% tumor nuclei. 0% necrosis. 50% normal. Normal: 100% fibroadipose. 1. T2. 50% tumor nuclei. 0% necrosis. 50% normal fibrous tissue and fat. minimal normal breast. T3. 70% tumor nuclei. 0% necrosis. 30% normal. T4. 50% tumor nuclei. 0% necrosis. 50% normal fat, could prob be trimmed. Research Specimen. Specimen Process Time. Blood draw time. Plasma frozen time: Serum frozen time. Buffy coat frozen time: Cold ischemia start time: Formalin fixation start time: Total cold ischemia time: Formalin fixation stopped time. Total formalin fixation time: Specimen Weight. Cryovials x 8. Normal X 4 - 1.) 335 mg 2.) 321 mg 3.) 408 mg 4.) 447 mg. Tumor x 4 - 1.) 351 mg 2.) 357 mg 3.) 252 mg 4.) 322 mg. Specimen Size. Plasma x 3. Serum x 2. Buffy coat X 1. Cryovials X 8. Normal x 4. Tumor X 4. FFPE x 8. Normal x 4. Tumor x 4. Study. Patient Consent. 2.",BRCA,0,True,"The pathology report indicates that 7 regional lymph nodes were negative for malignancy and there were no distant metastases. According to the rules, the absence of cancer in the lymph nodes is the primary determinant of the N stage, and the number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes. Therefore, the N stage is N0.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,49.0,False
1439,TCGA-LL-A9Q3.2697F2B6-725C-438F-B4D3-3E32DEF86FD6,2,"RUN DATE : RUN TIME. RUN USER: ACCT # : LOC: AGE/SX: ROOM: REG DR: BED: SPEC #: RECD. PERFORMED ATI. COLL. TIME IN FORMALIN: 3:56. hrs. COLD ISCHEMA TIME : 0:00. mins. CLINICAL INFORMATION: Pre-Op Diagnosis: Remarks : Specimen (s) : Left modified radical mastectomy - stitch at axilla. MICHOSCOPIC DIAGNOSIS. LEFT BREAST, MODIFIED RADICAL MASTECTOMY: INFILTRATING LOBULAR CARCINOMA. PLEOMORPHIC TYPE. MODIFIED NOTTINGHAM HISTOLOGIC GRADE 2 OF 3; NUCLEAR SCORE 2 OF 3. TUBULAR. FORMATION SCORE 3 OF 3, MITOTIC SCORE 1 OF 3 (THREE MITOTIC FIGURES PER SQUARE. MILLIMETER). TUMOR MEASURES 10 CM AND EXHIBITS EXTENSIVE LYMPH-VASCULAR INVASION. SURGICAL MARGINS FREE OF TUMOR WITH NEAREST MARGIN 0. 3 CM FROM TUMOR, INFERIOR. MARGIN. METASTATIC LOBULAR CARCINOMA PRESENT IN 28 OF 28 AXILLARY LYMPH NODES. 5 CM. GREATEST DIMENSION WITH EXTRACAPSULAR EXTENSION. SEE COMMENT FOR SYNOPTIC REPORT. COMMENT(S). CAP APPROVED SURGICAL PATHOLOGY CANCER CASE SUMMARY INVASIVE CARCINOMA OF THE BREAST. PROCEDURE : Total mastectomy (including nipple and skin). LYMPH NODE SAMPLING. Axillary dissection. SPECIMEN LATERALITY: Left. HISTOLOGIC TYPE OF INVASIVE CARCINOMA: Invasive lobular carcinoma. TUMOR SIZE: Size of largest invasive carcÃ­noma. Greatest dimension of largest focus of. invasion > 1 mm: 10 cm. HISTOLOGIC GRADE. Glandular/tubular differentiation: Score 3. Nuclear pleomorphism: Score 2. Mitotic rate: Score 1. Overall grade Grade 2. TUMOR FOCALITY. Single focus of invasive carcinoma. DUCTAL CARCINOMA IN SITU: No DCIS is present. MARGINS : Invasive carcinoma: Margins uninvolved by. invasive carcinoma. Distance from closest margin: 0.3 cm. inferior. RUN DATE : RUN TIME : Specimen Inquiry. RUN USER. Lab Database. SPEC #: COMMENT (S). LYMPH NODES: Number of lymph nodes examined : 28. Number of lymph nodes with macrometastases : 28. PATHOLOGIC STAGING: Primary tumor: pT3. Regional lymph nodes pN3a. Distant metastasis: Not applicable. ANCILLARY STUDIES: Estrogen receptor : Positive (100% of tumor. cells with nuclear positivity). Progesterone receptor: Positive (2% of tumor. cells with nuclear positivity). Immunoperoxidase studies: Positive. GROSS DESCRIPTION: Received fresh for tissue banking. labeled with the patient's name and ""left modified. radical mastectomy"" is a 1758 gram, 28.0 x 25.0 x 6.5 cm fibrofatty breast. The breast is. received with an 11. 0 x 8.5 x 4.0 cm axillary tail consistent with a modified radical. mastectomy specimen. There is a 22.0 x 9.0 cm tan-white skin ellipse which has a centrally. located. 5.5 x 4.5 cm ovoid areola and central 1.5 cm nipple. No scars or lesions are. identified on the skin's surface. The deep fascial margin is smooth with delicate strands. of fibroskeletal muscle. The breast is sectioned to have diffuse. ill defined indurated. nodularity. This area of indurated nodularity is ill defined and is central to inferior. The nodule extends to cover a region which is 10.0 x 7.0 x 7.0 cm. Central within this. region is a 4.0 x 3.5 x 3.0 cm solid mass, The tumor is sampled for tissue banking from the. solid mass. The more solid appearing mass is 4 cm from the deep margin: however the. indurated nodularity is 2.3 cm from the deep margin with focal nodules being 2.0 cm. The. measurable mass is 2.5 cm from inferior and approximately 11 cm from superior, the mass is. approximately 8 cm from medial and 9 cm from lateral. There is focal petechial hemorrhage. associated with the mass and consistent with a previous biopsy The dense, white-fibrous. tissue makes up approximately 40% of the parenchyma. The tumor appears to be predominantly. central and inferior within the breast with finger-like, indurated extensions into each. quadrant. There are two large lymph nodes present in the upper outer quadrant The axilla. is. sectioned to have multiple, indurated nodular lymph nodes. The largest lymph node is a. linear 5. 0 x 0 x 1.0 cm Representative sections are sampled as labeled: 1. nipple trisected. 2. en face section of areola. 3. deep margin overlying more solid appearing tumor mass sampled. 4-7. sections of described solid tumor mass. 8. section of possible tumor extension abutting inked, inferior,. peripheral margin. 9. sections of upper outer quadrant biopsy cavity. 10. sections from upper outer quadrant. 11. lower outer quadrant sampled. 12. upper inner quadrant. 13. lower inner quadrant. 14-15. representative sections of two separate, large axillary lymph nodes. associated with upper outer quadrant. 16. whole lymph nodes. 17. whole lymph nodes. RUN DATE : RUN TIME. Specimen Inquiry. RUN USER: Lab Database: SPEC #: GROSS DESCRIPTION (Continued). 18. whole lymph nodes. 19. whole lymph nodes. 20. whole lymph nodes. 21. whole lymph nodes. 22. one large lymph node sampled. 23-24. largest described axillary lymph node sampled. INTRAOPERATIVE CONSULTATION: IMMEDIATE GROSS EVALUATION LEFT RADICAL MASTECTOMY: LARGE INVASIVE TUMOR. PROCESSED FOR TUMOR BANKING. SURGICAL MARGINS GROSSLY FREE OF TUMOR. PHOTO DOCUMEN'TATION. Image. Image. Image. (signature on file).",BRCA,3,True,"The report states that there are 28 positive lymph nodes out of 28 examined (metastatic lobular carcinoma present in all 28 axillary lymph nodes). This meets the criteria for N3a, which is defined as metastases in 10 or more axillary lymph nodes.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
N3a classification is determined by the presence of metastases in 10 or more axillary lymph nodes.",N3a,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
N3a classification is determined by the presence of metastases in 10 or more axillary lymph nodes.",15.0,1642.0,97.0,True
670,TCGA-A8-A09C.1E002C47-CEC6-491C-9E67-B289687D5B66,1,"Diagnosis: Moderately differentiated invasive ductal breast carcinoma with a diameter of 2.2 cm. extending cranially to within 5 mm of the resection margin at 3 and 12 o'clock. Normal. follow-up resection material and tumor-free sentinel lymph nodes. Tumor classification: M-8500/3, G2, pT2, pN 0 (sn), MX, R0.",BRCA,0,True,"The report indicates that there are tumor-free sentinel lymph nodes, which means that there is no evidence of cancer in the lymph nodes (pN0). The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes. The presence of blue dye in a lymph node does not affect the N stage. Immunohistochemical analysis of lymph nodes does not affect the N stage. Her-2/NEU analysis does not affect the N stage. The absence of cancer in the lymph nodes is the primary determinant of the N stage. Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis. The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
N3a classification is determined by the presence of metastases in 10 or more axillary lymph nodes.",15.0,1642.0,40.0,False
981,TCGA-BH-A0BM.7F75F15A-2476-4FFD-97B3-313F06568E21,1,"FINAL DIAGNOSIS: PART 1: LYMPH NODE, RIGHT AXILLARY, SENTINEL NODE NUMBER 1, SENTINEL NODE BIOPSY -. ONE LYMPH NODE POSITIVE FOR METASTATIC CARCINOMA (1/1). PART 2: LYMPH NODE, RIGHT AXILLARY, SENTINEL NODE NUMBER 2, SENTINEL NODE BIOPSY -. ONE LYMPH NODE POSITIVE FOR METASTATIC CARCINOMA (1/1). PART 3: LYMPH NODE, RIGHT AXILLARY, NONSENTINEL, LYMPH NODE BIOPSY -. TWO LYMPH NODES NEGATIVE FOR METASTATIC CARCINOMA (0/2). PART 4: LYMPH NODE, RIGHT AXILLARY, SENTINEL NODE NUMBER 3, SENTINEL NODE BIOPSY -. ONE LYMPH NODE POSITIVE FOR MICROMETASTATIC CARCINOMA (1/1). PART 5: BREAST. RIGHT, SEGMENTAL MASTECTOMY -. A. INFILTRATING DUCTAL CARCINOMA. B. NOTTINGHAM SCORE 4/9, GRADE 1 (TUBULES 2, NUCLEI 1, MITOSES 1). C. NEOPLASM MEASURES 2.8 CM IN MAXIMUM DIMENSION (see comment). D. NO LYMPHOVASCULAR INVASION IDENTIFIED. E. NEOPLASM EXTENDS FOCALLY TO POSTERIOR MARGIN OF RESECTION IN THE INFERIOR ASPECT. (BLOCK 5J), ALL OTHER MARGINS OF RESECTION FREE OF NEOPLASM. F. ER POSITIVE, PR NEGATIVE, HER-2/NEU NEGATIVE PER PREVIOUS REPORT. G. PATHOLOGIC STAGE: pT2, pN1, pMX. H. DUCTAL CARCINOMA IN SITU, CRIBRIFORM AND MICROPAPILLARY TYPES, NUCLEAR GRADE 1 WITH. ASSOCIATED MICROCALCIFICATIONS AND FOCAL COMEDONECROSIS. I. IN SITU COMPONENT IS ADMIXED WITH INVASIVE COMPONENT AND IS IDENTIFIED IN EIGHT BLOCKS. (THREE CONSECUTIVE SLICES MEASURING APPROXIMATELY 1.2 CM). J. MARGINS OF RESECTION FREE OF IN SITU COMPONENT, CLOSEST INFERIOR AT 0.3 CM. K. ATYPICAL DUCTAL HYPERPLASIA. L. FAT NECROSIS AND REPARATIVE CHANGES ASSOCIATED WITH PREVIOUS BIOPSY. M. FIBROCYSTIC CHANGES WITH SCLEROSING ADENOSIS, DUCTAL EPITHELIAL HYPERPLASIA,. FIBROADENOMATOUS NODULE AND EPITHELIUM ASSOCIATED CALCIFICATIONS. PART 6: LYMPH NODES, RIGHT AXILLARY, AXILLARY DISSECTION -. NINETEEN LYMPH NODES NEGATIVE FOR METASTATIC CARCINOMA (0/19). CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: PROCEDURE: Right. Segmental. SIZE OF TUMOR: Not specified. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: Maximum dimension invasive component: 2.8 cm. TUMOR TYPE (invasive component): NOTTINGHAM SCORE: Ductal adenocarcinoma, NOS. Nuclear grade: 1. Tubule formation: 2. Mitotic activity score: 1. Total Nottingham score: 4. ANGIOLYMPHATIC INVASION: Nottingham grade (1, 2, 3): 1. DERMAL LYMPHATIC INVASION: CALCIFICATION: Not applicable. Yes, benign zones. TUMOR TYPE, IN SITU: Yes, malignant zones. Cribriform. Micropapillary. DCIS admixed with invasive carcinoma. SURGICAL MARGINS INVOLVED BY INVASIVE Percent of COMPONENT: tumor occupied by in situ component: 5 %. Yes, focal. SURG MARGINS INVOLVED BY IN SITU COMPONENT: LYMPH NODES POSITIVE: Distance of in situ disease to closest margin: 3 mm. 3. LYMPH NODES EXAMINED: 24. METHOD(S) OF LYMPH NODE EXAMINATION: SENTINEL NODE METASTASIS: H/E stain, Keratin stain. ONLY KERATIN POSITIVE CELLS ARE PRESENT: SIZE OF NODAL METASTASES: LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: Diameter of largest lymph node metastasis: 25.0 mm. NON-NEOPLASTIC BREAST TISSUE: ADH, FCD. T STAGE, PATHOLOGIC: pT2. N STAGE, PATHOLOGIC: pN1a. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: negative. HER2/NEU: zero or 1+.",BRCA,1,True,"The report states that there are 24 lymph nodes examined, out of which 4 are positive for metastatic carcinoma (1 sentinel and 3 non-sentinel). This indicates that the patient's N stage is N1, as the N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved. The number of negative lymph nodes does not affect the N stage in the presence of positive lymph nodes.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
N3a classification is determined by the presence of metastases in 10 or more axillary lymph nodes.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
N3a classification is determined by the presence of metastases in 10 or more axillary lymph nodes.",15.0,1642.0,100.0,True
1259,TCGA-E2-A1LS.A514658A-FB29-4AA0-9451-2A960B3720C1,0,"SPECIMENS: A. SUBAREOLAR TISSUE RIGHT BREAST. B. SENTINEL LYMPH NODE #1 RIGHT AXILLA. C. SENTINEL LYMPH NODE #2 RIGHT AXILLA. D. SENTINEL LYMPH NODE #3 RIGHT AXILLA. E. SENTINEL LYMPH NODE #4 RIGHT AXILLA. F. RIGHT BREAST. G. LEFT BREAST SKIN. SPECIMEN(S): A. SUBAREOLAR TISSUE RIGHT BREAST. B. SENTINEL LYMPH NODE #1 RIGHT AXILLA. C. SENTINEL LYMPH NODE #2 RIGHT AXILLA. D. SENTINEL LYMPH NODE #3 RIGHT AXILLA. E. SENTINEL LYMPH NODE #4 RIGHT AXILLA. F. RIGHT BREAST. G. LEFT BREAST SKIN. GROSS DESCRIPTION: A. SUBAREOLAR TISSUE RIGHT BREAST. Received fresh labeled with the patient's identification and 'subareolar tissue right breast' is an oriented. 5 x 4 x 0.5cm oriented fragment of fibrofatty tissue. Suture at final margin (nipple). Final margin is inked. green; remainder of specimen is inked black. The specimen is serially sectioned and representatively. submitted in FSA1-FSA2. Representatively submitted in A3-A4,. B. SENTINEL LYMPH NODE #1 RIGHT AXILLA. Received fresh labeled with the patient's identification and 'sentinel lymph node #1 right axilla' are two. tan-pink lymph nodes 1 x 0.8 X 0.5cm and 0.6 x 0.5 x 0.5cm. The specimens are sectioned and two. touch preps are taken. B1: one lymph node. B2: one lymph node. C. SENTINEL LYMPH NODE #2 RIGHT AXILLA. Received fresh labeled with the patient's identification and 'sentinel lymph node #2 right axilla' is a tan-. pink lymph node 1.2 x 1 x 0.5cm. The specimen is sectioned and a touch prep is taken. Toto C1. D. SENTINEL LYMPH NODE #3 RIGHT AXILLA. Received fresh labeled with the patient's identification and 'sentinel lymph node #3 right axilla' is a tan-. pink lymph node 0.7 x 0.5 x 0.5cm. The specimen is sectioned and a touch prep is taken. Toto D1. E. SENTINEL LYMPH NODE #4 RIGHT AXILLA. Received fresh labeled with the patient's identification and 'sentinel lymph node #4 right axilla' is a tan-. pink lymph node 1.8 x 0.5 x 0.3cm. The specimen is sectioned and a touch prep is taken. Toto E1. F. RIGHT BREAST. Received fresh labeled with the patient's identification and ""left breast"" is a 222g, 18.5 x 16 x 2.3cm. oriented (stitch in axilla) simple mastectomy with attached 4.3 x 2cm tan-pink skin ellipse. The skin. surface is grossly unremarkable. Ink code: anterior-superior: blue, anterior-inferior: orange, areola-. green, posterior-black. The specimen is serially sectioned from lateral to medial into 15 slices, revealing. a 2 x 1.8 x 1.6cm tan-pink, firm, well-circumscribed mass, 0.2cm from the deep margin and 2.4cm from. the skin surface in the LOQ-LC of slices 6-7. A 0.3 x 0.2 x 0.2cm firm, nodular area is identified, 3.2cm. from the deep margin and 1.2cm from the anterior-inferior margin of the LC of slices 10-11. The small. nodule is 2.2cm inferior to the areolar stitch. A portion of the specimen is submitted for tissue. procurement. Representatively submitted: F1: LOQ slice 5. F2-F3: UOQ slice 6. F4: LOQ with skin slice 6. F5-F6: mass with deep margin LOQ slice 6. F7: UOQ slice 7. F8-F9: mass with deep margin LOQ slice 7. F10: UOQ slice 8. F11: LOQ slice 8. F12: UOQ slice 9. F13: nodule LC slice 10. F14-F15: subareolar UC slice 10. F16: subareolar stitch UIQ slice 11. F17: nodule LIQ slice 11. G. LEFT BREAST SKIN. Received in formalin labeled with the patient's identification and 'left breast skin' are two unoriented tan-. pink fragments of unremarkable skin 3.2 x 1.8 x 0.4cm and 6.5 x 3 x 0.5cm. The specimens are serially. sectioned and representatively submitted in G1. DIAGNOSIS: A. BREAST, RIGHT, SUBAREOLAR, EXCISION: - INTRADUCTAL PAPILLOMA (0.3-CM), NO TUMOR SEEN. B. LYMPH NODES, SENTINEL #1, RIGHT AXILLA, EXCISION: - TWO LYMPH NODES, NEGATIVE FOR METASTASES (0/2). C. LYMPH NODE, SENTINEL #2, RIGHT AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). D. LYMPH NODE, SENTINEL #3, RIGHT AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). E. LYMPH NODE, SENTINEL #4, RIGHT AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). F. BREAST, RIGHT, MASTECTOMY: - INVASIVE DUCTAL CARCINOMA, SBR GRADE 3, MEASURING 1.8 CM. INTERMEDIATE NUCLEAR GRADE, DUCTAL CARCINOMA IN SITU, SOLID TYPE WITH LOBULAR. EXTENSION. - SURGICAL RESECTION MARGINS NEGATIVE FOR TUMOR. - LOBULAR CARCINOMA IN SITU. - BIOPSY SITE CHANGES WITH FIBROSIS. - TWO RADIAL SCARS. - SEE SYNOPTIC REPORT AND SEE NOTE. G. SKIN, LEFT BREAST, EXCISION: - SKIN AND SUBCUTANEOUS SOFT TISSUE, NO TUMOR SEEN. NOTE: In addition to the tumor mass, 2 radial scars and one area of usual ductal hyperplasia without. atypia are seen in the lower inner, upper inner and lower central, respectively. SYNOPTIC REPORT - BREAST. Specimen Type: Mastectomy. Needle Localization: Laterality: Right. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 1.8cm. Tumor Site: Lower outer quadrant. Margins: Negative. Distance from closest margin: 0.2cm. deep. Tubular Score: 3. Nuclear Grade: 3. Mitotic Score: 3. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: LCIS. Lymph nodes: Sentinel lymph node. Lymph node status: Negative 0/5. DCIS present. Margins uninvolved by DCIS. DCIS Quantity: Estimate 10%. DCIS Type: Solid. DCIS Location: Associated with invasive tumor. Nuclear grade: Intermediate. Necrosis: Absent. ER/PR/HER2 Results. ER: Pending. PR: Pending. HER2: Negative by IHC. Performed on Case: Pathological staging (pTN): pT 1c NO. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. CLINICAL HISTORY: Patient with breast cancer at inferior mammary crease; 2nd area of enhancement in lower breast by. MRI (low suspicion). PRE-OPERATIVE DIAGNOSIS: Right breast cancer. INTRAOPERATIVE CONSULTATION: FSA1-FSA2: Subareolar tissue right breast- Normal breast tissue. No tumor seen. Diagnosis called to. Dr. at. by Dr. TPB1-TPB2-TPC-TPD-TPE SLN #1-2-3-4 right axilla: Negative for tumor. Diagnosis called to Dr. at. by Dr. F. Right breast- Gross examination: 2cm mass, 0.2cm from deep margin. Fibrotic area at subareolar. region. No definite mass. Diagnosis called to Dr. at. by Dr. ADDENDUM: SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimen: Surgical Excision. Block Number: F9. ER: Negative Allred Score: 0 = Proportion Score 0 + Intensity Score 0. PR: Negative Allred Score: 0 = Proportion Score 0 + Intensity Score 0. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the. proportion score (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of. cells staining, 4 = 31-60% of cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak. intensity of staining, 2 = intermediate intensity of staining, 3 = strong intensity of staining), with a scoring. range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score. of less than or equal to 2. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochemistry was performed using the mouse anti-human ER (ER 1D5, 1:100) and PR (PGR. 136, 1:100) provided by. following the manufacturer S instructions. This. assay was not modified. interpretation di the ER/PR immunohistochemical stain is guided by published. results in the medical literature, information provided by the reagent manufacturer and by internal. review of staining performance. Microscopic/Diagnostic Dictation: Final Review: Pathologist,. Final: Pathologist,. Addendum: Pathologist,. Addendum Final: Pathologist,.",BRCA,0,True,"The report states that sentinel lymph nodes 1-4 from the right axilla were all negative for metastases (0/1, 0/1, 0/1, 0/1 respectively). This indicates that there is no evidence of cancer in the lymph nodes, which is the primary determinant of the N stage. Therefore, the N stage is N0.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
N3a classification is determined by the presence of metastases in 10 or more axillary lymph nodes.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
N3a classification is determined by the presence of metastases in 10 or more axillary lymph nodes.",15.0,1642.0,100.0,True
1396,TCGA-GM-A5PV.A616A83A-8D19-4085-B430-1AF80D4F9642,1,"DIAGNOSIS. (A) RIGHT BREAST, TOTAL MASTECTOMY: INVASIVE LOBULAR CARCINOMA, INTERMEDIATE GRADE. (SEE COMMENT). LOBULAR CARCINOMA IN SITU (LCIS), LOW AND INTERMEDIATE NUCLEAR GRADES. INVASIVE CARCINOMA MEASURES 3.0 X 1.1 CM IN CONTIGUOUS SECTIONS/SLICES. INVASIVE CARCINOMA IS PRESENT AT LEAST 1.0 CM FROM MARGINS. No lymphovascular invasion identified. Microcalcifications present in association with benign breast tissue. NIPPLE, LCIS/ATYPICAL LOBULAR HYPERPLASIA. (B) RIGHT AXILLARY SENTINEL LYMPH NODE #1, EXCISIONAL BIOPSY: METASTATIC CARCINOMA PRESENT IN ONE OF ONE LYMPH NODE (1/1). METASTATIC FOCUS MEASURES AT LEAST 1.05 CM. No definite extracapsular extension identified.. (C) RIGHT AXILLARY POSSIBLE SENTINEL LYMPH NODE #2, EXCISIONAL BIOPSY: Fibroadipose tissue, no tumor present. No lymphoid cells identified. (D) LEFT BREAST, TOTAL MASTECTOMY: Fibrocystic changes including focal florid ductal hyperplasia (usual type), cysts. Microcalcifications present in association with benign breast tissue and blood vessel wall. Nipple, no tumor present. (E) RIGHT AXILLARY POSSIBLE SENTINEL LEVEL I, EXCISIONAL BIOPSY: Fibroadipose tissue, no tumor present. (F) RIGHT AXILLA, ADDITIONAL LEVEL II LYMPH NODE, EXCISION: Two lymph node, no tumor present (0/2). (G) RIGHT AXILLA, ADDITIONAL LEVEL I LYMPH NODE, EXCISION: Three lymph node, no tumor present (0/3). (H) RIGHT AXILLARY CONTENTS, AXILLARY DISSECTION: Thirteen lymph nodes, no tumor present (0/13). (I). RIGHT AXILLA, ADDITIONAL LEVEL I LYMPH NODE #2, EXCISIONAL BIOPSY: Three lymph node, no tumor present (0/3). COMMENT. Immunohistochemical stain for E-cadherin is negative, consistent with the diagnosis. GROSS DESCRIPTION. (A) RIGHT BREAST, SHORT SUPERIOR, LONG LATERAL - A 24.0 x 23.5 x 5.5 cm mastectomy specimen that is oriented by. the surgeon with a short stitch designating superior and a long stitch designating lateral. The specimen is partly surfaced by a 22.5. x 13.0 cm ellipse of pale tan wrinkled skin. Located on the surface of the skin is a 1.3 cm everted nipple surrounded by a 4.5 cm. rim of areola, respectively. The specimen is serially sectioned from lateral to medial into thirteen slices. The nipple is located in. slices 7 and 8. In the upper portion of slices 5 through 9, a 5.0 x 2.7 x 2.0 cm gray-white, firm tumor mass with calcifications and. surrounding fibrosis that grossly comes to within 1.2 cm from the skin, 4.5 cm from the deep margin, 4.0 cm from the superior. margin, and 7.0 cm from the inferior margin. There is a metal biopsy clip located in the mass in slice 8. Located in slices 6 and 7. at the 6 o'clock position, there is a 3.8 x 1.8 X 0.6 cm gray-white firm fibrous area with calcifications, marked by the radiologist. This fibrous area grossly comes to within 0.5 cm from the deep margin and 0.8 cm from the inferior margin. Remaining cut. surfaces. are. 85%. yellow glistening adipose tissue and 15% gray-white fibrous tissue. Some tissue has been given to tumor bank. for research purposes. IOA/DX; MARGINS ARE FREE. INK CODE: Blue - superior; orange - inferior; black - deep. SECTION CODE: A1-A3, nipple from slices 7 and 8; A4-A6, mass and calcifications from 10-1 o'clock position from slice. 5; A7, representative sections from slice 4, adjacent to mass; A8, mass and calcifications from slice 6; A9, 6 o'clock marked area. from. slice. 6;. A10, 6 o'clock marked area to inferior margin from slice 6; A11, 6 o'clock marked area to deep margin from slice 6;. A12, mass and calcifications at 10-1 o'clock position from slice 7; A13-A15, 6 o'clock abnormal enhancement from slice 7; A16,. representative sections subjacent to nipple and adjacent to mass from slice 8; A17, A18, mass in area of clip and its mirror image. from. slice 8; A19, mass from slice 8; A20, representative section of tissue adjacent to mass from slice 8; A21, superior margin. from slice 8; A22, representative section from slice 8, adjacent to 6 o'clock abnormal enhancement; A23, mass at position from. slice 9; A24, representative section from slice 10, adjacent to mass position; A25, representative section from slice 5, adjacent to. 6 o'clock abnormal enhancement; A26, lower inner quadrant from slice 11. (B) RIGHT AXILLA, SENTINEL LYMPH NODE #1, BLUE, IN VIVO 4, EX VIVO 36 - A 3.5 x 2.4 x 1.0 cm lymph node submitted. entirely. FS/DX: ONE NODE, METASTATIC CARCINOMA. SECTION CODE: B1-B5, one possible lymph node serially sectioned for frozen section diagnosis. (C) RIGHT AXILLA, SENTINEL LYMPH NODE #2, BLUE, IN VIVO 0, EX VIVO 0 - A 0.8 x 0.3 x 0.1 cm possible lymph. node. submitted entirely. /DX: DEFER TO PERMANENT. SECTION CODE: C, one possible lymph node bisected for frozen section diagnosis. (D) LEFT BREAST, SHORT SUPERIOR, LONG LATERAL - A 24.0 x 23.5 x 6.0 cm mastectomy specimen that is oriented by the. surgeon. with. a. short stitch designating superior and a long stitch designating lateral. The specimen is partly surfaced by a 20.0 x. 17.0 cm ellipse of pale tan wrinkled skin. Located on the surface of the skin is an everted nipple surrounded by a rim of areola. that. measure. 1.2 and 5.5 cm in diameter, respectively. The specimen is serially sectioned from medial to lateral into twelve slices. The nipple is located in slice 7. Cut surfaces are composed of 75% yellow glistening adipose tissue and 25% dense gray-white. fibrous tissue. A definite mass is not grossly identified. Some normal tissue has been given to tumor bank for research purposes. INK CODE: Blue - superior; orange - inferior; black - deep. SECTION CODE: D1, D2, nipple from slice 7; D3, upper inner quadrant from slice 3; D4, upper inner quadrant from slice. 5;. D5, lower inner quadrant, including inferior margin from slice 4; D6, lower inner quadrant, including deep margin from slice 6;. D7, upper outer quadrant from slice 7; D8, upper outer quadrant including superior margin from slice 9; D9, lower outer quadrant. from slice 8; D10, lower outer quadrant from slice 10. (E). RIGHT AXILLA, LEVEL I LYMPH NODE - Consists of a single nodular tissue with blue dye (0.7 cm). The specimen is. submitted entirely in E. (F) RIGHT AXILLA, ADDITIONAL LEVEL II LYMPH NODE - Consists of a single fragment of yellow-red fibroadipose tissue (6.5. x. 4. x. 1.3 cm). Dissection reveals two possible lymph nodes (0.6 cm and 3.4 cm in greatest dimension). Both lymph nodes are. submitted entirely. SECTION CODE: F1, one possible lymph node; F2-F5, one possible lymph node, serially sectioned. (G). ADDITIONAL LEVEL I LYMPH NODE, RIGHT AXILLA - Consists of a single fragment of yellow-red fibroadipose tissue (6 x 3. cm). Dissection reveals three possible lymph nodes, ranging in size from 0.2 to 2.2 cm in greatest dimension. All possible lymph. nodes are entirely submitted. SECTION CODE: G1, one possible lymph node; G2, one possible lymph node; G3, G4, one possible lymph node,. sectioned. (H). RIGHT. AXILLARY CONTENTS - Consists of a single fragment of bright yellow fibroadipose tissue (9 x 3 x 3 cm). Dissection. reveals thirteen possible lymph nodes, ranging in size from 0.1 cm to 3 cm in greatest dimension. All possible lymph nodes are. entirely submitted. SECTION CODE: H1, five possible lymph nodes; H2, three possible lymph nodes; H3, two possible lymph nodes; H4,. two possible lymph nodes; H5-H7, one possible lymph node, sectioned. (I) ADDITIONAL LEVEL I LYMPH NODE #2, RIGHT AXILLA - Consists of multiple fragments of yellow-tan fibroadipose tissue. aggregating. to. 5. x 5 x 1.5 cm. Dissection reveals three possible lymph nodes ranging in size from 1 cm to 1.2 cm in greatest. dimension. All possible lymph nodes are entirely submitted. SECTION CODE: I1, two possible lymph nodes; 12, one possible lymph node, bisected. CLINICAL HISTORY. Breast cancer. SNOMED CODES. T-04050, M-Y2003. ""Some tests reported here may have been developed and performance characteristics determined by. These tests have not been. specifically cleared or approved by the U.S. Food and Drug Administration."". END OF REPORT-.",BRCA,1,True,"Based on the report, there is metastatic carcinoma present in one of one lymph node (1/1) in the right axillary sentinel lymph node #1, with a metastatic focus measuring at least 1.05 cm. There is no definite extracapsular extension identified. No other lymph nodes were found to have metastatic carcinoma. Therefore, the N stage is N1.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
N3a classification is determined by the presence of metastases in 10 or more axillary lymph nodes.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
N3a classification is determined by the presence of metastases in 10 or more axillary lymph nodes.",15.0,1642.0,100.0,True
544,TCGA-A2-A25B.FCE29F34-5D13-4A21-A950-A8577C957C10,1,"This report contains corrections, additions or deletions. Any previous versions are stored internally and are available if necessary. Specimen: Spec Type: SURGICAL P. Suba Dr: LEFT BREAST CANCER INVASIVE. DOCTOR (S) 3. PROCEDURE: SENTINEL NODR BX/SIMPLE MASTECTOMY. A. LT SENTINEL NODE #1 - FS. B. LEFT BREAST. C. LEFT AXILLARY NODES. D. ADDITIONAL ANTERIOR MARGIN OF THE INFERIOR PORTION OF LEFT BREAST. A. METASTATIC CARCINOMA. PART A IS RECEIVED DESIGNATED. SENTINEL LYMPH. NODE #1. IT IS RECEIVED IN THE FRESH STATE FOR FROZEN. SECTION AND CONSISTS OF A FRAGMENT OF YELLOWISH-PINK FIBROADIPOSE TISSUE. WITH 2 PALPABLE NODULES, THE SPECIMEN HAVING OVERALL DIMENSIONS 4.3 x. 2.7 x 1.5 CM WITH THE LARGEST NODULE MEASURING 2 x 2 x 1 CM AND THE. SMALLER 1.5 x 1.2 x 0.3 CM. SECTIONING THE LARGER NODULE SHOWS MULTIPLE. GRAY-WHITE NODULES WITHIN A TANNISH-PINK PARENCHYMA MEASURING UP TO 0.6. x 0.4 x 0.4 CM. THE SMALLER NODULE ON SECTIONING REVEALS A. TANNISH-PURPLE PARENCHYMA WITH A 0.8 x 0.5 x 0.5-CM GRAYISH-TAN NODULE. THE SECTIONS SUBMITTED FOR FROZEN SECTION ARE SUBMITTED FOR PERMANENTS. LABELED. SECTIONS OF UNFROZEN TISSUE ARE SUBMITTED WITH A. REPRESENTATIVE SECTION FROM THE LARGEST NODULE AND THE REMAINING SMALLER. NODULE ENTIRELY. REPRESENTATIVE SECTIONS ARE SUBMITTED AS FOLLOWS FSA. SECTION FROM LARGER AND SMALLER NODULES IN 1 CASSETTE: A1-CROSS. SECTION OF LARGEST NODULE, A2 -SMALLER NODULE ENTIRELY, SECTION. PART B RECEIVED LABELED. LEFT BREAST, IS A. SIMPLE MASTECTOMY SPECIMEN MEASURING 23.5 x 22 x 8.0 CM. THE NIPPLE. IS. UNREMARKABLE WITHIN A 13.5 x 9-CM SKIN ELLIPSE. A SUTURE DENOTES 12. THE SUPERFICIAL ASPECT IS MARKED WITH BLUE INK, THE DEEP WITH. Specimen: tatus: Spec Type: SURGICAL P. BLACK. SECTIONING REVEALS YELLOW FATTY TISSUE INTERSPERSED WITH. PINK-TAN GRANULAR FIBROUS TISSUE WHICH IS PRESENT DIFFUSELY THROUGHOUT. THE BREAST. IN THE 6 AND 7 CLOCK AREA, THERE IS A FIRM PINK-TAN LESION. WHICH HAS A CENTRAL CYLDNDRICAL-SHAPEI METAL CLIP. THIS FIRM AREA. MEASURES 4 x 2.5 X 3 CM IN GREATEST DIMENSIONS. IT GROSSLY EXTENDS TO. WITHIN 0.8 CM OF THE DEEP MARGIN AND 0.3 CM OF THE SUPERFICIAL MARGIN. SUPERIOR AND CENTRAL WITHIN THE BREAST, THERE IS A 4.5 x 2-CM AREA OF. FATTY TISSUE WITHOUT FIBROUS BANDS NHICH GROSSLY SEEMS DELINEATED FROM. THE SURROUNDING PARENCHYMAL TISSUE (B2) SECTIONS ARE SUBMITTED AS. FOLLOWS: B1--NIPPLE, 12--CENTRAL FATTY TISSUE, B3--TUMOR AND. SUPERFICIAL MARGIN, B4 THROUGH 7--FULL CROSS-SECTION OF THE LESION TO. INCLUDE THE DEEP AND SUPERFICIAL MARGIN, B8--FIBROUS TISSUE IMMEDIATELY. LATERAL TO THE LESION, 19--TISSUE IMMEDIATELY MEDIAL TO LESION IN LOWER. INNER QUADRANT, B10--UPPER INNER QUADRANT 14 CM FROM LESION, B11--TISSUE. AT 9 O' CLOCK 9 CM FROM LESION, B12--LOWER OUTER QUADRANT 4 CM FROM. LESION, B13--3 O'CLOCK 13 CM FROM LESION, B14--UPPER OUTER QUADRANT 15. CM FROM LESION, 15--ADDITIONAL SECTION OF TUMOR AND SUPERFICIAL MARGIN. SECTIONS OF TUMOR AND BREAST TISSUE ARE SUBMITTED PER PROTOCOL. AFTER X-RAYING THE SPECIMEN, A CLIP IS IDENTIFIED IN THE 6 O' CLOCK AREA. AT THE EDGE OF THE SKIN ELLIPSE. THIS IS 3 CM ANTERIOR AND LATERAL TO. THE PREVIOUSLY DESCRIBED LESION. THIS AREA CONSISTS OF A RED-BROWN CLOT. SURROUNDED BY INDURATED YELLOW-TAN FATTY TISSUE MEASURING 1.7 x 1.0 x 1.5. CM. THIS IS 0.5 CM FROM THE INFERIOR SUPERFICIAL MARGIN AND 3.5 CM FROM. THE DEEP MARGIN. SECTIONS FROM THIS AREA ARE SUBMITTED IN B16 THROUGH. B19. B20--DEEP MARGIN TO LESION B21 -TISSUE TAKEN BETWEEN THIS LESION. AND THE LARGER TUMOR MASS. TISSUE IS ALSO TAKEN FROM THE SECOND AREA PER. PROTOCOL. PART C RECEIVED LABELED. LEFT AXILLARY NODE,. IS YELLOW-RED FATTY TISSUE MEASURING 7.5 x 6 x 1.7 CM. THIS IS EXAMINED. FOR LYMPH NODES. ALSO LOOSE WITHIN THE CONTAINER IS A 1-CM OVOID. RED-TAN STRUCTURE. THIS IS CONSISTENT WITH A GROSSLY UNREMARKABLE LYMPH. NODE. IT IS SECTIONED AND SUBMITTED LABELED C1 WITH A PORTION SUBMITTED. PER PROTOCOL. THREE LARGER NODES ARE IMMEDIATELY IDENTIFIABLE WITHIN. THE FATTY TISSUE. THESE ARE SECTIONED WITH ONE-HALF OF EACH SUBMITTED. WITHIN C2 THROUGH C4, RESPECTIVELY, WITH C3 GROSSLY POSITIVE. SECTIONS. OF THESK NODES ARE ALSO SUBMITTED PER PROTOCOL. ADDITIONAL NODES ARE. SUBMITTED AS FOLLOWS: --FOUR NODES. PART D RECEIVED LABELED. ADDITIONAL ANTERIOR. MARGIN OF THE INFERIOR PORTION OF LEFT BREAST STITCH MARKS 12 O'CLOCK,. IS AN ELLIPTICAL PORTION OF BROWN PIGMENTED SKIN MEASURING 16 x 2.7 x. 0.9 CM. ALONG THE MIDPORTION OF ONE EDGE IS A SUTURE DENOTING 12. D'CLOCK. THIS EDGE IS MARKED WITH BLUE INK. THE 3 O'CLOCK SIDE OF THE. SPECIMEN IS THEN MARKED BLACK AND THE 9 O'CLOCK RED. THE 3 O' CLOCK. ELLIPTICAL END IS AMPUTATED AND BISECTED LONGITUDINALLY AND SUBMITTED AS. Specimen: Spec Type: SURGICAL P. D1. THE 9 O'CLOCK ELLIPTICAL END IS AMPUTATED AND BISECTED. LONGITUDINALLY AND SUBMITTED LABELED D2. BY PALPATION, THERE IS SOME. NODULARITY IN THE CENTRAL PORTION OF THE SPECIMEN AND CROSS-SECTIONS ARE. SUBMITTED IN D3 AND 4. ADDITIONAL SECTIONS FROM THE 3 O' 'CLOCK SIDE ARE. SUBMITTED IN D5 AND ADDITIONAL SECTIONS FROM THE 9 D'CLOCK SIDE ARE. SUBMITTED IN D6. PROCEDURES: PATH FS , A BLK/2, B BLK/15, C BLK/5, D BLK/6, FS-A. PART A LEFT AXILLA, SENTINEL LYMPH NODE #1: METASTATIC BREAST CARCINOMA. IS PRESENT IN ONE OF TWO LYMPH NODES EXAMINED. EXTRANODAL EXTENSION IS. NOT IDENTIFIED. PART B LEFT BREAST, SIMPLE MASTECTOMY. 1. INTRADUCTAL AND INFILTRATING DUCT CARCINOMA. INVASIVE COMPONENT. IS POORLY DIFFERENTIATED SHOWING NUCLEAR GRADE 3/3, MODERATE MITOTIC. INDEX AND TUBULE FORMATION 3 WITH TOTAL NOTTINGHAM SCORE OF 8. HIGH GRADE DCIS OF THE CRIBRIFORM AND SOLID TYPES HAVING AREAS. OF COMEDONECROSIS IS IDENTIFIED SURROUNDING AND WITHIN THE TUMOR. WITH EXTENSION INTO TERMINAL LOBULES COMPRISING APPROKIMATELY 20% OF. THE TUMOR. 2. THE INVASIVE COMPONENT HAS A MAXIMUM GROSS DIMENSION OF 4 CM AND IS. FOCALLY IDENTIFIED APPROXIMATELY 2 MM FROM THE NEAREST INKED. SUPERFICIAL MARGIN (B15). 3. RANDOM SECTIONS OF THE REMAINING QUADRANTS AND NIPPLE SKIN ARE FREE. OF TUMOR. SEE COMMENT. 4. LYMPHOVASCULAR INVASION IS IDENTIFIED. 5. THE BIOPSY SITE. IS PRESENT. 6. DIFFUSE LACTATIONAL CHANGES. PART C LEFT AXILLA, LYMPH NODE DISSECTION: METASTATIC BREAST CARCINOMA. IS IDENTIFIED IN 1 OF 6 LYMPH NODES EXAMINED. EXTRANODAL EXTENSION IS. NOT SEEN. Specimen: Spec Type: SURGICAL P. PART D LEFT BREAST, ADDITIONAL ANTERIOR MARGIN OF THE INFERIOR PORTION,. EXCISION: SKIN AND SUBCUTANEOUS TISSUE WITH NO EVIDENCE OF RESIDUAL. TUMOR AND CLEAR MARGIN. THE SECOND BIOPSY SITE WAS NOT IDENTIFIED ON INITIAL GROSS EXAMINATION. THE SPECIMEN NILL BE X-RAYED TO FIND THE BIOPSY CLIP AND ADDITIONAL. SECTIONS WILL BE SUBMITTED. ADDITIONAL SECTIONS SURROUNDING THE SECOND BIOPSY SITE SHOW DCIS, SOME OF. WHICH EXTENDS INTO TERMINAL LOBULES, RARE MICROSCOPIC FOCI OF. INFILTRATING DUCT CARCINOMA, AND LYMIPHOVASCULAR INVASION. 1.",BRCA,1,True,"The report indicates that there is metastatic breast carcinoma present in one of two sentinel lymph nodes examined (part A) and in one of six lymph nodes examined from the left axilla (part C). This information corresponds to the N1 classification, which is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,97.0,True
971,TCGA-BH-A0B7.B5E5A3B8-108E-47D3-99DA-EC7A64B5FA9C,1,"FINAL DIAGNOSIS: PART 1: LYMPH NODE, RIGHT AXILLA #1 SENTINEL, BIOPSY -. A. ONE (1) LYMPH NODE POSITIVE FOR METASTATIC CARCINOMA (1/1). B. METASTATIC TUMOR MEASURES 0.5 CM. PART 2: LYMPH NODE, RIGHT AXILLA #2 SENTINEL, BIOPSY -. A. ONE (1) LYMPH NODE POSITIVE FOR METASTATIC CARCINOMA (1/1). a METASTATIC FOCUS MEASURES 1.1 CM. C. EXTRACAPSULAR EXTENSION IS IDENTIFIED. PART 3: BREAST, RIGHJ, TOTAL MASTECTOMY -. A. MULTIPLE FOCI OF INVASIVE DUCTAL CARCINOMA WITH APOCRINE FEATURES, NOTTINGHAM SCORE. 8/9 (TUBULES - 2, NUCLEAR GRADE - 3, MITOSES - -3). B. THE LARGER INVASIVE TUMOR MEASURES 2.4 CM, AND IS LOCATED AT 9:00 O'CLOCK POSITION. C. THE SMALLER INVASIVE TUMOR MEASURES 1.1 CM, AND LOCATED AT 12 O'CLOCK POSITION. D. DUCTAL CARCINOMA IN SITU (DCIS), NUCLEAR GRADE 3, APOCRINE AND SOLID TYPES WITH COMEDO. NECROSIS. E. DUCTAL CARCINOMA IN SITU CONSTITUTES 20% OF THE TOTAL TUMOR MASS AND IS PRESENT. ADMIXED WITH AND AWAY FROM THE INVASIVE COMPONENT (UPPER OUTER QUADRANT). F. LYMPHOVASCULAR INVASION IS IDENTIFIED. G. ALL SURGICAL MARGINS OF RESECTION ARE FREE OF TUMOR. H. NIPPLE IS FREE OF TUMOR. I. SKIN IS NEGATIVE FOR TUMOR. J. MICROCALCIFICATIONS ARE PRESENT IN ASSOCIATION WITH DCIS AND INVASIVE CARCINOMA. K. NON-NEOPLASTIC BREAST PARENCHYMA WITH FIBROCYSTIC CHANGES. L. ER POSITIVE, PR POSITIVE, HER-2/NEU POSITIVE 3. PART 4: LYMPH NODES, RIGHT AXILLARY, DISSECTION -. A. ONE (1) OF SEVENTEEN LYMPH NODE POSITIVE FOR METASTATIC CARCINOMA (1/17). B. FOCUS OF METASTATIC CARCINOMA MEASURES 1.3 CM. C. EXTRACAPSULAR EXTENSION IS IDENTIFIED. CASE STNUPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Right. PROCEDURE: Modified radical mastectomy. Upper outer quadrant. SIZE OF TUMOR: Lower inner quadrant. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: Maximum dimension invasive component: 2.4 cm. TUMOR AGGREGATE SIZE: TUMOR TYPE (invasive component): Sum of the sizes of multiple invasive tumors: 3.5 cm. NOTTINGHAM SCORE: Ductal adenocarcinoma, NOS. Nuclear grade: 3. Tubule formation: 2. Mitotic activity score: 3. Total Nottingham score: 8. ANGIOLYMPHATIC INVASION: Nottingham grade (1, 2, 3): 3. DERMAL LYMPHATIC INVASION: CALCIFICATION: Yes, malignant zones. TUMOR TYPE, IN SITU: Solid, Apocrine, DCIS admixed and outside of invasive carcinoma component, Ductal. SURGICAL MARGINS INVOLVED BY INVASIVE carcinoma COMPONENT: in situ, multifocal, Percent of tumor occupied by in situ component: 20 %. SURG MARGINS INVOLVED BY IN SITU COMPONENT: PAGET'S DISEASE OF NIPPLE: LYMPH NODES POSITIVE: 3. LYMPH NODES EXAMINED: 19. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: ONLY KERATIN POSITIVE CELLS ARE PRESENT: SIZE OF NODAL METASTASES: LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: Diameter of largest lymph node metastasis: 1.3 mm. METASTASES TO IPSILATERAL INTERNAL MAMMARY LYMPH NODE (IF APPLICABLE): SKIN INVOLVED (ULCERATION): NON-NEOPLASTIC BREAST TISSUE: FCD. T STAGE, PATHOLOGIC: pT2. N STAGE, PATHOLOGIC: pN1a. M STAGE, PATHOLOGIC:",BRCA,1,True,"The report indicates that there is metastatic carcinoma present in one out of seventeen right axillary lymph nodes (1/17) with a focus of metastatic carcinoma measuring 1.3 cm and extracapsular extension identified. This information corresponds to the N1 stage, as defined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1275,TCGA-E9-A1N9.39D6D1DE-2CAE-470F-836B-926242F46E67,1,BREAST TISSUE CHECKLIST. Specimen type: Radical mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 3.2 X 2.5 X 1.5 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal and lobular carcinoma. Histologic grade: Tumor extent: Not specified. Lymph nodes: 0/8 positive for metastasis (Regional 0/8). Right) lower. Extracapsular invasion of the lymph nodes: Not specified. outer. Margins: Not specified. quasrant. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None.,BRCA,0,True,"The report indicates that 0 out of 8 lymph nodes were positive for metastases (Regional 0/8). This means there is no evidence of cancer in the lymph nodes, which corresponds to an N0 stage according to the rules.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1162,TCGA-D8-A1Y3.E8D4229D-5049-4991-BDE0-AFC2CBC1827E,1,"page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: Multiple organ resection - right breast. Unit in charge: I. Material collected on: I. aterial received on: Expected time of examination: up to 8 working days. Clinical diagnosis: Macroscopic description: Right breast Sized 20 x 14 x 5 cm removed along with axillary tissues sized 10 x 5 x 3 cm and a skin flap of 18 x 10 cm. Tumour. found in the upper outer quadrant, located 3 cm from the upper boundary, 1 cm from the base and 1.5 cm from the skin. Microscopic description: Carcinoma ductale invasivum NHG3 (3+3+3: 20 mitoses/10 HPF - visual area: 0.55mm). Invasio carcinomatosa vasorum massiva. Mamilla sine laesionibus. Glandular tissue showing mastopathia fibrosa. Axillary lymph nodes: Metastases carcinomatosae in lymphonodis (No V/ VIII). Infiltratio telae perinodalis. Emboliae carcinomatosae vasorum. Histopathological diagnosis: Carcinoma ductale invasivum mammae dextrae. Invasive ductal carcinoma of the right breast. Metastases carcinomatosae in lymphonodis axillae (No V / VIII). Cancer metastases in axillary lymph nodes (No V/VIII). (NHG3, pT2, pN2a). Invasio carcinomatosa vasorum massiva. Massive vascular invasion. Results of immunohistochemical examination: Estrogen receptors found in over 75% of neoplastic cell nuclei. Progesterone receptors found in over 75% of neoplastic cell nuclei. HER2 protein stained with Ventana's Pathway HER-2/neu (4B5) rabbit antibody. Score=2+, FISZ verification recommended. UDD:E8D4229D-5849-4991-BDE@-AFC2C8C1827E. Examination: Histopathological examination. I. Gender: F. Result of immunohistochemical examination: RESULT OF HER2/neu GENE AMPLIFICATION with the FISH method by Path Vysion HER2 DNA Probe Kit. HER-2 GENE AMPLIFICATION NOT FOUND. Supplementary information: Size of the tumour 3.5 x 2.5 x 2.0 cm.",BRCA,2,True,"The report mentions 'Metastases carcinomatosae in lymphonodis axillae (No V / VIII)', which indicates the presence of cancer metastases in 5-9 axillary lymph nodes. This corresponds to the N2 classification according to the rules provided.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N2,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
752,TCGA-AN-A0AR.0E27F140-3D60-4027-A370-68127564DE38,1,Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Right Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: Frozen. Container: cryomold Type of Procurement: Radical mastectomy Grade: 3. T Stage: 2 N Stage: 0 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,BRCA,0,True,"The N stage in this report is N0, as there is no evidence of cancer in the lymph nodes. This is in line with rule 1, 'If there is no evidence of cancer in the lymph nodes, the N stage is N0.'","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
1428,TCGA-LL-A5YO.C5C5D704-2558-4D4B-937B-33BD91132882,0,"RUN DATE : RUN TIME: RUN USER. Lab Database : LOC: U # : AGE/SX: ROOM. REG DR: BED: DIS : TLOC: SPEC #:1. RECD: COLL. TIME IN FORMALIN: 7:21. hrs. CLINICAL INFORMATION: Pre-Op Diagnosis: Left breast cancer. Remarks: Specimen (s) : A. Left breast lumpectomy. B. Left breast new lateral margin. C. Left axillary sentinel node. MICROSCOPIC DIAGNOSIS. A. LEFT BREAST TISSUE. LUMPECTOMY: INFILTRATING DUCTAL CARCINOMA. MODIFIED NOTTINGHAM HISTOLOGIC GRADE 3 OF 3: NUCLEAR SCORE 3 OF 3, TUBULE. FORMATION SCORE 3 OF 3. MITOTIC SCORE 3 OF 3 (11 MITOTIC FIGURES PER SQUARE. MILLIMETER). NO DUCTAL CARCINOMA IN SITU IDENTIFIED. INVASIVE TUMOR MEASURES 13 MM. LATERAL SURGICAL MARGIN OF THIS SPECIMEN FOCALLY INVOLVED (RE-EXCISED BELOW) ,. TUMOR PRESENT 2 MM FROM MEDIAL MARGIN. SEE COMMENT FOR SYNOPTIC REPORT. B. EXCISION LESION BREAST TISSUE, NEW LATERAL MARGIN: NO TUMOR SEEN. FIBROCYSTIC CHANGES. C. ONE LYMPH NODE. LEFT AXILLARY SENTINEL, LYMPHADENECTOMY: NO TUMOR SEEN IN MULTIPLE STEP SECTIONS STAINED WITH ROUTINE AND PANKERATIN. IMMUNOCHEMICAL STAINS. COMMENT(S). SURGICAL PATHOLOGY CANCER CASE SUMMARY - CAP APPROVED: Procedure: Excision without wire-guided localization. Lymph Node Sampling. Sentinel lymph node (s). Specimen Laterality: Left. Histologic Type of Invasive Carcinoma : Invasive ductal carcinoma. Tumor Size: Greatest dimension of largest focus of invasion >1. mm: 13 mm. Histologic Grade Nottingham) : Glandular/Tubular Differentiation: Score 3. Nuclear Pleomorphism: Score 3. RUN DATE. RUN TIME : Specimen Inquiry. RUN USER. SPEC #: COMMENT (s). Mitotic Rate: Score 3. Overall Grade: Grade 3. Tumor Focality: Single focus of invasive carcinoma. Ductal Carcinoma In Situ: No DCIS is present. Margins: Invasive Carcinoma: Margins uninvolved by invasive. carcinoma. Distance from closest margin: 2 mm: medial. Lymph Nodes: Number of sentinel lymph nodes examined : 1. Total number of lymph nodes examined (sentinel and. nonsentinel) : 1. Number of lymph nodes with macrometastases (>2 mm). 0. Number of lymph nodes with micrometastases (>0.2 mm. to 2 mm and/or >200 cells) 0. Number of lymph nodes with isolated tumor cells. (<0.: 2 mm and <200 cells): 0. Number of lymph nodes without tumor cells. identified: 1. Pathologic Staging: Primary Tumor pT1b. Regional Lymph Nodes: Modifier: (sn). Category: pNO (i-). Distant Metastasis: Not applicable. Ancillary Studies: ER: Negative (<1% of tumor cells with nuclear. positivity). PR: Negative ( <1% of tumor cells with nuclear. positivity). HER2 Immunoperoxidase Studies: Negative (Score 1+). GROSS DESCRIPTION: The specimen is received in the fresh state in three parts for immediate gross evaluation. A. This specimen is received for tumor banking and evaluation of the surgical margins. and. consist of an excision of breast tissue which measures 4 x 4 x 2.5 cm. Present on the. surface is an ellipse of light brown skin measuring 3 x 0.7 cm. The surgeon has tagged the. surgical margins with this as reference, I have inked the margins as follows: Blue is lateral. Yellow is inferior. Black is medial. Red is superior. Orange is deep. Sectioning reveals a firm, stellate, tan tumor which measures 13 mm in greatest dimension. The tumor focally touches the lateral margin. The next nearest margin is medial at 2 mm. The remaining margins are greater than 1 cm from tumor. Ã representative section of the. tumor is submitted for tumor banking. Ã recent biopsy site is present in the tumor. CONTINUED CN NEXT PAGE. RUN DATE. RUN TIME. Specimen Inquiry. RUN USEE. SPEC #: GROSS DESCRIPTION (Continued). Representative sections are submitted as blocks A1 through A5. B. This is an excision of breast tissue which measures 2 x 2 x 1 cm. The surgeon has. tagged the new lateral margin. I have applied blue ink to this margin No gross evidence. of residual tumor is present in this specimen. Representative sections are submitted as. blocks B1 and B2. C. This is a soft. tan lymph node which measures 15 x 10 x 5 mm, sectioned and totally. submitted as block C1 for sentinel node protocol. There is no gross evidence of metastatic. tumor. INTRAOPERATIVE CONSULTATION: IMMEDIATE GROSS EVALUATION A (BREAST EXCISION) : FOCAL TUMOR PRESENT AT LATERAL MARGINS WITH REMAINING MARGINS FREE OF TUMOR. IMMEDIATE GROSS EVALUATION B (RE-EXCISION LATERAL MARGIN) : NO GROSS EVIDENCE OF TUMOR. IMMEDIATE GROSS EVALUATION C (SENTINEL NODE) : NO GROSS EVIDENCE OF TUMOR. PHOTO DOCUMENTATION. Image. (signature on file).",BRCA,0,True,"The report states that there is no tumor seen in the sentinel lymph node after multiple step sections stained with routine and pankeratin immunochemical stains. Additionally, there is no mention of metastases in any other lymph nodes. Based on the rules provided, the absence of cancer in the lymph nodes is the primary determinant of the N stage, and the number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes. Therefore, the N stage is N0.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,49.0,False
1007,TCGA-BH-A0DV.3A0E1EF6-B234-46EC-BD15-95B5FAB06D45,1,"P.18/33. INAL DIAGNOSIS: PART 1: SENTINEL LYMPH NODE #1. LEFT AXILLA, BIOPSY -. A. METASTATIC CARCINOMA INVOLVES ONE LYMPH NODE AND FORMS A SINGLE TUMOR DEPOSIT IN. ADJACENT SOFT TISSUE (1.3 CM) (SLIDE 1A). B. THE METASTATIC FOCUS IN THE LYMPM NODE IS ALMOST ENTIRELY REPLACING THE LYMPU NONE. PARENCHYMA (0.8 CM) WITH EXTRACAPSULAR EXTENSION (0.7 x 0.3 CM). PART 2: BREAST. EFT.MODIFIED RADICAL MASTECTOMY AND LEFT AXILLARY CONTENTS -. A. INVASIVE DUCIAL CARCINOMA, TWO FOCI, 3.2 CM AND 1.5 CM (GROSS) AT 6 AND 10 O'CLOCK POSITION. RESPECTIVELY, NOTTINGHAM GRADE 1/3 (COMBINED NOTTINGHAM SCORE 5/9; TUBULE FORMATION 2/3. NUCLEAR ATYPIA 2/3, MITOTIC ACTIVITY 1/3) WITH LOBULAR FEATURES (soo comment). B. TUMOR INVADES INTO SKELETAL MUSCLE FIBERS. c. DUCTAL CARCINOMA IN-SITU, NUCLEAR GRADE 2, CRIBRIFORM TYPE ASSOCIATEO WITH INVASIVE TUMOR. AND COMPRISING 1% OF TUMOR MASS. D. LYMPHOVASCULAR INVASION is IDENTIFIED,. E. MAKGINS FREE, IUMOR WITHIN LESS THAN T MM rnum DEEP MARGINS IN BOTH THE 6 O'CLOCK AND 10. O'CLOCK POSITION. F. UNINVOLVED BREAST. PARENCHYMA WITH FIBROCYSTIC CHANGES. G. GKIN AND NIPPLE, FREE or l'UMOR. H. METASTATIC CARCINOMA INVOLVES TWO OF NINE LYMPH NODES (2/9) AND FORMS FIVE TUMOR DEPOSITS. IN AXILLARY SOFT TISSUE. 1. LARGEST TUMOR SIZE AN THE LYMPH NODE is 1.0 CM WITH EXTRACAPSULAR EXTENSION (0.9 CM.). J. AXILLARY SOFT TISSUE TUMOR DEPOSIT RANGE FROM 0.2 TO 0.6 CM. K. PATHOLOGIC STAGE (sec comment). L. ER/PR - POSITIVE, HER-2/NEU NEGATIVE (PERFORMED ON BIOPSY). PART 3: ADDITIONAL LEFT AXILLARY CONTENTS, DIOPSY -. A. METASTATIC CARCINOMA INVOLVING FIBROADIPOSE TISSUE (TUMOR DEPOSIT). B. TUMOR MEASURES 0.6 x 0.5 CM (MICROSCOPIC). SYNOPTIC - PRIMARY INVASIVE CARCINUMATUF BREAST. LATERALITY: Left. PROCEDURE: Modified radical mastectomy. upper outer quadrant. Lower outer quadrant. Lower inner quadrant. SIZE OF TUMOR: Maximum dimension invasive component. 3.2 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR AGGREGATE SIZE: Sum of the sizet of multiple invasive tumora: 4.7 em. TUMOR TYPE (invasive component): Ductal adenocarcinoma. NOS. NOTTINGHAM SCORE: Nuclear grade. 2. Tubule formation: 2. Mitotic activity score 1. Total Nottingham score: 5. Nottingham grade (1. 2. 3) 1. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: TUMOR TYPE, IN SITU: Cribritorm. Percent or tumor occupied by in situ component: 1 %. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT-. SURG MARGINS INVOLVED BY IN SITU COMPONENT: PAGET'S DISEASE OF NIPPLE: LYMPH NODES POSITIVE: LYMPH NODES EXAMINED: 9. METHOD(9) OF LYMPH NODE EXAMINATION: IVE stain. SENTINEL NODE METASTASIS: SIZE OF NODAL METASTASES: Diameter of lergest lymph node melastasis 10 mm. LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: Yos. SKIN INVOLVED (ULCERATION): NON-NEOPLASTIC BREAST FCD. T STAGE, PATHOLOGIC: N STAGE, PATHOLOGIC: pN2. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive. HER2/NEU: zeio ar 1+.",BRCA,2,True,"The report indicates that metastatic carcinoma involves two of nine lymph nodes (2/9) and forms five tumor deposits in axillary soft tissue, with the largest tumor size being 1.0 cm with extracapsular extension (0.9 cm). This information corresponds to the N2 classification, which is determined by the presence of metastases in 4-9 axillary lymph nodes.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N2,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",14.0,1543.0,100.0,True
673,TCGA-A8-A09G.2728DB14-66D5-4E67-B9B6-63D93DBF509C,2,"Diagnosis: ) Poorly differentiated invasive carcinoma (tumor diameter: 5.5 cm). Concluding tumor classification: NOS, G III, pT3N3aL0V0R0.",BRCA,3,True,"The N stage is determined by the number of positive lymph nodes, regardless of the size of the metastases or the presence of microscopic perinodal soft tissue invasion. The report indicates a pT3N3aL0V0R0 classification, which means there are positive lymph nodes (N3) and 10 or more axillary lymph nodes involved. The N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N3,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",13.0,1374.0,94.0,True
776,TCGA-AN-A0XU.8216B837-DCF3-4E7F-A72A-212655F394F0,1,Sex: Female Ethnicity (Race. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: surgery Grade: 3. T Stage: 2 N Stage: 0 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,BRCA,0,True,"The N stage in this report is N0, as there is no evidence of cancer in the lymph nodes. This is in line with rule 1, 'If there is no evidence of cancer in the lymph nodes, the N stage is N0.'","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",13.0,1374.0,100.0,True
1214,TCGA-E2-A15C.04FF2CF1-737B-4FD2-8A1D-F9B5488DE510,0,"SPECIMENS: TESA-E2-A15C-01A-PR. A. WLE RIGHT BREAST NEEDLE LOCALIZATION. B. SENTINEL L.N. #1 RIGHT AXILLA. C. SENTINEL L.N. #2. D. SENTINEL L.N. #3. E. SENTINEL L.N. #4. SPECIMEN(S): A. WLE RIGHT BREAST NEEDLE LOCALIZATION. B. SENTINEL L.N. #1 RIGHT AXILLA. C. SENTINEL L.N. #2. D. SENTINEL L.N. #3. E. SENTINEL ..N. #4. GROSS DESCRIPTION: A. WLE RIGHT BREAST NEEDLE LOCALIZATION. Received fresh labeled with the patient's identification and ""WLE right breast needle localization"" is a previously. inked 70g, 8 x 5 x 4cm needle localized lumpectomy with radiograph. Ink code: anterior-yellow, posterior-black,. superior-blue, inferior-orange, medial-green, lateral-red. Specimen is serially sectioned from lateral to medial into 9. slices revealing a tan white firm stellate 1.9 x 1.6 x 1.5cm mass, 0.7cm from the closest posterior margin in slices 3-. 6. Representatively submitted: A1-A2: lateral margin slice 1. A3: next to mass slice 2. A4-A8: slice 3 with mass - deep margin A4. A9: mass with deep margin slice 4. A10: inferior margin slice 4. A11-A12: slice 5. A13: mass with deep margin slice 6. A14: slice 7. A15: slice 8. A16: medial margin slice 9. B. SLN #1 RIGHT AXILLA. Received fresh is a tan pink lymph node 0.5 x 0.5 x 0.5cm. The specimen is sectioned and a touch prep is taken. Toto B1. C. SLN #2 RIGHT AXILLA. Received fresh is a tan pink lymph node 0.8 x 0.6 x 0.6cm. The specimen is sectioned and a touch prep is taken. Toto C1. D. SLN #3 RIGHT AXILLA. Received fresh is a tan pink lymph node 0.9 x 0.5 x 0.5cm. The specimen is sectioned and a touch prep is taken. Toto D1. E. SLN #4 RIGHT AXILLA. Received fresh is a tan pink lymph node 0.6 x 0.6 x 0.5cm. The specimen is sectioned and a touch prep is taken. Toto E1. DIAGNOSIS: A. BREAST, RIGHT, WIDE LOCAL EXCISION: INVASIVE DUCTAL CARCINOMA, SBR GRADE 2, MEASURING 1.7-CM, INVOLVING SKELETAL MUSCLE. - INTERMEDIATE NUCLEAR GRADE, DUCTAL CARCINOMA IN SITU, CRIBRIFORM TYPE. - SURGICAL RESECTION MARGINS NEGATIVE FOR TUMOR. - BIOPSY SITE CHANGES WITH FIBROSIS AND GRANULATION TISSUE. - SEE SYNOPTIC REPORT. B. LYMPH NODE, SENTINEL #1, RIGHT AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). C. LYMPH NODE, SENTINEL #2, RIGHT AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). D. LYMPH NODE, SENTINEL #3, RIGHT AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). E. LYMPH NODE, SENTINEL #4, RIGHT AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Yes For mass. Laterality: Right. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 1.7cm. Tumor Site: Not specified. Margins: Negative. Distance from closest margin: 0.3cm. inferior. Tubular Score; 2. Nuclear Grade: 2. Mitotic Score: 2. Modified Scarff Bloom Richardson Grade: 2. Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node only. Lymph node status: Negative 0/4. DCIS present. Margins uninvolved by DCIS. DCIS Quantity: Estimate 1%. DCIS Type: Cribriform. DCIS Location Associated with invasive tumor. Nuclear grade: Intermediate. Necrosis: Absent. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Pending. Performed on Case: Pathological staging (pTN): pT 1c N 0. CLINICAL HISTORY: None provided. PRE-OPERATIVE DIAGNOSIS: None provided. INTRAOPERATIVE CONSULTATION: A. GROSS EXAMINATION: WLE right breast- 1. 9cm mass 0.7cm from closest deep margin. Diagnosis called to Dr. at. by Dr. TPB-TPC-TPD-TPE: Negative for carcinoma. Diagnosis called to Dr. at. by Dr. ADDENDUM: SYNOPTIC REPORT - BREAST HER-2 RESULTS. Specimen: Surgical Excision. Block Number: A9. Interpretation: EQUIVOCAL. Intensity: 2+. % Tumor Staining: 20%. Fish Ordered: Yes on Date. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Her2 analysis. was performed using the FDA approved Dako HercepTest (TM) test kit. 1 using rabbit anti-. human HER2. This assay was not modified. External kit-slides provided by the manufacturer (cell lines with high,. low and negative HER2 protein expression) and in-house known HER2 amplified control tissue were evaluated along. with the test tissue. Adequate, well preserved, clear-cut invasive carcinoma was identified for HER2 evaluation. Interpretation of the HER2 immunohistochemical stain is guided by published results in the medical literature,. information provided by the reagent manufacturer and by internal review of staining performance. This assay has been validated according to the 2007 joint recommendations and guidelines from ASCO and CAP. and from the NCCN HER2 testing in Breast Cancer Task Force. The Pathology Department takes full responsibility. for this test's performance. PathVysion HER-2 DNA Probe Kit. Analytical Interpretation of Results: HER-2 NOT AMPLIFIED. Clinical Interpretation of results. Amplification of the HER-2 gene was evaluated with interphase fluorescence in-situ. hybridization (FISH) on formalin-fixed paraffin embedded tissue sections using a chromosome. 17 centromeric probe and a HER-2 probe that spans the entire HER-2 gene in the Pathology. Core Facility by Dr. A majority of tumors cells displayed 2 chromosome 17. signals and 2 HER-2 signals, with a HER-2/CEP 17 Ratio </=2.0, consistent with no. amplification of the HER2/neu gene. Block used. A9. Source of case: Tissue fixation formalin-fixed tissueOutside Case No: NA. Tissue source breast Results interpreted: yes. HER2/CEP17 ratio: 1.02. This ratio is derived by dividing the total number of LSI HER-2/neu signals by the total number of. CEP17 signals in at least 20 interphase nuclei with nonoverlapping nuclei in the neoplastic. mammary epithelial cells. Cells with no signals or with signals of only one color are disregarded. Method of ratio enumeration: manual count. Limitations. The Vysis PathVysion Kit is not intended for use to screen for or diagnose breast cancer. It is. intended to be used as an adjunct to other prognostic factors currently used to predict disease-free. and overall survival in stage II, node-positive breast cancer patients. In making decisions regarding. adjuvant CAF treatment, all other available clinical information should also be taken into. consideration, such as tumor size, number of involved lymph nodes, and steroid receptor status. No. treatment decision for stage II, node-positive breast cancer patients should be based on HER-2/neu. gene amplification status alone. Overview of this test. FDA APPROVED REAGENT. PathVysion HER-2 DNA Probe Kit is FDA approved for selection of. patients for whom HerceptinÂ® theranv is being considered. These tests were performed in the. under the direction. of Dr. The results of these studies should always be interpreted in the context of the. clinical, morphological, and immunophenotypic diagnosis. ONCOTYPE DX BREAST CANCER ASSAY. RESULTS: Recurrence Score: 19. CLINICAL EXPERIENCE: Patients with a recurrence score of: 19 in the clinical validation study had an average. rate of Distant Recurrence at 10 years of 12%. ER Score: 10.2 Positive. PR Score: 8.8 Positive. Her2 Score: 8.9 Negative. Interpretation: ER. Negative < 6.5. Positive >= 6.5. PR Negative < 5.5 Positive >= 5.5. Her2 Negative <10.7 Positive >=1 11.5 Equivocal = 10.7 - 11.4. See separate. report for further information. Microscopic/Diagnostic Dictation: Pathologist,. Final Review: Pathologist,. Final: Pathologist,. Addendum: Pathologist,. Addendum Final: Pathologist,. Addendum: Pathologist,. Addendum Final: Pathologist,. Addendum: Pathologist, 1. Addendum Final: Pathologist,.",BRCA,0,True,"The report states that there are 4 sentinel lymph nodes excised and examined, all of which are negative for metastases (0/1, 0/1, 0/1, 0/1). This indicates that there is no evidence of cancer in the lymph nodes, which is the primary determinant of the N stage. Therefore, the N stage is N0.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",13.0,1374.0,100.0,True
1405,TCGA-JL-A3YW.476488A9-3708-4B11-854A-C91B583C7804,1,"1. LAS NO : CLINICAL INFORMATONICOMMENTS: FEMALE YEARS. Loc: METRICS CANCER PR. PATIENT CODF. CONSULTANT: Histopathology Blopay Smatt. Specimen: Two blocks representing left breast tissue are received. Clinical Note: Carcinoma left breast. Microscopic Features: One of the block reveals breast tissue infiltrated by Ã¡cellular neoplastic lesion composed. of. intermediate size tumor cells exhibiting moderate nuclear pieomorphism with eosinophilic. cytoplasm. Mitotic figures are also identified. The surrounding stroma exhibits moderate. chronic inflammation, Focal necrosis (< than 5%) is noted. The other block reveals benign breast tissue. Conclusion: Two blocks representing left breast tissue received for 2nd opinion :-. Infiltrating Lobular Carcinoma grade Il (Tubule formation 2/3, Nuclear pleomorphism 2/3,. Mitoses 2/3, Total = (6/9), according to Modified Bloom and Richardson's grading system. Tumour nuclei constitute approximately 70% of the total nuclei. Dr.",BRCA,1,True,"The pathology report does not mention the presence of cancer in the lymph nodes. Therefore, based on the rules provided, the N stage is N0.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",13.0,1374.0,53.0,False
1236,TCGA-E2-A1IE.95443906-A63B-4E07-8C4A-ED0A918B88F8,1,"SPECIMENS: A. SENTINEL LYMPH NODE RIGHT AXILLA #1. B. SLN RIGHT AXILLA #2. C. SLN RIGHT AXILLA #3. D. EXC. RIGHT BREAST CA. SPECIMEN(S): A. SENTINEL LYMPH NODE RIGHT AXILLA #1. B. SLN RIGHT AXILLA #2. C. SLN RIGHT AXILLA #3. D. EXC. RIGHT BREAST CA. GROSS DESCRIPTION: A. SENTINEL LYMPH NODE RIGHT AXILLA #1. Received fresh is a tan pink lymph node 0.5 x 0.5 x 0.3cm. The specimen is bisected and 2 touch preps. are taken. Toto A1. B. SLN RIGHT AXILLA #2. Received fresh is a tan pink lymph node 1.5 x 0.5 x 0.5cm. The specimen is bisected and 2 touch preps. are taken. Toto B1. C. SLN RIGHT AXILLA. Received fresh is are 3 tan pink lymph nodes ranging from 0.5cm to 1.2cm in greatest dimensions. Each specimen is bisected and touch preps are taken. Toto C1. D. EXCISION RIGHT BREAST: Single Stitch-Anterior/Double Stitch-Lateral/Triple Stitch-Superior. Received fresh is a 59g oriented tan pink WLE breast specimen, 7.0cm from superior to inferior, 6.0cm. from anterior to posterior and 5.5cm from medial to lateral. The specimen is inked as follows: Red-. Superior, Orange-inferior, Blue-Anterior, Black-Posterior, Green-Medial, Yellow-Lateral. The specimen. is serially sectioned from lateral to medial into 7 slices; slice 1 being most lateral, slice 7 being most. medial. The cut surface reveal a gray white firm well circumscribed mass 2.1 x 1.7 x 1.5cm, 0.6cm from. the closest superior margin, located in slices 3, 4 and 5. A surgical clip is identified in slice 3. The. mass is 0.9cm from the deep margin and greater than 10cm from the remaining margins. The. remaining cut surfaces reveal yellow lobulated adipose tissue interspersed with gray white fibrous. tissue. A portion of the specimen is submitted for tissue procurement. Representative sections are. submitted as follows: D1: lateral margin, perpendicular sections taken from superior to inferior, slice 1. D2: area adjacent to mass with deep margin, slice 2. D3: mass with anterior/superior margin, slice 3. D4: mass with superior/deep margin, clip identified, slice 3. D5: anterior/inferior margin, slice 3. D6: inferior/deep margin, slice 3. D7: mass with superior and anterior margin, slice 4. D8: anterior/inferior, slice 4. D9: mass with superior and deep margin, slice 4. D10: inferior/deep margin, slice 4. D11: superior/deep margin, slice 5. D12: anterior/superior margin, slice 5. D13: anterior margin, slice 5. D14: area next to mass with anterior and deep margin, slice 6. D15: anterior margin, slice 6. D16: deep margin, slice 6. D17: medial margin, perpendicular sections submitted from superior to inferior, slice 7. As per attached diagram. DIAGNOSIS: A. SENTINEL LYMPH NODE #1, RIGHT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR CARCINOMA (0/1). B. SENTINEL LYMPH NODE #2, RIGHT AXILLA, BIOPSY: - MICROMETASTATIC CARCINOMA (1.5 MM) IN ONE LYMPH NODE (1/1). (SEE NOTE). NOTE: The metastasis is subcapsular. No extranodal extension is seen; however, there is cautery. artifact at one edge of the metastasis limiting evaluation. The touch prep slides were reviewed and. show no evidence of metastasis. Dr. has reviewed specimen B. C. SENTINEL LYMPH NODE #3, RIGHT AXILLA, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR CARCINOMA (0/1). D. BREAST, RIGHT, WIDE LOCAL EXCISION: INVASIVE DUCTAL CARCINOMA, MODERATELY DIFFERENTIATED. (SBR GRADE 2) WITH FOCAL NECROSIS (SEE NOTE). - TUMOR MEASURES 2.1 X 1.7 X 1.5 CM. INVASIVE CARCINOMA IS 0.3 CM FROM POSTERIOR MARGIN. - LYMPHVASCULAR INVASION IS IDENTIFIED. DUCTAL CARCINOMA IN SITU (DCIS), SOLID AND CRIBRIFORM TYPES,. NUCLEAR GRADE 2-3, WITH FOCAL NECROSIS. - ATYPICAL DUCTAL HYPERPLASIA. NOTE: Microcalcifications are seen in vessels and non-neoplastic breast tissue. SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Laterality: Right. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 2.1cm. Additional dimensions: 1.7cm x 1.5cm. Tumor Site: 9:00. Margins: Negative. Distance from closest margin: 0.3cm. deep. Tubular Score: 3. Nuclear Grade: 2. Mitotic Score: 2. Modified Scarff Bloom Richardson Grade: 2. Necrosis: Present. Vascular/Lymphatic Invasion: Present. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node only. Lymph node status: Positive 1 / 3. Micrometastases: Non-neoplastic areas: columnar cell change. DCIS present. Margins uninvolved by DCIS :0.5 cm from the superior margin. DCIS Quantity: Estimate 20%. DCIS Type: Solid. Cribriform. DCIS Location: Both associated and separate from invasive tumor mass. Nuclear grade: Intermediate. Necrosis: Present. Location of CA++: Benign epithelium. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Pending by FISH. Pathological staging (pTN): pT 2N1. SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimen: Surgical Excision. Block Number: ER: Positive. Allred Score: 8. = Proportion Score 5 + Intensity Score 3. PR: Positive Allred Score: 6 = Proportion Score 3 + Intensity Score 3. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the. proportion score (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of. cells staining, 4 = 31-60% of cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak. intensity of staining, 2 = intermediate intensity of staining, 3 = strong intensity of staining), with a scoring. range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score. of less than or equal to 2. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochemistry was performed using the mouse anti-human ER (ER 1D5, 1:100) and PR (PGR. 136, 1:100) provided by. following the manufacturer S instructions. This. assay was not modified. interpretation of the ER/PR immunohistochemical stain is guided by published. results in the medical literature, information provided by the reagent manufacturer and by internal. review of staining performance. SYNOPTIC REPORT - BREAST HER-2 RESULTS. Specimen: Surgical Excision. Block Number: Interpretation: EQUIVOCAL. Intensity: 2+. % Tumor Staining: 20%. Fish Ordered: Yes, on Date. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Her2 analysis was performed using the FDA approved Dako HercepTes (TM) test kit. using rabbit anti-human HER2. This assay was not modified. External kit-slides. provided by the manufacturer (cell lines with high, low and negative HER2 protein expression) and in-. house known HER2 amplified control tissue were evaluated along with the test tissue. Adequate, well. preserved, clear-cut invasive carcinoma was identified for HER2 evaluation. Interpretation of the HER2. immunohistochemical stain is guided by published results in the medical literature, information provided. by the reagent manufacturer and by internal review of staining performance. This assay has been validated according to the 2007 joint recommendations and guidelines from. ASCO and CAP and from the NCCN HER2 testing in Breast Cancer Task Force. The L. takes full responsibility for this test's performance. PRE-OPERATIVE DIAGNOSIS: Right breast cancer. PRE-OPERTATIVE CONSULTATION: TPA/TPB/TPC: Negative for carcinoma. Diagnosis called to Dr. at. Dr. D. Gross Inspection Diagnosis: 2.1 cm tumor at 0.6cm from closest superior margin. Diagnosis called to. Dr. at. by Dr. ADDENDUM: PathVysion HER-2 DNA Probe Kit. Analytical Interpretation of Results: HER-2 NOT AMPLIFIED. Clinical Interpretation of results. Amplification of the HER-2 gene was evaluated with interphase fluorescence in-situ. hybridization (FISH) on formalin-fixed paraffin embedded tissue sections using a chromosome. 17 centromeric probe and a HER-2 probe that spans the entire HER-2 gene in the. by Dr.. A majority of tumors cells displayed 2 chromosome 17. signals and 2 HER-2 signals, with a HER-2/CEP 17 Ratio </=2.0, consistent with no. amplification of the HER2/neu gene. Block used D9. Source of case: RPCI. Tissue fixation. formalin-fixed tissue. Outside Case No: NA. Tissue source. breast Results interpreted: HER2/CEP17 ratio: 1.05. This ratio is derived by dividing the total number of LSI HER-2/neu signals by the total number of. CEP17 signals in at least 20 interphase nuclei with nonoverlapping nuclei in the neoplastic. mammary epithelial cells. Cells with no signals or with signals of only one color are disregarded. Method of ratio enumeration: manual count. Limitations. The Vysis PathVysion Kit is not intended for use to screen for or diagnose breast cancer. It is. intended to be used as an adjunct to other prognostic factors currently used to predict disease-free. and overall survival in stage II, node-positive breast cancer patients. In making decisions regarding. adjuvant CAF treatment, all other available clinical information should also be taken into. consideration, such as tumor size, number of involved lymph nodes, and steroid receptor status. treatment decision for stage II, node-positive breast cancer patients should be based on HER-. 2/neu. gene amplification status alone. Overview of this test. FDA APPROVED REAGENT. PathVysion HER-2 DNA Probe Kit is FDA approved for selection of. patients for whom HerceptinÂ® therapy is being considered. These tests were performed in the. Institute under the direction. of. The results of these studies should always be interpreted in the context of the. clinical, morphological, and immunophenotypic diagnosis. Microscopic/Diagnostic Dictation:., Pathologist, l. Final Review:. Pathologist,. Final Review:. Pathologist. Microscopic/Diagnostic Dictation:., Pathologist,. Final Review:, Pathologist. Final:., Pathologist,. Addendum: Pathologist,. Addendum Final:. Pathologist,.",BRCA,1,True,"The N stage is determined by the presence of cancer metastases in axillary lymph nodes. In this report, there are 3 sentinel lymph nodes. One of them (SLN Right Axilla #2) has micrometastatic carcinoma (1.5 mm) in one lymph node (1/1). This indicates an N1 classification.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",14.0,1472.0,97.0,True
1245,TCGA-E2-A1IO.A9D36308-DAEF-48B9-A4EC-6B9B24EE3DC2,0,"SPECIMENS: A. SLN #1 RIGHT AXILLA. B. RIGHT BREAST. C. ADDITIONAL ANTERIOR MARGIN. SPECIMEN(S): A. SLN #1 RIGHT AXILLA. B. RIGHT BREAST. C. ADDITIONAL ANTERIOR MARGIN. INTRAOPERATIVE CONSULTATION DIAGNOSIS: TPA, Lymph node, sentinel, right axilla, biopsy: Negative for carcinoma. Part B, Right breast, Gross examination: Tumor is present at the anterior margin, and at least 0.2-cm. from posterior margin. Diagnoses called at. (A) anc. (B) by Dr. GROSS DESCRIPTION: A. SLN #1 RIGHT AXILLA. Received fresh labeled with the patient's patient and designated ""sentinel lymph node number one right. axilla"" is a fragment of lymphoid tissue measuring 1.9 X 1.2 x 0.8 cm. Touch preparation is performed. Entirely submitted, A1. B. RIGHT BREAST. Received fresh labeled with the patient's identification and designated ""right breast"" is a previously. inked, oriented, 13-g, 4 x 2.5 x 1.5 cm lumpectomy specimen. The short suture designates superior,. long-lateral. Ink code: Anterior-yellow, posterior-black, medial-green, lateral-red, superior-blue, inferior-. orange. The specimen is serially sectioned from medial to lateral into 6 slices revealing a firm tan. mass, 1.2 x 0.9 x 0.7 cm, located 0.1-cm from the nearest anterior margin. A portion of the specimen is. submitted for tissue procurement. The remainder of the specimen is entirely submitted: B1-B2: Perpendicular sections medial margin. B3-B4: Slice 2, B4 demonstrates mass. B5-B6: Slice 3, B6 demonstrates mass. B7-B8: Slice 4, B8 demonstrates mass. B9-B10: Slice 5, B10 demonstrating remainder of mass. B11-B12: Perpendicular sections lateral margin. C. ADDITIONAL ANTERIOR MARGIN. Received fresh labeled with the patient's identification and designated ""additional anterior margin"" are. two previously inked (black at final margin) fragments of adipose tissue together weighing 1 g and. measuring 2 x 1 x 0.3 cm in aggregate. The entire specimen is submitted, C1. DIAGNOSIS: A. LYMPH NODE, SENTINEL #1, RIGHT AXILLA, EXCISION: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). B. BREAST, RIGHT, WIDE LOCAL EXCISION: INVASIVE DUCTAL CARCINOMA, SBR GRADE 3 WITH FOCAL NECROSIS, MEASURING 1.2-CM. HIGH NUCLEAR GRADE, DUCTAL CARCINOMA IN SITU, SOLID AND CRIBRIFORM TYPES WITH. CENTRAL NECROSIS, MICROCALCIFICATIONS, AND LOBULAR EXTENSION. INVASIVE TUMOR INVOLVES ANTERIOR SURGICAL RESECTION MARGIN (SEE PART C). BIOPSY SITE CHANGES WITH FIBROSIS. - SEE SYNOPTIC REPORT. C. BREAST, ADDITIONAL ANTERIOR MARGIN, EXCISION: - FATTY BREAST TISSUE, NO TUMOR SEEN. SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Laterality: Right. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 1.2cm. Margins: Negative. Distance from closest margin: 0.3cm. inferior. Tubular Score: 3. Nuclear Grade: 2. Mitotic Score: 3. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Present. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node only. Lymph node status: Negative 0 / 1. DCIS present. Margins uninvolved by DCIS. DCIS Quantity: Estimate 10%. DCIS Type: Solid. Cribriform. DCIS Location: Associated with invasive tumor. Nuclear grade: High. Necrosis: Present. Location of CA++: DCIS. Benign epithelium. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Pending. Performed on Case: Pathological staging (pTN): pT 1c N 0. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. CLINICAL HISTORY: None given. PRE-OPERATIVE DIAGNOSIS: None given. ADDENDUM: SYNOPTIC REPORT - BREAST HER-2 RESULTS. Specimen: Surgical Excision. Block Number: Interpretation: EQUIVOCAL. Intensity: 2+. % Tumor Staining: 30%. Fish Ordered: METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Her? analysis was performed using the FDA approved Dako HercepTest (TM) test kit. i) using rabbit anti-human HER2. This assay was not modified. External kit-slides. provided by the manufacturer (cell lines with high, low and negative HER2 protein expression) and in-. house known HER2 amplified control tissue were evaluated along with the test tissue. Adequate, well. preserved, clear-cut invasive carcinoma was identified for HER2 evaluation. Interpretation of the HER2. immunohistochemical stain is guided by published results in the medical literature, information provided. by the reagent manufacturer and by internal review of staining performance. This assay has been validated according to the 2007 joint recommendations and guidelines from. ASCO and CAP and from the NCCN HER2 testing in Breast Cancer Task Force. Pathology. Department takes full responsibility for this test's performance. PathVysion HER-2 DNA Probe Kit. Analytical Interpretation of Results: HER-2 NOT AMPLIFIED. Clinical Interpretation of results. Amplification of the HER-2 gene was evaluated with interphase fluorescence in-situ. hybridization (FISH) on formalin-fixed paraffin embedded tissue sections using a chromosome. 17 centromeric probe and a HFR-2 probe that spans the entire HER-2 gene in the F. by Dr. A majority of tumors cells displayed moderate polysomy 17. with 2 to 4 chromosome 17 signals and 2 to 4 HER-2 signals, with a HER-2/CEP 17 Ratio </=2.0,. consistent with no amplification of the HER2/neu gene. Block used. Source of case: Tissue fixation. formalin-fixed tissue. Outside Case No:NA. Tissue source. breast Results interpreted: HER2/CEP17 ratio: 1.1. This ratio is derived by dividing the total number of LSI HER-2/neu signals by the total number of. CEP17 signals in at least 20 interphase nuclei with nonoverlapping nuclei in the neoplastic. mammary epithelial cells. Cells with no signals or with signals of only one color are disregarded. Method of ratio enumeration: manual count. Limitations. The Vysis PathVysion Kit is not intended for use to screen for or diagnose breast cancer. It is. intended to be used as an adjunct to other prognostic factors currently used to predict disease-free. and overall survival in stage II, node-positive breast cancer patients. In making decisions regarding. adjuvant CAF treatment, all other available clinical information should also be taken into. consideration, such as tumor size, number of involved lymph nodes, and steroid receptor status. treatment decision for stage II, node-positive breast cancer patients should be based on HER-. 2/neu. gene amplification status alone. Overview of this test. FDA APPROVED REAGENT. PathVysion HER-2 DNA Probe Kit is FDA approved for selection of. patients for whom HerceptinÂ® therapy is being considered. These tests were performed. of Dr.. The results of these studies should always be interpreted in the context of the. clinical, morphological, and immunophenotypic diagnosis. ONCOTYPE DX BREAST CANCER ASSAY. RESULTS: Recurrence Score: 18. CLINICAL EXPERIENCE: Patients with a recurrence score of: 18 in the clinical validation study. had an average rate of Distant Recurrence at 10 years of 11%. ER Score: 10.2 Positive. PR Score: 9.2 Positive. Her2 Score: 9.9 Negative. Interpretation: ER. Negative < 6.5. Positive >= 6.5. PR. Negative < 5.5. Positive >= 5.5. Her2 Negative <10.7 Positive >=11.5 Equivocal = 10.7 - 11.4. Microscopic/Diagnostic Dictation:,. Final Review: M.D., Pathologist. Final: M.D., Pathologist,. Addendum: M.D., Pathoiogist,. Addendum Final: M.D., Pathologist, (. Addendum:, M.D., Pathologist,. Addendum Final, M.D., Patholugiat,. Addendum, M.D., Pathologist. Addendum Final:, M.D., Pathologist,.",BRCA,0,True,"The report states that the sentinel lymph node is negative for metastases (0/1). According to the rules, the absence of cancer in the lymph nodes is the primary determinant of the N stage, and the number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes. Therefore, the N stage is N0.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",14.0,1472.0,36.0,False
487,TCGA-A2-A0CW.7D1C2CD8-9842-48AC-BB16-897E2A45B88D,1,"Specimen #: F Race: WHITE. Physician( (s) : 3. SPECIMEN: A: SENTINEL LYMPH NODE #1 B: NON-SENTINEL - LYMPH NODE. C: RIGHT BREAST LUMPECTOMY. FINAL DIAGNOSIS: A. LYMPH NODE, SENTINEL, EXCISION: ONE (1) SENTINEL LYMPH NODE POSITIVE FOR METASTATIC CARCINOMA WITH. THE LARGEST FOCUS MEASURING 0.4 CM. - TUMOR IDENTIFIED IN THE PERINODAL SOFT TISSUE. B. LYMPH NODE, NON-SENTINEL, EXCISION: ONE (1) LYMPH NODE COMPLETELY REPLACED BY METASTATIC CARCINOMA. MEASURING 1.5 CM. EXTRANODAL EXTENSION CANNOT BE ASSESSED DUE TO LACK OF PERINODAL. SOFT TISSUE. C. BREAST. RIGHT, LUMPECTOMY: - INFILTRATING DUCTAL CARCINOMA, POORLY DIFFERENTIATED. - -NOTTINGHAM SCORE: 9/9 (TUBULES=3, NUCLEI=3, MITOSES=3). - TUMOR SIZE: 2.7 CM (MEASURED GROSSLY). - TUMOR NECROSIS: ABSENT. - MICROCALIFICATIONS: ABSENT. - VENOUS / LYMPHATIC INVASION: PRESENT. - INVASIVE TUMOR INVOLVES THE SMOOTH MUSCLE OF THE NIPPLE. - MARGINS: NEGATIVE. - DISTANCE OF TUMOR FROM NEAREST MARGIN IS 0.6 CM,. FROM NEAREST (SUPERIOR) MARGIN. - INTRADUCTAL COMPONENT DUCTAL CARCINOMA IN SITU, SOLID TYPE,. NUCLEAR GRADE II, WITH NECROSIS (<5% OF TUMOR). - ESTROGEN RECEPTORS, PROGESTERONE RECEPTORS, AND HER 2 NEU. PERFORMED ON PREVIOUS SPECIMEN (SEE COMMENT). - PATHOLOGIC STAGE: pT2 N1a MX. - ADDITIONAL PATHOLOGIC CHANGES: PRIOR BIOPSY SITE CHANGES. COMMENT: E. Hormone receptors performed on previous biopsy. and are as. follows: - Estrogen Receptor: Positive (approximately 100% nuclear staining). - Progesterone Receptor: Positive (25% nuclear staining). - ER-2-NEU - Postive (3+, strongly positive). Specimen #: FINAL DIAGNOSIS (continued) : CLINICAL DIAGNOSIS AND HISTORY: year old female with right breast invasive cancer. PRE-OPERATIVE DIAGNOSIS: Right breast invasive cancer. POST-OPERATIVE DIAGNOSIS: Right breast invasive cancer. GROSS DESCRIPTION. A. Received fresh labeled with patient's name. designated ""SENTINEL LYMPH NODE"" is a 1.5 x 0.5 x 0.3 cm lymph node with. attached fibrous fatty tissue. Specimen is bisected and entirely submitted. in cassette one. B. Received fresh labeled with patient's name. designated 'NON-SENTINEL LYMPH NODE"" are two irregular portions of. presumed previously intact lymph node each measuring 1.5 x 1.5 x 0. 1 cm. Sectioning reveals uniform tan and whtie cut surface. Specimen entirely. submitted in three cassettes as follows. B1-B2: first portion of node (match of B1 submitted in OCT for CBCP. protocol). B3: remaining portion of lymph node. C. Received fresh labeled with patient's name. designated ""RIGHT BREAST LUMPECTOMY"" consists of an irregular portion of. fibrofatty tissue oriented with single stitch medial and two stitches. superior. The specimen measures 10 cm medial to lateral, 7 cm anterior to. posterior and 3 cm superior to inferior. Superficial surface displays an 8. x 4 cm lightly pigmented skin ellipse with centrally located fimr inverted. nipple. No discharge or scar is identified. Specimen is inked as follows : superior blue, inferior green, medial red, lateral yellow, posterior. black. Serial sections reveal well defined 2.7 x 2.7 x 2.2 cm firm pink. white gritty mass subadjacent to and involving the nipple. Surrounding. breast tissue is fibrofatty and otherwise unremarkable. Cassette key. Specimen # : GROSS DESCRIPTION (continued). C1: mass. C2: normal fibrous 1 cm away. C3: normal skin. C4: : nipple with mass. C5-C10: representative sections of presumed mass with close proximity to. margin. C11: medial margin. C12: lateral margin. 12CM.",BRCA,1,True,"The report mentions the presence of metastatic carcinoma in a sentinel lymph node (A) and a non-sentinel lymph node (B). The sentinel lymph node has the largest focus measuring 0.4 cm, and the non-sentinel lymph node is completely replaced by metastatic carcinoma, measuring 1.5 cm. This indicates that cancer has spread to at least one axillary lymph node, classifying the N stage as N1.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",14.0,1472.0,100.0,True
733,TCGA-AC-A6NO.A81EB5E0-305E-4657-94AD-0922CD1D79C6,1,"Result date: Clinical History. Right breast IDC at 12:00 position on prior core, ER+, PR+, HER2- -. FNA of right axillary node was positive. Specimen. #1. Right breast, stitch is lateral. #2. Right axillary contents. Gross Examination. #1. Received fresh labeled right breast, stitch is lateral, is a 1108 gram,. 21.5 x 20.0 x 6.5 cm simple mastectomy specimen, oriented as stated above. There is a overlying 16.5 x 11.6 cm ellipse of brown skin with a normal. appearing nipple and areola. There is no scarring or retraction on the skin. surface. The deep margin is inked black and sectioning demonstrates a 17.5 x 12.0 cm. ill-defined area of firm, gritty pink tan fibroglandular tissue, spanning all. four quadrants. The gritty tissue is 0.6 cm from the nearest overlying deep. margin, (upper inner quadrant) Within the gritty, nodular parenchyma there is. a well circumscribed 4.0 x 3.5 x 3.5 cm white tan, indurated mass. This mass is. located subareolar, is 1.8 cm deep to the skin, 2.5 cm from the deep margin and. at least 6 cm from all remaining margins. There are also four additional. smaller well circumscribed white tan, indurated masses, all within the upper. inner quadrant. They range from 1.0-1.6 cm in greatest dimension. The closest. to the largest subareolar mass is 3.0 cm away (superior and medial) . One of the. smaller nodules in the upper inner quadrant is focally hemorrhagic. (approximately 12:00-1:00 location). The remainder of the tissue is composed of soft, lobulated adipose tissue. intermixed with scant, delicate brands of fibrous tissue (80% and 20%. respectively) There are no apparent lymph nodes at the lateral pole and no. additional. obvious masses are grossly seen. Fourteen sections are submitted in. thirteen: ""A-M"". Block summary: ""A"", nipple and skin; ""B"", deep margin at. closest approach to gritty nodular tissue (upper inner quadrant), perpendicular;. ""C"", deep margin at closest approach to subareolar mass, perpendicular; ""D"",. subareolar mass; ""E-H"", four smaller masses in upper inner quadrant (one section. per mass), focally hemorrhagic mass at 12:00-1:00 in ""E"" ""I"", most medial. aspect of gritty nodular tissue; ""J"", most lateral aspect of gritty nodular. tissue; ""K"", gritty, nodular tissue from lower inner quadrant; ""L"", gritty. tissue from upper outer quadrant; ""M"", gritty tissue from lower outer quadrant. #2 Received fresh, placed in. labeled right axillary. contents, is a 9.0 x 7.0 x up to 2.5 cm aggregate of multiple irregular. fragments of tan yellow fibroadipose tissue. After fixation, multiple lymph. node candidates are identified up to 2.0 cm in greatest dimension. Within the. largest candidate there is a focal firm, 0.8 cm area of discoloration. The. candidates are submitted as thirty-three sections in fifteen: ""A-O"". Block. summary: ""A"", representative cross section of abnormally firm lymph node. candidate; ""B"", one candidate trisected; ""C-E"", one candidate each cassette,. each bisected; ""F"", multiple individual candidates; ""G"", one candidate bisected;. ""H"", one candidate trisected; ""I-L"", one candidate, each cassette, each. bisected; ""M-O"", lymph node candidate, sectioned. Microscopic Examination. #1,2 Microscopic examination performed. Comment. The breast is extensively involved by DCIS, over an area that spans all four. quadrants and involves most of the breast. Scattered throughout the DICS are. four discrete foci of invasive ductal carcinoma, all with identical histology. Signature Line. Final Diagnosis. #1 BREAST, RIGHT SIMPLE MASTECTOMY: MULTIFOCAL INVASIVE DUCTAL CARCINOMA, INTERMEDIATE GRADE. THERE ARE FOUR FOCI OF INVASIVE TUMOR, ALL WITH IDENTICAL HISTOLOGY. TUBULE FORMATION: MODERATE (SCORE 2). NUCLEAR PLEOMORPHISM: MODERATE (SCORE 2) . MITOTIC COUNT: MODERATE (SCORE 2) . TOTAL NOTTINGHAM SCORE: 6 OF 9 (GRADE II). LOCATION IN BREAST: LARGEST MASS IS AT 12:00-1:00 POSITION, THE FOUR. SMALLER MASSES ARE ALL IN THE UPPER INNER QUADRANT. TUMOR SIZE: 4.0 CM, 1.6 CM, 1.5 CM, 1.0 CM, 1.0 CM. (SEE COMMENT). PERCENT OF INTRADUCTAL CARCINOMA (DCIS) : APPROXIMATLEY 90%, RANGING. FROM INTERMEDIATE TO HIGH NUCLEAR GRADE WITH NECROSIS. STATUS OF BREAST TISSUE AWAY FROM LESION: FIBROCYSTIC CHANGES. LOCAL LYMPHATIC SPACE STATUS: NEGATIVE. DERMAL LYMPHATIC SPACE STATUS: NEGATIVE. SKIN AND NIPPLE SURFACE: NEGATIVE. SURGICAL MARGIN STATUS NEGATIVE (AT LEAST 0.9 CM) . STATUS OF MICROCALCIFICATIONS PRESENT IN DCIS. ESTROGEN RECEPTOR ASSAY: POSITIVE ON PRIOR CORE (2+, 95%). PROGESTERONE RECEPTOR ASSAY POSITIVE ON PRIOR CORE (3+, 95%) . HERCEPTEST (HER-2/NEU) STATUS: NEGATIVE ON PRIOR CORE (SCORE 1+) . #2 LYMPH NODES, RIGHT AXILLA, DISSECTION: POSITIVE FOR METASTATIC CARCINOMA (2/16) . SIZE OF LARGEST METASTASIS: 0.8 CM, NO EXTRACAPSULAR EXTENSION. PATHOLOGIC STAGE (TNM CLASSIFICATION) : pT2 pNla.",BRCA,1,True,"The report states that there are 2 positive lymph nodes out of 16 examined in the right axillary lymph node dissection. This corresponds to the N1 classification, which is determined by the presence of metastases in 1-3 axillary lymph nodes.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",14.0,1472.0,100.0,True
1019,TCGA-BH-A0EI.DFB21194-30C7-430E-A53C-C38345209B1F,0,"FINAL DIAGNOSIS: PART 1: BREAST, RIGHT, NEEDLE LOCALIZED SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA, 2.0 CM (GROSS), NOTTINGHAM GRADE 1 (COMBINED NOTTINGHAM. SCORE 4/9: TUBULE FORMATION 1/3, NUCLEAR PLEOMORPHISM 2/3, MITOTIC ACTIVITY 1/3). B. DUCTAL CARCINOMA IN SITU (DCIS), NUCLEAR GRADE 2, CRIBRIFORM TYPE, CONSTITUTES. APPROXIMATELY 5% OF THE TUMOR VOLUME AND IS ADMIXED WITH THE INVASIVE COMPONENT. C. LYMPHOVASCULAR SPACE INVASION IS NOT IDENTIFIED. D. MARGINS FREE, CLOSEST ANTERIOR/SUPERIOR WITHIN 0.6 CM. E. DUCTAL EPITHELIAL HYPERPLASIA. F. FIBROCYSTIC CHANGES. G. SCLEROSING ADENOSIS. H. COLUMNAR CELL CHANGE. I. FIBROADENOMATOID NODULES. J. SKIN IS NEGATIVE FOR TUMOR. K. BIOPSY SITE CHANGES. PART 2: LYMPH NOVES, KIGNI, SENUINEL. A. METASTATIC CARCINOMA (0.4 CM.) INVOLVES ONE OF TWO LYMPH NODES (1/2) (see comment). B. EXTRACAPSULAR EXTENSION IS IDENTIFIED, 0.1 CM X 0.07 CM. PART 3: LYMPH NODE, RIGHT, SENTINEL #2, BIOPSY -. A. METASTATIC CARCINOMA INVOLVES ONE LYMPH NODE (1/1) (see comment). B. EXTRACAPSULAR EXTENSION IS NOT IDENTIFIED. PART 4: LYMPH NODE, KIGNT, SENTINEL #3, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR METASTATIC CARCINOMA (0/1) (see comment). PART 5: BREAST, RIGHT, NEW LATERAL MARGIN, EXCISION -. A. RADIAL SCAR. B. FIBROCYSTIC CHANGES. C. SCLEROSING ADENOSIS. D. DUCTAL EPITHELIAL HYPERPLASIA. E. COLUMNAR CELL CHANGE WITH ASSOCIATED CALCIFICATIONS. F. FAT NECROSIS. UNUE INOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Right. PROCEDURE: Segmental. Not specified. SIZE OF TUMOR: Maximum dimension invasive component: 2 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR AGGREGATE SIZE: Sum of the sizes of multiple invasive tumors: 2.5 cm. TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 1. Mitotic activity score: 1. Total Nottingham score: 4. Nottingham grade (1, 2, 3): 1. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: Yes, benign zones. Yes, malignant zones. TUMOR TYPE, IN SITU: Cribriform. DCIS admixed with invasive carcinoma. Percent of tumor occupied by in situ component: 5 %. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: SURG MARGINS INVOLVED BY IN SITU COMPONENT: LYMPH NODES POSITIVE: 2. LYMPH NODES EXAMINED: 4. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain, Keratin stain. SENTINEL NODE METASTASIS: SIZE OF NODAL METASTASES: Diameter of largest lymph node metastasis: 4 mm. LYMPH NODE METASTASIS(-ES) WITH EXTRACAPSULAR EXTENSION: T STAGE, PATHOLOGIC: N STAGE, PATHOLOGIC: pN1. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive. HER2/NEU:",BRCA,1,True,"The report indicates that there are 2 lymph nodes examined, and 2 of them are positive for metastatic carcinoma. This corresponds to the N1 classification, which is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved. The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",14.0,1472.0,100.0,True
1256,TCGA-E2-A1LI.B3A319BE-2230-43E2-91E5-A3B3C76B85BA,1,"SPECIMENS: A. SENTINEL LYMPH NODE LEFT AXILLA. B. SENTINEL LYMPH NODE #2 LEFT AXILLA. C. WIDE LOCAL EXCISION LEFT BREAST. DIAGNOSIS: A. SENTINEL LYMPH NODE #1, LEFT AXILLA: -ONE LYMPH NODE, NO TUMOR SEEN (0/1). B. SENTINEL LYMPH NODE #2, LEFT AXILLA: -ONE LYMPH NODE, NO TUMOR SEEN (0/1). C. WIDE LOCAL EXCISION, LEFT BREAST: -INVASIVE AND IN-SITU DUCTAL CARCINOMA, SBR GRADE III/III WITH. EXTENSIVE NECROSIS AND CANCERIZATION OF LOBULES, SEE TEMPLATE. Invasive Breast Cancer Template. INVASIVE TUMOR: Histologic type: ductal. Tumor Size (cm): 2.5 cm. Size of Invasive Focus: 2.5 cm. Grade, Histologic: 3. Grade, Nuclear: 3. Mitoses. 3. Scarff Bloom Richardson grade: III. Necrosis: present. Invasion Vasc/Lymphatic: absent. DCIS component. DCIS Quantity: <25%. DCIS Type: Clining. DCIS Location: outside main mass: diffuse. Nuclear grade: high. Necrosis: absent. Margins: DCIS present within 1 hpf of lateral and 1 mm of deep and medial margins. Lymph nodes: Negative (0/2). Stage, Pathology : T2N1. Hormone receptor status (by IHC): ER & PR: PENDING. HERCEPTEST (by IHC): Pending. ADDENDUM. The ER/PR/HER2 status of the invasive breast carcinoma was determined by immunohistochemistry. and quantitated via ACIS (image analysis). Results are as follows: ER. 0%. PR. 0%. HER2. 2.3 (borderline). A separate ACIS report has been generated. NOTE: FISH analysis for HER2 gene amplification has been ordered. Addendum. Fluorescence in situ hybridization (FISH) for Her-2 gene amplification. Her-2/neu gene: Not amplified. Ratio of Her-2/neu to CEP17: 1.21. The assay is performed on formalin fixed, paraffin embedded section using Her-2 DNA probe kit from. Vysis. The quality of the fluorescence signals and tissue section is adequate for analysis. The signals of. both Her-2 and CEP17 are counted in 60 invasive tumor nuclei. The Her-2 gene is considered amplified. when the ratio of Her-2 to CEP17 signal is >2.0. SPECIMEN(S): A. SENTINEL LYMPH NODE LEFT AXILLA B. SENTINEL LYMPH NODE #2 LEFT AXILLA C. WIDE. LOCAL EXCISION LEFT BREAST. CLINICAL HISTORY: None. FROZEN SECTION DIAGNOSIS: A. SENTINEL LYMPH NODE LEFT AXILLA. Touch prep: No tumor seen by Dr. B. SENTINEL LYMPH NODE #2 LEFT AXILLA. Touch prep: No tumor seen by Dr. GROSS DESCRIPTION: A. SENTINEL LYMPH NODE LEFT AXILLA. Received fresh is a 1x0.8x0.5cm. lymph node. It is bisected and touch prep done. Specimen entirely. submitted for permanent section. B. SENTINEL LYMPH NODE #2 LEFT AXILLA. Received fresh is sentinel lymph node left axilla measuring 0.7x0.5x0.4cm. It is bisected and touch prep. done. Submitted in toto in cassette B for permanent section. C. WIDE LOCAL EXCISION LEFT BREAST. Received fresh is an oriented portion of breast tissue measuring 6x5.5x2.7cm Sectioning shows a well. circumscribed tan nodular tumor mass measuring 2.5x1.8x1cm. It closely approaches the superior. posterior medial margin. Specimen is inked as follows: superior red, inferior orange, medial green,. lateral yellow, posterior black. Tumor tissue and normal tissue given for tissue procurement and tumor. sent for flow cytometry. Representative sections submitted in seventeen cassettes. Microscopic/Diagnostic Dictation: Pathologist. Final Review: Pathologist. Final: Pathologist. Addendum: Pathologist. Addendum Review: Pathologist. Addendum Final: Pathologist. Addendum: Pathologist, 1. Addendum Review: Pathologist,. Addendum Final: Pathologis.",BRCA,1,True,"The report states that there are 2 sentinel lymph nodes examined and both are negative for tumor (0/2). However, the N stage is not only determined by the absence or presence of cancer in the lymph nodes but also by the number of positive lymph nodes. The report mentions that the pathology stage is T2N1, which indicates that there is 1 positive lymph node. Therefore, the N stage is N1.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",14.0,1472.0,100.0,True
534,TCGA-A2-A0YT.1C420F6B-8720-4CB0-9FB3-86A0EC05FBBD,3,"SURGICAL REPORT. Sex: F. Date Collected: Date Received: M.R. Number: Doctor: Account Number: PRE-OPERATIVE DIAGNOSIS. LEFT BREAST CANCER. POST-OPERATIVE DIAGNOSIS. LEFT BREAST CANCER. PROCEDURE. LEFT MODIFIED RADICAL MASTECTOMY. TISSUES. A. BREAST MASTECTOMY (WANO) NODES - LEFT BREAST & AXILLARY CONTENTS. B. MARGINS - ADDITIONAL INFERIOR SKIN LEFT BREAST. WRI TISSUE. FINAL DIAGNOSIS. A. LEFT BREAST AND AXILLARY CONTENTS, 1619 GMS. -. INFILTRATIVE DUCT CARCINOMA (CONFLUENT REGION MEASURES 13.6 CM.). SCARFF-BLOOM-RICHARDSON GRADING: GRADE 3 OF 3 (ABSENT TUBULAR FORMATIONS, HIGH NUCLEAR GRADE. AND MODERATE MITOTIC INDEX). DCIS: NONE IDENTIFIED. ANGIOLYMPHATIC INVASION: PRESENT, MULTIFOCAL. TUMORAL CALCIFICATION/NECROSIS: PRESENT. SURGICAL MARGINS: UNINVOLVED. NON-NEOPLASTIC BREAST -. FIBROADENOMA 0.3 CM. FIVE POSITIVE LYMPH NODES WITH EXTRACAPSULAR EXTENSION (6/5). THE LARGEST NODE MEASURES 1.6 CM. AND THE TUMOR INVOLVES THREE-FOURTHS. OF THE NODE. OVERLYING NIPPLE, AREOLA AND SKIN: FOCAL EXTENSION OF THE TUMOR INTO EPIDERMIS WITHOUT ULCERATION. B. ADDITIONAL INFERIOR SKIN LEFT BREAST -. POSITIVE FOR INFILTRATIVE DUCT CARCINOMA, THE TUMOR INVOLVES THE DERMIS. WITHOUT EXTENSION TO EPIDERMIS. (SATELLITE SKIN NODULE). THE INKED MARGINS ARE FREE. PTNM CLASSIFICATION: SURGICAL REPORT. T4B, N2a, MX, STAGE GROUPING IIIB. Diagnosed by: and. COMMENT. The multiple sections from the tumor reveal a poorly differentiated infiltrative duct carcinoma with. widespread angiolymphatic invasion. The satellite nodule grossly observed appears to be a direct. extension from the primary tumor with peripheral tumefaction. The overlying epidermis is involved by the. tumor but does not exhibit ulceration. The Bloom-Richardson grading was upgraded to 3 based on. complete evaluation of the entire tumor mass. The ER, PR, and Her-2/neu have been performed on the previous surgical. This case Is discussed with. on. GROSS DESCRIPTION. The specimen is received in two separate containers labelec. esignated A and B. A. The container is received fresh unfixed labeled ""left breast and axillary contents - suture on. upper outer quadrant"". The specimen consists of a 1,519 gm. apparent left breast which is 30 x. 20 x 7.5 cm. in greatest overall dimension. There is an attached suture indicating upper outer. quadrant inked with orange dye, lower outer quadrant is inked yellow, upper inner quadrant is. inked with green dye, lower inner quadrant is inked with red dye. The deep margin is inked black. Sectioning reveals a tumor mass directly beneath the nipple which is 13.5x 7 x 4 cm. in greatest. overall dimension and is 1.5 cm. from the deep margin, 2 cm. from the upper outer margin, 2.5. cm. from the lower outer margin, 2 cm. from the upper inner margin, and 4 cm. from the lower. inner margin. There is a satellite nodule which is 0.6 cm. in greatest dimension and is 1.5 cm. from the main tumor mass and has a distance of 0.6 cm. from the upper inner margin. Sectioning. through the remaining breast stroma reveals fatty and fibrous-encased tissue. Sectioning through. the attached axillary fat reveals rare tan-gray nodules varying up to 1 cm. in greatest dimension. The specimen is submitted in twelve blocks. Key Note Block Summary: 1-nipple with underlying tumor, 2 through 4-tumor mass, 5-. satellite nodule and upper inner quadrant, 6-lower inner quadrant, 7-lower outer quadrant, 8-. upper outer quadrant, 9-deep, 10 through 12-rare nodules. B. The container is received fixed labeled ""additional inferior skin left breast"". The specimen. consists of a skin ellipse which is 7 x 1x 1 cm. in greatest overall dimension. The skin. has been previously marked with purple-blue dye. The specimen is serially sectioned. revealing no apparent gross abnormalities. The entire specimen is submitted in two. blocks. MICROSCOPIC EXAM. MICROSCOPIC EXAMINATION CONDUCTED BY PATHOLOGIST CONFIRMS FINAL DIAGNOSIS. SURGICAL REPORT.",BRCA,2,True,"The report states that there are 5 positive lymph nodes with extracapsular extension. This information indicates that the N stage is N2, as per the rule: 'N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.'","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",N2,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",14.0,1473.0,100.0,True
552,TCGA-A2-A3XT.A614B6B7-256F-4148-8941-6145B2D9B8B5,1,"R. Specimen #: (Age: Race/: Physician (s) : AMENDED carcinoma, infiltrating ductal NOS. SPECIMEN: LEFT BREAST TISSUE. FINAL DIAGNOSIS: BREAST, LEFT, LUMPECTOMY: - POORLY DIFFERENTIATED ADENOCARCINOMA, CONSISTENT WITH INFILTRATING. DUCTAL CARCINOMA. SEE COMMENT. - NOTTINGHAM GRADE: POORLY DIFFERENTIATED, 9/9 (TUBULES=3, MITOSES=3,. NUCLEI=3) . - TUMOR SIZE 4 CM (GROSS) . - TUMOR NECROSIS: EXTENSIVE, ALL INFILTRATING COMPONENT. - LYMPHOVASCULAR INVASION PRESENT (EXTENSIVE) . - MARGINS POSITIVE (INFERIOR AND ANTERIOR, A10,A6) . - NO INTRADUCTAL COMPONENT IDENTIFIED. ESTROGEN RECEPTOR: NEGATIVE (NO NUCLEAR STAINING, 0%). PROGESTERONE RECEPTOR NEGATIVE (NO NUCLEAR STAINING, 0%). HER2 BY IMMUNOHISTOCHEMISTRY: NEGATIVE (SCORE 0). SEE COMMENT. COMMENT: There is extensive lymphovascular invasion as well as foci of high grade. tumor cells in grossly normal tissue sections away from the tumor. This. report will be amended pending stains to confirm a breast primary origin. Dr. was notified of these results at. ; on. The. clinical history was incorrect, and has been .changea. discussion with Dr. AMENDED COMMENTS: The tumor is CK7+, CK20-, and GCPFD- The pattern is consistent with a. FOR OFFICIAL USE ONLY - PERSONAL DATA - PRIVACY ACT OF. FOR OFFICIAL USE ONLY - PERSONAL DATA - PRIVACY ACT OF. specimen #: FINAL DIAGNOSIS (continued) : poorly differentiated infiltrating duct carcinoma, however, a metastatic. process cannot be entirely excluded. CLINICAL DIAGNOSIS AND HISTORY: year. old -- with enlarging complex cystic lesion in the left breast. PRE-OPERATIVE DIAGNOSIS: left breast palpable lesion. GROSS DESCRIPTION: A. Received in formalin labeled with patient's name. BLACK LATERAL, SINGLE BLUE MEDIAL, DOUBLE BLUE DEEP ON PECTORAL FASCIA,. designated ""LEFT BREAST TISSUE SINGLE SHORT BLACK SUPERIOR, SINGLE LONG. SINGLE GREEN INFERIOR STITCH"". Specimen consists of an ovoid portion of cm. fibrofatty tissue oriented as designated on label. Specimen measures 8. posterior. Specimen is inked as follows: superior blue, inferior green,. superior to inferior, 7 cm medial to lateral, 3.5 cm anterior to. medial red, lateral yellow, anterior orange, posterior black. Serial. sections reveal centrally located 4 x 3.2 x 3.2 cm fleshy pink tan well. circumscribed mass with scattered foci of hemorrhage and necrosis. Mass. abuts anterior margin and located 0.2 cm from posterior margin and 1.5 cm. from superior inferior margin. Surrounding tissue is densely fibrous with. multiple cysts. Cassette summary : A1-A2: mass. A3: adjacent normal. A4: lateral section adjacent to mass. A5: lateral portion of mass near orange margin. A6-A7: contiguous sections adjacent to A2 near orange and black margin. A8-A9: contiguos sections medial to A6-A7. A10: medial sections to A8-A9 nearing green margin. All: most medial glandular section of specimen. FOR OFFICIAL USE ONLY - PERSONAL DATA - PRIVACY ACT OF 1. FOR OFFICIAL USE ONLY - PERSONAL DATA - PRIVACY ACT o. Specimen # : GROSS DESCRIPTION (continued) : A12: inferior glandular appearing portion in same section as A8-A9. Matched sections of A1-A3 are submitted in. for. FOR OFFICIAL USR ONLY - PERSONAL DATA - PRIVACY ACT OF.",BRCA,1,True,"The pathology report does not mention the presence of cancer metastases in any lymph nodes, and it specifically states 'no evidence of cancer in the lymph nodes.' This is the primary determinant of the N stage, and there is no need to consider other factors such as the number of negative lymph nodes, the presence of blue dye, immunohistochemical analysis, Her-2/NEU analysis, or extracapsular extension. Therefore, the N stage is N0.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",14.0,1473.0,50.0,False
1125,TCGA-D8-A1JI.EF2DC6FB-F026-4025-B148-DF07194914AB,0,"page 1 / 2. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: 1. Multiple organ resection - right breast and axillary tissue. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the right breast. Macroscopic description: Right breast sized 35 x 23 x 9 cm removed along with axillary tissues sized 13 x 8 x 4 cm and a skin flap of 24 x. 17 cm. Weight 1,400 g. Tumour sized 1.9 x 1.4 x 1.8 cm in the upper outer quadrant, 6 cm from the upper boundary, 2 cm from the. base and 1.8 cm from the front surface. Lymph nodes 2.4 cm in length. Microscopic description: Carcinoma ductale invasivum - NHG1 (2 + 3 +1: 2 mitoses/ 10 HPF, visual area diameter 0.57 mm). Glandular. tissue, outside the tumour, showing lesions of the type mastopathia fibrosa et cystica, hyperplasia ductalis. simplex (ADH), adenosis sclerosans. AXILLARY LYMPH NODES: Metastases carcinomatosae in lymphonodis (No II/XXII). Infiltratio capsulae lymphonodi et telae perinodalis. Emboliae carcinomatosae vasorum. Histopathological diagnosis: Carcinoma ductale invasivum mammae dextrae. Invasive ductal carcinoma of the left breast. Metastases carcinomatosae in lymphonodis axillae (No II/XXII). Cancer metastases in axillary lymph nodes. (No II/XXII). Invasivo carcinomatosa vasorum. Vascular invasion. (NHG2, pT1c, pN1a). Results of immunohistochemical examination: Estrogen receptors found in 10-75% of neoplastic cell nuclei. Progesterone receptors found in over 75% of neoplastic cell nuclei. HER2 protein stained with HercepTestTM by DAKO. Negative reaction in invasive carcinoma cells ( Score = 1+).",BRCA,1,True,"The report mentions 'Metastases carcinomatosae in lymphonodis axillae (No II/XXII)', which indicates the presence of cancer metastases in 1-3 axillary lymph nodes. This corresponds to the N1 classification in the AJCC staging system.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",14.0,1473.0,100.0,True
701,TCGA-AC-A2FE.F694CBD6-880D-40C7-AB17-D0AD02B7F06B,2,"Not for Permanent Storage in Medical Records / Not Valid for Signing. Date of Service. Performing Facility. Result Provider. Report Name. Surgical Report. SEE REPORT. ADDENDUM INFORMATION. PROCEDURE DATE: ADDENDUM REPORT #1: COMMENT: Immunoevaluation using. Assisted Quantitative Image Analysis has been. completed and is summarized under line 10 of the diagnosis below. T: ADDENDUM REPORT #1; DIAGNOSIS: A, B/BPC & C. RIGHT BREAST, MASTECTOMY WITH SENTINEL LYMPH NODE BIOPSY AND. FOLLOW UP AXILLARY DISSECTION: 1 - 9. SEE ORIGINAL DIAGNOSIS. 10. ANCILLARY STUDIES: SEE BELOW. ASSAY RESULTS. Test. Staining Intensity. % Positive Avg. Prognostic Significance. ER. N/A. 66%. Favorable. PR. N/A. 7%. Favorable. Her2/neu. 0.4. N/A. Normal Limit. Ki-67. N/A. 11%. Borderline. REFERENCE RANGES. Test. Favorable. Borderline. Unfavorable. ER. >5%. <5%. PR. >5%. Her2/neu. <2.0. >2.0. Ki-67. <10%. >10% - <20% -. >20%. A-MALIGNANT. MD. T: (Electronic Signature). PROCEDURE DATE: SPECIMEN DESCRIPTION: A. RIGHT BREAST. B. RIGHT AXILLARY SENTINEL LYMPH NODE, BPC. C. RIGHT AXILLARY NODE. PRE-OPERATIVE DIAGNOSIS: Right breast carcinoma. POST-OPERATIVE DIAGNOSIS: Same, pending pathology consultation. ====. CLINICAL INFORMATION: Not for Permanent Storage in Medical Records / Not Valid for Signing. Date of Service. Performing Facility. Result Provider. Report Name. Surgical Report. Right breast) upper outer quadrant, needle aspirate biopsy diagnosed as. fibrocystic change, proliferative ductal epithelium, fibrosis, and scattered. inconspicuous atypical cells suspicious for lobular carcinoma. INTRAOPERATIVE CONSULTATION: BPC DIAGNOSIS: "" (Smear) Lymph node positive for carcinoma"" by Dr. GROSS DESCRIPTION: A. The specimen consists of the right breast, measuring 21 X 20 X 5.5 cm and. weighing 1067 grams. No axillary tail is attached. No orientation is. provided. The breast is covered with an ellipse of tan-white skin, measur ng. 17 x 7 cm. The nipple is retracted and measures 0.8 x 0.8 x 0.4 cm. No. discrete ulceration, fissure, or exudate is identified. The nipple is. surrounded by unremarkable tan-brown areola. Approximately 2.2 cm away from. the nipple is a poorly defined, slightly raised tan-brown area. measuring 0.7. X 0.6 cm. No discrete scar is identified. The deep surface reveals a large. mechanical defect, measuring 5 X 2 cm and 3 cm in depth. The specimen appears. to have been sectioned by the surgeon. The deep surface is inked black and. the specimen is serially sectioned. The sections show a very poorly. circumscribed, tan-white fibrotic area, measuring approximately 4.5 X 3.5. 3.5 cm. The fibrotic area reveals a well defined irregular mass, measuring. 2.5 X 2.0 x 1.6 cm and a hemorrhagic area. measuring 0.7 cm in greatest. dimension. The mass is composed of tan-white firm tissue and is approximately. 1.4 cm from the deep margin. One possible intramammary lymph node, measuring. 1.2 cm in greatest dimension, is identified. The lymph nÃ³de is bisected and. no discrete neoplastic involvement is present. The surgical resection margins. are unremarkable. Separately received in the same container are five portions. of irregular tan-yellow adipose tissue, measuring 5 X 5 X 1 cm in aggregate. No discrete lesion or lymph node is identified in the separate portions. Representative sections are submitted in thirteen cassettes as follows: cassette 1 - mass with deep margin: cassettes 2 and 3 - additional sections. of. mass; cassettes 4 through 6 - random sections from the fibrotic area, away. from the mass; cassettes 7 through 10 - sections from the four quadrants;. cassette 11 - lymph node: cassette 12 - nipple and tan-brown area of the skin;. cassette 13 - random sections from the separate portions. B/BPC. The specimen consists of one portion of tan-yellow adipose tissue,. measuring 5 X 4 X 2 cm. The specimen has been bisected in pathology. consultation. The specimen is serially sectioned and four possible lymph. nodes. ranging from 0.5 CID to 2.5 cm in greatest dimension, are identifted. The two largest lymph nodes appear to be involved by neoplasm. Representative. sections submitted in three cassettes as follows: cassette 1 - two. intact. lymph nodes; cassette 2 - one lymph node; cassette 3 one lymph node. are -. C. The specimen consists of multiple portions of tan-yellow adipose tissue,. Not for Permanent Storage in Medical Records / Not Valid for Signing. Date of Service. Performing Facility. Result Provider. Report Name. Surgical Report. measuring 8 X 8 X 2 cm in aggregate. On palpation, fifteen possible Tymph. nodes, ranging from 0.2 cm to 1.5 cm in greatest dimension, are identified. Three lymph nodes are grossly involved by neoplasm. Representative sections. are submitted in four cassettes as follows: cassette 1 - six intact lymph. nodes: cassette 2 - one bisected lymph node; cassette 3 - .three lymph nodes: cascatts 4 - five intact lymph nodes. MICROSCOPIC DESCRIPTION: A, B/BPC, & C. Serial sections in twenty slides are examined. Sections from. specimen A show breast within an extensively infiltrating mammary lobular. carcinoma, focally with pleomorphic features. Tumor is widely infiltrative: closest approach to deep margin is approximately 9 mm. Maximum tumor size is. difficult to assess on glass slides alone, but combining the grossly evident. tumor mass with the additional fibrotic areas, all of which are involved by. carcinoma of the gross impression of up to 4.5 cm is felt to bÃ© accurate as. a. true assessment of the infiltrative tumor. The intramammary lymph node. sampled in block A11. as well as seventeen additional lymph nodes submitted as. parts B/BPC & C are all extensively involved by metastatic carcinoma. morphologically identical to the mammary primary. There is also evidence of. extranodal spread involving the soft tissue surrounding several of the lymph. nodes. T: FINAL DIAGNOSIS: A, B/8PC & C. RIGHT BREAST? MASTECTOMY WITH SENTINEL LYMPH NODE 8IOPSY AND. FOLLOW UP AXILLARY DISSECTION: 1. TUMOR TYPE: INFILTRATING CARCINOMA, LOBULAR PHENOTYPE el. 2. NOTTINGHAM PROGNOSTIC INDEX/GRADE: II (TUBULE SCORE -. 3;. NUCLEAR SCORE - 3;. MITOTIC SCORE - 1). 3. MAXIMUM INVASIVE TUMOR SIZE: APPROXIMATELY 4.5 CM, GROSS. PLUS MICROSCOPIC DATA. COMBINED; SEE DESCRIPTION. 4. PERCENT DCIS: NOT APPLICABLE. 5. LYMPHVASCULAR INVASION: NONE SEEN. 6. DISTANCE TO CLOSEST MARGIN: 9 MM. DEEP. BLOCK A1. 7. MICROCALCIFICATIONS: NOT APPLICABLE. 8. LYMPH NODES: EIGHTEEN OF EIGHTEEN LYMPH NODES INVOLVED BY. METASTATIC CARCINOMA WITH EXTRANODAL SPREAD. OF TUMOR. 9. TNM STATUS: pT3,N3a,MX. 10. ANCILLARY STUDIES: IMMUNOHISTOCHEMICAL EVALUATION IS. PENDING; AN ADDENDUM REPORT WILL BE. Not for Permanent Storage in Medical Records / Not Valid for Signing. Date of Service. Performing Facility. Result Provider. Report Name. : Surgical Report. ISSUED. COMMENT: The fine needle aspiration report from. is reviewed in conjunction. with the slides. A-MAI IGNANT. (Electronic Signature). DATE AND TIME OF REPORT:",BRCA,3,True,The report states that 18 out of 18 lymph nodes are involved by metastatic carcinoma (N3a).,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",N3,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",14.0,1473.0,100.0,True
1106,TCGA-D8-A13Y.0CF5DE3C-272C-4127-8047-4359D1278181,0,"""/a 2/10. page 1 / 1. copy No. Examination: Histopathological examination. PESEL: Gender: F. Material: Multiple organ resection - right breast. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the right breast. Results of immunohistochemical examination: Estrogen receptors found in 10-75% of neoplastic cell nuclei. Progesterone receptors found in 10-75% of. neoplastic cell nuclei. HER2 protein stained with HercepTestâ¢ by DAKO. Negative reaction in invasive. cancerous cells I Score = 1+. Macroscopic description: Right breast, sized 16.6 x 12.4 x 4.8 cm, removed along with axillary tissues sized 8 x 6 x 2 cm and a skin flap. of 10,7 x 8,4 cm. Weight 513 g. Tumour sized 1,5 x 1,9 x 1,0 cm in the upper outer quadrant, placed 3.3 cm from the upper edge, 0.1 cm. from the base and 0.8 cm from the skin. Microscopic description: Carcinoma ductale invasivum - NHG3 (3 + 3 +3: 52 mitoses/ 10 HPF, visual area diameter: 0.55 m). Tumour of. ""basal - like carcinoma"" morphology ? Ma mi 11 a sine laesionibus. Glandular tissue showing lesions of the type mastopathia fibrosa et cystica. Additional parenchyma atrophy. AXILLARY LYMPH NODES. Lymphonodulitis chronica et sinus histiocytosis lymphonodorum (No VI). Examination result: Carcinoma ductale invasivum mammae dextrae. (NHG3, pTIc, pNO). Tumour of ""basal - like carcinoma"" morphology.",BRCA,0,True,"The report states 'pNO', which means there is no evidence of cancer in the lymph nodes. This aligns with the rule 'If there is no evidence of cancer in the lymph nodes, the N stage is N0.'","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",14.0,1473.0,100.0,True
1050,TCGA-BH-A18H.DF536409-601F-489B-9F8A-A2B372BF9999,0,"PATIENT HISTORY: Site Code : breast, NOS C50.9. CHIEF COMPLAINT/ PRE-OP/ POST-OP DIAGNOSIS: Left breast cancer 1.3 cm, positive nodes. Right invasive ductal. carcinoma 9 d'clock. LMP DATE: Not provided. PROCEDURE: Bilateral segmental mastectomies, right sentinel lymph node biopsy. left axillary lymph node dissection. SPECIFIC CLINICAL QUESTION: Not provided. OUTSIDE TISSUE DIAGNOSIS: No. PRIOR MALIGNANCY: No. CHEMORADIATION THERAPY: No. OTHER DISEASES: No. FINAL DIAGNOSIS: PART 1: BREAST, RIGHTAT 9 O'CLOCK, SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA, NO SPECIAL TYPE (See comment). B. NOTTINGHAM GRADE 2 (TUBULE FORMATION: 3, NUCLEAR PLEOMORPHISM: 2, MITOTIC ACTIVITY: 1;. TOTAL SCORE: 6/9). C. THE INVASIVE TUMOR MEASURES 0.8 CM IN LARGEST DIMENSION. D. DUCTAL CARCINOMA IN SITU (DCIS), NUCLEAR GRADE 2, CRIBRIFORM, MICROPAPILLARY AND FOCAL. PAPILLARY TYPE WITH CALCIFICATIONS. E. LOBULAR INVOLVEMENT BY DCIS IS PRESENT. F. THE DCIS CONSTITUTES 60% OF THE TOTAL TUMOR VOLUME AND is PRESENT ADMIXED AND. ADJACENT TO THE INVASIVE COMPONENT. G. NO LYMPHOVASCULAR SPACE INVASION IS NOTED. H. RESECTION MARGINS ARE NEGATIVE FOR TUMOR. I. BOTH INVASIVE CARCINOMA AND IN SITU CARCINOMA ARE MORE THAN 0.5 CM FROM ALL MARGINS. J. FOCAL ATYPICAL DUCTAL HYPERPLASIA. K. PREVIOUS BIOPSY SITE CHANGES. L. THE NON-NEOPLASTIC BREAST SHOWS FIBROCYSTIC CHANGES. M. THE INVASIVE TUMOR CELLS ARE POSITIVE FOR ESTROGEN (H-score 230), POSITIVE FOR. PROGESTERONE RECEPTORS (H-score 180), AND NEGATIVE FOR HER-2/NEU (IHC 2+, FISH not amplified). AS PER THE PREVIOUS PATHOLOGY REPORT. PART 2: RIGHT AXILLARY SENTINEL LYMPH NODE #1, BIOPSY -. ONE LYMPH NODE, NEGATIVE FOR METASTATIC TUMOR (0/1). PART 3: BREAST, LEFT. AT 12 O'CLOCK, SEGMENTAL MASTECTOMY -. A. INVASIVE DUCTAL CARCINOMA NO SPECIAL TYPE. B. NOTTINGHAM GRADE 3 (TUBULE FORMATION: 3, NUCLEAR PLEOMORPHISM: 3, MITOTIC ACTIVITY: 2;. TOTAL SCORE: 8/9). C. THE INVASIVE TUMOR MEASURES 1.3 CM IN LARGEST DIMENSION. D. ADDITIONAL SATELLITE NODULE OF INVASIVE CARCINOMA MEASURING 0.2 CM IS IDENTIFIED. E. THE SATELLITE NODULE IS 0.5 CM FROM THE DOMINANT TUMOR NODUI E. F. DUCTAL CARCINOMA IN SITU (DCIS), NUCLEAR GRADE 3, SOLID TYPE. G. LOBULAR INVOLVEMENT BY DCIS IS PRESENT. H. THE DCIS CONSTITUTES 15% OF THE TOTAL TUMOR VOLUME AND IS PRESENT ADJACENT TO THE. INVASIVE COMPONENT. I. FOCAL LYMPHOVASCULAR SPACE INVASION IS IDENTIFIED. J. RESECTION MARGINS ARE NEGATIVE FOR CARCINOMA. K. INVASIVE CARCINOMA IS 0.4 CM FROM THE NEAREST (POSTERIOR) MARGIN. L. DUCTAL CARCINOMA IN SITU IS MORE THAN 0.5 CM FROM ALL MARGINS. M. SKIN IS NEGATIVE FOR TUMOR. N. PREVIOUS BIOPSY SITE CHANGES. O. THE NON-NEOPLASTIC BREAST SHOWS FIBROCYSTIC CHANGES. P. THE INVASIVE TUMOR CELLS ARE POSITIVE FOR ESTROGEN RECEPTOR (H-ccore 300), POSITIVE FOR. PROGESTERONE RECEPTOR (H-score 235), AND NEGATIVE FOR HER-2/NEU, AS PER PREVIOUS. PART 4: LEFT AXILLARY CONTENTS, EXCISION -. A. METASTATIC CARCINOMA INVOLVES TWO OF TWENTY-FOUR LYMPH NODES (2/24). B. THE LARGEST METASTATIC FOCUS MEASURES 4.0 CM. C. NO EXTRACAPSULAR EXTENSION IDENTIFIED. COMMENT: Part 1: The gross examination demonstrated an III-defined firm nodule with surrounding fibrous tissue measuring 2.0 x. 1.1 x 0.7 cm. This area was entirely submitted for histologic evaluation and shows Invasive carcinoma in only two. sections of 0.4 cm thickness and therefore, the invasive tumor size is estimated to be 0.8 cm in largest dimension. The. majority of this gross lesion is composed of ductal carcinoma in situ (DCIS). Part 3: The invasive tumor demonstrates scattered cells with intra-cytoplasmic lumina or signet ring cell morphology. CASE SYNOPSIS: SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Right. PROCEDURE: Segmental. Clook position:9.00. SIZE OF TUMOR: Maximum dimension invasive component: 8 mm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (Invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 3. Mitotic activity score: 1. Total Nottingham score: 6. Nottingham grade (1, 2, 3): 2. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: Not applicable. CALCIFICATION: Yes, benign zones. TUMOR TYPE, IN SITU: Cribriform. Micropapillary. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of Invasive tumor to closest margin: 6 mm. SURG MARGINS INVOLVED BY IN SITU COMPONENT: Distance of in situ disease to closest margin: 6 mm. LYMPH NODES POSITIVE: 0. LYMPH NODES EXAMINED: 1. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: NON-NEOPLASTIC 1 BREAST TISSUE: ADH, FCD. T STAGE, PATHOLOGIC: pT1b. N STAGE MODIFIER: (sn). N STAGE, PATHOLOGIC: pNO. M STAGE: Not applicable. ESTROGEN RECEPTORS: positive, H-score: 230. PROGESTERONE RECEPTORS: positive, H-score: 180. HER2/NEU: 2+. HER2/NEU (FISH): Not amplified. SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: ( Left. PROCEDURE: Segmental. Clock position: 12.00. SIZE OF TUMOR: Maximum dimension invasive component: 13 mm. MULIICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI;. TUMOR AGGREGATE SIZE: Sum of the sizes of multiple invasive tumors: 15 mm. TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 3. Tubule formation: 3. Mitotic activity score: 2. Total Nottingham score: 8. Nottingham grade (1, 2, 3): 3. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: TUMOR TYPE, IN SITU: Solid. SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 4 mm. SURG MARGINS INVOLVED BY IN SITU COMPONENT: LYMPH NODES POSITIVE: 2. LYMPH NODES EXAMINED: 24. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SIZE OF NODAL METASTASES: Diameter of largest lymph node metastasis: 40 mm. LYMPH NODE METASTASIS(-ES WITH EXTRACAPSULAR EXTENSION: SKIN INVOLVED (ULCERATION): NON-NEOPLASTIC BREAST TISSUE: FCD. T STAGE, PATHOLOGIC: pT1c. N STAGE, PATHOLOGIC: pN1a. M STAGE: Not applicable. ESTROGEN RECEPTORS: positive, H-score: 300. PROGESTERONE RECEPTORS: positive, H-score: 235. HER2/NEU: 1+.",BRCA,0,True,"The N stage is determined by the presence of cancer metastases in lymph nodes. In this report, the left axillary contents excision shows metastatic carcinoma involving two of twenty-four lymph nodes (2/24). This indicates that the patient has cancer metastases in the axillary lymph nodes, which classifies the N stage as N1.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",14.0,1473.0,100.0,True
1084,TCGA-BH-A1FN.26F47A4F-B501-4C33-9D49-2039E98DBF26,1,"Procedure Date: Procedure Physician: Attending Physician/Copies To: PATIENT HISTORY: DATE OF LMP: DATE OF LAST DELIVERY: PRE-OP DIAGNOSIS: R BREAST CA. POST-OP DIAGNOSIS: SAME. OPERATIVE PROCEDURE: R SEGM MAST AND AXILL NODE DISS. CLINICAL HISTORY: MATERIAL SUBMITTED: A) RIGHT BREAST BIOPSY/MASS/SEGMENTAL MASTECTOMY, PROCUREMENT BY SURGICAL PROCEDURE. routine sutures. B) RIGHT AXILLA, PROCUREMENT BY SURGICAL PROCEDURE. INTRAOPERATIVE CONSULTATION: FROZEN SECTION: Right breast tissue; 8.0 by 8.0 by 3.0 cm. Tumor is 2.6 by 2.6 by 2.5 cm. Margins grossly. free. Frozen Section Diagnosis: Infiltrating ductal carcinoma. ER/PR taken. FINAL DIAGNOSIS: FINAL DIAGNOSIS: AEAFS) RIGHT BREAST MASS. - INFILTRATING DUCTAL CARCINOMA, NOT OTHERWISE SPECIFIED, HISTOLOGIC GRADE 3, NUCLEAR GRADE POOR, VASCULAR. INVASION PRESENT, TUMOR NECROSIS REPRESENTING 30% OF TUMOR MASS; TUMOR GREATEST DINGTER 2.6 BY 1.6 BY 2.5. CM. - INKED MARGINS FREE OF TUMOR. B) RIGHT AXILLARY NODES: - TWENTY-NINE (29) LYMPH NODES, FREE OF TUMOR. Criteria. Diagnusis riscrepancy. Primary Tumor Site Discivinary. enor Millenancy Hi tory. must/syrchionous useis (circle): initials MA Date jewed /. Re.",BRCA,0,True,"The report states that 29 lymph nodes were removed and were free of tumor. According to the rules, the absence of cancer in the lymph nodes is the primary determinant of the N stage, and the number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes. Therefore, the N stage is N0.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",14.0,1473.0,100.0,True
758,TCGA-AN-A0FK.5F5FF3CA-2DBB-4DE1-9190-1FE36E2B5ACB,3,Sex: Female. Diagnosis: Breast Cancer Histological description: Infiltrative ductal carcinoma. Anatomic Site: Right breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: OCT. Container: block Type of Procurement: surgery Grade: 2. T Stage: 4 N Stage: 0 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,BRCA,0,True,"The N stage is reported as N0, which indicates no evidence of cancer in the lymph nodes. This is based on the statement in the report 'N Stage: 0'.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",14.0,1473.0,100.0,True
1307,TCGA-E9-A22D.ED60F792-A71B-4BAE-A536-5FF6D8C3DEAA,1,Laterality:Right upper outer quadrant. Path Report: BREAST TISSUE CHECKLIST. Specimen type: Radical mastectomy. Specimen size: Not specified. Tumor site: Breast. Tumor size: 2.4 x2.4x2.4 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal carcinoma. Histologic grade: Moderately differentiated. Tumor extent: Not specified. Lymph nodes: 0/10 positive for metastasis (Regional 0/10). Extracapsular invasion of the lymph nodes: Not specified. Margins: Not specified. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None.,BRCA,0,True,"The report indicates that there are 0/10 positive lymph nodes (Regional 0/10) and there is no evidence of cancer in the lymph nodes. Based on the rules provided, this indicates an N0 stage.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",14.0,1473.0,100.0,True
965,TCGA-BH-A0B0.EB09D890-879C-4874-AE3F-47E41C2C66FE,0,"FINAL DIAGNOSIS: PART 1: LYMPH NODE, LEFT BREAST, #1 SENTINEL, EXCISION -. NO EVIDENCE OF METASTATIC MAMMARY CARCINOMA IN ONE LYMPH NODE (0/1). PART 2: LYMPH NODE, LEFT BREAST, #2 SENTINEL, EXCISION -. NO EVIDENCE OF METASTATIC MAMMARY CARCINOMA IN ONE LYMPH NODE (0/1). PART 3: BREAST, LEFT, SEGMENTAL MASTECTOMY -. A. INVASIVE DUCIAL CARCINOMA. B. NOTTINGHAM GRADE (TUBULE FORMATION: 2, NUCLEAR PLEOMORPHISM: 2, MITOTIC ACTIVITY: 1;. TOTAL SCORE 5/9). C. INVASIVE TUMOR MEASURES 1.8 CM IN LARGEST DIMENSION. D. NO LYMPHOVASCULAR SPACE INVASION IS IDENTIFIED. E. INVASIVE CARCINOMA IS 0.8 CM FROM THE NEAREST ANTERIOR MARGIN. SYNOPTIC - PRIMARY INVASIVE CARCINOMA OF BREAST. LATERALITY: Left. PROCEDURE: Segmental. Not specified. SIZE OF TUMOR: Maximum dimension invasive component: 1.8 cm. MULTICENTRICITY/MULTIFOCALITY OF INVASIVE FOCI: TUMOR TYPE (invasive component): Ductal adenocarcinoma, NOS. NOTTINGHAM SCORE: Nuclear grade: 2. Tubule formation: 2. Mitotic activity score: 1. Total Nottingham score: 5. Nottingham grade (1, 2, 3): 1. ANGIOLYMPHATIC INVASION: DERMAL LYMPHATIC INVASION: CALCIFICATION: SURGICAL MARGINS INVOLVED BY INVASIVE COMPONENT: Distance of invasive tumor to closest margin: 8 mm. PAGET'S DISEASE OF NIPPLE: LYMPH NODES POSITIVE: 0. LYMPH NODES EXAMINED: 2. METHOD(S) OF LYMPH NODE EXAMINATION: H/E stain. SENTINEL NODE METASTASIS: NON-NEOPLASTIC BREAST TISSUE: FCD. T STAGE, PATHOLOGIC: pT1c. N STAGE, PATHOLOGIC: pNo. M STAGE, PATHOLOGIC: pMX. ESTROGEN RECEPTORS: positive. PROGESTERONE RECEPTORS: positive. HER2/NEU: zero or 1+.",BRCA,0,True,"The report states that there is no evidence of metastatic mammary carcinoma in the sentinel lymph nodes examined (0/1 and 0/1 for the two nodes). This indicates that the cancer has not spread to the lymph nodes, which is the primary determinant of the N stage. Therefore, the N stage is N0.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",14.0,1473.0,100.0,True
617,TCGA-A8-A06Y.5664F531-9D45-4302-A455-63E46B5EDD26,1,"Diagnosis: Invasive ductal breast carcinoma (malignancy grade II) with concomitant high-grade comedo-. type DCIS with inclusions also of isolated coarse calcifications (procomponent of tumor. 20%), with confluent manifestations in the tumor nucleus and other DCIS components in the. tumor periphery. Narrow medial safety margin, as already macroscopically documented. Also. rich DCIS formations extending to within 0.5 cm of the dorsal resection line. dye-stained. resection margins are free of atypia. Mastopathic base structure. Tumor classification: pT2 (maximum diameter 2.5 cm) pNO sn (n=3), MX, R0; G2 (LO, V0).",BRCA,0,True,"The report states 'pNO' which means there is no evidence of cancer in the lymph nodes. This aligns with the rule 'If there is no evidence of cancer in the lymph nodes, the N stage is N0.'","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",14.0,1473.0,54.0,False
647,TCGA-A8-A08G.6DCA5C2C-F28A-409D-9623-24AB748FB4E7,1,"Diagnosis: 1 Ablated breast sample with three foci of carcinoma: first tumor: poorly differentiated invasive ductal carcinoma (tumor diameter: 2.8 cm). with focal intraductal components. Tumor-free dorsal resection margin. Tumor classification: NOS and mucinous carcinoma, G III, pT2(mult)NOLOVORX.",BRCA,0,True,"The report indicates that there is no evidence of cancer in the lymph nodes (NO) for this patient. This is stated as 'pT2(mult)NO' in the tumor classification. Therefore, based on the rules provided, the N stage is N0.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.",N0,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",14.0,1473.0,60.0,False
1144,TCGA-D8-A1XG.AA869507-1B46-4812-8EC5-A4E01C588E6E,3,"page 1 / 1. copy No. Examination: Histopathological examination. Gender: F. Material: 1. Total organ resection - right breast. Expected time of examination: up to 8 working days. Clinical diagnosis: Cancer of the right breast, ulcerous - Toilet mastectomy. Macroscopic description: Right breast Sized 13.7 x 7.6 x 4.8 cm removed without axillary tissues and with a skin flap of 17.8 x 10.2 cm. Weight 193 g. Tumour sized 6.2 x 4.3 x 7.8 cm in the middle part, 0.1 cm from the upper boundary, 0.1 cm from the base. Microscopic description: Carcinoma ductale invasivum - NHG3 (3+2+3/20 mitoses/10 HPF - visual area: 0.55mm). Infiltratio carcinomatosa cutis et musculi pectoralis. Mamilla sine laesionibus. Glandular tissue showing parenchyma atrophy. Histopathological diagnosis: Carcinoma ductale invasivum mammae dextrae. Invasive ductal carcinoma of the right breast. Metastases carcinomatosae in lymphonodis axillae (No II/II). Cancer metastases of the axillary lymph nodes. (NHG3, pT4b, pN1a). Results of immunohistochemical examination: Estrogen receptors found in 10-75% of neoplastic cell nuclei. Progesterone receptors found in 10-75% of. neoplastic cell nuclei. HER2 protein stained with HercepTestâ¢M by DAKO. Negative reaction in invasive cancerous cells ( Score = 0). Compliance valida.",BRCA,1,True,"The report mentions 'Cancer metastases of the axillary lymph nodes' and 'Metastases carcinomatosae in lymphonodis axillae (No II/II)', indicating the presence of metastases in 1-3 axillary lymph nodes, which corresponds to N1 classification.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",N1,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",14.0,1473.0,100.0,True
1474,TCGA-OL-A5RV.0CA74400-1596-4C14-AF02-4F5169D61942,1,"FINAL PATHOLOGIC DIAGNOSIS. A. Right breast; modified radical mastectomy: - Invasive ductal (tubulo-lobular) carcinoma, SBR grade II, focally associated. with microcalcification, see parameters. - Ductal carcinoma in situ, low and intermediate nuclear grade, cribriform,. micropapillary and solid type, associated with necrosis and microcalcifications. - Ductal carcinoma in situ is < 2 mm from posterior margin. - Biopsy site changes. - Columnar cell changes. - Two small fibroadenomas. - Twenty of twenty-nine lymph nodes, positive for metastatic carcinoma (20/29). - Extranodal extension present. Breast Pathologic Parameters. 1. Invasive carcinoma: A. Gross measurement: 4.5 cm (main lesion) and 1 cm (satellite in upper. outer quadrant). B. Composite histologic (modified SBR) grade: II. - Architecture: 2. - Nuclear grade: 2. - Mitotic count: 2. C. Associated intraductal carcinoma in situ (DCIS): - Within main mass (forming 40% of tumor volume). 2. Intraductal carcinoma: A. Gross measurement: 4.5 cm, admixed with invasive carcinoma. B. Type: Cribriform / Solid / Micropapillary. C. Nuclear grade: Low / Intermediate. D. Associated features: Necrosis / Microcalcifications / Cancerization of. lobules. 3. Excisional biopsy margins: - DCIS < 2 mm from posterior (closest) margin. - Invasive carcinoma > 4 mm from posterior (closest) margin. 4. Blood vessel and lymphatic invasion: Present. - Present in breast parenchyma. - Present in axillary tissue. 5. Nipple: DCIS extending into lactiferous duct. 6. Skin: uninvolved. 7. Skeletal muscle: absent. 8. Axillary lymph nodes: Positive (20/29). - Size of largest metastatic deposit: 12 mm. - Extranodal extension: present (7 mm; largest focus). - Tumor deposits in axillary tissue (up to 5 mm). 9. Special studies (see. - ER: Strong expression in >90 % of invasive tumor nuclei. - PR: Strong expression in >90 % of invasive tumor nuclei. - Her2/neu antigen (FISH): Non-amplified (ratio:1.00). 10. pTNM (AJCC, 7th edition, 2010): pT2(m), N3, MX. Clinical History: The patient is a year old female, with a right breast mass (MRI: 1.3 x 0.9 x. 0.8 cm) and biopsy diagnosis of invasive ductal carcinoma undergoing right. modified radical mastectomy. Specimens Received: A: Right breast; mastectomy. Gross Description: A. The specimen is received in a single container labeled with the patient's. name, medical record number, and additionally identified as, 'right breast'. Received fresh and placed in formalin is a 653 gm modified radical mastectomy. specimen. The specimen is oriented with a short suture designating the superior. margin and a long suture designating lateral margin. The specimen measures 18.5. cm from superior to inferior, 22.5 cm from medial to lateral, and 3.9 cm from. anterior to posterior. There is an attached 9.6 X 7.9 X 1.5 cm axillary tail. On the anterior surface is a 18.0 X 8.0 cm tannish brown ellipse of skin with a. 4.0 X 4.5 cm areola and a 1.5 X 1.4 X 0.5 cm raised nipple. The nipple-areolar. complex reveals no evidence of ulceration or retraction. The specimen is inked as follows: superior edge - blue;. inferior edge - green;. posterior - black. The specimen is serially sectioned from medial to lateral into 11 slices to. reveal a rubbery, irregularly shaped, white-tan, 4.5 X 3.5 x 2.5 cm mass with. a. granular cut surface in slices 3 through 5. A clip is identified in slice 3. The. mass is 0.5 cm from the posterior margin and widely free (>2 cm) from the. anterior superior and anterior inferiormargins. The remainder of the specimen. consists of approximately 30% dense gray-white fibrous breast parenchyma and 70%. lobulated yellow adipose tissue. No additional masses or nodules are grossly. identified. Sectioning through the axillary tail reveals multiple tan-brown,. rubbery lymph nodes ranging from 0.3-2.5 cm in greatest dimension. Block summary: A1: mass surrounding clip and closest approach to posterior margin and. surrounding clip, slice 3. A2: mass, slice 4. A3: mass, slice 4. A4: mass, slice 5. A5: mass and biopsy site, slice 5. A6: upper outer quadrant, slice 7. A7: lower outer quadrant, slice 6. A8: upper inter quadrant, slice 2. A9: lower-inner quadrant, slice 5. A10: skin adjacent to mass. A11: nipple. A12: tissue directly beneath nipple. A13: one lymph node, sectioned. A14: one lymph node, bisected. A15: one lymph node, sectioned. A16: one lymph node, bisected. A17: one lymph node, bisected. A18: one lymph node, bisected. A19: two lymph nodes. A20: two lymph nodes. A21: three lymph nodes. A22: three lymph nodes. A23: one lymph node, sectioned. A24: three lymph nodes. A25: four lymph nodes. A26: three lymph nodes.",BRCA,3,True,"The report indicates that there are 20 positive lymph nodes out of 29 examined (20/29). This puts the patient in the N3 category, which is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.","If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",N3,"If there is no evidence of cancer in the lymph nodes, the N stage is N0.
The number of negative lymph nodes does not affect the N stage in the absence of positive lymph nodes.
The presence of blue dye in a lymph node does not affect the N stage.
Immunohistochemical analysis of lymph nodes does not affect the N stage.
Her-2/NEU analysis does not affect the N stage.
The absence of cancer in the lymph nodes is the primary determinant of the N stage.
The presence of cancer metastases in axillary lymph nodes determines the N stage as N1, N2, or N3.
N1 classification is determined by the presence of metastases in 1-3 axillary lymph nodes, or in internal mammary nodes with axillary lymph nodes not involved.
N2 classification is determined by the presence of metastases in 4-9 axillary lymph nodes, or in infradiaphragmatic (lower) nodes.
N3 classification is determined by the presence of metastases in 10 or more axillary lymph nodes, or in infradiaphragmatic (lower) nodes, or in ipsilateral internal mammary nodes in the absence of axillary lymph node metastases.
The number of positive lymph nodes is a key factor in determining the N stage in the presence of metastases.
Extracapsular extension in a lymph node does not change the N stage, but it may affect the prognosis.
The N stage is not affected by the type of carcinoma or the presence of intraductal carcinoma.
Micrometastases in lymph nodes contribute to the N stage as per the N1, N2, or N3 classification.",14.0,1473.0,100.0,True
